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Abstract 
Introduction 
Undernutrition (underweight, stunting and wasting) affects hundreds of millions of children globally.  
Cambodia’s progress in combatting undernutrition has stalled.  In 2014, 32% of children under five were 
stunted, 24% were underweight and 10% were wasted.  There is consensus on the urgency of finding 
effective interventions for preventing undernutrition.  Therefore, this project developed an innovative, 
locally-produced multiple micronutrient fortified lipid-based nutrient supplement (LNS) snack for use as a 
ready-to-use supplementary food (RUSF) using fish rather milk as the animal-source food. 
Context and aim 
We conducted two trials with the novel RUSF.  The first assessed the RUSF’s acceptability as a snack or 
mixed with borbor (white rice porridge) compared to Corn-Soy Blend Plus Plus (CSB++) and borbor 
fortified with micronutrient powders (MNP).  The second assessed its effectiveness in reducing growth 
faltering in comparison to CSB++, MNP, and an unsupplemented control group. 
Methods 
The acceptability trial was a non-blinded, 4 x 4 crossover design.  Healthy children aged nine to twenty-
three months (n = 92) ate each of four foods for three consecutive days.  Outcomes measured were 
children’s consumption, caregivers’ assessment of children’s preferences and caregivers’ ranking of the 
foods.  The effectiveness trial was a non-blinded, cluster-randomised control trial.  Healthy children aged 
six to seventeen months (n = 485) were allocated to one of three intervention groups or the control group 
for six months.  The main outcome was anthropometric status measured as weight-for-age (WAZ), height-
for-age (HAZ), weight-for-height (WHZ), and mid-upper arm circumference (MUAC).   
Results 
In acceptability testing, the median percentage consumed of the test food servings ranged from 21 - 50% 
(p = 0.003).  The odds of children consuming over 50% were greatest for borbor fortified with MNP versus 
RUSF snack (unadjusted OR = 6.79, CI = 2.80 - 16.47, p < 0.001).  However, the median energy children 
received when consuming the RUSF with borbor (57 kcal) or as a snack (48 kcal) was greater than with 
CSB++ (15 kcal) or borbor fortified with MNP (18 kcal), (p < 0.001).  Therefore, although children ate less 
RUSF, it provided approximately three times more kilocalories.  Caregivers reported that their children had 
the highest preference for borbor fortified with MNP, and the second highest preference for the RUSF 
xviii 
snack.  Caregivers themselves ranked the novel RUSF snack highest.  Thus, the innovative RUSF was 
considered sufficiently acceptable to proceed to an effectiveness trial.   
Analysis of the effectiveness of the RUSF in preventing undernutrition shows that growth faltered from 
baseline to endline, with no significant differences between the intervention and control.  In unadjusted 
analysis, the RUSF group had greater increases in MUAC (0.04cm, SE = 0.01, p = 0.008) than CSB++ or 
the control (0.03cm, SE = 0.01, p = 0.027; and 0.02cm, SE = 0.01, p = 0.010 respectively).  For other 
outcomes, the RUSF did not differ significantly from the control, which had decreased WAZ and HAZ (-
0.02, SE = 0.01, p = 0.001; and -0.07, SE = 0.01, p < 0.001 respectively) and no significant change in WHZ. 
In adjusted analysis, high consumers of RUSF had increased MUAC (0.08cm, SE = 0.03, p = 0.003) in 
comparison to the control, but no statistically significant differences to CSB++ or MNP for any outcome. 
Low consumers of RUSF had increased WAZ, WHZ and MUAC (0.03, SE = 0.01, p = 0.006; 0.04, SE = 
0.02, 0.026; and 0.05cm, SE = 0.02, p = 0.004 respectively).  Low consumers of RUSF had statistically 
significantly increased HAZ compared to CSB++ (0.06, SE = 0.03, p = 0.031), but otherwise had no 
differences to CSB++ or MNP for any other anthropometric measures.  Birthweight, sex, iron status, and 
diarrhoea significantly affected anthropometric status.  Bottle feeding and maternal body mass index (BMI) 
also had significant effects on anthropometric status.   
Discussion 
Our trial showed that the RUSF slowed but did not prevent growth faltering in a representative population 
that included non-moderately acutely malnourished in a food secure setting.  In similar trials, growth 
generally continued to falter for all or some anthropometric outcomes, as was the case in our trial.   
One possible explanation for continued growth faltering is the high prevalence of diarrhoea in our 
population (32% at baseline).  Another is that supplementary foods in medium to large quantities (40-
110g/day in the RUSF and CSB++ groups) displaced normal intakes of food and breastmilk.    
In addition to displacing breastmilk and family foods, supplementary foods may disempower and deskill 
caregivers, increase consumption of processed foods, and divert funding from other potentially effective 
nutrition interventions.  Thus, there may be potential risks of using supplementary foods to prevent 
undernutrition amongst children who are not moderately acutely malnourished, in food secure settings, and 
over the long term.   
xix 
Conclusion and contribution to policy, practice, and research 
Our acceptability trial demonstrated that the novel, fish-based RUSF is acceptable as a supplementary food. 
However, neither our novel RUSF nor the other specialised products tested prevented undernutrition in our 
target group in the quantities provided.  Thus, more research is needed to identify interventions that prevent 
undernutrition in Cambodian children.  Since child undernutrition is multifactorial, isolated nutrition-
specific interventions are unlikely to suffice.  Rather, an integrated, life course approach that addresses the 
multiple causes of undernutrition is necessary.  These findings are highly relevant to undernutrition 
prevention programming in low and middle-income countries. 
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Chapter 1:  Rationale and description of the project 
The context in which the project was developed 
By 2013, progress in combatting undernutrition had stalled in Cambodia.  Given that a great proportion 
of undernutrition is accrued from six to twenty-three months of age due to the inadequacy of 
complementary feeding, providing supplementary food to prevent growth faltering seemed a promising 
solution.  The products that were being used for the prevention of undernutrition, namely Corn-Soy 
Blend Plus Plus (CSB++) and Sprinkles multiple micronutrient powders (MNP), were relatively 
expensive to procure and ship to Cambodia.  Ruptures in stock and spoilage due to poorly managed 
warehousing and distribution were common.  Moreover, the acceptability of these products was 
questionable.  The situation was similar for BP-100™, the therapeutic food that was being used to treat 
severe acute malnutrition (SAM) (1).  Plumpy'Nut™, another therapeutic food, had been tested but had 
limited acceptability (2).  Existing specialised food products that had been used or trialled in Cambodia 
are shown in Figure 1.1. 
Low acceptability of CSB++  
Globally, CSB++ is widely used to treat and prevent moderate acute malnutrition (MAM).  A fortified 
blended flour that is cooked to make a porridge, it is primarily distributed by the United Nations World 
Food Program (WFP) to children aged six to twenty-three months with the aim of preventing 
undernutrition.  In Cambodia, despite performing well in acceptability tests (3), it was not well accepted 
in practice (4).  In June 2014, the WFP in Cambodia phased out CSB++ distribution.   
Limited effectiveness of MNP in preventing undernutrition 
MNP are powdered food supplements containing essential vitamins and minerals that are added to 
prepared food.  They were being distributed through the Cambodian health system to children aged six 
to twenty-three months, but coverage was limited (5).  Although they proved acceptable and effective 
at reducing anaemia, in keeping with experience elsewhere, they had not improved growth (6).   
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Low acceptability of Plumpy'Nut™ 
Plumpy'Nut™ is a ready-to-use therapeutic food (RUTF) based on peanuts that is produced by Nutriset 
in France.  It was trialled in Cambodia in 2008 and was not well accepted (2).  This has been taken as 
evidence that there may be low acceptability of peanut-based ready-to-use foods (RUFs) in South-East 
Asia.  However, this study (2) was not an acceptability trial in the usual sense but a qualitative, socio-
anthropological study that drew on grey literature and interviews, and reflected implementation or 
effectiveness issues more than acceptability.  Since then, two other studies in Cambodia and Vietnam 
have found peanut-based pastes (Eezypaste and Plumpy'Nut™) quite acceptable, at least to children 
though possibly not to caregivers (7, 8).  Therefore, the perceived lack of acceptability of peanut-based 
products in South-East Asia is questionable.  Nevertheless, given that the rate of aflatoxin contamination 
of peanuts in the region is quite high and quality control capacity rather low (9-11), it would be advisable 
to avoid a locally-produced peanut-based product. 
Limited use of commercial supplementary foods 
Commercial baby foods, mostly the products of companies such as Nestle but also some created by 
GRET, a French nongovernmental organisation (NGO), are available in Cambodia.  However, a recent 
study estimated that only 20% of Cambodian caregivers purchase this kind of supplementary food for 
their children (12).  
Figure 1.1: Existing specialised food products that had been used or trialled in Cambodia. Left to right: 
CSB++, BP-100™, Plumpy'Nut™, and Sprinkles MNP. 
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A local alternative to existing products 
Given the limited success of the existing supplementary and therapeutic products, the Cambodian 
Ministry of Health (MoH), was seeking an alternative.  The aim was to produce a food locally, based 
on locally available ingredients, containing macro and micronutrients.  Locally-produced products are 
more likely to be acceptable than imported products.  Whether they would be cheaper and would 
contribute money and capacity to the local economy is debatable (13-15).  A 2013 systematic review 
on specially formulated foods for treating children with MAM in low- and middle-income countries 
concluded that it was vital to develop and test foods with a high energy and nutrient density that would 
be acceptable to the target population.  The review also noted that most research on supplementary 
foods was from Africa, and that evidence on the acceptability and effectiveness of supplementary foods 
elsewhere would be useful (16). 
Using the experience from Vietnam 
In 2009 in Vietnam, UNICEF, along with the French National Research Institute for Sustainable 
Development (IRD) and the National Institute of Nutrition of Vietnam, developed an RUTF from 
mainly local ingredients including rice, soy, mungbeans, sugar, milk powder, oil, and multiple 
micronutrients.  It was called HEBI, meaning High Energy Bar for Integrated Management of Acute 
Malnutrition (IMAM).  This product proved more acceptable than and as effective as Plumpy'Nut™ (7) 
and is now used in eleven provinces in Vietnam (8).   
In mid-2013, IRD in Cambodia partnered with a local NGO, the Reproductive and Child Health 
Alliance (RACHA), to conduct an acceptability trial of various products, including CSB++, BP-100™, 
HEBI, and Eezypaste, a peanut lipid-based nutrient supplement (LNS) made in India (8).  The 
Vietnamese RUTF and even the Eezypaste were found more acceptable than CSB++ and BP-100™, 
confirming that acceptability of CSB++ and BP-100™ was low.   
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Rationale for our project 
Based on this trial, and in the absence of any other affordable, acceptable, effective, locally-produced 
Cambodian RUTF or ready-to-use supplementary food (RUSF), the MoH, in partnership with UNICEF, 
IRD and the Cambodian Department of Fisheries Post-harvest Technologies and Quality (DFPTQ), 
began developing a novel RUF, based on the same concept as the Vietnamese product.  The product 
used local ingredients and was developed in two formulations.  The first was an RUTF for the treatment 
of severe acute malnutrition, and the second was an RUSF to be used for the prevention of 
undernutrition.  The trials involving the RUSF are presented in this dissertation. 
Objectives of the trials 
The objectives of the trials described in this dissertation were twofold.  First, we aimed to assess the 
acceptability of the locally-produced Cambodian RUSF for children under two years and their 
caregivers, in comparison to existing supplements and supplementary foods that were being used in 
Cambodia to prevent undernutrition.  Second, we aimed to establish the novel RUSF’s effectiveness in 
preventing undernutrition in Cambodian children under two years in comparison to MNP, CSB++, and 
an unsupplemented control group.    
Acceptability trial 
Regardless of how effective a product may be, it is vital to determine its acceptability in a given setting. 
In other words, children must be willing to eat the product and caregivers must be prepared to feed it to 
them.  Acceptability to children can be measured by how much they eat and how readily, while 
acceptability to caregivers is measured in terms of their sensory perception of the organoleptic qualities 
of the food, that is, of the smell, colour, consistency, and taste (17).  Other factors in acceptability may 
include price and convenience of preparation.   
In June 2015, the RUSF was tested for acceptability with children aged nine months to two years and 
their caregivers.  It was compared to CSB++, and MNP mixed with borbor, a white rice porridge which 
is the traditional weaning food.  Consumption in terms of portion of serving consumed, the caregiver’s 
4
perception of the child’s preference, and acceptability to caregivers were the main outcomes.  These 
outcomes indicated how well accepted the RUSF is by children and caregivers, and how likely they 
would be to eat it if it were provided in the context of programming for the prevention and treatment of 
undernutrition.   
Effectiveness trial 
The next step was to assess the effectiveness of the RUSF in preventing undernutrition and promoting 
optimal growth and development.  A six-month effectiveness trial was conducted where the impact of 
the RUSF on children aged six to seventeen months was compared to the impact of CSB++, MNP, and 
to a control group consuming an unsupplemented diet, typically borbor at an early age (e.g. six to nine 
months) and thereafter, family foods.  The main outcomes were anthropometric changes in weight-for-
age z-score (WAZ), height-for-age z-score (HAZ), weight-for-height z-score (WHZ), and mid-upper 
arm circumference (MUAC).   
This dissertation 
This dissertation describes the RUSF and the two trials, conducted in 2015 and 2016, that tested its 
acceptability and effectiveness in preventing growth faltering among children under two years in 
Cambodia.   
My role in this research project 
My role in the wider research project (of which this dissertation forms one part), was to coordinate and 
conduct the acceptability and effectiveness trials for the RUSF.  This included conducting a literature 
review, writing the trial protocols, applying for ethical approval, and registering the trials.  Once the 
trials were approved by the relevant ethics committees (see Appendices 1.1 – 1.3), it was my task to 
write and field test the data collection and data entry tools, hire and train data collectors, select study 
sites and randomise them to the trial arms.  I collaborated on finalising the development and packaging 
of the RUSF, procured the CSB++, MNP and other study materials and equipment.  I organised the 
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recruitment and enrolment of participants, supervised the data collection and entry including translation 
and transcription, and organised logistics.  I cleaned the data and conducted the analysis, and prepared 
presentations, publications, and donor reports. 
Outline of this dissertation 
Chapter 2 describes the background to the trials, including the prevalence of undernutrition globally 
and in Cambodia, and the aetiology of undernutrition.  It outlines a framework for understanding 
undernutrition, including contributing factors and consequences, and a framework for addressing 
undernutrition.  A review of the literature identifies gaps and how this research addresses those gaps.  
Chapter 3 describes the novel RUSF.  Chapters 4 and 5 describe the methodology and the results of the 
acceptability trial, while Chapters 6 and 7 describe the methodology and results of the effectiveness 
trial.  Chapter 8 recounts the policy and programmatic environment and the decision-making process 
behind the development and trialling of the RUSF.  Chapter 9 discusses the significance of trials and 
the contribution of this research to the literature on prevention of undernutrition.  Chapter 10 
summarises the findings of the trials and makes recommendations for future research. 
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Chapter 2: Background and literature review 
Introduction 
Globally, undernutrition affects over 150 million children under five years (1).  A significant proportion 
of global morbidity and mortality is linked, directly or indirectly, to undernutrition.  However, 
efficacious interventions exist and could significantly reduce the burden of undernutrition if 
implemented at scale.  Of the ten interventions recommended in the 2013 Lancet Series, the prevention 
of undernutrition and growth faltering was considered one of the most promising and cost-effective in 
terms of reduced mortality (2).  In Cambodia, progress on combatting child undernutrition has stalled 
in the past decade, with inadequate complementary feeding being an important contributor to the 
problem (3).  Our project sought to improve complementary feeding by developing a locally-produced, 
ready-to-use supplementary food (RUSF) for the prevention of growth faltering.   
Malnutrition – the global context 
Malnutrition encompasses undernutrition, overnutrition and micronutrient deficiency.  Undernourished 
children can be stunted (short for their age), wasted (thin), or both.  Underweight is a composite measure 
which may reflect wasting, stunting or a combination of the two.  These various forms of undernutrition 
are defined by anthropometric indicators calculated using World Health Organisation (WHO) 2006 
Child Growth Standards (ANTHRO version 3.2.2 January 2011) and expressed as z-scores for weight-
for-height (WHZ), length/ height-for-age (L/HAZ) and weight-for-age (WAZ), along with mid-upper 
arm circumference (MUAC).  For detailed definitions of malnutrition, see Appendix 2.1.   
Prevalence of malnutrition globally, with particular reference to South-East Asia  
Asia and Africa continue to be the regions most affected by all forms of malnutrition.  In 2019, more 
than half of all stunted children (55%) were in Asia, and more than a third (39%) were in Africa (1).   
Over two thirds of all wasted children (68%) were in Asia and over a quarter (28%) were in Africa (1).  
At the same time, almost half of all overweight or obese children (47%) were in Asia and a quarter 
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(24%) were in Africa (1).  In South-East Asia, the prevalence of stunting is high, with fourteen million, 
or 25% of children under five years affected (1).  Wasting affects five million (9%) – half of whom are 
severely wasted - and over four million children (8%) are overweight (1).  Stunting can occur 
simultaneously with wasting or overweight, but there are no current estimates of the number of children 
suffering from more than one form of malnutrition (1).   
Prevalence of undernutrition is underestimated 
These numbers are underestimations.  Because nutrition surveys are cross sectional, with measurements 
taken at one point in time, a proportion of wasting cases that are seasonal or short duration may be 
missed (4).  Many more millions of children suffer from growth faltering without being identified as 
wasted or stunted (5).   
The prevalence of malnutrition in Cambodia  
Cambodia made strides in reducing malnutrition in the earlier part of the millennium.  From the first 
Demographic and Health Survey (DHS) in 2000 to 2005, prevalences of stunting, wasting and 
underweight were reduced.  However, despite the fact that Cambodia is transitioning to a middle-
income country, its progress in combatting undernutrition has stagnated, as shown by the DHSs since 
2005 (3).  While stunting among children under five years has continued to decline, wasting and 
underweight have changed little since 2005, as seen in Figure 2.1.   
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Prevalence of stunting  
The 2014 Cambodia DHS (3) reported that one-third of all children under five years were stunted (HAZ 
< -2).  Stunting was apparent even in infants under six months.  Stunting increased with age, peaking at
36-47 months, with almost half (40%) of children in that age group being stunted.  
Prevalence of wasting 
A high prevalence of wasting (WHZ < -2) persisted in 2014 (3).  In children aged twelve to seventeen 
months (the age of our subjects at the end of the trial), wasting was 14.5%, which is effectively the 
threshold (15%) that would trigger universal supplementary feeding in an emergency (6).  There was 
no consistent relationship between wasting prevalence and age. 
Prevalence of underweight  
In 2014, one-quarter of all Cambodian children under five years were underweight (3).  Overall, the 
prevalence increased from birth to a peak at 40-42 months.  The age-related prevalence of underweight 
Figure 2.1:  Trends in nutritional status of children under 5 years (percentage), 2000 to 2014.  
Source: Cambodian Demographic and Health Survey, 2015. 
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mirrors the age-related prevalence of stunting, which strongly suggests inadequate diet during the 
complementary feeding period. 
Prevalence of overweight 
The prevalence of overweight and obesity amongst Cambodian children was low in 2014 and had 
neither increased nor decreased since 2010 (3).  However, the prevalence of concurrent stunting and 
overweight is rising (7), suggesting that overweight, obesity and non-communicable diseases may 
become a public health problem for children in Cambodia.  This is relevant given that overweight (body 
mass index, BMI ≥ 25.0) and obesity is increasing rapidly among Cambodian women of reproductive 
age (3).  Table 2.1 shows comparative malnutrition rates among Cambodian children taken from the 
2014 Cambodian Demographic and Health Survey (CDHS) (3).     
Cambodian Demographic and Health 
Survey 2014 
Stunting % 
(HAZ) 
Wasting % 
(WHZ) 
Underweight 
% 
(WAZ) 
Overweight % 
(WHZ) 
Age: < -3 < -2 < -3 < -2 < -3 < -2 > 2
6-8 months (n = 252) 1.2 13.1 2.3 6.5 1.9 8.5 4.8 
9-11 months (n = 225) 3.9 16.6 2.3 14.2 3.0 15.4 3.1 
12-17 months (n = 515) 6.4 28.1 3.1 10.6 2.6 21.2 3.5 
Under 5 years, nationally (n = 4,893) 8.9 32.4 2.3 9.6 4.7 23.9 2.0 
Under 5 years, Phnom Penh (n = 391) 4.9 17.9 1.0 8.4 2.2 12.9 3.7 
Table 2.1:  Prevalence of malnutrition in Cambodia. Percentage of children classified as malnourished according 
to height-for-age (HAZ), weight-for-height (WHZ), and weight-for-age (WAZ).   
Source: Cambodian Demographic and Health Survey 2014. 
Prevalence of micronutrient deficiency  
Until the inclusion of a micronutrient module in the 2014 CDHS, there was limited information on the 
micronutrient status of women of reproductive age and children under five years in Cambodia (8-10).  
Anaemia has been considered a critical public health problem and affects approximately half of all 
Cambodian children under five years.  Confirmed iron deficiency (ferritin < 12 μg/L) affects 9% of 
children aged six to eleven months (3).  Iodine deficiency is an urgent public health problem, with 
almost half of Cambodian children in urban areas having urinary iodine insufficiency (3, 11).  Also of 
significant concern is vitamin A deficiency which affects over 10% of children aged six to eleven 
months (3).   
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 Cambodian children continue to suffer from undernutrition  
Continued economic progress in Cambodia has not contributed to improved nutrition for children.  This 
project aimed to address that situation.  
 
Aetiology of stunting and wasting  
Wasting and stunting have generally been thought to reflect different health and nutrition insults over 
different periods.  Historically, wasting has been viewed as a short-term, acute response to recent illness 
or reduced food intake and generally as less prevalent than stunting (12), although potentially fatal.  
Stunting has been considered chronic, the long-term result of persistent undernutrition or inadequate 
feeding, micronutrient deficiency, and/or repeated illness.  While irreversible if not addressed 
immediately, stunting has generally not been considered fatal.  Wasting tends to be higher in younger 
children, and to decline by two years of age, while stunting follows a converse trajectory, increasing 
until two years (13).  That wasting precedes stunting is unsurprising, as a child’s body responds to its 
environment by privileging linear growth at the expense of weight in the first instance, but ultimately, 
sacrifices linear growth to survival (4, 12).   
 
Wasting and stunting have been viewed separately 
Thus, wasting has tended to be considered in terms of mortality in emergency settings, whereas stunting 
has been viewed in terms of its negative impact on individual health over the longer term.  
Consequently, there has been a separation in policies and programming, with wasting seen as the remit 
of emergency responses, and stunting as the responsibility of development programming.  This 
separation has been reinforced in recent years, as stunting has come to be considered the primary 
indicator of inadequate nutrition.  It is thought to reflect long-term undernutrition and has important 
consequences for broader health and national development (5, 14).   A focus on the economic outcomes 
of stunting aims to galvanise policy support and encourage a focus on the basic and underlying as well 
as the proximate causes of undernutrition (13, 15).   
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Wasting and stunting are related 
Increasingly, however, there is recognition of the significant overlap between these different 
manifestations of undernutrition (4).  Most wasting does not occur in emergency settings; wasting in 
emergencies is the tip of the iceberg, and given the underlying burden of undernutrition, it takes very 
little to push a child into severe undernutrition (6).  It has become evident that stunting, like wasting, 
contributes significantly to morbidity and mortality (2, 16).  Mortality hazard ratios, or the likelihood 
of dying, increases as children become more stunted or wasted.  In comparison with children who are 
not undernourished, moderately stunted or wasted children are (respectively) 2.3 or 3.4 times more 
likely to die, and severely stunted or wasted children are (respectively) 5.5 or 11.6 times more likely to 
die (4).  However, children who are both stunted and wasted - even moderately stunted and moderately 
wasted - have a mortality hazard ratio of 12.3, which is higher than severely wasted children (17).  The 
impact of individual and multiple anthropometric deficits on mortality is shown in Table 2.2. 
Anthropometric deficit Hazard ratio (95% CIs) 
Moderately stunted (HAZ < -2) 2.3 (1.9 – 2.7) 
Moderately wasted (WHZ < -2) 3.4 (2.9 – 4.0) 
Severely stunted (HAZ < -3) 5.5 (4.6 – 6.5) 
Severely wasted (WHZ < -3) 11.6 (9.8 – 13.8) 
Wasted and stunted  (HAZ and WHZ < -2) 12.3 (7.7 – 19.6) 
Table 2.2: Mortality analysis of individual and multiple anthropometric deficits.   
Source: Khara  & Dolan (2014). Technical briefing paper: Associations between wasting and stunting, policy, 
programming, and research implications. Emergency Nutrition Network 
Growth faltering should be viewed comprehensively 
The previously used terms - acute and chronic undernutrition – can therefore be viewed as ambiguous 
and ill-defined, implying short-termism (in the case of “acute”), and not accurately reflecting the 
nutritional and biological processes that are happening (4, 6, 18).  A focus on either wasting or stunting 
risks entrenching the artificial and inefficient policy and programmatic divide in undernutrition 
programming (4).   Nutritional deficits should be dealt with comprehensively, rather than separating 
stunting and wasting in policy and programming.  For that reason, this dissertation focuses on growth 
faltering, including stunting and wasting, that is, linear and ponderal growth faltering respectively.   
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Framework for understanding undernutrition 
The factors contributing to undernutrition are multiple, overlapping, and intergenerational.  The context, 
contributing factors and impacts of undernutrition were outlined in the 1990 UNICEF framework on 
the causes and consequences of maternal and child undernutrition (Figure 2.2).  This framework, which 
describes the basic, underlying and immediate causes of undernutrition (13, 19), has been used and 
adapted over the years.   
 
 
Figure 2.2: UNICEF framework of the relations between poverty, food insecurity, and other underlying and 
immediate causes to maternal and child undernutrition and its short-term and long-term consequences.   
Source: Black et al, 2008. 
 
Basic causes 
At the most fundamental level there is the political, social, economic and community context that 
delivers, or fails to deliver, access to health care and education; food and agriculture systems that make 
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quality food available; adequate water and sanitation systems; employment and livelihood security.  At 
this level, one can include the social and cultural norms and beliefs that support and empower women 
and caregivers, thereby promoting the protection of children.  Delivery of these social goods requires 
an enabling environment for improved nutrition. 
Underlying causes 
At the intermediate level, poverty, food insecurity, and lack of health services combine to create or 
ameliorate an unhealthy living environment (in terms of water, sanitation and hygiene), and household 
food insecurity; and family factors such as poor maternal health (including mental health) and nutrition, 
early and closely spaced pregnancies, and inadequate child care and stimulation.  These intermediate 
causes can be ameliorated with nutrition sensitive interventions that ensure adequate incomes, social 
safety nets, family planning and health services, education for women and children, and adequate 
decision-making power for women to provide sound parenting. 
Immediate causes 
The preceding factors give rise to the immediate causes of undernutrition, namely, dietary inadequacy 
and disease.  The former requires nutrition specific interventions aimed at ensuring healthy mothers and 
gestations, breastfeeding and complementary feeding, treatment of undernutrition, and responsive 
feeding practices.  Such interventions may be aimed at adolescent and preconception health and 
nutrition; birth spacing; maternal and child dietary supplementation as well as broader micronutrient 
supplementation and food fortification; improving breastfeeding, complementary feeding, dietary 
diversity and feeding practices; and treatment of severe acute malnutrition (SAM).  The impact of 
inadequate nutrition may persist over several generations, primarily through the maternal line, although 
women who were undernourished as girls but improve their pre-conception health and nutrition 
significantly can go on to have nearly normal length babies (20).  Therefore, the first 1,000 days of life 
from conception through pregnancy to the child’s second birthday, are a critical window of opportunity 
(21).  Additional interventions are needed in that period to ensure optimal nutrition, reduce the burden 
of infection, and improve caring and parenting practices.   
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 What follows is a more detailed description of these immediate causes and potential solutions, 
particularly those that are most relevant and promising in the Cambodian context. 
 
Factors contributing to undernutrition, with specific reference to Cambodia  
The immediate causes of undernutrition in Cambodia are sub-optimal infant and young child feeding 
and repeated infection due to underlying unhealthy water, sanitation and hygiene facilities and practices, 
the combination of which results in a nutrient balance that is inadequate for achieving optimal growth 
outcomes and micronutrient status (3).   
 
Optimal infant and young child feeding (IYCF) 
Suboptimal infant feeding practices jeopardise a child’s health and nutritional status.  The first twenty-
four months of a child’s life are crucial, since most stunting occurs by the age of two years (22), after 
which the likelihood of catching up is low (23).  The critical interventions in this period are early 
initiation of breastfeeding (within an hour of birth), exclusive breastfeeding (EBF) for the first six 
months, and adequate complementary feeding from six months with continued breastfeeding until at 
least two years (24, 25).  Despite global consensus on these interventions, optimal infant feeding 
indicators are far from being met.   
 
Breastfeeding globally 
Scaling up breastfeeding could prevent the deaths of over 800,000 children each year, as well as 
protecting against morbidity in later life (26).  Between 22 – 44% of neonatal deaths could be avoided 
if infants were breastfed within the first hour of life (25, 27, 28).  Globally, lost productivity and health 
care costs due to lack of breastfeeding amount to over 300 billion US dollars per year, yet less than half 
of all newborns are breastfed within an hour of birth or are breastfed exclusively for the first six months 
(26).  In developing countries, continued breastfeeding is declining, with only half of all children are 
still breastfed at two years (29).   
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Breastfeeding in Cambodia  
Breastfeeding indicators showed promising improvements from 2005 to 2010, but most of these were 
not sustained, particularly in Phnom Penh, as can be seen in Figure 2.3 (3, 8, 30).   Timely initiation of 
breastfeeding after birth decreased, and prelacteal feeding increased in Phnom Penh.  Exclusive 
breastfeeding to six months declined, as did continued breastfeeding to two years.  The median duration 
of breastfeeding fell from 4.3 months in 2010 to 3.7 in 2014.  Bottle feeding, usually of infant formula 
or canned milk (often sweetened), among children of all ages has grown rapidly since 2005.  The 
increased availability and pervasive promotion of breastmilk substitutes may explain the decline in 
breastfeeding indicators, particularly in Phnom Penh (31, 32). 
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Figure 2.3:  Selected breastfeeding trends in Cambodia, 2005 to 2014.  
Adapted from Cambodian Demographic and Health Surveys, 2005, 2010 and 2014. * From Pries et al., 2016. 
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Complementary feeding 
The transition from breastmilk only to the introduction of complementary foods at around six months 
of age is nutritionally sensitive, and growth faltering may occur if the diet is inadequate at this time. 
Poor complementary feeding can result in inadequate energy and nutrient intakes to achieve optimal 
growth and micronutrient status (33).  Most growth faltering occurs by the age of two years, with the 
period from six to eleven months being particularly risky (34).  Appropriate complementary feeding 
entails a minimum dietary diversity (MDD), that is, eating from at least four food groups each day, and 
minimum food frequency (MFF) (35).  Deficits in the quantity and quality of complementary food can 
be due to insufficient quantities of food, infrequent feedings, and inadequate dietary diversity, resulting 
in diet that fails to provide the necessary macro and micronutrients required by the rapidly growing 
child (36).  Traditional complementary foods, or weaning foods, are often porridges or gruels based on 
the staple cereal of the society.  For example, borbor, a white rice porridge made on water with added 
salt or sugar, is the traditional weaning food in Cambodia and through much of South-East Asia.  Such 
porridges are high volume in relation to energy and nutrient density, filling small baby stomachs and 
displacing breastmilk and nutritious foods, without providing the macro and micronutrients needed to 
sustain the child’s high growth velocity during the first two years of life (37).  In addition, the phytates 
in cereal-based porridges may inhibit the absorption of iron and zinc, making it even more difficult to 
meet essential nutrient requirements (38).   
Less than a third of the world’s children aged six to twenty-three months meet the requirements for 
minimum dietary diversity and only about half meet minimum meal frequency.  For infants six to eleven 
months, these rates are even lower, with dietary diversity being a particular issue (37).  While adequate 
minimum meal frequency is associated with a lower risk of underweight, adequate dietary diversity is 
associated with a lower risk of underweight and a lower risk of stunting. 
Complementary feeding in Cambodia  
Table 2.3 describes infant and young child feeding practices in Cambodia in 2014.  Most Cambodian 
infants aged six to eight months had begun consuming complementary food, although this age group 
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was the least likely to meet minimum standards in complementary feeding.  Nationally, less than one-
third of children aged six to twenty-three months met minimum standards, while in Phnom Penh, two-
thirds met minimum standards (3).  Feeding practices did not vary with the sex of the child.  Children 
in the highest wealth quintile, and those whose mothers had completed secondary education or higher, 
were more likely to meet minimum standards (3).   
Among all children(breastfed and non-breastfed) 6-23 months, 
percentage fed: 
Breast milk, 
milk, or milk 
products1 
4+ food groups2 Minimum meal 
frequency 
(MMF)3 
With 3 IYCF 
practices4 
Age in months 
6-8 98 18 72 16 
9-11 98 39 70 27 
12-17 92 55 77 38 
6-23, Nationally 84 48 72 30 
6-23, in Phnom Penh 97 83 92 61 
Mothers education: 
None 80 34 67 20 
Primary 85 44 71 27 
Secondary or higher 84 58 76 39 
Wealth quintile 
Lowest 79 33 65 19 
Middle 83 44 73 26 
Highest 92 69 82 49 
Table 2.3: Infant and young child feeding (IYCF) practices of youngest children aged 6-23 months (breastfed and 
non-breastfed) living with their mother. 
1 Breastfeeding, or not breastfeeding and receiving two or more feedings of milk products 
2 Food groups: a. milk products; b. grains, roots, and tubers; c. vitamin A-rich fruits and vegetables; d. other 
fruits and vegetables; e. eggs; f. flesh foods; g. legumes and nuts. 
3 For breastfed children 6-8 months: semi/solid food at least twice daily for infants and at least three times daily; 
for breastfed children 9-23 months semi/solid food at least three times a day; for non-breastfed children 6-23 
months: semi/solid food or milk feeds at least four times daily. 
4 For non-breastfed children 6-23 months: milk products at least twice a day, MMF, and semi/solid foods from at 
least four food groups not including milk products. 
Feeding styles 
Over the past twenty years, there has been growing recognition that the way infants and young children 
are fed can have an impact on their current and future nutritional status (39-41).  Three feeding styles – 
controlling, laissez-faire, and responsive have been identified (42).  Responsive feeding is a style that 
is neither too forceful nor too indulgent but utilises positive verbal and non-verbal communication and 
gestures to encourage the child to eat, while feeding to cues of hunger and satiety (41).  The immediate 
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outcome of responsive feeding is that the child eats sufficient amounts of nutritious (as opposed to 
unhealthy) foods with appropriate frequency.  The evidence indicates that responsive feeding is 
associated with increased energy intake and improved child growth (43, 44).  In the long term, 
responsive feeding helps children to learn to recognise hunger and satiety and acquire healthy eating 
habits (40).  In settings where caregivers have limited time, or possibly limited competency (as in the 
case of siblings caring for younger children), responsive feeding can be compromised (39).  Laissez-
faire, or highly permissive feeding styles, are anecdotally observed in Cambodia, although no literature 
exists.   
Commercial snacks and beverages 
Feeding styles will be of increasing importance in the nutrition transition underway in Cambodia (39), 
as Cambodian children are increasingly exposed to unhealthy snacks, sugary beverages, and foods high 
in salt, sugar, fat, and excess protein (41).  Junk foods contribute to overweight and obesity and 
potentially to micronutrient deficiency by displacing breastmilk and nutritious food (45, 46).  Laissez-
faire feeding styles in the context of high availability of commercial snacks that are low in nutrients but 
attractive to children can compound poor nutritional outcomes (40, 41). 
Illness and infection contribute to undernutrition 
A vicious cycle exists between undernutrition and infectious disease (47).  Infection and disease can 
lead to undernutrition in several ways (48).  Combatting infection can demand a considerable increase 
in energy and nutrient requirements, which diverts nutrients away from growth.  Young children may 
not be able to consume the additional food necessary, especially since infection often suppresses 
appetite.  At the same time, infectious disease can impair the absorption and use of energy and nutrients. 
Repeated exposure to intestinal diseases can lead to a permanent reduction in absorptive capacity (49).  
Moreover, caregivers sometimes withhold food from sick children in the mistaken belief that restricting 
food intake will speed recovery (36).  Conversely, undernutrition increases a child’s risk of contracting 
disease, and prolonging its duration (48).  Thus, an unfortunate synergy exists between infection and 
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undernutrition, resulting in the undernutrition-infection complex.  Additionally, limited access to health 
care and inadequate health seeking behaviour compound both infection and undernutrition (50). 
Inadequate water, sanitation and hygiene contribute to illness and infection 
Infectious diseases that are commonly and closely associated with undernutrition include diarrhoea, 
respiratory disease, malaria, measles, tuberculosis, and human immunodeficiency virus (HIV) (47).  
Unclean water, inadequate sanitation and poor hygiene practices expose children to disease, particularly 
diarrhoea and intestinal parasites.  Up to 50% of the disease burden of undernutrition could be related 
to poor water, sanitation and hygiene which expose children to water-related diseases, especially 
diarrhoea, and helminth infestation (47, 51).  Handwashing with soap, drinking potable water, and 
appropriate disposal of faeces could reduce the risk of diarrhoea by half (2).   
Water, sanitation, hygiene and illness and infection in Cambodian children 
Water-borne disease is a major cause of infection in young Cambodian children (52).  In Cambodian 
urban centres, including Phnom Penh where our study took place, water and sanitation facilities are 
adequate.  Most urban households (92%) use the same water source all year round, and most of those 
water sources (75%) are located on the household premises.  Almost all urban households (95%) use 
an improved, or potable, water source.  In addition, 69% of urban households use an appropriate method 
of treating their water prior to drinking it.  With respect to sanitation, 83% of urban households have 
access to improved, not shared sanitation facilities.  Hand hygiene has improved almost twenty 
percentage points since 2010, with nearly all urban households (94%) having a place for handwashing 
with soap and water (3).   
Despite improvements in water, sanitation, and hygiene practices in Phnom Penh, in the two weeks 
prior to the 2014 DHS, approximately 20% of children under aged six to twenty-three months had had 
diarrhoea, and 2% had had bloody diarrhoea.  The prevalence of diarrhoea was surprisingly high in 
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Phnom Penh, at 17% for children under five years (3).  Hookworm and other intestinal parasites affected 
19% of mothers and 10% of children, particularly in rural areas (3, 53).  Acute respiratory infection, 
another major cause of morbidity and mortality in children under five years, affected between 6-7% of 
Cambodian children aged 6-35 months (3).   
Maternal age at first birth in Cambodia 
Pregnancy in adolescence can result in poorer growth and nutritional status, as well as greater risk of 
birth complications for mothers and babies (13, 54).  Since 2010, there has been an increase in teenage 
fertility in Cambodia.  Although mean age for first births in Phnom Penh was 24 years in 2014, 6% of 
women aged 15-19 who were interviewed for the 2014 DHS were pregnant or were already mothers 
(3).  Of all women responding, 11% and 28% had delivered their first child by the age of eighteen or 
twenty years respectively (3).   
Birth order and birth spacing in Cambodia 
Birth order and spacing have an impact on child undernutrition (13, 55).  Among Cambodian children, 
first-born infants, and those of birth order six or higher (in total, 23% of all children) were more likely 
to be low birthweight (3).  The prevalence of stunting was high (37%) when the space between births 
was less than 24 months.  In 2014, 12% non-first births in Phnom Penh occurred less than 24 months 
after the preceding birth (3).   
Maternal anthropometric status in Cambodia 
Maternal anthropometric status has important implications for birth outcomes, birthweight, and future 
child nutritional status (54).  In 2014, 14.0% of women in Phnom Penh were underweight, meaning 
they had a body mass index (BMI) of less than 18.5 (3).  Children of underweight mothers compared to 
children of normal weight mothers were more likely to be stunted (44% versus 32%), wasted (19% 
versus 9%), and underweight (11% versus 4%). 
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Birthweight in Cambodia 
There is a close association between low birthweight and poor nutritional status (56).  In Cambodia, 
high prevalences of low birthweight contribute to persistently high prevalence of undernutrition (3).  
Almost one in ten babies (8%) had low birthweight (defined as < 2.5kg).   Two-thirds (63%) of children 
who were born with low birthweight or were reported small at birth were stunted.  Low and very low 
birthweight babies were also more likely to be wasted (17% and 24% respectively) compared to of 
average or higher birth weight babies, 9% of whom were wasted (3).   
 
Rural versus urban children in Cambodia  
According to the 2014 CDHS (3), rural children were more likely to be stunted than urban children 
(34% versus 24%).  Prevalences varied from 18% in Phnom Penh to 44% in the most remote provinces.  
However, the prevalence of stunting has decreased more in rural than in urban areas since 2010 when 
rural and urban stunting were 56% and 25% respectively (8).  In terms of wasting, rural children 
generally had a prevalence that was only slightly higher than urban children (10% versus 8%), although 
some rural provinces reached 15%.  The prevalence of underweight was higher among rural than urban 
children (25% versus 15%).   
 
Poverty and wealth in Cambodia 
The prevalence of stunting was much higher among children in the poorest compared to the richest 
households (42% versus 19%).  Similarly, the prevalence of underweight was more than twice as high 
for children in the lowest versus the highest wealth quintile (31% versus 13%).  Wasting was highest 
(11%) in the lowest two wealth quintiles but was still present (7%) in the highest wealth quintile (3). 
 
Mother’s educational status in Cambodia  
The 2014 CDHS (3) found that mothers with no education compared to secondary education or higher 
were more likely to have stunted children (39% versus 27%) and twice as likely to have severely stunted 
children (13% versus 7%).  While maternal secondary education compared to no education was 
associated with slightly lower prevalence of wasting overall (10% versus 12%), it made little difference 
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in the prevalence of severe wasting (3).  The prevalence of underweight did not vary greatly with 
mother’s education, but the prevalence of severe underweight was twice as high in children whose 
mothers had no education versus mothers with a secondary education or more (7% versus 4%). 
Sex and undernutrition in Cambodia  
There was little to no sex differential in stunting, wasting or underweight (3). 
Consequences of undernutrition 
Undernutrition is associated with increased morbidity and mortality both in the short and long term.  It 
is estimated that undernutrition is implicated in some 45% of deaths in children under five years 
resulting in at least three million child deaths each year (14).  As seen in Table 2.2, the mortality risk 
for children suffering from severe wasting, severe stunting, or even moderate stunting and wasting is 
five to twelve times greater than it is for non-malnourished children (4).  Undernourished children who 
survive may have impaired physical and cognitive development and reduced educational potential (23).  
They may grow into adults with lower earning and productive capacity, which may render them poorer 
and more vulnerable to the living conditions that engender ill-health and poor nutrition for them, their 
household, and their offspring over the longer term (23).  At a larger scale, this translates to impaired 
national productivity and limits economic and social growth (57).  Thus, in addition to the individual 
ill-health it causes, undernutrition leads to poverty and vulnerability, which in their turn, increase the 
risk of children being undernourished.  The cycle of undernutrition thus created jeopardises the 
achievement of broader development goals (58).   
Cost of malnutrition with particular reference to Cambodia 
Malnutrition impacts social and economic development, as shown previously in Figure 2.2  The cost of 
malnutrition - including undernutrition, overnutrition, and micronutrient deficiency - to the global 
economy is calculated at US$3.5 trillion (58).  Improvements in nutrition tend to lag behind economic 
growth, and anticipated improvements are not necessarily realised (59).  Decreasing poverty does not 
automatically lead to decreased undernutrition (60). 
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As seen previously, the rapid economic growth that is transforming Cambodia into a middle-income 
country has not been accompanied by concomitant improvements in nutrition.  Instead, Cambodia has 
stalled in its progress on undernutrition. The prevalence of childhood stunting and wasting remain 
unacceptably high, as well as persistent micronutrient deficiencies and growing prevalence of 
overweight.  Sixty percent of child mortality in Cambodia is attributable to undernutrition suffered in 
utero or in the first five years of life (61).   
An evaluation of the cost of malnutrition was conducted in Cambodia in 2014.  This assessment 
considered a number of pathways through which malnutrition contributes to economic burden, 
including of the loss of future workforce resulting from child mortality and disability; child cognitive 
deficits leading to poor school performance and diminished adult productivity; decreased productivity 
in current adult workers; and excess use of healthcare and welfare services.  Malnutrition was estimated 
to account for a loss of between 1.5-2.5% of gross domestic product (GDP) or US$250-400 million 
annually (61).   
Framework for addressing undernutrition, with specific reference to Cambodia  
There is sufficient evidence on interventions that could be effective in preventing maternal and child 
undernutrition if they were implemented at scale (2, 22, 62).  The 2013 Lancet Maternal and Child 
Undernutrition series, using the UNICEF framework, developed the “Framework for Actions to 
Achieve Optimum Foetal and Child Nutrition and Development” (55), shown in Figure 2.4 below. 
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Figure 2.4: Framework for actions to achieve optimum foetal and child nutrition and development.  
Source: Black et al, 2013. 
Ideally, nutrition interventions would take place at all points in the life-cycle to ensure optional growth. 
However, when resources are limited, the pragmatic approach is to identify the point when interventions 
have the greatest potential impact.  In Cambodia, most growth faltering accrues from six to twenty 
months, during the complementary feeding period (54), which suggests that this is the optimal target 
age for addressing undernutrition. 
Improving complementary feeding 
It is possible to broadly attribute the relative contribution of each phase of the life cycle to nutrition 
status, at least in terms of stunting.  Dewey and Huffman (54), comparing growth curves for Cambodian 
children to the WHO Child Growth Standard, found that by three years of age, Cambodian children 
have a 6cm height deficit, with 17% of growth faltering occurring by the age of six months, 67% by 
twelve months, and the final 33% being incurred from one to three years of age (Figure 2.5).   
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Thus, the majority of growth faltering in Cambodia occurs from six to twenty months.  This knowledge 
is useful in deciding how to address childhood undernutrition and allocate nutrition resources.  Given 
Dewey and Huffman’s analysis, it is reasonable to focus on improving complementary feeding as a 
strategy for preventing undernutrition in Cambodian children, bearing in mind that complementary 
feeding refers to continued breastfeeding while introducing complementary foods (54).   
Adequate complementary feeding can reduce and prevent undernutrition (2).  Interventions aimed at 
ensuring adequate complementary feeding include improving the existing diet, providing micronutrient 
supplements, or providing supplementary food with or without micronutrients (63).   
Improving the existing diet 
In the long-term, it is important to improve diets for the whole population, in Cambodia and globally. 
The logistically and environmentally sustainable food-based approaches that are described by the EAT-
Lancet Commission on Food, Planet, Health are more likely to avoid the potential negative outcomes 
that could result from provision of a limited range of macro and micronutrients (64).  Thus far, however, 
attempts to improve upon traditional diets have yielded only moderate success in terms of micronutrient 
status or growth, particularly for the poorest people (63).  Dietary modelling prior to 2014 based on 
Figure 2.5:  Cumulative difference in stature (length or height) 
between Cambodian children (both sexes) and the median of the 
WHO Child Growth Standard (for girls).   
Source: Dewey and Huffman, 2009. 
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foods that were currently consumed in Cambodia suggested that traditional diets were unlikely to 
provide all the micronutrients required.  Thus, it was thought unlikely that interventions aimed at 
enhancing complementary feeding using existing (unprocessed or minimally processed) foods would 
succeed in addressing child undernutrition in a timely manner or on the scale necessary, particularly for 
the most vulnerable children (65, 66).   
Since two-thirds of the undernutrition suffered by Cambodian children occurs during the 
complementary feeding period (54), focussing on improving complementary feeding, through provision 
of micronutrient supplements or supplementary food, was thought more likely to be effective.   
Micronutrient supplements 
Provision of micronutrient supplements is a common nutrition intervention, which is relatively 
inexpensive and logistically feasible.  Supplements can be individual micronutrients such as iron syrup, 
or multiple micronutrients, often in the form of individually-packed powders such as Sprinkles 
micronutrient powders (MNP) that are added to food, or tablets that can be crushed and mixed with 
food (67).  Since co-occurring micronutrient deficiencies are more likely than specific deficiencies, 
provision of multiple micronutrients is more beneficial and cost-effective than supplementation with 
individual micronutrients (68-72) .   
However, while micronutrient supplements can address specific micronutrient deficiencies, there is no 
evidence that micronutrient supplementation alone, in the absence of a diet with sufficient energy, 
protein and lipids, contributes to sustained improvements in linear growth (2, 22, 63, 69, 73-80).  Thus, 
micronutrients are more likely to contribute to positive outcomes when they are provided as multiple 
micronutrients and in combination with macronutrients (68, 73).   
Supplementary foods  
Providing a supplementary food with macro- and micronutrients is more likely to improve nutritional 
status than providing either macronutrients or micronutrients alone (2, 22, 68).  Specially formulated 
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supplementary foods with a high energy and nutrient density can be used to enhance complementary 
feeding, thereby preventing growth faltering, and promoting improved linear growth, weight gain and 
micronutrient status.  These energy-dense supplementary foods contain both macro and micronutrients 
and include a source of protein and lipids such as powered milk, soy or peanuts, and usually multiple 
micronutrients (81, 82).  Until recently, prevention of undernutrition relied on fortified blended 
products, such as Corn-Soy Blend Plus (CSB++, now called Supercereal Plus).  These require 
preparation; CSB++ is mixed with water to make a porridge.  Other specialised foods, like BP-100™ 
biscuits, are ready to eat with no preparation.  Increasingly, ready-to-use foods (RUFs) are being 
formulated as lipid-based nutrient supplements (LNSs) which are often pastes, such as the peanut-based 
products, Plumpy'Nut™ (a therapeutic food) or Plumpy'Doz™ (a supplementary food).  These new 
lipid-based products are proving more effective than fortified blended foods (18).  By comparison, 
LNSs are higher in energy, have a longer shelf life, and, since they require no preparation, are more 
convenient (81, 83, 84).  
Supplementary foods, especially LNSs, have proved effective in treating moderate acute malnutrition 
(MAM) (18).  The provision of supplementary food in food insecure settings has been shown to have a 
significant, if small, impact on linear and ponderal growth (85).  Our trial tested whether a 
supplementary food would have a similar impact in food secure setting with a representative population 
of children (including a prevalence of MAM comparable to the national prevalence). 
Review of recent studies related to supplementary foods 
Most studies are with SAM or MAM children in food insecure settings 
To date, the majority of trials of supplementary foods for the prevention or treatment of undernutrition 
have been conducted on children with SAM or MAM and in food insecure settings.  The effectiveness 
of the WHO protocol for SAM treatment has been demonstrated.  Furthermore, a number of systematic 
reviews have concluded that specially formulated foods can improve growth for children with MAM, 
and that LNSs tend to be slightly more effective than fortified blends (86-88), suggesting that for MAM 
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children, providing supplementary food, preferably LNS, is better than doing nothing.  However, the 
evidence is somewhat limited and not high quality (18, 87).  Even for MAM children, growth may still 
be suboptimal (89), especially with respect to wasting prevention (84). 
Few studies include representative populations in food secure settings 
Relatively few studies have assessed the impact of providing supplementary foods on the growth of a 
representative population of children (with MAM and non-MAM children, i.e. WHZ > -3 and < +3, 
and/or MUAC > 11.5cm) in a food secure setting.  Due to the different terminology (for example, 
prevention of undernutrition versus treatment of MAM), study designs, methodologies, settings, and 
participants, it is difficult to compare trials.   
The tables below summarise selected literature and systematic reviews, as well as effectiveness trials 
that are most relevant to our research, in other words, those trials that provided supplementary foods to 
a representative population of children aged six to twenty-three months.  Table 2.4 describes the relevant 
narrative and systematic reviews, while Table 2.5 summarises the individual trials.  The latter are 
organised in order of decreasing similarity to our trial, beginning with studies that were most similar to 
our trial in that they had untreated control groups and representative populations.  Next, studies with 
untreated control groups but non-representative populations are summarised, followed by studies with 
no control or a treated control group. 
Evidence from the literature and systematic reviews  
The literature and systematic reviews considered a range of feeding interventions including 
micronutrient supplements, cereal and protein (usually legume) blends, small quantity lipid-based 
nutrient supplements (SQ-LNSs), ready-to-use therapeutic foods (RUTFs), and local foods.  The 
reviews which considered similar interventions, namely specially formulated supplementary foods, are 
most relevant to our trial.  Matsungo et al. (90), looking at a representative (non-SAM) population, 
found that SQ-LNSs had no clear impact on linear growth.  The studies in the review by Dewey et al. 
included severely acutely malnourished children (63).  Although malnourished children sometimes had 
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improved ponderal growth, Dewey concluded that the overall impact of supplementary feeding on child 
growth was mixed.  Panjwani et al. (85) and Lassi et al. (91) looked at representative populations in 
food secure and insecure settings.  In food insecure environments, provision of supplementary food had 
a small positive effect on linear and ponderal growth.  However, none of the studies considered 
provision of supplementary food in food secure environments.  The reviews by Kristjansson et al. (92) 
and Sguassero et al. (93) were of provision of supplementary foods that were not specially formulated 
and were therefore less comparable to our trial. The former concluded that the impact of supplementary 
feeding was positive while the latter found the impact negligible.  Both noted that a positive impact was 
more likely with younger and less well-nourished children. 
Thus, the evidence from the literature and systematic reviews (Table 2.4) is mixed.  Where 
improvements in anthropometric measures were noted, they were generally small to negligible.   
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Systematic reviews 
Author 
(year) 
Study 
design and 
methods 
Aim Setting Age and nutritional 
status at recruitment 
Outcomes 
Matsungo et 
al. (2017) 
Narrative 
literature 
review 
(7 studies) 
To assess the efficacy 
of SQ-LNS in 
prevention of growth 
faltering. 
Malawi, 
Ghana, 
Burkina 
Faso, Haiti 
6–23 months 
Representative 
population i.e. not 
SAM 
Inconclusive evidence on the efficacy of SQ-
LNSs for improving linear growth.  Two studies 
showed no differences and five studies showed 
differences in growth and stunting between 
intervention and control groups.  
Panjwani & 
Heidkamp 
(2017) 
Systematic 
review and 
meta-
analysis 
(16 studies) 
To review and 
synthesize the current 
literature for the 
impact of CF 
interventions on linear 
and ponderal growth, 
with the specific goal 
of updating 
intervention-outcome 
linkages in the Lives 
Saved Tool (LiST). 
Global, 
11 LMICs 
6–23 months 
Representative 
population i.e. blanket 
supplementation or 
studies including 
mildly/moderately 
underweight children; 
excluded studies that 
only enrolled children 
with WAZ, HAZ or 
WHZ < -3 
Nutrition education/counselling had a small 
significant impact on HAZ in food-secure 
populations [standardized mean difference 
(SMD): 0.11; 95% CI: 0.01, 0.22] but not on 
WHZ.   
CF with or without nutrition education had a 
small, significant effect in food-insecure settings 
on both HAZ (SMD: 0.08; 95% CI: 0.04, 0.13) 
and WHZ (SMD: 0.05; 95% CI: 0.01, 0.08). 
Kristjansson 
et al. (2015) 
Systematic 
review and 
meta-
analysis 
(32 studies) 
To assess the 
effectiveness of SF 
interventions for 
improving physical 
and psychosocial 
health. 
Global, 
21 LMICs 
and 3 HICs 
3-59 months 
Socio-economically 
disadvantaged groups 
(nutritional status was 
not an in/exclusion 
criteria) 
- Weight gain: 0.12kg more than control over 6
months (95%CI 0.05 – 0.18)
- Height gain: 0.27cm more than control over 6
months (95%CI 0.07 – 0.48)
- WAZ: MD 0.15, 95%CI 0.05 - 0.24
- HAZ:  MD 0.15, 95%CI 0.06 - 0.24
- WHZ:  MD 0.10 95%CI -0.02 - 0.22
SF had positive effects on growth in LMICs, 
especially for younger and poorer/ less well-
nourished children.  
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Systematic reviews, continued 
Author 
(year) 
Study 
design and 
methods 
Aim Setting Age and nutritional 
status at recruitment 
Outcomes 
Lassi et al. 
(2013) 
Systematic 
review and 
meta-
analysis 
(16 studies) 
To assess the impact of 
CF education and 
provision of CF with 
or without education 
on growth and 
morbidity. 
Global, 
15 LMICs  
6–23 months 
Representative 
population i.e. 
excluded studies of 
food given for 
therapeutic purposes 
In food secure setting, CF education improved: 
- HAZ (SMD: 0.23; 95% CI: 0.09, 0.36)
- WAZ (SMD 0.16, 95% CI: 0.05, 0.27)
- Stunting (RR 0.71; 95% CI: 0.56, 0.91).
In food insecure setting: 
- CF education improved growth (increased
height, weight, HAZ, WAZ, but stunting rates
not reduced)
- Provision of CF improved HAZ, WAZ
Sguassero et 
al. (2012) 
Systematic 
review 
(8 RCTs) 
To evaluate the 
effectiveness of 
community-based SF 
for promoting physical 
growth. 
Global, 
9 LMICs 
0-59 months 
Nutritional status was 
not an in/exclusion 
criteria, some studies 
included malnourished 
children  
In children < 12 months, MD in length 0.19 cm; 
95%CI 0.07 - 0.31 
SF has a negligible impact on child growth. 
Dewey & 
Adu-
Afarwuah 
(2008) 
Systematic 
review 
(42 studies, 
5 on food 
provision 
alone) 
To review the efficacy 
and effectiveness of 
CF interventions in 
developing countries. 
Global, 
25 LMICs  
6–23 months 
Nutritional status not 
an in/exclusion criteria 
The impact of CF intervention (food alone) on 
child growth was mixed.  Two studies showed 
improved growth; three studies showed no 
impact. 
Table 2.4: Selected reviews investigating the impact of the provision of supplementary foods on growth of infants and young children. 
CF, complementary feeding or complementary food/s; CI, confidence interval/s; HAZ, height-for-age z-score; HIC, high-income country/ies; LiST, Lives Saved 
Tool; LMIC, low- or middle-income country/ies; LNS, lipid-based nutrient supplement/s; MD, mean difference; RR, relative risk; SAM, severe acute 
malnutrition; SF, supplementary feeding; SMD, standardized mean difference; SQ-LNS, small-quantity lipid-based nutrient supplement/s; WAZ, weight-for-age z-
score; WHZ, weight-for-height z-score. 
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Evidence from the individual trials 
Table 2.5 summarises the individual trials (some of which were included in the literature and systematic 
reviews) that aimed to prevent undernutrition using supplementary foods.  The individual trials that were 
most similar to our trial were those with untreated control groups and representative populations (94-98).  
The trial in a food insecure setting (96) improved WHZ and reduced stunting considerably.  Children in one 
trial very similar to ours had modest improvements in HAZ and WAZ (95).  Other similar trials showed no 
improvement in HAZ (94) or in any anthropometric outcome (98).  Lutter et al. noted that despite increases 
in HAZ and WAZ in the intervention group, growth faltering was not prevented (97).   
Interestingly, the largest positive impacts were seen in the next two trials with untreated control groups and 
representative populations.  These used foods that were not specially formulated, namely eggs or meat, as 
the supplementary food and demonstrated improvements of far greater magnitude than the previous trials 
that provided specially formulated supplementary foods (99, 100). 
Two short (twelve-week) trials comparing untreated control groups with moderately acutely malnourished 
children had mixed results.  In one, WHZ increased (101), whereas in the other (102), there were no 
statistically significant differences between the control and intervention groups.   
The next group of studies compared supplementary foods to each other but not to a control.  Again, the 
results were mixed.  WHZ increased in one of the trials (103), but not another (104), and in a third (105) 
WHZ, WAZ and HAZ all improved.  No significant differences were seen for two trials (106, 107) and in 
one of them, growth faltering was not prevented (107).  In one trial, WHZ increased but HAZ decreased, 
and overall, growth was considered suboptimal (89).   
The outcomes from the individual trials in Table 2.5 suggest that specially formulated supplementary foods 
had only a modest impact in preventing undernutrition.  Where there were increases in z-scores for WAZ, 
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HAZ or WHZ, they were usually less than 0.25 as a result of interventions that were often six months or 
more.  In some cases, the prevalence of underweight, stunting or wasting decreased, suggesting that even 
those small effects on anthropometric outcomes may have prevented progression to undernutrition. 
However, the summary of the relevant literature demonstrates that specially formulated supplementary 
foods have had limited clinical significance on children’s growth.   
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Studies with untreated control group and representative population 
Author 
(year) 
Study design 
and methods 
Aim Setting Age and nutritional 
status at 
recruitment 
Outcomes 
Maleta et 
al. (2015) 
RCT 
(N = 1,932) 
12-month trial
To test if the change 
in mean LAZ would 
be greater in LNS 
than control group. 
Semi-urban, 
Malawi 
6-18 months 
Representative 
population, WLZ ≥-2 
No statistically significant differences between 
groups for any anthropometric outcome (LAZ, 
WAZ, WLZ, MUAC). 
Mangani et 
al. (2015) 
RCT 
(N = 840) 
6-month trial
To test if LNSs 
promote linear 
growth and reduce 
severe stunting. 
Rural 
Malawi 
6-18 months 
Representative 
population, weight 
for length ≥80% of 
WHO reference 
median 
From 9-12 months of age, mean change in HAZ 
was -0.15, -0.02, -0.12 and -0.18 (P = 0.045) for 
control, milk–LNS, soy–LNS and CSB groups, 
respectively.  No statistically significant 
differences in stunting between groups.   
Impact smaller than expected.  No evidence that 
LNS supplementation lowers stunting incidence. 
Iannotti et 
al. (2014) 
RCT 
(N = 589) 
6-month trial
To test efficacy of 
daily LNS for 
increased linear 
growth. 
Urban slum, 
Haiti 
6–11 months 
Representative 
population, WHZ>-3 
Compared with the control group the 6-month 
LNS group had increased HAZ by 0.13 ± 0.05 
and WAZ by 0.12 ± 0.05. 
Isanaka et 
al. (2009) 
Cluster 
randomised 
trial 
(N = 3,533) 
3-month trial
To evaluate the 
effect of 3-month 
distribution of RUTF 
on nutritional status 
of children aged 6 to 
60 months. 
Niger, food 
insecure 
6-59 months 
Representative 
population, weight-
for-height ≥ 80% 
National Centre for 
Health Statistics 
reference median 
Difference in WHZ between intervention and 
control groups from baseline to endline 0.22 z 
(95% CI, 0.13 to 0.30). 
Significant reduction in all wasting of 36% 
(95%CI 17 - 50) and 58% (95%CI 43 - 68) in 
severe wasting. 
Lutter et al. 
(2008) 
Program 
evaluation, 
nonrandomly 
chosen control 
(N = 319) 
11-month trial
To evaluate the 
effectiveness of a CF 
provided through 
health system in 
reducing prevalence 
of underweight  
Poor peri-
urban and 
rural 
Ecuador 
9–25 months  
Representative 
population, open to 
all children in village 
Positive and significant differences for HAZ, 
WAZ, and prevalence of underweight for 
intervention compared to control group.  
However, growth faltering was not halted. 
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Studies with untreated control group and representative population using supplementary foods that were not specially formulated 
Author 
(year) 
Study design 
and methods 
Aim Setting Age and nutritional 
status at 
recruitment 
Outcomes 
Iannotti et 
al. (2017) 
RCT 
(N = 163) 
6-month trial
To test the efficacy 
of giving 1 egg per 
day to children 
beginning at ages 6 
to 9 months. 
Rural 
Ecuador, 
indigenous 
population 
with high 
stunting. 
6-15 months 
Representative 
population, all 
healthy children in 
target area. 
Intervention group had significantly increased: 
- HAZ (0.63, 95%CI 0.38–0.88)
- WAZ (0 61, 95%CI 0.45–0.77)
- WHZ (0.33, 95%CI 0.14–0.51)
Stunting was reduced by 47%. 
Underweight was reduced by 74% 
Tomedi et 
al. (2012) 
Quasi-
experimental 
design 
(N = 276) 
7-month
intervention
To assess feasibility 
and effectiveness of 
using locally 
available foods to 
prevent malnutrition 
and improve child 
growth. 
Rural Kenya 
high rates of 
malnutrition, 
food insecure 
6–20 months 
Representative 
population, open to 
all children  
WHZ > -2 
Significant difference between intervention and 
control groups: 
- Difference in change in mean WAZ (0.82)
- Difference in change in mean WHZ (1.19)
- wasting prevalence (0% v. 8.9%)
- underweight prevalence (6.3% v. 23.0%).
- HAZ decreased in both groups.
Studies with untreated control group and non-representative population (moderately acutely malnourished) 
Author 
(year) 
Study design 
and methods 
Aim Setting Age and nutritional 
status at 
recruitment 
Outcomes 
Thakwalak-
wa et al. 
(2012) 
RCT 
(N = 299) 
12-week trial 
To compare CSB to 
LNS in terms of 
improving weight 
gain of moderately 
underweight 
children. 
Malawi (lean 
season, food 
insecure) 
6–15 months 
Underweight, WAZ 
< -2 but WHZ > -3
LNS group’s WHZ increased by 0.22 z-scores in 
comparison to control (p = 0.049)  
Kuusipalo 
et al. 
(2006) 
RCT 
(N = 125) 
12-week trial 
To assess growth in 
moderately 
underweight 
ambulatory infants 
given fortified 
spread. 
Rural 
Malawi 
6–17 months 
Underweight, WAZ 
< -2 but WHZ > -3
No statistically significant differences between 
groups for any anthropometric outcome 
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Studies with no control group or treated control group 
Author 
(year) 
Study design 
and methods 
Aim Setting Age and nutritional 
status at 
recruitment 
Outcomes 
Choudhury 
et al. 
(2016) 
Matched 
intervention 
trial (N = 980) 
Treated 
control group 
5-month trial
To compare weight 
and height gain 
between underweight 
children receiving 
micronutrient 
powders and food 
supplement and well-
nourished children 
receiving 
micronutrient 
powders only. 
Urban slum, 
Dhaka, 
Bangladesh 
6–23 months 
Intervention group: 
WAZ < -2  
Control: well-
nourished 
Suboptimal weight and height gain were 
observed among intervention and control 
groups.  WHZ increased for intervention group.  
HAZ decreased similarly for both groups.   
Sayyad-
Neerkorn et 
al. (2015) 
Prospective 
intervention 
trial 
(N = 1,967 ) 
15-month trial
To compare long-
term 
supplementation of 
LNSs and CSB++ on 
the incidence of 
acute malnutrition 
and stunting in 
young children. 
Rural Niger, 
non-lean 
season 
6–23 months 
Representative 
population, SAM 
children referred for 
treatment. 
No significant differences in MAM, SAM or 
stunting for the two products. 
Skau et al. 
(2015) 
Randomised 
trial (N = 419) 
9-month trial
To evaluate the 
efficacy of 2 novel 
CF foods (WinFood 
and WinFood-Lite) 
compared to CSB+ 
and CSB++. 
Food 
insecure 
setting, rural 
Cambodia 
6–15 months 
Representative 
population, all 
children WHZ > -3 
WAZ, HAZ and WHZ decreased for all groups.  
No statistically significant differences between 
groups. 
Purwestri 
et al. 
(2012) 
Longitudinal 
intervention 
study 
(N = 99) 
6-week
intervention
To compare 
outcomes of daily 
and weekly 
distribution of Nias 
biscuit. 
Nias island, 
Indonesia 
6-59 months 
Mildly acutely 
malnourished, WHZ 
-2 to -1.5
WHZ increased in both groups (0.61 ± 0.56; 
0.37 ± 0.41) 
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Studies with no control group or treated control group, continued 
Author 
(year) 
Study design 
and methods 
Aim Setting Age and nutritional 
status at 
recruitment 
Outcomes 
Lin et al. 
(2008) 
Randomised 
trial (N = 240) 
12-month
intervention
To compare the 
effect on growth of 
peanut-/soy-based 
fortified spread and 
corn porridge 
fortified with fish 
powder as CFs. 
Rural 
Malawi 
6–18 months 
Representative 
population, all 
children without 
SAM 
Children receiving the fortified spread gained 
110 g (95% CI 220 - 10) more than children 
receiving the fish powder from 6–12 months.  
No other significant differences between groups.  
Growth still not normal compared to 
international standards. 
Ruel et al. 
(2008) 
Cluster 
randomised 
trial 
(N = 1,481) 
9- or 18-month
intervention
To compare the 
effect of a preventive 
and a recuperative 
approach of food-
assisted nutrition 
program on child 
growth. 
Haiti Recuperative: 
underweight (WAZ 
<–2), 6-59 months, 
for 9 months  
Preventive: all 
children, 6–23 
months, for 18 
months  
Children from preventive model had 
significantly higher HAZ (+0·14), WAZ 
(+0·24), and WHZ (+0·24) than the recuperative 
group. 
Table 2.5:  Selected effectiveness trials investigating the impact of the provision of supplementary foods on growth of infants and young children. 
CF, complementary feeding or complementary food/s; CI, confidence interval/s; CSB, corn-soy blend; CSB+, corn-soy blend plus; CSB++, corn-soy blend plus 
plus; HAZ, height-for-age z-score; HIC, high-income country/ies; LAZ, length-for-age z-score; LMIC, low or middle-income country/ies; LNS, lipid-based 
nutrient supplement/s; MAM, moderate acute malnutrition; MD, mean difference; RCT, randomised controlled trial; RR, relative risk; RUTF, ready-to-use 
therapeutic food; SAM, severe acute malnutrition; SF, supplementary feeding; SMD, standardized mean difference; SQ-LNS, small-quantity lipid-based nutrient 
supplement/s; WAZ, weight-for-age z-score; WHO, World Health Organisation; WHZ, weight-for-height z-score; WLZ, weight-for-length z-score. 
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Gaps in the literature and significance of this research 
The development and comparison of new supplementary foods with current fortified blends and existing 
RUSFs, in terms of their potential for preventing and treating undernutrition, responds to a need noted 
by various researchers (14, 81, 86, 102, 108, 109) as well as to an existing programmatic need in 
Cambodia (110).  Such products need to be affordable, effective, and acceptable in terms of preparation 
as well as taste (111).   
Some critical gaps have been identified in the literature related to the composition of the supplementary 
food, the underrepresentation of Asian populations, and the lack of trials comparing the effectiveness 
of multiple micronutrient supplements with multiple micronutrient fortified supplementary foods.  An 
additional gap, as noted in the literature review above, is the related to the effectiveness of providing 
supplementary products to representative populations of children in food secure settings for the 
prevention of undernutrition.  This research addresses some of these gaps. 
Supplementary foods using meat, fish, or eggs rather than milk 
In our RUSF, milk was replaced with fish as a source of protein.  Few studies compare milk versus non-
milk animal-source foods in supplementary foods.   
In terms of acceptability, one study in Kenya compared a novel food (containing fish and termites) with 
CSB+ and found that the novel food was preferred (112).  However, most acceptability studies 
conducted with supplementary foods containing meat have generally concluded that when presented 
with novel foods, mothers prefer their traditional food, even if their children consumed equal amounts 
of the supplementary food or liked the supplementary food (111, 113).  Children may be willing to eat 
new foods, but ultimately, it is caregiver acceptance that determines whether a child will be given a 
particular food and will develop a taste for it (112).   
With respect to effectiveness, two studies have compared supplementary foods containing fish with 
other supplementary foods.  One, in Malawi, compared a peanut- and soy-based fortified spread to a 
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corn porridge fortified with fish powder.  It found that children consuming the porridge with fish powder 
gained less weight from 6-12 months, but from 12-18 months, the two supplementary foods performed 
similarly in terms of weight gain and linear growth (104).  The other, in Cambodia, compared a rice- 
and fish-based supplementary food, called Winfood, with CSB++ (which contains milk) and CSB+ 
(which does not contain any animal-source food).  It found that the products with animal-source foods 
promoted linear growth better than the product with no animal-source food (107).   
As the majority of the evidence is on milk-based products, our research fills a gap on the acceptability 
and effectiveness of supplementary foods containing non-milk animal-source foods.   
Geographical focus 
Most studies on supplementary foods are from sub-Saharan Africa, particularly Malawi (102, 104, 114-
120).  Asia, especially South-East Asia, is underrepresented (18, 86).  While there are a number of 
studies on micronutrient supplementation from South and South-East Asia (80, 121-124) including 
Cambodia (9, 74, 125-127), there are relatively few studies on the use of supplementary foods in Asia 
(63, 86, 93, 128-130).  In Cambodia, there are only a handful of studies, including an acceptability study 
that compared CSB++ and Wheat-Soy Blend++ (131); an effectiveness trial of a fish-based food (107), 
and a study on the peanut-based product, Plumpy'Nut™ (132).   
Multiple micronutrient supplements versus micronutrient-fortified supplementary foods 
Our research deepens the understanding of the effectiveness of multiple micronutrients provided with 
or without macronutrients, by comparing the RUSF and CSB++, both of which combine macronutrients 
and multiple micronutrients, with MNP which contain no macronutrients.  Only one study, in Ghana, 
compared multiple micronutrient supplements directly with supplementary foods.  That study compared 
Nutributter, a multiple micronutrient-fortified, peanut-based spread, with MNP and the multiple 
micronutrient tablets, Nutritabs (77), and found that Nutributter, with its combination of macronutrients 
and micronutrients, was the most efficacious in promoting growth and motor development.  To the best 
of our knowledge, ours is the first study comparing CSB++ to MNP. 
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Prevention versus treatment 
Although it is widely agreed that it is more effective to prevent undernutrition, and as early as possible 
(82), there are few studies on prevention (18, 133).  Researchers and programmers have had to rely on 
studies that conducted with children with SAM or MAM, or that are in emergency or food insecure 
settings.  As seen in Tables 2.4 and 2.5 above, identification of the participants by their nutritional status 
is not always precise and terminology may differ substantially between trials.   
What this research contributes 
This research contributes to the existing literature by addressing the evidence gaps discussed above.  It 
extends the nascent literature on the acceptability and effectiveness of supplementary foods containing 
a non-milk animal-source food and expands the knowledge on supplementary foods in South-East Asia, 
particularly Cambodia.  In addition, it deepens the existing research on the impact of multiple 
micronutrients alone or in combination with macronutrients.  It also contributes to our understanding 
of what it means and what is required to prevent undernutrition.  More broadly, it informs the 
development of locally-produced supplementary foods.   
From a programmatic standpoint, this research will help to expand the options for development and 
provision of supplementary foods, particularly in South-East Asia, where milk is neither produced nor 
consumed on a large scale.  It also assists in making important decisions such as whether to invest in 
multiple micronutrient supplements like Sprinkles MNP, versus supplementary foods containing both 
macronutrients and micronutrients.  Finally, our locally-produced RUSF has the potential to make a 
significant impact on child undernutrition in Cambodia and similar settings.  It might also help to 
simplify interventions in maternal and child nutrition; for example, it could potentially be used with 
pregnant and lactating women as well as children aged six to twenty-three months.   
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Chapter 3: Description of the RUSF 
The Cambodian ready-to-use supplementary food (RUSF) was conceived as an lipid-based nutrient 
supplement (LNS) containing an animal-source food, protein, lipids, energy, and multiple 
micronutrients.   
Animal-source foods 
Animal-source foods are high in protein, energy, and micronutrient availability, and have been 
associated with improved micronutrient status, linear growth, and non-fat mass gain compared to non-
animal-source foods (1, 2).  Therefore, the World Health Organisation (WHO) recommends daily 
consumption of animal-source foods (3).  Usually, milk or whey powder is the animal-source food used 
in supplementary foods including Corn-Soy Blend Plus Plus (CSB++) and various RUSFs (4, 5).  
However, milk powder is an expensive ingredient that is not produced locally and must be imported. 
Therefore, we aimed to replace it with a cheaper, local source of animal protein that is widely accepted 
by the target population.  There are precedents for replacing milk in supplementary foods for cost 
effectiveness (6), but until now, only a few supplementary foods have used meat, fish, or eggs (7-12).   
Fish as an alternative to milk 
In Cambodia, fish is inexpensive, readily available, and highly acceptable.  Globally, Cambodians are 
the largest consumers of freshwater fish per capita and even poor Cambodians have access to fish, 
especially small freshwater species (13).  Fish is served in a variety of ways, including as paste and 
sauce.  Fish was therefore used as the animal-source food to replace milk in our supplementary food.   
Protein, lipids, energy, and multiple micronutrients 
Additional sources of protein came from soy and mung beans, which are widely produced and 
consumed in Cambodia.  Rice, the Cambodian staple, provided energy, along with oil as the lipid source, 
and sugar for palatability.  The twenty micronutrients added were calcium, copper, folic acid, iron, 
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magnesium, phosphorus, potassium, selenium, vitamins A, B1, B2, B3, B5, B6, B7, B12, C, D, E, and 
zinc (see Appendix 3.1).  The resulting product was expected to be less expensive and more acceptable 
to Cambodians, while still meeting the recommendations for specially formulated foods (14-16).   
First version –paste 
The French National Research Institute for Sustainable Development (IRD) developed the first version 
of this product in paste form in early 2013.  It was compared to BP-100™, and found to be equally 
acceptable in younger children, although older children preferred BP-100™’s milky taste to the fishy 
flavour of the RUSF (17).   
Second version - stock cube 
The product was adapted to reduce the fish smell and make it into a drier, compact, stock cube-sized 
snack.  The cube was difficult to press into a standard shape and to package, and given the consistency 
of the paste, at least one researcher considered it a potential choking hazard.   
Figure 3.1: Filling the cylindrical wafer with LNS paste 
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Final version – snack 
It was therefore reformulated into a snack comprised of a crisp hollow wafer cylinder filled with the 
paste, as seen in Figure 3.1 above.  The unfilled wafers, made of rice flour, eggs, water, sugar, salt, and 
coconut, with small amounts of vanilla or sesame seeds as added flavour, are a common Cambodian 
snack food.  The final product can be seen in Figure 4.1 in the next chapter. 
Ingredients of the RUSF 
Table 3.1 below describes the ingredients of the RUSF.  More details can be found in Appendix 3.1 and 
in the acceptability protocol and results in Chapters 4 and 5. 
Ingredients g/100g 
Small indigenous fish 5.9 
Mung beans 9.6 
Rice 4.2 
Soy beans 12.2 
Icing sugar 10.3 
Maltodextrin 9.3 
Canola oil 3.7 
Palm vegetable shortening 14.0 
Desiccated coconut 1.5 
Rice bran 2.2 
Vitamin and mineral mix 0.9 
Rice flour 9.0 
Duck eggs 2.5 
Refined sugar 7.2 
Coconut 7.2 
Salt 0.0 
Flavour (vanilla or sesame seeds) 0.1 
Oil for cooking 0.4 
Table 3.1:  Ingredients of RUSF snack (paste and wafer) 
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Chapter 4: Methods of the acceptability trial 
This chapter describes the methodology of the acceptability trial.  Part of this chapter is published as: 
o Borg B, Mihrshahi S, Griffin M, Chamnan C, Laillou A, Wieringa FT. Crossover trial to test the
acceptability of a locally produced lipid-based nutrient supplement (LNS) for children under 2
years in Cambodia: a study protocol. BMJ Open. 2017;7(9).
This chapter begins by explaining the rationale for conducting the acceptability trial.  The next section 
is the published acceptability protocol.  The final section describes departures from the protocol and 
changes made to the product after the acceptability trial. 
Rationale for acceptability trial 
As described in Chapter 1, existing supplementary foods did not prove acceptable or effective in 
Cambodia.  Several reviews have recommended the development of locally-produced supplementary 
foods that are acceptable to the target population and appropriate for the local context (1-3).  It has been 
suggested that where possible, supplementary foods should use local ingredients in order to be more 
acceptable, and to limit costs.  For example, milk could be replaced with local protein (3).  That is what 
we attempted to do with our locally-produced ready-to-use supplementary food (RUSF). 
An essential step in developing specially formulated foods is testing acceptability.  Regardless of how 
effective a product may be, it still needs to be acceptable in a given setting.  In other words, children 
must be willing to eat the product and caregivers, to feed it to them.  Most trials of ready-to-use foods 
(RUFs) have been conducted in Africa (1, 2, 4).  Our trial assessed the novel RUSF’s acceptability to 
Cambodian children and caregivers. 
The following published protocol describes the planned methodology for the acceptability trial. 
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AbstrAct
Introduction The acceptability and efficacy of existing 
ready-to-use supplementary and therapeutic foods has 
been low in Cambodia, thus limiting success in preventing 
and treating malnutrition among Cambodian children. In 
that context, UNICEF and IRD have developed a locally 
produced, multiple micronutrient fortified lipid-based 
nutrient supplement. This food is innovative, in that it uses 
fish instead of milk as the animal source food. Very few 
supplementary foods have non-milk animal source foods, 
and in addition they have not been widely tested. This trial 
will assess the novel food’s acceptability to children and 
caregivers.
Methods and analysis This is a cluster-randomised, 
incomplete block, 4×4 crossover design with no blinding. 
It will take place in four sites in a community setting 
in periurban Phnom Penh. Healthy children aged 9–23 
months (n=100) will eat each of four foods for 3 days at 
a time. The amount they consume will be measured, and 
at the end of each 3-day set, caregivers will assess how 
well their child liked the food. After 12 days, caregivers 
themselves will do a sensory test of the 4 foods and will 
rank them in terms of preference.
Ethics and dissemination Ethical clearance was received 
from the University of Queensland Medical Research Ethics 
Committee (2014001070) and from Cambodia’s National 
Ethics Committee for Health Research (03/8 NECHR).
registration  ClinicalTrials. gov, identifier: LNS-CAMB-
INFANTS; NCT02257437. Pre-results.
bAckground And rAtIonAlE
It is estimated that undernutrition is impli-
cated in some 45% of deaths in children 
under 5 years.1 In Cambodia, progress in 
combatting malnutrition has stalled. In 2014, 
32% of all children under 5 years (and 40% 
of children aged 3–4 years old) were stunted, 
10% were wasted and 24% were underweight2 
indicating, respectively, chronic and acute 
malnutrition, and a combination of the two. 
This malnutrition may be attributed in large 
part to poor complementary feeding,2 which 
remains inadequate for achieving optimal 
growth outcomes and micronutrient status.
Adequate complementary feeding can 
reduce and prevent malnutrition.3 In 
Cambodia, the traditional weaning food is 
borbor, white rice porridge with added salt or 
sugar, which is low in nutrient density. Improve-
ments to complementary feeding may be 
achieved with supplements, such as micronu-
trient powders, and supplementary foods. The 
latter include fortified blended products that 
are mixed with water to make a porridge (eg, 
corn-soy blend++ or CSB++, now called Super-
cereal Plus), biscuits that can be eaten directly 
(such as BP100) or ready-to-use supplementary 
foods (RUSFs). RUSFs are usually lipid-based 
nutrient supplements (LNSs), which are often 
pastes such as the peanut-based Plumpy'Nut. 
Although until fairly recently, prevention of 
malnutrition has relied on fortified blended 
products, these new LNSs are proving very 
effective, both as RUSFs and ready-to-use ther-
apeutic foods (RUTFs). Compared with the 
existing products, LNSs are higher in energy, 
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Protocol
strengths and limitations of this study
 ► This trial will contribute to the literature comparing
supplementary foods using animal source foods
other than milk.
 ► It will also provide information on the kinds of
supplementary foods acceptable to a Southeast
Asian population.
 ► Testing over 3 days in an unfamiliar setting may
not be an indication of how caregivers and children
would accept the food over a longer period. However, 
should the food prove acceptable in trial, a 6-month
efficacy trial will follow. The latter trial will give
additional information on long-term acceptability.
group.bmj.com on September 7, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
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have a longer shelf life and are convenient since they 
require no preparation.4 5
Regardless of how effective a product may be, it still 
needs to be acceptable in a given setting. In other words, 
children must be willing to eat the product and caregivers 
must be willing to feed it to them. Acceptability to chil-
dren can be measured by how much they eat and how 
readily, while acceptability to caregivers is measured in 
terms of their sensory perception of the food, that is, of 
the smell, colour, consistency and taste.6 Other important 
factors affecting acceptability are price and convenience 
of preparation.
In Cambodia, various supplements and supplementary 
or therapeutic foods, including Sprinkles micronutrient 
powders, CSB++, BP100 and Plumpy'Nut, have been used 
or trialled. However, they have met with low levels of 
acceptability and success, either in trial or in practice.7–9 
Moreover, they are relatively expensive to procure and 
ship to Cambodia. For these reasons, and due to budget 
constraints, the United Nations World Food Program 
(WFP) in Cambodia phased out CSB++ distribution in 
2014. A recent study estimated that only 20% of Cambodian 
caregivers purchase supplementary foods for their chil-
dren.10 Hence, the Cambodian Ministry of Health sought 
a locally produced ready-to-use food (both therapeutic and 
supplementary versions) containing macronutrients and 
micronutrients that can be adapted for use in Cambodia. It 
is expected that locally produced products are more likely 
to be acceptable and cheaper than the imported products. 
They also have the advantage of contributing money and 
capacity to the local economy.11
In 2009 in Vietnam, UNICEF, the Institut de Recherche 
pour le Développement (IRD) and the National Institute 
of Nutrition had developed a supplementary food from 
local ingredients including rice, soy, mungbeans, sugar, 
milk powder, oil and multiple micronutrients.9 12 This 
product proved acceptable and effective and is now widely 
used. Drawing on that successful experience, UNICEF 
and IRD created a Cambodian ready-to-use food (in both 
supplementary and therapeutic versions) in early 2014, 
using fish, rice, soy, mungbeans, oil and sugar. Based on 
promising initial results, the product was finalised as a 
micronutrient-fortified snack.
objEctIvEs And hypothEsIs
This trial aims to establish the acceptability of the locally 
produced Cambodian RUSF for children under 2 years 
and their caregivers. Its acceptability will be compared 
with other supplementary foods that are or have been 
used in Cambodia, namely CSB++ and Sprinkles micro-
nutrient powders.
dEsIgn And MEthods
Trial design
The trial is a cluster-randomised, incomplete block, 
4×4 crossover design. The allocation ratio is 1:1. This will 
be an open trial with no blinding, because the 4 foods 
will be visibly different to participants and data collectors. 
The trial will take place in 2 parts over 2 weeks:
1. substudy 1: acceptability by children, 3 days × 4 foods
for a total of 12 days
2. substudy 2: acceptability by caregivers, 13th day.
Foods and preparation
Four foods will be tested. The RUSF in snack form, and 
the RUSF added to plain borbor, will be compared with 
CSB ++ porridge, and Sprinkles added to plain borbor.
CSB++ is the United Nations WFP’s standard supple-
mentary food to prevent malnutrition in children aged 
6–23 months. Sprinkles have been promoted and distrib-
uted by the Cambodian Ministry of Health to improve the 
micronutrient status of children aged 6–23 months.
CSB++ contains milk and is considered to be creamy, 
sweet and smooth.13 It requires 10 minutes of cooking. 
Sprinkles are added to food after cooking or heating and 
do not have a taste.14
study site
The study will be conducted in periurban Phnom Penh. 
This population has been selected because the urban 
poor comprise about one quarter of the Phnom Penh’s 
residents, or approximately one-quarter of a million 
people,15 who experience high rates of child underweight 
and stunting (35.6% and 29.1%, respectively).16 Further-
more, the populations are large and dense enough to 
yield the required sample size.
The study will be conducted in four test-feeding sites 
such as pagodas or health centres identified based on 
convenience. There will be two teams of data collectors 
working at two test-feeding sites each. In this way, all chil-
dren at a given site will be eating the same food, which 
will reduce bias related to social interaction and varied 
responses to different foods. Children and caregivers will 
come at the same time each day for the 12 days, which will 
reduce bias related to feeding times.
The four test-feeding sites will be randomly allocated 
to begin on one of the foods as shown in figure 1 below, 
using an Excel random number table and a randomised 
incomplete block design. The principal researcher will 
generate the allocation sequence. Children will not be 
randomised to a food, since all children at a given test-
feeding site will be eating the same food.
study participants
Participants will be recruited by convenience from the 
village/s close to the four sites. Village Health Support 
Group members (local health volunteers) will assist with 
recruitment. It is expected that there will be approxi-
mately equal numbers of female and male children and 
that the children’s caregivers will be mostly female. Care-
givers and children may be recruited if they meet the 
following inclusion and exclusion criteria:
► To facilitate child feeding, only singletons will be
eligible for inclusion.
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Figure 1 Food sequence schedule. CSB++, corn-soy blend++; LNS, lipid-based nutrient supplement.
► Children aged 9–23 months who have been eating
solids for at least 3 months will be eligible for inclu-
sion. This is to ensure that subjects are familiar with
solids and will not reject the food simply because they
are not yet familiar with solids. In addition, the target
group for these kinds of products is children aged
6–23 months.
► Only normally nourished or moderately malnourished 
children (mid-upper arm circumference (MUAC)
>115 mm, z-score for weight-for-height (WHZ) >−3)
who have been in good health for the past 3 days will
be eligible for inclusion. This is to ensure that subjects
are not experiencing any loss of appetite associated
with malnutrition or illness and to be able to refer
sick or severely acutely malnourished children for
treatment.
► Likewise, only caregivers who have no medical compli-
cations or illness will be eligible in order to avoid any
associated appetite loss and to refer for treatment.
► Children who have been using Sprinkles, CSB++
or similar supplementary foods or supplements will
be excluded, in order to ensure that the interventions
are equally unfamiliar and that children will not be
likely to reject or accept based on their unfamiliarity/
familiarity with a given food.
► Children with known food intolerances will be
excluded.
► Any caregivers or children who become ill during the
trial will be excluded and referred for treatment.
► Only children of caregivers who have provided signed
or fingerprinted consent will be eligible for inclusion.
Sample size
The main outcome of interest is the amount of food 
the children consume. We define acceptability as mean 
consumption of at least 50% of the food offered, and high 
acceptability as consumption of 75% or more, assume an 
SD of 30% and aim to detect a difference in consump-
tion of 20%.9 17 To ensure a precision of 0.05, power of 
0.8 and p<0.05, the required sample size is 20 children. 
Assuming 20% attrition, we need to enrol 24 children 
and caregivers. This sample size is the same as a similar 
acceptability study, and the attrition assumed is similar.17
The sample size was calculated using G*Power 
(V.3.1.9.2). The four clusters and repeated measures 
were taken into account in the calculation. The four sites 
were purposefully chosen to represent urban poor popu-
lations and were similar. Since this is effectively a pilot 
study inasmuch as we have no data on the acceptability 
of two of four of the foods, we have no knowledge about 
variability within or between cluster sizes, nor of how 
baseline covariates would affect the sample size. Thus, 
baseline covariates were not taken into account in sample 
size calculation.
However, with such a small sample size, it may not be 
possible to perform regressions. Therefore, we will recruit 
a sample of 100 caregivers and children, which is consid-
ered a typical sample size for a hedonic test18 and is larger 
than most of the samples for similar studies.9 13 17 19 20 
Attrition rates in those studies have been less than 10%; 
therefore, our sample size of 100 should be more than 
adequate. We expect to recruit 20–30 participants per 
cluster.
data collection
Baseline and anthropometric data
On the day before the start of the trial, potential partic-
ipants will be assessed for eligibility at the test-feeding 
site, using an exclusion form, and through the collec-
tion of baseline data, including demographic, anthropo-
metric, morbidity and dietary data (breastfeeding, food 
frequency and dietary diversity).
Anthropometric measures include weight to the nearest 
0.1 kg (with SECA scale), recumbent length to the nearest 
0.1 cm (with wooden UNICEF height boards) and MUAC 
to the nearest 1 mm (with a UNICEF flexible insertion 
tape).
Substudy 1: acceptability to children
On the 12 days of substudy 1, data will be collected daily 
including time of arrival and of last feeding or breast 
feeding, and morbidity data pertaining to the previous 
24 hours. Caregivers will be asked to bring their child to 
their designated test-feeding site. They will be asked not 
to feed their child for the preceding hour, if possible. The 
same food will be given 3 days in a row, to allow averaging 
of results and reduce the effect of chance findings.
Children will receive the four foods, namely the 
RUSF snack, RUSF added to borbor, CSB++ porridge and 
Sprinkles added to borbor, for 3 days each over 12 days. 
Children in each group will taste each food in a different 
sequence (to balance for carryover effects), as in figure 1 
below.
A woman from each of the four sites will be hired and 
trained to prepare an appropriate quantity of the food 
each day, under the study team’s supervision.
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The prepared food will be served into small bowls 
(labelled with the child’s code). Clean preweighed 
napkins will be given to the caregiver to clean the child’s 
mouth and catch spits and spills. Each bowl will contain 
one of the following:
► 100 g of CSB++,
► 2 pieces of RUSF (approximately 32 g) added to borbor
to make 100 g,
► Sprinkles (approximately 1 g) added to borbor to make
100 g,
► 2 pieces of RUSF (approximately 32 g).
The bowl, spoon (not used for RUSF snack), napkins
and food will be weighed on an electronic kitchen scale 
to the nearest 0.1 g.
The caregivers will be asked to feed their child for 
15–30 minutes or until the child refuses to eat any more. 
The amount of food consumed within 15–30 minutes or 
until the child stops eating and twice refuses attempts to 
feed will be recorded in grams and percentage of total.17 
The bowl with remaining food, spoon and napkins will be 
weighed after the child has finished eating.
Children will not be separated from their caregivers at 
any point. Children will not be forced to eat the foods. If 
they become excessively distressed, they will be given the 
option of taking a break or withdrawing.
After eating the food for 3 days, each caregiver will 
be asked to assess how he or she thinks the child liked 
the food, taking into account the amount eaten and the 
child’s reactions and emotional state during feeding. 
Responses will be recorded by staff on a data collection 
form, using a five-point hedonic scale (1=disliked a lot, 
2=disliked a little, 3=neither liked nor disliked, 4=liked a 
little and 5=liked a lot). The hedonic scale is a standard 
tool for measuring food acceptability, that is, how much a 
consumer likes or dislikes a product.18
Substudy 2: acceptability to caregivers
On the 13th day, caregivers will be asked to come to the 
test-feeding site, alone if possible. Baseline data will be 
collected from caregivers, including their pregnancy 
status, and morbidity data pertaining to the previous 
3 days.
First, in a sensory test, the foods will be presented to 
caregivers one at a time. No weighing is necessary, and 
caregivers will not be expected to eat a whole bowl. 
Between foods, the caregiver will be asked to rinse his/
her mouth out with water. Caregivers will rate them 
with respect to colour, consistency, smell, taste and their 
overall opinion. Responses will be recorded by staff on a 
data collection form, using the five-point hedonic scale 
(1=very bad, 2=bad, 3=neither bad nor good, 4=good and 
5=very good). A score of 3=neither bad nor good will be 
considered the threshold for acceptance of the food.
Then the foods will be presented at the same time, 
and caregivers will be asked to rank them. Responses will 
be recorded by staff on a data collection form (1=best, 
2=second best, 3=third best and 4=least good or worst).
Finally, a smaller number of caregivers8–12 will be asked 
to stay for a focus group discussion related to infant 
feeding practices and more detailed reasons for prefer-
ence ranking. Caregivers will be asked if they would use 
or buy the novel RUSF and their reasons for doing so, 
including the perceived benefits and value (monetary) 
of using such a product. The discussion will be led in 
the Khmer language by facilitator. A notetaker will be 
responsible for electronic recording, as well as taking 
notes, especially about non-verbal communication. The 
recording will be transcribed and translated into English.
outcomes and their measurement
The main outcome of interest is how much the children 
consume. In the absence of clear guidelines on accept-
ability for supplementary food, we define acceptability as 
mean consumption of at least 50% (50 g of the porridges 
or 16 g of the snack) of the food offered in approximately 
15–30 min and consumption of 75% (75 g or 24 g, respec-
tively) or more as high acceptability. This is in keeping 
with similar acceptability studies.9 17
The secondary outcome is caregivers’ assessment of 
their child’s preference for the food. It is likely that care-
givers’ assessment of their child’s preference is strongly 
correlated to the child’s consumption; thus, this subjec-
tive maternal/caregiver assessment is considered an 
appropriate method of determining acceptability of a 
food to a child.19
A third outcome is caregivers’ ranked preference for 
the food, as preference of the caregiver also determines 
in large part whether a new food will be used or not.19 21
These outcomes indicate how well accepted the food 
is by children and caregivers and how likely they would 
be to eat the food or feed it to their children if it were 
provided in the context of programming for the preven-
tion of malnutrition.
statistical analysis
All data will be double-entered in Excel and will be anal-
ysed in the statistical software STATA V.13.1.
Since repeated measures are being taken, the assump-
tion of independence is not satisfied, and all statistical 
tests will be for dependent samples. For all tests, signifi-
cance levels will be considered p<0.05.
Consumption: percentage and kilocalories consumed of the 
serving offered
The main outcome of interest is how much the children 
consume in terms of percentage and kilocalories. The 
independent variable is the food, and the dependent vari-
able is consumption. Thus, multiple means of consump-
tion will be compared.
The consumption data will be analysed using a mixed 
effects model to determine whether there is a statistically 
significant difference in consumption of the different 
foods. A mixed effects model has been chosen (in pref-
erence to analysis of variance) because it deals well with 
missing values in repeated measures.22
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Preference: children
The secondary outcome is caregivers’ assessment of their 
child’s preference for the food. The independent variable 
is the food, and the dependent variable will be the mean 
of preference ratings on the hedonic scale.1–5 The prefer-
ence data will be analysed using a mixed effects model to 
determine whether there is a statistically significant differ-
ence in preferences for the different foods.
Ranking: caregivers
A third outcome is caregivers’ ranked preference for 
the food. The independent variable is the food and the 
dependent variable will be the mean of the rankings 
of the foods. The ranking data will be analysed using 
a mixed effects model to determine whether there is a 
statistically significant difference in the ranking of the 
different foods.
Enrolment data
Enrolment data describing the characteristics of the 
recruited children (eg, sex, age, anthropometric 
measures, morbidity and breastfeeding status) and care-
givers (eg, age, morbidity and breastfeeding status) will be 
reported as means±SD for continuous measures. Anthro-
pometric indices will be calculated using WHO 2006 stan-
dards (ANTHRO V.3.2.2, January 2011) and expressed 
as z-scores for weight-for-height (WHZ), weight-for-age 
(WAZ) and height-for-age (HAZ).
Any missing data will be treated as ‘missing at random’ 
and accounted for using mixed model and multiple impu-
tation. However, the immediate nature of data collection, 
on-site presence of a supervisor and follow-up methods 
should limit protocol non-adherence and missing data.
dIscussIon
The comparison of new supplementary foods with current 
fortified blends and existing RUSFs in terms of their 
potential for preventing malnutrition responds to a need 
noted by various researchers.5 6 11 23 24 It also responds to a 
specific need expressed by the policy makers and imple-
menters in the Cambodian Ministry of Health. Such 
products need to be affordable, effective and accept-
able.20 This locally produced Cambodian RUSF attempts 
to respond to those needs.
The comparators chosen, CSB++ and Sprinkles, have 
been used in Cambodia with limited success. CSB++ 
proved acceptable in trials but not in practice.7 13 Sprinkles 
appeared to be acceptable and did improve the micronu-
trient status of Cambodian children in one trial. However, 
there was no improvement in anthropometric measures, 
and the improved micronutrient status did not persist 
beyond the 18-month duration of supplementation.25
Since there is no evidence that micronutrient powders 
alone contribute to growth,26–31 it was decided that the 
novel food should contain both macronutrients and 
micronutrients and be energy dense, in order to promote 
linear growth and weight gain as well as improved 
micronutrient status.5 32 Moreover, since peanut-based 
RUSFs have not proved acceptable in Cambodia,8 9 and 
because local production standards may not be adequate 
to safeguard against aflatoxin contamination,33–35 peanut-
based products will not be used.
The WHO recommends daily consumption of animal 
source foods for their high protein, energy and micro-
nutrient availability and for their contribution to micro-
nutrient status, linear growth and non-fat mass gain.36–38 
Usually, milk or whey powder is the animal source 
food used in supplementary foods including CSB ++ 
and various RUSF/RUTFs.9 17 However, milk powder is 
expensive and imported. For this food, it was replaced 
with fish, which is inexpensive, readily available and more 
adapted to Cambodian tastes. While there are precedents 
for replacing milk in supplementary foods for cost-effec-
tiveness,23 until now, very few have used meat, fish or eggs, 
and they have generally not been tested for efficacy on 
a wide scale.19 20 39–41 Not surprisingly, given the novelty 
of the foods, the results of the acceptability studies have 
concluded that although caregivers prefer their tradi-
tional food, the children consumed equal amounts of the 
supplementary food or liked the supplementary food.19 20 
By comparing a supplementary food with fish and one 
with milk (CSB++) to Sprinkles with borbor (a food tradi-
tionally given to infants but also consumed by the wider 
population), our trial will contribute much-needed data 
on the food preferences of Cambodian caregivers and 
children. This will potentially open the way for further 
development of locally produced supplementary foods 
with an animal source food other than milk.
Finally, since most studies on supplementary foods are 
from Africa, this trial will be an important contribution to 
the body of evidence from Asia.24
Based on WFP’s experience7 and earlier acceptability 
studies,12 42 it is expected that the locally produced 
Cambodian RUSF will be more acceptable than CSB++ 
and Sprinkles. If it does prove acceptable, a 6-month effi-
cacy trial will follow.
If the novel RUSF proves efficacious in trial, UNICEF 
hopes to scale up production, with the aim of producing 
a local product that is cheaper than imported RUSFs. 
A variety of distribution methods will be considered, 
including free distribution to malnourished children (and 
possibly to pregnant women) as well as commercialisation.
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Departures from acceptability protocol and subsequent modifications 
The trial was conducted according to the protocol, with a minor variation made to the weight of the 
snack.  The snack was later modified based on feedback from the acceptability trial.   
Weight of RUSF 
The actual weight of two pieces of RUSF snack was 42g not 32g as noted in the protocol.  Each piece 
was approximately 20-21g, comprised of 16-17g of paste plus 4-5g of wafer.   
Modification of the RUSF based on the acceptability trial 
The 20g snack was a rather thick cylinder.  Feedback from caregivers and observations by the 
researchers and data collectors during the acceptability trial suggested that the snack was too thick, with 
each bite delivering too much paste to chew and swallow easily, especially for smaller children. 
Therefore, the snack was modified slightly.  The diameter of the wafer was decreased and consequently 
the amount of paste in each bite was less, making it easier to chew and swallow.  The final specifications 
of the snack were a 7.5cm long wafer weighing 3-4g, containing 7g of paste, for a total weight of 10-
11g.  Because the wafers were rolled and filled by hand, there was slight variation in dimensions and 
weight.  Six wafers were packed in a sachet.  This version of the snack (Figure 4.1) was used for the 
effectiveness trial.   
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Figure 4.1:Final version of RUSF.  Left: RUSF snack, wafer filled with LNS paste; right: RUSF packaging. 
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Chapter 5:  Results of the acceptability trial 
Part of this chapter has been published as: 
o Borg B, Mihrshahi S, Griffin M, Sok D, Chhoun C, Laillou A, Wieringa FT. Acceptability of
locally-produced Ready-to-Use Supplementary Food (RUSF) for children under two years in
Cambodia: A cluster randomised trial. Maternal & Child Nutrition. 2019;15(3).
This chapter describes the rationale, results, contribution, and implications of the acceptability trial.  It 
begins by outlining the need and justification for an acceptability trial, then briefly describes the main 
results.  This is followed by a description of what the acceptability study adds to the literature, and the 
implications for programming.  The final section is the publication. 
The justification for an acceptability trial 
Regardless of how effective a specially formulated food product may be, it must be acceptable to the 
target population if it is to deliver nutritional benefits (1, 2).  Existing products that have been trialled 
or used in Cambodia proved unsuccessful, primarily due to limited acceptability rather than limited 
effectiveness (3-7).  This is perhaps unsurprising, as most research and development on specially 
formulated foods is done in Africa, particularly Malawi (8-18), rather than South-East Asia (19-21) 
where food preferences are likely to differ.  There have been relatively few studies on the use of locally-
produced specially formulated foods in Asia (22-25) and very few in Cambodia (6, 26-29).  This study 
will help to fill the gap in the research pertaining to supplementary foods in Asia generally, and in 
Cambodia and South-East Asia in particular. 
Main results of the trial 
Our trial aimed to assess the acceptability of the novel ready-to-use supplementary food (RUSF) as a 
snack or mixed with borbor (white rice porridge), compared to Corn-Soy Blend Plus Plus (CSB++), 
and borbor fortified with micronutrient powder (MNP).  The foods in their prepared form are pictured 
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in Figure 5.1.  This non-blinded, randomised 4 x 4 crossover trial recruited ninety-five children aged 
nine to twenty-three months in peri-urban Phnom Penh, and took place over two weeks in June-July 
2015.  The test foods were offered for three consecutive days at testing sites.  Main outcomes were 
children’s consumption, caregivers’ assessment of children’s preferences, and caregivers’ ranking of 
the foods.  Median percentages of the test foods consumed differed, with percentages consumed ranging 
from 21 - 50% (p = 0.003).  The odds of children consuming over 50% were greatest for borbor fortified 
with MNP versus RUSF snack (unadjusted OR = 6.79, CI = 2.80 - 16.47, p < 0.001).  However, the 
median energy children received when consuming the RUSF with borbor (57 kcal) or as a snack (48 
kcal) was greater than when consuming CSB++ (15 kcal) or borbor fortified with MNP (18 kcal), (p < 
0.001).  Therefore, although children ate less RUSF, it provided approximately three times more 
kilocalories.  Caregivers reported that their children had the highest preference for borbor fortified with 
MNP.  Caregivers themselves ranked the novel RUSF snack highest.  Thus, the RUSF was considered 
sufficiently acceptable to proceed to an effectiveness trial.   
What this trial contributes to the literature 
This trial demonstrates that fish is a promising substitute for milk in a locally-produced Cambodian 
RUSF.  Even consumed in smaller quantities, the novel RUSF provided more energy than existing 
options. The novel RUSF snack was far more acceptable to caregivers than the existing supplementary 
food and supplements used in Cambodia.   
Figure 5.1: The four test foods compared in the acceptability trial. Left to right: RUSF snack; RUSF mixed with 
borbor; CSB++; borbor fortified with MNP. 
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Implications for programming 
Our acceptability trial confirmed that CSB++ has very low acceptability in Cambodia, and that our 
novel RUSF has high acceptability to caregivers.  Pending the results of the effectiveness trial, this 
finding will be very useful when selecting strategies for undernutrition prevention programming. 
The following published paper describes the results of the acceptability trial in detail. 
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In Cambodia, existing food products for treating or preventing undernutrition have
met with limited success. Therefore, in 2014, alternative ready‐to‐use foods were
developed. This trial aimed to assess the acceptability of the novel ready‐to‐use sup-
plementary food (RUSF) as a snack or mixed with borbor (white rice porridge), com-
pared with corn–soy blend plus plus (CSB++) and borbor fortified with micronutrient
powder (MNP). The nonblinded, randomised 4 × 4 crossover trial recruited 95 children
aged 9–23 months from communities in peri‐urban Phnom Penh. Small quantities
(100 g for porridges, 42 g for snack) of each food were offered for three consecutive
days at testing sites (homes of health volunteers). Main outcomes were children's con-
sumption, caregivers' assessment of children's preferences, and caregivers' ranking of
the foods. Median percentage consumed of the test food servings ranged from 21 to
50% (p = 0.003). The odds of children consuming over 50% were greatest for borbor
fortified with MNP versus RUSF snack (unadjusted OR = 6.79, CI = 2.80–16.47,
p < 0.001). However, the median energy children received when consuming the RUSF
with borbor (57 kcals) or as a snack (48 kcals) was greater than with CSB++ (15 kcals)
or borbor fortified with MNP (18 kcals; p < 0.001). Therefore, although children ate
less RUSF, it provided approximately three times more kilocalories. Caregivers
reported that their children had the highest preference for borbor fortified with
MNP. Caregivers themselves ranked the novel RUSF snack highest. Thus, the innova-
tive RUSF was considered sufficiently acceptable to proceed to an effectiveness trial.
KEYWORDS
Acceptability, Corn Soy Blend Plus (CSB++), Lipid‐based nutrient supplement (LNS), Ready‐to‐use
supplementary food (RUSF), Sprinkles micronutrient powders, Test feeding1 | INTRODUCTION
Although Cambodia is transitioning to a middle‐income country,
progress in combatting undernutrition has slowed. In 2014, 32% of
children under 5 years were stunted, 10% were wasted, and 24%
were underweight (National Institute of Statistics, 2015). Undernutri-
tion can be partly attributed to poor complementary feeding. Thewileyonlinelibrary.com/jouenergy and nutrient density of traditional complementary foods, par-
ticularly borbor (white rice porridge, the traditional weaning food in
Cambodia), is too low to sustain the high growth velocity during
the first 2 years of life.
The various supplements and supplementary or therapeutic foods
that have been used or tested in Cambodia have met with low levels
of acceptability and success, in trial or in practice. In 2009,© 2019 John Wiley & Sons Ltdrnal/mcn 1 of 13
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Key messages
• Fish is a an organoleptically promising substitute for
milk in a locally produced Cambodian ready‐to‐use
supplementary food (RUSF).
• Even consumed in smaller quantities, the novel RUSF
provided more energy than existing options.
• The novel RUSF snack was far more acceptable to
caregivers than the existing supplementary food and
supplements used in Cambodia.
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bs_bs_bannerPlumpy'Nut® was trialled in Cambodia and was poorly accepted
(Boudier, 2009), as was the case elsewhere in the region (Nga et al.,
2013). The United Nations World Food Programme (WFP) had found
corn–soy blend plus plus (CSB++, also known as Supercereal Plus) less
acceptable and effective than expected (WFP, 2014a). Anecdotally,
BP‐100™, the therapeutic food that was used to treat severe acute
malnutrition had also had limited acceptability (Wieringa, 2014). The
limited acceptability of CSB++ and BP‐100™ was confirmed in a taste
trial (Ketsana, 2013). Meanwhile, the Vietnamese National Institute of
Nutrition, with UNICEF and the French National Research Institute for
Sustainable Development (IRD), had developed a ready‐to‐use food
(RUF) called (RUF) called HEBI (High Energy Bar for IMAM – Integrated
Management of Acute Malnutrition) in 2009 (Nga et al., 2013). HEBI
was locally produced with rice, soy, mungbeans, and imported milk
powder. It resembled the popular Vietnamese delicacy, “mooncake.” It
proved more acceptable than, and as effective as, Plumpy'Nut®
and is now widely and successfully used in Vietnam's Integrated
Management of Acute Malnutrition programming (Peters, 2014;
Phuong et al., 2014). Based on the low acceptability and effectiveness
of these imported products, it was determined that a local product
was needed.
At the behest of the Ministry of Health (MoH), UNICEF, IRD
and the Cambodian Department of Fisheries Post‐harvest Technolo-
gies and Quality began collaborating on the development of a
locally produced, culturally acceptable, multiple micronutrient‐
fortified RUF, in therapeutic and supplementary versions. The
resulting product is unique in that it is one of the few RUFs using
an animal source food other than milk. Milk powder, an expensive,
imported ingredient, has been replaced with small freshwater fish.
The latter are inexpensive, readily available and more adapted to
local tastes, since Cambodians are the world's largest consumers of
freshwater fish (Vilain, Baran, Gallego, & Samadee, 2016). Combined
with rice, soy, mungbeans, oil, and sugar, this novel RUF should be
less expensive and more acceptable to Cambodians. This trial tested
the acceptability of the ready‐to‐use supplementary food (RUSF),
whereas a separate trial tested the acceptability of the ready‐to‐
use therapeutic version of the food with severely acutely malnour-
ished children (Sigh et al., 2018).1.1 | The role of RUSFs
It is widely accepted that specialised fortified products have a place in
supplementing the traditional diet, thereby preventing growth falter-
ing amongst children (S. de Pee, 2015; S. de Pee, Bloem, MW, 2009;
Dewey & Young Child Nutrition Working Group: Formulation, 2009;
Golden, 2009; Michaelsen, Grummer‐Strawn, & Begin, Michaelsen,
Grummer‐Strawn, & Begin, 2017). RUFs that are formulated as lipid‐
based nutrient supplements (LNSs) are particularly promising, as they
have a long shelf life and require no preparation (S. de Pee, Bloem,
MW, 2009; S. de Pee, Manary, Mark, Ashorn, Per, de Pee, Manary,
& Ashorn, 2011). There is an acknowledged need for the development
of novel RUFs and their comparison with existing products (S. de Pee,
Bloem, MW, 2009; Kuusipalo, Maleta, Briend, Manary, & Ashorn,
2006; Lazzerini, 2013; Manary, 2006; WHO, 2013). In the pastdecade, numerous studies have aimed to contribute to an understand-
ing of the use of locally produced specialised foods (Ackatia‐Armah
et al., 2015; Ahmed et al., 2014; Anderson, Bediako‐Amoa, &
Steiner‐Asiedu, Anderson, Bediako‐Amoa, & Steiner‐Asiedu, 2014;
Arimond et al., 2015; Bauserman et al., 2015; Bogard et al., 2015; Flax
et al., 2009; Hy Ta & Martinaud, 2014; Iuel‐Brockdorf et al., 2015;
Lagrone, Cole, Schondelmeyer, Maleta, & Manary, 2010; Lagrone
et al., 2012; Skau et al., 2015; Weber et al., 2017).
Regardless of how effective a product may be, it must be
acceptable in a given setting if it is to deliver nutritional benefits
(Dibari et al., 2013; Iuel‐Brockdorf et al., 2016). Because most
research on supplementary foods is from Africa, this study is an
important contribution to the body of evidence on food preferences
from Asia (Lazzerini, 2013). As an early step in the product develop-
ment and testing, we conducted an acceptability trial on the fish‐
based RUSF, to test whether the new product was acceptable to
children and their caregivers. The RUSF was compared with prod-
ucts that are currently used to improve the nutritional status of
young children, namely CSB++ and a MNP (Sprinkles), which are
used as a home fortificant. Acceptability was assessed in terms of
children's consumption (in percentage of the serving and calories
consumed), caregivers' assessment of children's preferences, and
caregivers' own ranking of the foods.2 | METHODS
This trial aimed to establish the acceptability of the locally produced
Cambodian RUSF for children under 2 years and their caregivers, with
a view to proceeding to an effectiveness trial. The methods have been
described in the protocol published previously (Borg et al., 2017).2.1 | Trial design
The study was a cluster randomised, 4 × 4 crossover design comparing
four food types. Each child tested each of the four foods. This was an
open study with no blinding, since the four foods were visibly differ-
ent to participants, data collectors, and the principal investigator
(who was present during data collection).69
TABLE 1 Energy and nutrient profile and characteristics of novel RUSF and comparators
RUSF CSB++ MNP
Recommended daily
serving size
40–110 g depending on
age of child
100 g dry CSB++ (made into
porridge with added water)a
1 sachet (1 g)
Main ingredients of supplementary foods and supplements, not including borbor (g/100 g)b
Ingredients Rice 13.2
Soy and mungbeans 21.8
Fish 5.9
Sugar 26.8
Oil/shortening 18.1
Micronutrient mix 0.9
Coconut 8.7
Rice bran 2.2
Egg 2.5
Flavouring 0.1
Corn 58.3
Soy beans 20.0
Skim milk powder 8.0
Sugar 9.0
Oil/shortening 3.0
Micronutrient mix 0.2
Dicalcium phosphate
anhydrous 1.23
Potassium chloride 0.27
Micronutrients only
Nutrient profile per 100 g of product (Dry CSB++)b
Energy (kcal/100 g) 484 410
Protein (g/100 g) 13.1 16
Carbohydrates (g/100 g) 51.6
Lipids (g/100 g) 24.4 9
Fibre (g/100 g) 1.6 3
Added multiple micronutrients per 100 g (dry for CSB++)b
Vitamin A 1,080 μg 540 μg 400 μg
Vitamin D 58.4 μg 4.6 μg 5 μg
Vitamin B1 (thiamine) 0.28 mg 0.47 mg 0.5 mg
Vitamin B2 (riboflavin) 0.78 mg 0.84 mg 0.5 mg
Vitamin B6 0.65 mg 2.1 mg 0.5 mg
Phosphorus 246 mg 530 mg ‐
Calcium 302 mg 260 mg ‐
Pantothenic acid 0.75 mg 7.3 mg ‐
Copper 0.75 mg ‐ 0.56 mg
Vitamin E 10.7 mg 9.8 mg 5 mg
Folic acid 94.2 μg 115 μg 150 μg
Iron 6.0 mg 8.9 mg 10 mg
Magnesium 48.4 mg ‐
Vitamin B3 (niacin) 7.3 mg 7.2 mg 6 mg
Vitamin C 52.8 mg 100 mg 30 mg
Zinc 7.5 mg 7.5 mg 4.1 mg
Potassium 194.8 mg 990 mg ‐
Vitamin B12 10.7 μg 2.3 μg 0.9 μg
Biotin 105.6 μg ‐ ‐
Selenium 89 μg ‐ 17 μg
Iodine ‐ 60 mg 90 μg
Vitamin K ‐ 115 μg ‐
Other characteristics/considerations
Taste Fishy Creamy, sweet (Skau et al., 2012) Should not
have a taste (Salam et al., 2013)
Preparation Ready to use 10 min cooking Add to cooked
food
Acceptability in Cambodia To be tested Acceptable in trial (Skau et al., 2012), but not in
practice (WFP, 2014a)
Yes (Jack et al., 2012)
Effectiveness in reducing
malnutrition
To be tested Not inferior to peanut‐based
RUSFs, which are the most
effective in promoting linear
growth and weight gain (LaGrone et al., 2012,
Manary & Yang, 2012)
Improves micronutrient status
but not linear growth or weight
gain (de Pee & Bloem, 2009;
Dewey & Adu‐Afarwuah, 2008;
Jack et al., 2012)
(Continues)
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TABLE 1 (Continued)
RUSF CSB++ MNP
Intra‐household sharing Unknown Yes (LaGrone et al., 2012) None noted (Jack et al., 2012)
Packaging Unknown Packaging may encourage
sharing (de Pee & Bloem, 2009,
Nackers et al., 2010)
Looks like “medicine,”
thus may discourage
sharing (de Pee & Bloem, 2009,
Nackers et al., 2010)
Local production capacity Unknown None (de Pee & Bloem, 2009) None
Cost To be determined. Goal
is <US$0.10/day
Less expensive than peanut‐based RUSFs
if produced locally (Manary & Young, 2012),
but also have to consider logistics, time to
treat, and relapse (Nackers et al., 2010)
Very cheap to produce
at US$0.025/daily dose
(Zlotkin, 2009), but also
have to consider logistics
Nutrient profile of daily serving in acceptability trialabc
RUSF with borbor CSB++ porridge Borbor with MNP RUSF snack
Serving size of test meal 42 g RUSF +60 g borbor 100 g (17% dry
CSB++)
1 sachet (1 g) +
99 g borbor
42 g RUSF
Energy (kcal/serving) 184 70 41 160
Protein (g/100 g) 5.9 2.7 1.1 5.2
Carbohydrates (g/100 g) 23.4 12.1 15.7 14.0
Lipids (g/100 g) 9.1 1.5 0.1 9.0
Fibre (g/100 g) 0.6 0.5 0.1 0.5
Note. CSB++: corn–soy blend plus plus; MNP: micronutrient powder; RUSF: ready‐to‐use supplementary food.
aWorld Food Programme (2014b).
bManufacturers.
c2007 Vietnamese food composition tables.
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bs_bs_banner2.2 | Comparators—The four foods
The first version of the novel RUF was developed in 2014 (Peters,
2014) by a local, quality‐certified food factory, Vissot, which produced
the food using readily available Cambodian ingredients—rice, freshwa-
ter fish, soy, and mungbeans—as well as oil, sugar, and micronutrient
premix. Based on initial acceptability testing, the product was refined
to improve the smell and form. Snack consumption, even amongst
young children, is common in Cambodia (Pries et al., 2016; WFP,
2014b; World Vision, 2015). Therefore, to improve the likelihood of
acceptability (Nga et al., 2013), we took a Cambodian snack, a wafer
approximately 9 cm long with an internal diameter of 0.5 cm, and filled
it with the RUF paste.
The RUSF was compared with other supplementary foods or
supplements, which have been used in Cambodia. The first was
CSB++, which is the United Nations World Food Programme's
standard supplementary food to prevent undernutrition in children
aged 6–23 months. The second was MNPs, supplements that have
been promoted and distributed by the MoH to improve the micronu-
trient status of children aged 6–23 months. The novel RUSF was
served in two different ways—as a snack or mixed with borbor.
One objective was to ascertain which way of serving was more
acceptable. The characteristics of each food, including energy and
nutrient profile, and a description of the test food serving, are
described in Table 1.
2.3 | Study site, subjects, and sample size
The study took place over 2 weeks in June–July 2015 in four test‐
feeding sites selected for convenience in peri‐urban Phnom Penh (seeFigure 1). Sites were the homes of health volunteers who invited care-
givers and children from the community to participate.
Our protocol defined acceptability as a mean consumption of at
least 50% of the test food serving. Thus, our sample size was calcu-
lated based on the main outcome, consumption of more than 50%
of the serving. Based on a recent similar study in Cambodia (Skau,
Sok, & Wieringa, 2012), we assumed an SD of 30%, and aimed to
detect a difference in consumption of 20%. To ensure a precision of
0.05, power of 0.8, and p < 0.05, the required sample size was 44 chil-
dren, or 53 children if we assumed 20% attrition. A typical commercial
hedonic test sample is 75–150 consumers (Stone, Bleibaum, &
Thomas, 2012), and recent crossover trials of acceptability had
samples of 50–100 children (Anderson et al., 2014; Konyole et al.,
2012; Nga et al., 2013; Skau et al., 2012; Weber et al., 2017). There-
fore, we aimed to recruit 100 caregiver‐child pairs, and ultimately
recruited 95.
Only healthy singletons aged 9–23 months who were not
severely acutely malnourished (mid‐upper arm circumference (MUAC)
greater than 115 mm, weight‐for‐height z‐score, (WHZ) greater
than −3) and with no known food intolerances who had been eating
solids for at least 3 months were included. Thus, subjects were less
likely to reject the food simply because they were not yet familiar with
solids, or because they were experiencing any lack of appetite due to
illness or undernutrition.
The four sites were randomly allocated to begin on one of the
foods using an Excel random number table generated by the principal
researcher. Thus, children were not individually randomised to a food,
and all children at a given site were eating the same food over the
same period. This reduced bias related to social interaction and varied
responses to different foods. Each site tasted each food in a different71
FIGURE 1 Enrolment in acceptability trial
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bs_bs_bannersequence to balance for carry‐over effects, as in Supplementary
Figure 1.
Following recruitment, caregivers were asked to bring their child
to their designated test‐feeding site for the next 12 days. Children
and caregivers came at the same time each day (either at 8 a.m. or
10 a.m.), which reduced bias related to feeding times. They were asked
not to feed their child for the preceding hour, if possible. All children
at a given site ate the same food for three consecutive days to allow
averaging of results and to reduce the effect of chance findings.2.4 | Children's consumption and caregiver
assessment of acceptability
The health volunteers had been trained to prepare the borbor and the
CSB++ porridges according to instructions to ensure consistency.
They prepared the porridges in their homes, just before the children
and caregivers arrived. The prepared food was served in small bowls
(labelled with the child's code). Each bowl contained 100 ± 1 g of
CSB++ porridge (17% dry CSB++ with water added), RUSF (two pieces
weighing approximately 22 g per piece, or ~42 g total) added to borbor
(~58 g), or MNP (1 g sachet) added to borbor (99 g). When served as a
snack, the two pieces of RUSF weighed approximately 42 g.
The bowl, spoon, napkins, and food were weighed on an elec-
tronic kitchen scale to the nearest 0.1 g. The test food was added
(100 g of the porridges, or two pieces of the snack) and the weight
was recorded. Caregivers were asked to feed their child for 15–
30 minutes or until the child refused to eat any more. After the child
has finished eating, the bowl with remaining food, spoon, and tissues
(used to clean the child's mouth and catch spits and spills) were
weighed to the nearest 0.1 g. The difference gave the number of
grammes consumed.
During statistical analysis, the consumption in grammes was con-
verted to the percentage of serving consumed, in order to be able tocompare the servings of the different foods, which were of different
initial weights. The kilocalories consumed per serving were calculated
using information provided by the manufacturer and the 2007 Viet-
namese food composition tables.
After 3 days eating the same food, caregivers were asked to
assess how they thought the child liked the food, taking into account
the amount eaten and the child's reactions and emotional state
during feeding. This subjective caregiver assessment of child
preference is considered an appropriate method of determining
acceptability of a food to a young child (Pachón, et al., 2007).
Responses were recorded using a five‐point hedonic scale (1 [Disliked
a lot], 2 [Disliked a little], 3 [Neither liked nor disliked], 4 [Liked a little],
and 5 [Liked a lot]), a standard tool for measuring food acceptability
(Stone et al., 2012). A score of 3 or more was considered acceptance
of the food.2.5 | Caregivers' ranking and focus group discussions
On the 13th day, the caregivers were asked to rank all four foods (1 [best],
2 [second best], 3 [third best], and 4 [least good or worst]) based on their
own perception of each product. On the 14th day, four focus group
discussions (FGDs) were conducted (one at each feeding site) with a
smaller number of caregivers (usually 8–12). Discussions were led in
Khmer language by a Cambodian facilitator. A Cambodian notetaker
made a written and audio record, which was transcribed and translated
into English.2.6 | Outcomes
The main outcome of interest was how much the children consumed
of each test food. In the absence of clear guidelines on acceptability
for supplementary food, our protocol defined acceptability as mean
consumption of at least 50% of the food offered. Because72
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bs_bs_bannerconsumption was not normally distributed, it was recoded as low or
high acceptability (less than or more than 50%, respectively) for the
mixed‐effects logistic regression. The secondary outcomes were care-
givers' assessment of their child's preference for each food, caregivers'
ranking of each food, and mean kilocalorie intake. Caregivers were
asked to assess their child's preferences for different foods on a scale
of 1 (disliked a lot) to 5 (liked a lot). Preferences were then recoded as
low (1,2) or high (3‐5), for the mixed effects logistic regression. Care-
givers were asked to rank the foods according to their own preference
from 1 (liked most) to 4 (liked least). Caregiver rankings were then
recoded as a high (1,2) or low (3,4) for the mixed effects logistic
regression. Because a measure of consumption in grammes or per-
centage of serving does not take into account the nutrient density
of the different foods, we also calculated kilocalorie intake.2.7 | Covariates
Data was collected on the following covariates, which were screened
for inclusion in the analytical models: sex and age of the child; previ-
ous use of supplements and supplementary foods such as CSB++ or
MNP; breastfeeding status (still breastfeeding or not); age at which
complementary feeding was started (before or after 6 months);
anthropometric measures at baseline, ie, weight‐for‐age z‐score,
height‐for‐age z‐score, WHZ, and mid‐upper arm circumference; the
child's illness; and the child's last breastfeeding/eating (less or more
than an hour before the consumption test).2.7.1 | Statistical analysis
All data were double‐entered in Excel and analysed in the statistical
software STATA version 13.1. Outcome variables were recoded to
categorical, binary variables to deal with non‐normality and/or for eas-
ier interpretation. Mean and median consumption (grammes, percent-
age of serving, and kilocalories) were analysed. For all outcomes, initial
univariate screening of covariates was conducted at p ≤ 0.2 level
using simple logistic regression, and collinearity assumptions were
checked, in order to determine which covariates to include in the
model. A complete mixed effects logistic regression was then fitted
to the data. Manual, thematic analysis was used to analyse the FGDs.TABLE 3 Consumption in terms of median grammes, percentage, and kil
Food consumed
(serving size, kcals/serving)
Grammes consume
median (IQR)
Borbor with MNP (100 g, 41 kcals/serving) 50.4 (24.2–84.5)
RUSF with borbor (100 g, 184 kcals/serving) 30.9 (11.7–63.9)
CSB++ (100 g, 70 kcals/serving) 21.3 (7.8–67.4)
RUSF snack (42 g, 160 kcals/serving) 12.6 (7.0–20.9)
P values
Note. CSB++: corn–soy blend plus plus; MNP: micronutrient powder; RUSF: re
test. No p value shown for grammes consumed because test foods were differ
*p < 0.01. **p < 0.001.2.7.2 | Ethical approval and trial registration
Ethical clearance was received from the University of Queensland
Medical Research Ethics Committee (2014001070) and from
Cambodia's National Ethics Committee for Health Research (03/8
NECHR). Written informed consent was obtained from all the care-
givers before recruitment. The trial was registered at ClinicalTrials.
Gov (identifier: LNS‐CAMBINFANTS; NCT02257437).3 | RESULTS
3.1 | Baseline characteristics
Of 105 children presenting, 95 were recruited. One child was
excluded and referred for treatment because of severe acute malnutri-
tion (WHZ < −3). Nine children were excluded because they were less
than 9 months or more than 2 years of age. Ninety‐two children com-
pleted the study. The caregivers of the three children who dropped
out said they were too busy to attend daily for 2 weeks, despite hav-
ing been informed of the study duration at recruitment. The baseline
characteristics are presented in Table 2. There were slightly more
female than male children, and the average age was 15.4 months.
There were no significant differences in the anthropometric measures
or feeding indicators across the four sites.3.2 | Children's consumption of foods
Consumption was non‐normally distributed, therefore only median
consumption is shown in Table 3. Grammes consumed are provided
for information but cannot be compared, as serving sizes differed.
Children had the highest median consumption of borbor fortified with
MNP at 50.4% (IQR = 24.2–84.5) and the lowest of the CSB++ at
21.3% (IQR = 7.8–67.4). The difference in the proportion of test foods
consumed was statistically significant (p = 0.003). Kilocalorie intake
showed a slightly different picture, with median kilocalorie intake
lowest for CSB++ and borbor fortified with MNP at 14.9 kcals
(IQR = 5.4–47.2) and 18.2 kcals (IQR = 8.7–30.4), respectively. Kilocal-
orie intake was highest for the RUSF with borbor or as a snack at
56.9 kcals (IQR = 21.5–117.5) and 48.1 kcals (IQR = 26.8–79.6),
respectively. The difference in the kilocalories consumed for each test
food was statistically significant (p < 0.001).ocalories consumed per serving
d % serving consumed
median (IQR)
Kilocalories consumed
median (IQR)
50.4 (24.2–84.5) 18.2 (8.7–30.4)
30.9 (11.7–63.9) 56.9 (21.5–117.5)
21.3 (7.8–67.4) 14.9 (5.4–47.2)
30.1 (16.7–49.2) 48.1 (26.8–79.6)
0.003* <0.001**
ady‐to‐use supplementary food. P values computed using Kruskal–Wallis
ent serving sizes. Asterisks highlight significant p values.
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are presented in Table 4. The unadjusted odds of children consuming
more than 50% of borbor fortified with MNP were higher than the
odds of them consuming more than 50% of RUSF snack, RUSF with
borbor or CSB++ (OR = 6.79; 95% CI = 2.80–16.47; p < 0.001;
OR = 3.91; 95% CI = 1.71–8.96; p = 0.001; OR = 3.59; 95% CI = 1.58–
8.16; p = 0.002, respectively). The odds of children consuming more
than 50% of RUSF snack compared with the odds of them consuming
more than 50% of CSB++, and the odds of children consuming more
than 50% of RUSF with borbor in comparison with the odds of them
consuming more than 50% of RUSF snack or CSB++ were not statisti-
cally significant.
The results for the adjusted model were very similar, with the
odds of children consuming more than 50% of borbor fortified with
MNP being higher than the odds of them consuming more than 50%
of any of the other foods. The only predictor variable that was statis-
tically significant was sex. Girls had much lower odds than boys of eat-
ing 50% or more of any food (OR = 0.27; 95% CI = 0.09–0.85;
p = 0.25). None of the other covariates that were adjusted for in the
model made a statistically significant difference to the odds of eating
50% or more of any food.TABLE 4 Odds ratios of children's consumption, caregiver assessment o
Children's consumption
Unadjusted OR 95% CI P va
Borbor‐MNP vs. RUSF snack 6.79 2.80–16.47 <0.0
Borbor‐MNP vs. RUSF‐borbor 3.91 1.71–8.96 0.0
Borbor‐MNP vs. CSB++ 3.59 1.58–8.16 0.0
RUSF snack vs. RUSF‐borbor 0.58 0.25–1.35 0.2
RUSF snack vs. CSB++ 0.53 0.23–1.23 0.1
RUSF‐borbor vs. CSB++ 0.92 0.41–2.07 0.8
Adjusted
Borbor‐MNP vs. RUSF snack 7.12 2.84–17.84 <0.0
Borbor‐MNP vs. RUSF‐borbor 4.27 1.82–10.00 0.0
Borbor‐MNP vs. CSB++ 3.40 1.47–7.87 0.0
RUSF snack vs. RUSF‐borbor 0.60 0.25 1.42 0.2
RUSF snack vs. CSB++ 0.48 0.20–1.14 0.0
RUSF‐borbor vs. CSB++ 0.80 0.35–1.82 0.5
Adjusted for
Sex 0.27 0.09–0.85 0.0
Age 1.02 0.90–1.15 0.7
Mid‐upper arm circumference (MUAC) 0.58 0.31–1.08 0.0
Illness 1.50 0.57–3.94 0.4
Last eating/breastfeeding before test (<1 hr ago) 0.51 0.16–1.66 0.2
Site
Site 2 0.51 0.10–2.56 0.4
Site 3 1.12 0.25–4.97 0.8
Site 4 1.11 0.25–5.00 0.8
Note. CSB++: corn–soy blend plus plus; MNP: micronutrient powder; RUSF: re
aExpressed as RUSF snack versus borbor‐MNP, OR = 11.97, 95% CI = 5.20–27
were fit for the primary outcome (consumption) and the secondary outcomes
Asterisks highlight significant p values.
*p < 0.05. **p < 0.01. ***p < 0.001.3.3 | Caregiver assessment of child preference for
foods
Table 4 shows that the unadjusted odds that caregivers reported that
their children had a high preference for borbor fortified with MNP was
almost three times the odds of them reporting that their children had a
high preference for RUSF with borbor or CSB++ (OR = 2.99; 95%
CI = 1.42–6.28; p = 0.004; and OR = 2.92; 95% CI = 1.40–6.08;
p = 0.004, respectively). The odds that caregivers reported that their
children had a high preference for the RUSF snack were twice the
odds of them reporting a high preference for RUSF with borbor or
CSB++ (OR = 2.19; 95% CI = 1.07–4.48; p = 0.033; and OR = 2.13;
95% CI = 1.05–4.34; p = 0.037, respectively). The results for the
adjusted model were fairly similar, although the odds of caregivers
reporting that their children had a high preference for the RUSF snack
compared with the odds of reporting a high preference for CSB++
were not quite statistically significant. None of the covariates made
a statistically significant difference to the odds of caregivers reporting
that their children had a high preference for any of the foods. As seen
in Table 5, there were significant differences in hedonic ratings of the
test foods (p = 0.003). Most caregivers felt that children liked borborf child preference, and caregiver rankings of foods
Caregiver assessment of
child preference Caregiver rankings of foods
lue OR 95% CI P value OR 95% CI P value
01*** 1.37 0.65‐2.88 0.408 0.08a 0.04–0.19 <0.001***
01** 2.99 1.42‐6.28 0.004** 1.25 0.70‐2.23 0.458
02** 2.92 1.40‐6.08 0.004** 3.37 1.76‐6.46 <0.001***
02 2.19 1.07–4.48 0.033* 14.92 6.47‐34.41 <0.001***
40 2.13 1.05–4.34 0.037* 40.34 16.67‐97.61 <0.001***
35 0.98 0.49–1.94 0.942 2.70 1.41–5.20 0.003**
01*** 1.63 0.75‐3.53 0.218 0.08 0.04–0.19 <0.001***
01** 3.59 1.65‐7.79 0.001** 1.18 0.65‐2.13 0.591
04** 3.35 1.56‐7.20 0.002** 3.54 1.82‐6.88 <0.001***
45 2.21 1.06–4.60 0.035* 14.20 6.13 – 32.88 <0.001***
96 2.06 0.99–4.27 0.052 42.65 17.38–104.65 <0.001***
91 0.93 0.46–1.89 0.849 3.00 1.54–5.86 0.001**
25* 0.99 0.46‐2.13 0.970 0.99 0.60–1.61 0.952
85 0.96 0.88–1.05 0.377 0.99 0.94–1.05 0.822
85 0.88 0.60–1.29 0.523 1.01 0.79–1.29 0.914
13 0.90 0.41–2.01 0.803 0.75 0.39–1.43 0.384
66 1.07 0.39–2.91 0.895 1.30 0.59–2.90 0.514
16 0.87 0.30–2.54 0.804 1.04 0.51–2.11 0.910
78 2.73 0.94–7.92 0.065 1.03 0.53–2.00 0.942
92 2.37 0.79–7.08 0.122 1.05 0.52–2.10 0.893
ady‐to‐use supplementary food.
.52, p < 0.001. Unadjusted and adjusted mixed‐effects regression models
(caregiver assessment of child preference and caregiver rankings of foods).
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TABLE 5 Caregiver assessment of child preference and caregiver rankings of test foods
Caregiver assessment of
child preference for test foods Borbor‐MNP n = 90a RUSF‐borbor n = 87a CSB++ n = 91a
RUSF snack
n = 90a
(1) Disliked a lot, n (%) 15 (16.7%) 18 (20.7%) 24 (26.4%) 9 (10.0%)
(2) Disliked a little, n (%) 6 (6.7%) 21 (24.1%) 16 (17.6%) 19 (21.1%)
(3) Neither liked nor disliked, n (%) 14 (15.6%) 12 (13.8%) 13 (14.3%) 19 (21.1%)
(4) Liked a little, n (%) 28 (31.1%) 22 (25.3%) 16 (17.6%) 30 (33.3%)
(5) Liked a lot, n (%) 27 (30.0%) 14 (16.1%) 22 (24.2%) 13 (14.4%)
p = 0.003*
Odds of low (1 + 2) vs high (3 + 4 + 5) ranking 0.30 0.81 0.78 0.45
Caregiver ranking of
test foods (N = 92a) Borbor‐MNP RUSF‐borbor CSB++ RUSF snack
(1) Like most, n (%) 12 (13.0%) 10 (10.9%) 6 (6.5%) 64 (69.6%)
(2) Like 2nd best, n (%) 31 (33.7%) 28 (30.4%) 13 (14.1%) 20 (21.7%)
(3) Like 3rd best, n (%) 25 (27.2%) 33 (35.9%) 31 (33.7%) 3 (3.3%)
(4) Like least, n (%) 24 (26.1%) 21 (22.8%) 42 (45.7%) 5 (5.4%)
p < 0.001**
Odds of high (1 + 2) vs. low (3 + 4) ranking 0.88 0.70 0.26 10.49
Note. CSB++: corn–soy blend plus plus; MNP: micronutrient powder; RUSF: ready‐to‐use supplementary food.
aCaregiver assessment of child preference for test foods was conducted every 3rd day. Therefore, n reflects attendance on the given day/s. Caregiver rank-
ing was conducted on day 13, and N reflects attendance on that day. P‐values computed using chi‐squared. Asterisks highlight significant p‐values:
*p < 0.01. **p < 0.001.
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borbor and CSB++ a lot or a little (44.8% and 44.0%, respectively).
Almost half the caregivers (47.7%) said that their children like the
RUSF snack a lot or a little.3.4 | Caregiver ranking of foods
Table 4 shows that caregivers had far greater odds of giving the novel
RUSF snack a high ranking compared to giving CSB++, RUSF with
borbor (OR = 40.34; 95% CI = 16.67–97.61; p < 0.001; and OR = 14.92;
95% CI = 6.47–34.41; p < 0.001; respectively) or borbor fortified with
MNP a high ranking (OR = 11.97; 95% CI = = 5.20–27.52; p < 0.001,
which is the other way of expressing OR = 0.08, CI = 0.04–0.19,
p < 0.001 for borbor fortified with MNP versus RUSF snack). Care-
givers had slightly greater odds of giving borbor fortified with MNP
or RUSF with borbor a high ranking compared with giving CSB++ a
high ranking (OR = 3.37; 95% CI = 1.76–6.46; p < 0.001; OR = 2.70;
95% CI = 1.41–5.20; p = 0.003). The odds of caregivers giving borbor
fortified with MNP and RUSF with borbor different rankings were not
statistically significant. The odds that caregivers gave foods a high
ranking were not significantly affected by any predictor variables. As
seen in Table 5, there were significant differences in caregivers' rank-
ings of the test foods (p < 0.001). The majority of caregivers (69.6%)
liked the RUSF snack the most, and almost half (45.7%) liked CSB++
the least.3.5 | Focus group discussions
The analysis of the FGDs confirms that caregivers liked the CSB++
least, and the RUSF snack best. Generally, caregivers agreed that the
taste, smell, colour, and presentation of the snack were acceptable,although a number of caregivers mentioned that the snack had a fishy
smell. They liked the wafer, saying that it is familiar, and that their chil-
dren liked to hold the snack, which then encouraged them to eat more.
A number of caregivers mentioned that their children's appetite
seemed improved after eating the snack. Some caregivers mentioned
that the wafer was thick and the filling got stuck to their children's pal-
ate. This led to the reformulation of the snack in a thinner wafer.
Many caregivers said that they would consider feeding the snack to
their children two or three times a day, citing improved and weight
gain as incentives. Others felt their children would get bored with
the snack if they ate it so frequently.4 | DISCUSSION
4.1 | Consumption—Percentage of serving
Children in our trial consumed significantly more borbor fortified with
MNP in comparison to other foods. This is probably because borbor is
very familiar, and MNP is not thought to change the taste or smell. In
comparison, they did not eat as much of the RUSF snack. This is
understandable; even though each food was provided over 3 days to
reduce food neophobia, it typically takes repeated exposures to
increase acceptance of unfamiliar foods (Gibson & Cooke, 2017;
Konyole et al., 2012).
Compared with similar trials, children in our trial consumed a
smaller percentage of all food servings (Adu–Afarwuah et al., 2011;
Ahmed et al., 2014; Konyole et al., 2012; Nga et al., 2013; Pachón
et al., 2007; Phuka et al., 2011; Weber et al., 2017), although a Cambo-
dian trial with fortified blended foods had similar rates of consumption
(Skau et al., 2012). Low rates of consumption may be related to laissez‐
faire feeding styles (Wondafrash, Amsalu, & Woldie, 2012), which are76
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related to the unfamiliar environment, as children are likely to eat more
during home feeding (Konyole et al., 2012), and to the fact that care-
givers did not model consumption of the foods during the test feeding
(Blissett & Fogel, 2013; Dovey, Staples, Gibson, & Halford, 2008;
Wardle & Cooke, 2008).4.2 | Consumption—Energy intake
Few acceptability studies have considered energy consumed as an
outcome (Ahmed et al., 2014; Dibari et al., 2013), possibly because
in most studies, the foods or servings were isocaloric (Adu‐Afarwuah
et al., 2011; Dibari et al., 2013; Pachón et al., 2007; Weber et al.,
2017). The larger portion size required for fortified blends to deliver
calorific content has been noted (Iuel‐Brockdorf et al., 2015; Nackers
et al., 2010). Research on small‐quantity LNSs is explicit that, given
the small gastric volume of young children, smaller portions of more
nutrient dense foods are preferable in order to avoid displacement
of breastmilk and local foods that enhance dietary diversity, including
animal‐source foods, fruits, and vegetables (Arimond et al., 2015;
Matsungo, Kruger, Smuts, & Faber, 2017).
Thus, if we take energy consumption into consideration, we note
that even the smaller amounts of RUSF snack or RUSF with borbor
that children consumed, provided about three times more energy than
the CSB++ or borbor fortified with MNP consumed. This is not surpris-
ing, because borbor is low in energy and nutrient density, and even
CSB++ is high in volume relative to energy and nutrient density.
Therefore, even children consuming large amounts of borbor fortified
with MNP or CSB++ will not consume the quantity of macronutrients
(kilocalories, protein, or fat) as children consuming a food that is high
in energy and nutrient density, such as our novel RUSF.4.3 | Caregiver assessment of child preference for
foods
It is useful to ascertain caregivers' perceptions of their child's food
preference, as has been done in some other studies (Ali et al., 2013;
Iuel‐Brockdorf et al., 2015; Pachón et al., 2007). Although caregivers
assessed that their children liked borbor fortified with MNP slightly
more than the RUSF snack, they still thought that their children had
a fairly high preference for the RUSF snack, especially in comparison
with CSB++ and RUSF with borbor. However, it is also important to
acknowledge that this outcome may not be conclusive, as caregivers
may hesitate to express negative opinions (Bauserman et al., 2015;
Iuel‐Brockdorf et al., 2015).4.4 | Caregiver ranking of foods
The attitude and practices of caregivers are paramount in determining
whether children will ultimately accept a novel food (Konyole et al.,
2012). In our study, ranking forced caregivers to make choices, which
is more conclusive than preference scales, and may help to mitigate
the socially acceptable responding encountered in other studies
(Bauserman et al., 2015; Iuel‐Brockdorf et al., 2015). Caregiversranked our novel RUSF snack very highly. The unusually high odds
ratio of the caregiver ranking the RUSF snack highly versus ranking
CSB++ highly (OR = 40.34, CI = 16.67–97.61, p < 0.001) demonstrates
how much more caregivers liked the RUSF snack than CSB++. We can
therefore expect that they would give the RUSF snack to their chil-
dren, and in doing so, that their children would come to accept the
snack. Moreover, high consumption of fish, soy, and mungbeans in
Cambodia, including during pregnancy and lactation, exposes new-
borns and young children to these flavours via amniotic fluid and
breastmilk (Ventura & Worobey, 2013) and may thus predispose chil-
dren to accepting those flavours in the novel RUSF.
It is also noteworthy for programming purposes that caregivers
ranked CSB++ very low. This confirms the field observations that
CSB++ had low acceptability (WFP, 2014b).4.5 | Focus group discussions
The FGDs supported the quantitative findings. As in some other stud-
ies, caregivers emphasised the health benefit of the snack (Ashorn
et al., 2015; Weber et al., 2017). Interestingly, as in another study,
caregivers reported that after eating the RUSF, their children had
more appetite for eating other foods offered, which pleased caregivers
(Cohuet et al., 2012). As in other studies (Phuka et al., 2011; Segrè
et al., 2015; Weber et al., 2017), caregivers stated that they would
be willing to pay for the RUSF snack. Caregivers indicated that they
would be willing to pay between 300 and 1,000 riel (US$0.07–0.25)
for the RUSF, which is similar to what they currently pay for snacks
(Pries et al., 2016; World Vision, 2015).4.6 | Snack or porridge
Despite a Cambodian (indeed global) preference for soft, porridge‐like
foods for younger children, our study found that caregivers would be
more likely to give their child the RUSF snack than to mix the RUSF
with borbor. This may be because, when mixed with warm borbor,
the fish smell of the RUSF became stronger. Also, it was noted that
even the younger children had no difficulty holding the snack them-
selves to suck on it, if not bite and chew it. Some caregivers broke
the snack into smaller pieces to help the younger children eat it. Given
this finding, future caregivers will be encouraged to use the RUSF as a
snack, although it will be noted that the RUSF can be mixed with
borbor or other foods, especially for younger children, as is suggested
with some other LNSs (Arimond et al., 2015). This also concurs with
evidence that consumption of snacks is very common amongst infants
and young children in Phnom Penh even in the lowest wealth tercile
(Pries et al., 2017; Pries et al., 2016; WFP, 2014b; World Vision, 2015).4.7 | Strengths and limitations of this study
This trial contributes to the literature comparing supplementary foods
using animal‐source foods other than milk and foods acceptable to a
South East Asian population. Having said that, the study was limited
to peri‐urban Phnom Penh and may not be representative of rural
areas or of neighbouring countries.77
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over design and cluster randomisation, along with the use of ranking,
make this study robust. Nevertheless, despite attempting to avoid bias
toward any of the foods, unintentional interviewer and respondent
bias may have favoured the novel RUSF in caregiver assessments.5 | CONCLUSIONS
This trial contributes much‐needed data on the acceptability of a novel
RUSF to Cambodian caregivers and children. Moreover, it sheds light
on the acceptability of supplementary foods with an animal‐source
food other than milk. Although children ate less of the RUSF snack
than of the other, more familiar foods, the RUSF (whether eaten as a
snack or with borbor) provided more energy than CSB++ or borbor for-
tified with MNP. Moreover, caregivers ranked the RUSF snack very
highly, demonstrating that our locally produced RUSF, using fish
instead of milk, is more acceptable to Cambodian caregivers than the
commonly used MNP and CSB++. In view of these results, the
research team felt confident to proceed to a 6‐month trial to test
the RUSF's effectiveness in preventing growth faltering. Given that
testing over 3 days in an unfamiliar setting may not be an indication
of how caregivers and children would accept the food over a longer
period, we note that the subsequent 6‐month effectiveness trial will
also give additional information on long‐term acceptability.
ACKNOWLEDGMENTS
The authors thank the staff of Department of Fisheries Post‐Harvest
Technologies and Quality Control of Cambodia (DFPTQ) and the
Cambodian MoH (Phnom Penh Municipal Health Department) for
their support. We thank Sanne Sigh, Remco Peters, Marjoleine
Dijkhuizen, and Lyndon Paul (Vissot) for their work on the product
development. B. B. thanks Dr. Eliana Jimenez Soto for her support
and comments on the protocol and data collection tools. We also
thank the data collection and data entry teams for their efforts, and
the caregivers and children of Svay Pak Sangkat for their participation.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.
CONTRIBUTIONS
BB developed the research protocol, trial design, and questionnaires,
and refined these with FTW, SM, MG, DS, CC, and AL. AL and FTW
secured funding. BB managed data collection with support from DS.
BB conducted the statistical analysis with support from MG. BB wrote
the manuscript and all authors subsequently commented on the
manuscript and approved the final version.
ORCID
Bindi Borg https://orcid.org/0000-0002-2764-9788
Arnaud Laillou https://orcid.org/0000-0002-2315-223X
REFERENCES
Ackatia‐Armah, R. S., McDonald, C. M., Doumbia, S., Erhardt, J. G., Hamer,
D. H., & Brown, K. H. (2015). Malian children with moderate acutemalnutrition who are treated with lipid‐based dietary supplements
have greater weight gains and recovery rates than those treated with
locally produced cereal‐legume products: A community‐based, clus-
ter‐randomized trial. The American journal of clinical nutrition, 101(3),
632–645.
Adu‐Afarwuah, S., Lartey, A., Zeilani, M., & Dewey, K. G. (2011). Accept-
ability of lipid‐based nutrient supplements (LNS) among Ghanaian
infants and pregnant or lactating women. Maternal & Child Nutrition,
7(4), 344–356. https://doi.org/10.1111/j.1740‐8709.2010.00286.x
Ahmed, T., Choudhury, N., Hossain, M. I., Tangsuphoom, N., Islam, M. M.,
de Pee, S., & Christian, P. (2014). Development and acceptability test-
ing of ready‐to‐use supplementary food made from locally available
food ingredients in Bangladesh. BMC Pediatrics, 14, 164. https://doi.
org/10.1186/1471‐2431‐14‐164
Ali, E., Zachariah, R., Dahmane, A., Van den Boogaard, W., Shams, Z., Akter,
T., & Harries, A. D. (2013). Peanut‐based ready‐to‐use therapeutic
food: Acceptability among malnourished children and community
workers in Bangladesh. Public Health Action, 3(2), 128–135. https://
doi.org/10.5588/pha.12.0077
Anderson, A. K., Bediako‐Amoa, B., & Steiner‐Asiedu, M. (2014). Accept-
ability of chicken powder in home prepared complementary foods for
children in Ghana. African Journal of Food, Agriculture, Nutrition and
Development, 14(2), 8736–8747.
Arimond, M., Zeilani, M., Jungjohann, S., Brown, K. H., Ashorn, P., Allen, L.
H., & Dewey, K. G. (2015). Considerations in developing lipid‐based
nutrient supplements for prevention of undernutrition: Experience
from the International Lipid‐Based Nutrient Supplements (iLiNS) Pro-
ject. Maternal & Child Nutrition, 11, 31–61. https://doi.org/10.1111/
mcn.12049
Ashorn, U., Alho, L., Arimond, M., Dewey, K. G., Maleta, K., Phiri, N., &
Ashorn, P. (2015). Malawian mothers consider lipid‐based nutrient sup-
plements acceptable for children throughout a 1‐year intervention, but
deviation from user recommendations is common. The Journal of
Nutrition, 145(7), 1588–1595. https://doi.org/10.3945/jn.114.209593
Bauserman, M., Lokangaka, A., Kodondi, K.‐K., Gado, J., Viera, A. J.,
Bentley, M. E., & Bose, C. (2015). Caterpillar cereal as a potential com-
plementary feeding product for infants and young children: Nutritional
content and acceptability. Maternal & Child Nutrition, 11, 214–220.
https://doi.org/10.1111/mcn.12037
Blissett, J., & Fogel, A. (2013). Intrinsic and extrinsic influences on chil-
dren's acceptance of new foods. Physiology & Behavior, 121, 89–95.
https://doi.org/10.1016/j.physbeh.2013.02.013
Bogard, J. R., Hother, A.‐L., Saha, M., Bose, S., Kabir, H., Marks, G. C., &
Thilsted, S. H. (2015). Inclusion of small indigenous fish improves nutri-
tional quality during the first 1000 days. Food and Nutrition Bulletin,
36(3), 276–289. https://doi.org/10.1177/0379572115598885
Borg, B., Mihrshahi, S., Griffin, M., Chamnan, C., Laillou, A., & Wieringa, F.
T. (2017). Crossover trial to test the acceptability of a locally produced
lipid‐based nutrient supplement (LNS) for children under 2 years in
Cambodia: A study protocol. BMJ Open, 7(9), e015958. https://doi.
org/10.1136/bmjopen‐2017‐015958
Boudier, F. (2009). Socio‐anthropological Investigation Related to the
Acceptability of Plumpy'nut® in Cambodia. Retrieved from Paris:
Cohuet, S., Marquer, C., Shepherd, S., Captier, V., Langendorf, C., Ale, F., &
Grais, R. F. (2012). Intra‐household use and acceptability of ready‐to‐
use‐supplementary‐foods distributed in Niger between July and
December 2010. Appetite, 59(3), 698–705. https://doi.org/10.1016/j.
appet.2012.07.019
de Pee, S. (2015). Special nutritious solutions to enhance complementary
feeding. Maternal & Child Nutrition, 11, i–viii. https://doi.org/
10.1111/mcn.12265
de Pee, S., & Bloem, M. W. (2009). Current and potential role of specially
formulated foods and food supplements for preventing malnutrition
among 6‐ to 23‐month‐old children and for treating moderate malnutri-
tion among 6‐ to 59‐month‐old children. Food and Nutrition Bulletin,
30(3), S434–S463. https://doi.org/10.1177/15648265090303S30578
12 of 13 BORG ET AL.
bs_bs_bannerde Pee, S., Manary, M., & Ashorn, P. (2011). The devil is in the details.
Nutrition Reviews, 69(2), 116–117. https://doi.org/10.1111/j.1753‐
4887.2010.00366.x
Dewey, K. G., & Adu‐Afarwuah, S. (2008). Systematic review of the
efficacy and effectiveness of complementary feeding interventions in
developing countries. Maternal & Child Nutrition, 4 Suppl 1(s1),
24–85. https://doi.org/10.1111/j.1740-8709.2007.00124.x
Dewey, K. G., & Young ChildNutritionWorking Group: Formulation, S (2009).
Formulations for fortified complementary foods and supplements:
Review of successful products for improving the nutritional status of
infants and young children. Food and Nutrition Bulletin, 30(Suppl2),
S239–S255. https://doi.org/10.1177/15648265090302S209
Dibari, F., Bahwere, P., Huerga, H., Irena, A. H., Owino, V., Collins, S., &
Seal, A. (2013). Development of a cross‐over randomized trial method
to determine the acceptability and safety of novel ready‐to‐use thera-
peutic foods. Nutrition, 29(1), 107–112. https://doi.org/10.1016/j.
nut.2012.04.016
Dovey, T. M., Staples, P. A., Gibson, E. L., & Halford, J. C. G. (2008). Food
neophobia and ‘picky/fussy’ eating in children: A review. Appetite,
50(2), 181–193. https://doi.org/10.1016/j.appet.2007.09.009
Flax, V. L., Thakwalakwa, C., Phuka, J., Ashorn, U., Cheung, Y. B., Maleta, K., &
Ashorn, P. (2009). Malawian mothers' attitudes towards the use of two
supplementary foods for moderately malnourished children. Appetite,
53(2), 195–202. https://doi.org/10.1016/j.appet.2009.06.008
Gibson, E. L., & Cooke, L. (2017). Understanding food fussiness and its
implications for food choice, health, weight and interventions in young
children: The impact of Professor Jane Wardle. Current Obesity Reports,
6(1), 46–56. https://doi.org/10.1007/s13679‐017‐0248‐9
Golden, M. H. (2009). Proposed recommended nutrient densities for mod-
erately malnourished children. Food and Nutrition Bulletin, 30(3 Suppl),
S267–S342. https://doi.org/10.1177/15648265090303S302
Hy Ta, P., & Martinaud, C. (2014). Conclusion Report on Perception, Use
and Satisfaction Survey of a Local Fortified Complementary Food
(Bobor Rong Roeung) ‐ Nutrikhmer Project.
Iuel‐Brockdorf, A. S., Draebel, T. A., Fabiansen, C., Cichon, B., Christensen,
V. B., Yameogo, C., & Friis, H. (2015). Acceptability of new formulations
of corn‐soy blends and lipid‐based nutrient supplements in Province du
Passore, Burkina Faso. Appetite, 91, 278–286. https://doi.org/
10.1016/j.appet.2015.04.058
Iuel‐Brockdorf, A. S., Draebel, T. A., Ritz, C., Fabiansen, C., Cichon, B., Brix
Christensen, V., … Friis, H. (2016). Evaluation of the acceptability of
improved supplementary foods for the treatment of moderate acute malnu-
trition in Burkina Faso using a mixed method approach. Appetite, 99, 34–45.
Jack, S. J., Ou, K., Chea, M., Chhin, L., Devenish, R., Dunbar, M., … Gibson,
R. S. (2012). Effect of micronutrient sprinkles on reducing anemia.
Archives of Pediatrics & Adolescent Medicine, 166(9), 842–850. https://
doi.org/10.1001/archpediatrics.2012.1003
Ketsana, C. (2013). Draft report of RUTF acceptability trial in Prey Veng. .
Retrieved from Phnom Penh:
Konyole, S. O., Kinyuru, J. N., Owuor, B. O., Kenji, G. M., Onyango, C. A.,
Estambale, B. B., … Owino, V. O. (2012). Acceptability of amaranth
grain‐based nutritious complementary foods with dagaa fish
(Rastrineobola argentea) and edible termites (Macrotermes subhylanus)
compared to corn soy blend plus among young children/mothers dyads
in Western Kenya. Journal of Food Research, 1(3), 111–120. https://doi.
org/10.5539/jfr.v1n3p111
Kuusipalo, H., Maleta, K., Briend, A., Manary, M., & Ashorn, P. (2006). Growth
and change in blood haemoglobin concentration among underweight
Malawian infants receiving fortified spreads for 12 weeks: A preliminary
trial. Journal of Pediatric Gastroenterology and Nutrition, 43(4), 525–532.
https://doi.org/10.1097/01.mpg.0000235981.26700.d3
Lagrone, L., Cole, S., Schondelmeyer, A., Maleta, K., & Manary, M. J. (2010).
Locally produced ready‐to‐use supplementary food is an effective
treatment of moderate acute malnutrition in an operational setting.
Annals of tropical paediatrics, 30(2), 103–108.Lagrone, L. N., Trehan, I., Meuli, G. J., Wang, R. J., Thakwalakwa, C., Maleta,
K., & Manary, M. J. (2012). A novel fortified blended flour, corn‐soy
blend "plus‐plus," is not inferior to lipid‐based ready‐to‐use supplemen-
tary foods for the treatment of moderate acute malnutrition in
Malawian children. The American Journal of Clinical Nutrition, 95(1),
212–219. https://doi.org/10.3945/ajcn.111.022525
Lazzerini, M., Rubert, Laura, Pani, Paola. (2013). Specially formulated foods
for treating children with moderate acute malnutrition in low‐ and
middle‐income countries. The Cochrane Database of Systematic Reviews,
6, CD009584.
Manary, M. (2006). Local production and provision of ready‐to‐use thera-
peutic food (rutf) spread for the treatment of severe childhood
malnutrition. Food and Nutrition Bulletin, 27(Suppl3), S83–S89.
https://doi.org/10.1177/15648265060273S305
Manary, M., & Young, C. (2012) Comparing Milk Fortified Corn‐Soy Blend
(CSB++), Soy Ready‐to‐Use Supplementary Food (RUSF), and Soy/Whey
RUSF (Supplementary Plumpy®) in the Treatment of Moderate Acute
Malnutrition. Washington, DC: FANTA‐2 Bridge/FHI 360.; 2012.
Matsungo, T. M., Kruger, H. S., Smuts, C. M., & Faber, M. (2017). Lipid‐
based nutrient supplements and linear growth in children under 2
years: A review. The Proceedings of the Nutrition Society, 76(4),
580–588. https://doi.org/10.1017/s0029665117000283
Michaelsen, K. F., Grummer‐Strawn, L., & Begin, F. (2017). Emerging issues
in complementary feeding: Global aspects. Maternal & Child Nutrition,
13(Suppl 2). https://doi.org/10.1111/mcn.12444
Nackers, F., Broillet, F., Oumarou, D., Djibo, A., Gaboulaud, V., Guerin, P. J.,
& Captier, V. (2010). Effectiveness of ready‐to‐use therapeutic food
compared to a corn/soy‐blend‐based pre‐mix for the treatment of
childhood moderate acute malnutrition in Niger. Journal of Tropical
Pediatrics, 56(6), 407–413. https://doi.org/10.1093/tropej/fmq019
National Institute of Statistics, Directorate General for Health, & ICF Inter-
national. (2015). Cambodia Demographic and Health Survey (2014).
Phnom Penh, Cambodia, and Rockville, Maryland. In USA.
Nga, T., Nguyen, M., Mathisen, R., Hoa, D., Minh, N., Berger, J., &Wieringa, F.
(2013). Acceptability and impact on anthropometry of a locally developed
ready‐to‐use therapeutic food in pre‐school children in Vietnam.Nutrition
Journal, 12(1), 120–120. https://doi.org/10.1186/1475‐2891‐12‐120
Pachón, H., Domínguez,M. R. L., Creed‐Kanashiro, H., & Stoltzfus, R. J. (2007).
Acceptability and safety of novel infant porridges containing lyophilized
meat powder and iron‐fortified wheat flour. Food and Nutrition Bulletin,
28(1), 35–46. https://doi.org/10.1177/156482650702800104
Peters, R. (2014). Development and acceptability of a fish‐based local ready‐
to‐use therapeutic food (RUTF): an intervention in pre‐school children in
Cambodia. (Masters), University of Copenhagen, Copenhagen.
Phuka, J., Ashorn, U., Ashorn, P., Zeilani, M., Cheung, Y. B., Dewey, K. G., &
Maleta, K. (2011). Acceptability of three novel lipid‐based nutrient sup-
plements among Malawian infants and their caregivers. Maternal &
Child Nutrition, 7(4), 368–377. https://doi.org/10.1111/j.1740‐
8709.2011.00297.x
Phuong, H., Nga, T., Mathisen, R., Nguyen, M., Hop, L. T., Hoa, D. T. B., &
Wieringa, F. T. (2014). Development and implementation of a locally
produced ready‐to‐use therapeutic food (RUTF) in Vietnam. Food and
Nutrition Bulletin, 35(2_suppl1), S52–S56. https://doi.org/10.1177/
15648265140352S108
Pries, A. M., Huffman, S. L., Champeny, M., Adhikary, I., Benjamin, M., Coly,
A. N., & Zehner, E. (2017). Consumption of commercially produced
snack foods and sugar‐sweetened beverages during the complemen-
tary feeding period in four African and Asian urban contexts.
Maternal & Child Nutrition, 13. https://doi.org/10.1111/mcn.12412
Pries, A. M., Huffman, S. L., Mengkheang, K., Kroeun, H., Champeny, M.,
Roberts, M., & Zehner, E. (2016). High use of commercial food products
among infants and young children and promotions for these products
in Cambodia. Maternal & Child Nutrition, 12, 52–63. https://doi.org/
10.1111/mcn.1227079
BORG ET AL. 13 of 13
bs_bs_bannerSalam, R. A., Macphail, C., Das, J. K., & Bhutta, Z. A. (2013). Effectiveness
of micronutrient powders (MNP) in women and children. BMC Public
Health, 13(Suppl 3), –S22.
Segrè, J., Winnard, K., Abrha, T. H., Abebe, Y., Shilane, D., & Lapping, K.
(2015). Willingness to pay for lipid‐based nutrient supplements for
young children in four urban sites of Ethiopia. Maternal & Child
Nutrition, 11, 16–30. https://doi.org/10.1111/mcn.12022
Sigh, S., Roos, N., Sok, D., Borg, B., Chamnan, C., Laillou, A., & Wieringa, F.
T. (2018). Development and acceptability of locally made fish‐based,
ready‐to‐use products for the prevention and treatment of malnutri-
tion in Cambodia. Food and Nutrition Bulletin, 39(3), 420–434.
https://doi.org/10.1177/0379572118788266
Skau, J., Touch, B., Chhoun, C., Chea, M., Unni, U., Makurat, J., … Roos, N.
(2015). Effects of animal source food and micronutrient fortification in
complementary food products on body composition, iron status, and
linear growth: A randomized trial in Cambodia. The American Journal
of Clinical Nutrition, 101(4), 742–751. https://doi.org/10.3945/
ajcn.114.084889
Skau, J. N. M., Sok, D., & Wieringa, F. (2012). Acceptability study of fortified
blended food products among children 12–36 months old children and
caregivers in Cambodia (unpublished). Phnom Penh: WFP.
Stone, H., Bleibaum, R. N., & Thomas, H. A. (2012). Sensory evaluation
practices (4th ed.). Burlington: Elsevier Science.
Ventura, A. K., & Worobey, J. (2013). Early influences on the development
of food preferences. Current Biology: CB, 23(9), R401–R408. https://
doi.org/10.1016/j.cub.2013.02.037
Vilain, C., Baran, E., Gallego, G., & Samadee, S. (2016). Fish and the nutri-
tion of rural Cambodians. Asian Journal of Agricultural and Food
Sciences., 4(1), 26–34.
Wardle, J., & Cooke, L. (2008). Genetic and environmental determinants of
children's food preferences. British Journal of Nutrition, 99(S1),
S15–S21. https://doi.org/10.1017/S000711450889246X
Weber, J. M., Ryan, K. N., Tandon, R., Mathur, M., Girma, T., Steiner‐
Asiedu, M., & Manary, M. J. (2017). Acceptability of locally producedready‐to‐use therapeutic foods in Ethiopia, Ghana, Pakistan and India.
Maternal & Child Nutrition, 13(2). https://doi.org/10.1111/mcn.12250
WFP. (2014a). Personal Communication.
WFP. (2014b). Technical Specifications for the manufacture of SuperCereal
Plus.
WHO. (2013). Guideline update: Technical aspects of the management of
severe acute malnutrition in infants and children. In. Geneva: World
Health Organization.
Wieringa, F. (2014). Personal communication.
Wondafrash, M., Amsalu, T., & Woldie, M. (2012). Feeding styles of care-
givers of children 6‐23 months of age in Derashe special district,
Southern Ethiopia. BMC Public Health, 12(1), 235–235. https://doi.
org/10.1186/1471‐2458‐12‐235
World Vision (2015). Personal Communication.
Zlotkin S. Overview of Efficacy, Effectiveness and Safety of MNPs: UNICEF;
2009 [Available from: http://www.unicef.org/nutritioncluster/files/
Revised_UNICEF_CombinedOverview_of_Efficacy_Effectiveness_and_
Safety_of_MNPs.pdf.SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Borg B, Mihrshahi S, Griffin M, et al.
Acceptability of locally‐produced Ready‐to‐Use Supplemen-
tary Food (RUSF) for children under two years in Cambodia:
A cluster randomised trial. Matern Child Nutr. 2019;e12780.
https://doi.org/10.1111/mcn.1278080
1 
Site Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 
7 
Day 
8 
Day 
9 
Day 
10 
Day 
11 
Day 
12 
1 RUSF + borbor Sprinkles + borbor CSB++ RUSF snack 
2 Sprinkles + borbor RUSF + borbor RUSF snack CSB++ 
3 CSB++ RUSF snack RUSF + borbor Sprinkles + borbor 
4 RUSF snack CSB++ Sprinkles + borbor RUSF + borbor 
Supplementary Figure 1: Food sequence schedule 
81
References 
1. Dibari F, Bahwere P, Huerga H, Irena AH, Owino V, Collins S, et al. Development of a cross-
over randomized trial method to determine the acceptability and safety of novel ready-to-use
therapeutic foods. Nutrition 2013;29(1):107-12.
2. Iuel-Brockdorf AS, Draebel TA, Ritz C, Fabiansen C, Cichon B, Brix Christensen V, et al.
Evaluation of the acceptability of improved supplementary foods for the treatment of moderate
acute malnutrition in Burkina Faso using a mixed method approach. Appetite. 2016;99:34-45.
3. UNICEF. Personal communication. Phnom Penh, Cambodia. 2014.
4. WFP. Personal communication. Phnom Penh, Cambodia. 2014.
5. Wieringa F. Personal communication. Phnom Penh, Cambodia. 2014.
6. Bourdier F. Socio-anthropological investigation related to the acceptability of Plumpy’nut in
Cambodia. Paris, France: Institut de Recherche pour le Développement; 2009.
7. Ketsana C. Draft report of RUTF acceptability trial in Prey Veng. Phnom Penh: RACHA; 2013.
8. Chang CY, Trehan I, Wang RJ, Thakwalakwa C, Maleta K, Deitchler M, et al. Children
successfully treated for moderate acute malnutrition remain at risk for malnutrition and death in
the subsequent year after recovery. J Nutr 2013; 143(2):215-20.
9. Flax VL, Phuka J, Cheung YB, Ashorn U, Maleta K, Ashorn P. Feeding patterns and behaviors
during home supplementation of underweight Malawian children with lipid-based nutrient
supplements or corn-soy blend. Appetite 2010; 54(3):504-11.
10. Kuusipalo H, Maleta K, Briend A, Manary M, Ashorn P. Growth and change in blood
haemoglobin concentration among underweight Malawian infants receiving fortified spreads for
12 weeks: a preliminary trial. J Pediatr Gastroenterol Nutr 2006;43(4):525-32.
11. Lagrone L, Cole S, Schondelmeyer A, Maleta K, Manary MJ. Locally produced ready-to-use
supplementary food is an effective treatment of moderate acute malnutrition in an operational
setting. Ann Trop Paediatr 2010;30(2):103-8.
12. Lagrone LN, Trehan I, Meuli GJ, Wang RJ, Thakwalakwa C, Maleta K, et al. A novel fortified
blended flour, corn-soy blend "plus-plus," is not inferior to lipid-based ready-to-use
supplementary foods for the treatment of moderate acute malnutrition in Malawian children. Am
J Clin Nutr 2012; 95(1):212-9.
13. Lin CA, Manary MJ, Maleta K, Briend A, Ashorn P. An energy-dense complementary food is
associated with a modest increase in weight gain when compared with a fortified porridge in
Malawian children aged 6-18 months. J Nutr. 2008;138(3):593.
14. Matilsky DK, Maleta K, Castleman T, Manary MJ. Supplementary feeding with fortified spreads
results in higher recovery rates than with a corn/soy blend in moderately wasted children. J Nutr
2009;139(4):773-8.
15. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, et al. Postintervention
growth of Malawian children who received 12-mo dietary complementation with a lipid-based
nutrient supplement or maize-soy flour. Am J Clin Nutr. 2009;89(1):382-90.
16. Wang RJ, Trehan I, Lagrone LN, Weisz AJ, Thakwalakwa CM, Maleta KM, et al. Investigation
of food acceptability and feeding practices for lipid nutrient supplements and blended flours used
to treat moderate malnutrition. J Nutr Educ Behav 2013;45(3):258-63.
17. Manary MJ. Local production and provision of Ready-to-use therapeutic food (RUTF) spread for
the treatment of severe childhood malnutrition. Food Nutr Bull 2006;27(Suppl.3):S83.
18. Manary M, Chang CY. Comparing milk fortified corn-soy blend (CSB++), soy Ready-to-use
supplementary food (RUSF), and soy/whey RUSF (Supplementary Plumpy®) in the treatment
of moderate acute malnutrition. Washington, DC: FANTA-2 Bridge/FHI 360; 2012.
19. Gera T, Pena-Rosas JP, Boy-Mena E, Sachdev HS. Lipid based nutrient supplements (LNS) for
treatment of children (6 months to 59 months) with moderate acute malnutrition (MAM): a
systematic review. PloS One. 2017;12(9):e0182096.
20. Lazzerini M, Rubert, L, Pani, P. Specially formulated foods for treating children with moderate
acute malnutrition in low- and middle-income countries. Cochrane Database Syst Rev 2013;
6:CD009584.
21. Lenters LM, Wazny K, Webb P, Ahmed T, Bhutta ZA. Treatment of severe and moderate acute
malnutrition in low- and middle-income settings: a systematic review, meta-analysis and Delphi
process. BMC Public Health. 2013;13 (Suppl.3):S23.
82
22. Pham VP, Nguyen VH, Salvignol B, Treche S, Wieringa FT, Dijkhuizen MA, et al. A six-month
intervention with two different types of micronutrient-fortified complementary foods had distinct
short- and long-term effects on linear and ponderal growth of Vietnamese infants. J Nutr. 2012;
142(9):1735-40.
23. Nga TT, Nguyen M, Mathisen R, Hoa DTB, Minh NH, Berger J, Wieringa FT. Acceptability and
impact on anthropometry of a locally developed ready-to-use therapeutic food in pre-school
children in Vietnam. Nutr J 2013;12(1):120.
24. Weber JM, Ryan KN, Tandon R, Mathur M, Girma T, Steiner‐Asiedu M, et al. Acceptability of
locally produced ready‐to‐use therapeutic foods in Ethiopia, Ghana, Pakistan and India. Matern
Child Nutr 2017;13(2).
25. Ahmed T, Choudhury N, Hossain MI, Tangsuphoom N, Islam MM, de Pee S, et al. Development
and acceptability testing of ready-to-use supplementary food made from locally available food
ingredients in Bangladesh. BMC Pediatr 2014;14:164.
26. Skau J, Nguyen M, Sok D, Wieringa F. Acceptability study of fortified blended food products
among 12-36 month-old children and caregivers in Cambodia. World Food Programme –
Cambodia Country Office; 2012 (Unpublished report).
27. Nurhasan M, Thang B, Skau J, Roos N, Wieringa F, Friis H, et al. WinFood Cambodia:
improving child nutrition through utilization of local food. 2014 (Unpublished report).
28. Sigh S, Roos N, Sok D, Borg B, Chamnan C, Laillou A, et al. Development and acceptability of
locally made fish-based, ready-to-use products for the prevention and treatment of malnutrition
in Cambodia. Food Nutr Bull 2018;39(3):420-34.
29. Skau J, Touch B, Chhoun C, Chea M, Unni U, Makurat J, et al. Effects of animal source food
and micronutrient fortification in complementary food products on body composition, iron status,
and linear growth: a randomized trial in Cambodia. Am J Clin Nutr 2015;101(4):742-51.
83
Chapter 6:  Methods of the effectiveness trial 
This chapter describes the methodology of the effectiveness trial.  Part of this chapter has been published 
as: 
o Borg B, Mihrshahi S, Griffin M, Sok D, Chhoun C, Laillou A, Berger J, Wieringa FT. Randomised
controlled trial to test the effectiveness of a locally-produced ready-to-use supplementary food
(RUSF) in preventing growth faltering and improving micronutrient status for children under two
years in Cambodia: a study protocol. Nutrition Journal. 2018;17(1):39.
The chapter begins by outlining the rationale for conducting the effectiveness trial.  This is followed by 
the published effectiveness protocol.  The final section describes departures from the protocol. 
Rationale for the effectiveness trial 
Having determined that the ready-to-use supplementary food (RUSF) was acceptable to children and 
caregivers, we proceeded to design the effectiveness trial.  Until then, most studies had been conducted 
with severely and moderately acutely malnourished children.  The effectiveness of using specially 
formulated ready-to-use therapeutic foods (RUTFs) for treating severe acute malnutrition (SAM) was 
well-established.  The focus had tended to be on creating locally-produced foods, especially lipid-based 
nutrient supplements (LNSs) and comparing their effectiveness to fortified blends (1-4).  It was widely 
acknowledged that the evidence was limited to the African context (3, 4), something which has not 
changed greatly since (5).  Research with small quantities of LNSs (as opposed to medium or 
large/therapeutic doses) had just begun (6).  Potential risks of specially formulated supplementary foods 
and the importance of assessing their impact on body composition had been noted (4).  The evidence 
the use of RUSFs for prevention of childhood undernutrition in representative populations, and even 
with children that were already moderately acutely malnourished, was mixed (2).  There was limited 
evidence on provision of supplementary foods in food secure settings (7).  Only one systematic review 
had expressly considered whether the setting was food secure or food insecure (8).  Our project was 
developed in that context. 
84
Effectiveness trial versus efficacy trial 
The acceptability protocol refers to a subsequent efficacy trial.  However, the researchers decided to 
proceed to an effectiveness trial.  The justification for that decision is explained here. 
This was a long trial (six months).  The enrolled children were not considered to be suffering from a 
clinical condition, inasmuch as most children were not moderately acutely malnourished.  In any case, 
treatment for moderate acute malnutrition is not provided in Cambodia.  This was a supplementary, not 
a therapeutic product.  It was not expected to cause harm, and “overdose” was considered unlikely.  For 
these reasons, it was considered neither possible nor necessary to maintain the ideal and controlled 
circumstances required for an efficacy trial.  Moreover, the trial budget was limited, and did not allow 
for the intensive follow up of the consumption of the food that would have been required for an efficacy 
trial.  Since any possible future treatment for moderate (and often even severe) acute malnutrition would 
be provided in the home, in real world and not clinical conditions, such intensive, expensive follow up 
does not seem justified.  Therefore, it was considered reasonable to proceed to an effectiveness trial.  
Comparability to other effectiveness trials 
The design of our project was comparable to that of effectiveness trials of other supplementary foods. 
For example, most were prospective and had an allocation ratio of 1:1 (9-14).  Some trials were cluster 
randomised (15, 16).  The age of children in the studies ranged from six months to five years.  Trials 
were typically eight to sixteen weeks’ duration (4), with two trials following children for nine months 
(9, 17).  Trials were usually unblinded although some were investigator-blinded (10, 12, 17).  Although 
most trials did not state whether they aimed to establish superiority, equivalence, or non-inferiority, two 
trials explicitly assessed non-inferiority (10, 12).  Most of the studies in the literature reviewed prior to 
the development of this trial protocol compared a version of Corn-Soy Blend (CSB) or micronutrient 
powders (MNP) with another food (9-12, 14, 16, 18).  
The following published protocol describes the planned methodology for the effectiveness trial. 
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Abstract
Background: Existing ready-to-use supplementary and therapeutic foods (RUSFs and RUTFs) have had limited
acceptance and effectiveness in Cambodia. This has hampered the treatment and prevention of child malnutrition.
An innovative, locally produced, multiple micronutrient fortified lipid-based nutrient supplement (LNS) has been
developed for use as an RUSF. Unlike most RUSFs, which contain milk, this product contains fish as the animal
protein. Few RUSFs have been formulated using non-milk animal-source foods and they have not been widely
tested. An acceptability trial that was conducted on this novel RUSF in June 2015 demonstrated that children will
eat the RUSF and that caregivers will feed it to their children. The current trial aims to evaluate the effectiveness of
the RUSF in preventing growth faltering and improving micronutrient status in Cambodian children.
Methods and analysis: This trial is a six-month, prospective, cluster randomised, non-blinded controlled trial
among infants in peri-urban Phnom Penh. The trial aims to establish the superiority of the novel RUSF, compared
to three alternatives (Corn-Soy Blend Plus Plus (CSB++) and Sprinkles micronutrient powders as active comparators,
and the unimproved diet as a control). The allocation ratio is 1:1. Healthy children (N = 540) aged six to eleven
months will be recruited. Data will be collected at baseline, and monthly thereafter for a period of six months.
Participants will be provided with a monthly supply of the food to which their village has been allocated.
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Discussion: There is an urgent need to develop locally produced and culturally acceptable RUSFs, and to compare
these with existing options in terms of their potential for preventing malnutrition, in Cambodia and elsewhere. This
trial will contribute much-needed data on the effectiveness of supplementary foods with an animal-source food
other than milk, by comparing a novel RUSF based on fish to one that uses milk (CSB++). Moreover, it will deepen
the understanding of the impact of multiple micronutrients provided with or without macronutrients, by
comparing the novel RUSF and CSB++, which combine macronutrients with multiple micronutrients, to Sprinkles,
which contains no macronutrients. In addition, it will augment the body of evidence from Asia.
Trial registration: ClinicalTrials.gov, Identifier: LNS-CAMB-INFANTS-EFF; NCT02257762.
Keywords: Ready-to-use supplementary food (RUSF), Lipid-based nutrient supplement (LNS), Childhood malnutrition,
Growth faltering, Corn-Soy Blend Plus Plus (CSB++), Supercereal Plus, Sprinkles micronutrient powders, Cambodia
Background and rationale
Undernutrition is an underlying cause in almost half of
all deaths in children under five years [1]. In Cambodia,
rates of malnutrition remain stubbornly high [2] with 32%
of all children under five years (and 40% of three to four
year-olds) stunted, 10% wasted, and 24% underweight [2].
Suboptimal infant feeding practices, in particular, poor
complementary feeding, result in inadequate energy and
nutrient intakes to achieve optimal growth and micronu-
trient status, and consequently, childhood malnutrition.
Adequate complementary feeding can prevent malnutri-
tion [3]. In Cambodia, the traditional weaning food is a
white rice porridge called borbor, which has very low nu-
trient density. Special supplementary foods, containing a
source of protein and lipids such as powered milk, soy or
peanuts, and multiple micronutrients, can be used to im-
prove complementary feeding. Supplementary foods can
be either foods requiring preparation e.g. fortified blended
products, such as Corn-Soy Blend++ (CSB++, now called
Supercereal Plus), that is mixed with water to make a por-
ridge; or ready-to-use e.g. biscuits, such as BP5. Until
fairly recently, prevention of malnutrition relied on forti-
fied blended products. However, increasingly, ready-to-use
foods are lipid-based nutrient supplements (LNSs) which
are often pastes, such as the peanut-based Plumpy’Doz™.
These energy-dense ready-to-use supplementary foods
(RUSFs) contain both macro and micronutrients [4, 5].
These new RUSFs are proving effective, as they have a
higher energy content, and have a longer shelf life, and,
since they require no preparation, are more convenient [5,
6]. Another common nutrition intervention is multiple
micronutrient supplements such as Sprinkles, used solely
to combat micronutrient deficiencies. These are
individually-packed powders that can be added to food.
Micronutrients are more likely to achieve growth out-
comes when they are combined with energy, for example,
in lipid-based nutrient supplements; there is no evidence
that micronutrient powders alone contribute to sustained
improvements in linear growth [7–12].
In Cambodia, various supplements and supplementary
or therapeutic foods, including micronutrient powders,
CSB++, BP100, and Plumpy’Nut™ have been used or
trialled. The United Nations World Food Program (WFP)
in Cambodia distributed CSB++ to children under two
years to prevent malnutrition. Micronutrient powders
(Sprinkles) have also been distributed through the public
health system, though coverage is limited. These products
are relatively expensive to procure and ship to Cambodia
and in the case of Sprinkles, are not as effective as foods
that contain macronutrients [9, 10]. Plumpy’Nut™, which
is produced in France by Nutriset, was trialled in
Cambodia in 2009 and was not well accepted [13]. Nor
was CSB++ very well accepted in practice [14]. Due to
lack of acceptability, and also due to budget constraints,
WFP phased out distribution of CSB++ in Cambodia in
June 2014. In addition, BP100, which is currently used in
Cambodia to treat severe acute malnutrition, has not been
well accepted [15].
For these reasons, the Cambodian Ministry of Health
sought a ready-to-use food (in both therapeutic and sup-
plementary versions) containing macro and micronutri-
ents that was locally-produced and therefore more likely
to be acceptable and cheaper than imported products.
In 2009 in Vietnam, UNICEF, IRD (Institute of Research
for Development) and the National Institute of Nutrition
developed a supplementary food from mainly local ingre-
dients including rice, soy, mung beans, sugar, milk powder,
oil and multiple micronutrients (called HEBI). This prod-
uct proved more acceptable and as effective as Plumpy’-
Nut™ and is now widely used in Vietnam [16]. In
mid-2013, IRD, partnering with UNICEF and the Cambo-
dian Department of Fisheries Post-harvest Technologies
and Quality (DFPTQ), began developing a novel RUSF
based on the same concept as the Vietnamese product.
WHO recommends daily consumption of animal-source
foods for their high protein, energy, and micronutrient
availability, which plant-based complementary food
alone cannot provide [17]. Animal-source foods have
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been associated with greater micronutrient status, linear
growth and non-fat mass gain compared to non-animal-
source food [18, 19]. Usually, milk or whey powder is the
animal-source food most commonly used in supplemen-
tary foods including CSB++ and various RUSFs [20, 21].
However, milk powder is an expensive (and often
imported) ingredient. Therefore, it could perhaps be re-
placed with a cheaper, local source of animal protein
that is widely accepted by the target population. There
are precedents for replacing milk in supplementary
foods for cost effectiveness [22], but until now, only a
handful of supplementary foods have used meat, fish or
eggs and they have generally not been tested for effect-
iveness on a wide scale [23–27]. The only known effect-
iveness study involving a supplementary food with fish
compared a peanut and soy-based fortified spread to a
corn porridge fortified with fish powder with six to
eighteen month old children, and found that children
consuming the porridge with fish powder gained less
weight from six to eleven months, but otherwise the two
supplementary foods performed similarly in terms of
weight gain from twelve to eighteen months and linear
growth [28]. In a number of studies, supplementing with
meat or milk (as opposed to a supplementary food prod-
uct containing no meat or milk), the nutritional improve-
ment was less than expected, and sometimes was only the
slowing of growth faltering [29, 30]. A study in Kenya is
the only one to have compared milk and meat, and found
meat had a greater impact, perhaps because milk inhibited
iron and zinc uptake [29]. In all of these studies, the lim-
ited impact of meat or milk may have been because the
additional food did not contain a sufficient range or quan-
tity of micronutrients to overcome deficiencies.
In Cambodia, fish is inexpensive, readily available and
highly acceptable to local tastes, and could therefore re-
place milk in a supplementary food. Combined with rice,
soy, mung beans, oil and sugar, the resulting product
should be less expensive and more acceptable to Cambo-
dians. IRD developed the first version of this product in
paste form in early 2014. It was compared to BP100, and
found to be equally acceptable in younger children, al-
though older children preferred BP100’s milky taste to
the fishy flavour of the RUSF.
The product was revised to reduce the fish smell and
make it into a snack. It was then tested for acceptability
in comparison to CSB++ and Sprinkles with borbor in
June 2015. That trial demonstrated that children will eat
the RUSF and that caregivers will feed it to their chil-
dren. The next step is to assess the effectiveness of the
food in preventing malnutrition, and promoting optimal
growth and development. Therefore, a six-month effect-
iveness trial will be conducted. The impact of the prod-
uct on children aged six to seventeen months will be
compared to the impact of CSB++, Sprinkles, and to a
control group consuming an unsupplemented diet, typ-
ically borbor at an early age (e.g. six to nine months) and
thereafter, family foods.
RUSF formulation
The RUSF has been formulated and produced locally,
using local inputs. Small freshwater fish were cleaned,
dried, roasted and ground. Soy and mung beans were
roasted and ground, then mixed with the fish and coconut.
This mix was extruded, then combined with multiple
micronutrient premix (DMS), icing sugar, maltodextrin
and canola oil to create the RUSF paste. Wafers were
hand-made from rice flour, eggs, water, sugar, salt and
coconut with small amounts of vanilla or sesame seeds for
added flavour. The wafer is a hollow cylinder between
8.5-9 cm long with an internal diameter of 0.4–0.5 cm.
Such wafers, unfilled, are a popular Cambodian snack.
The ingredients of the RUSF are detailed in Table 1.
Although there are no definitive guidelines for supple-
mentary foods, the RUSF was developed with the recom-
mended guidelines for the nutritional composition of
RUTFs in mind [31]. RUTFs should provide 520-550 kcal/
100 g with 10–12% and 45–60% of the total energy coming
from proteins and lipids respectively. Our RUSF contains
484 kcal/100 g, with 11% and 45% of the total energy com-
ing from proteins and lipids respectively. The energy con-
tent of the paste is 499 kcal/100 g. The wafer, filled with
the RUSF paste, yields a final snack weighing approxi-
mately 10-11 g, including 7 g of paste and 3-4 g of wafer,
with an energy content of approximately 48 kcal/piece.
Table 1 Ingredients of RUSF snack (paste and wafer)
Ingredients g/100 g
Small indigenous fish 5.9
Mung beans 9.6
Rice 4.2
Soy beans 12.2
Icing sugar 10.3
Maltrodextrin 9.3
Canola oil (g) 3.7
Palm vegetable shortening 14.0
Desiccated coconut 1.5
Rice bran 2.2
Vitamin and mineral mix 0.9
Rice flour 9.0
Duck eggs 2.5
Refined sugar 7.2
Coconut 7.2
Salt 0.0
Flavour (vanilla or sesame seeds 0.1
Oil for cooking 0.4
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All processing has been conducted in quality-certified
facilities. The novel RUSF will be tested for microbio-
logical safety (first five batches and every fifth batch
thereafter) at the Pasteur Institute in Phnom Penh.
Design and methods
Objective and Hypothesis
This trial aims to evaluate the effectiveness of the locally
produced RUSF on children aged six to seventeen months
in preventing growth faltering and improving micronu-
trient status. The impact of the product will be compared
to CSB++, Sprinkles, and to a control group consuming
an unsupplemented diet.
Based on trials with other RUSFs, and the Cambodian
experience with CSB++ [14], it is expected that this
novel RUSF will be as effective as CSB++, and more ef-
fective than Sprinkles or the standard diet in promoting
growth and preventing stunting [32, 33].
Trial Design
The trial is a prospective, cluster randomised, non-blinded
controlled trial among infants six to seventeen months of
age. The trial aims to establish the superiority of the novel
RUSF, using CSB++, and Sprinkles as active comparators
and the unimproved diet as a control. The allocation ratio
is 1:1. The study will take place over six months.
Comparators
The RUSF will be compared with:
1. CSB++: CSB++ has been chosen as a comparator
because it is currently the standard supplementary
food. WFP usually provides CSB++ for children aged
six months to two years to prevent malnutrition.
2. Sprinkles: Sprinkles micronutrient powders have
been chosen since they are a commonly provided
supplement in developing countries, such as Cambodia,
with low dietary diversity, and complementary foods
with low nutrient density [34].
3. Control: An unsupplemented diet, typically borbor
and family foods, has been chosen as a control
because this is the standard diet in Cambodia. Borbor
is the traditional food for weanlings (children
transitioning from exclusively milk diets to diets that
include complementary foods) and is often the only
food given until about nine months.
The active comparators comply with WFP and UNICEF
standards for supplementary foods, and have been used
and tested in Cambodia and elsewhere [18, 33, 35]. They
have been found to be safe and to have no unintended
side-effects. The table below contrasts the characteristics
of the RUSF and comparators (Table 2).
The potential comparators that will not be used are
BP100 (because it is designed to treat severe acute
malnutrition) and peanut-based RUSFs. The latter will
not be included because they are thought to be less ac-
ceptable, and are too expensive from current producers.
Moreover, including peanuts in a locally produced
Cambodian RUSF is not advisable as local production
standards may not be adequate to safeguard against af-
latoxin contamination, given that the rate of aflatoxin
contamination of peanuts in South-East Asia is prob-
ably quite high [36–38].
Outcomes and their measurement
The main outcome of interest is anthropometric status,
i.e. length/height-for-age (L/HAZ), weight-for-height
(WHZ) and weight-for-age (WAZ), calculated through
monthly weight and height measurements. A HAZ < − 2
indicates stunting, a WAZ < − 2 indicates underweight,
and a WHZ < − 2 indicates wasting. A secondary out-
come is children’s body composition. Body composition,
like linear growth, gives an indication of the quality of
nutritional recovery, inasmuch as non-fat or lean tissue
growth requires balanced nutrition while fat gain re-
quires only calories [39]. Body composition will be cal-
culated using triceps and subscapular skinfolds [40, 41].
Another secondary outcome is biochemical status, includ-
ing iron status and anaemia, infection measured by C-
reactive protein (CRP) and alpha-2 acid glycoprotein
(AGP), and parasite infestation. An additional outcome is
cognitive development and achievement of developmental
milestones.
Blinding
This will be an open trial with no blinding, since the
three foods will be visibly different to data collectors,
caregivers and children. The principal investigator (who
will do supervision in the field) and the staff administer-
ing the intervention will know which food has been allo-
cated to a given village.
Study setting
The study will be conducted in northern peri-urban
Phnom Penh (Khan Russey Keo, Mekong Health District).
This area has a large population of urban poor whose chil-
dren experience higher than average rates of underweight
and stunting [42, 43].
Allocation sequence generation and concealment
Randomisation of the interventions will occur at site level.
Using UNICEF data on health centre coverage, potential
villages and their populations (including the expected
population of children aged 6–11 months) will be listed.
Villages receiving Sprinkles or CSB++ will be excluded
based on information provided by UNICEF, WFP and the
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Table 2 Characteristics of the RUSF and comparators
CHARACTERISTIC RUSF CSB++ Sprinkles
Daily serving size 40-110g* 100 g dry CSB++ 1 sachet (1 g)
Animal-source food Fish Milk –
Energy (kcal/100 g) 484 410 –
Protein (g/100 g) 13 16 –
Carbohydrates (g/100 g) 52 67 –
Lipids (g/100 g) 24 9 –
Fibre (g/100 g) 1.6 3 –
Vitamin A 1080 μg 540 μg 400 μg
Vitamin D 60 μg 4.6 μg 5 μg
Vitamin B1 (thiamine) 0.59 mg 0.47 mg 0.5 mg
Vitamin B2 (riboflavin) 0.89 mg 0.84 mg 0.5 mg
Vitamin B6 0.84 mg 2.1 mg 0.5 mg
Phosphorus 474 mg 530 mg –
Calcium 366 mg 260 mg –
Pantothenic acid 1.75 mg 7.3 mg –
Copper 1.6 mg – 0.56 mg
Vitamin E 10.9 mg 9.8 mg 5 mg
Folic acid 230 μg 115 μg 150 μg
Iron 8 mg 8.9 mg 10 mg
Magnesium 137 mg –
Vitamin B3 (niacin) 9.63 mg 7.2 mg 6 mg
Vitamin C 53.4 mg 100 mg 30 mg
Zinc 8.4 mg 7.5 mg 4.1 mg
Potassium 806 mg 990 mg –
Vitamin B12 10 μg 2.3 μg 0.9 μg
Biotin 0.37 mg – –
Selenium 90 μg – 17 μg
Iodine – 60 mg 90 μg
Vitamin K 3 μg 115 μg –
Taste Fishy Creamy, sweet, smooth [52] Should not have a taste [53]
Preparation No 10 mins cooking No
Acceptability in Cambodia Yes Acceptable in trial [52], but not
in practice [14]
Yes [35]
Effectiveness in reducing malnutrition To be tested Not inferior to peanut-based RUSFs,
which are the most effective in
promoting linear growth and weight
gain [18, 33]
Improves micronutrient status
but not linear growth or weight
gain [5, 12, 35]
Intra-household sharing To be tested Yes [33] None noted [35]
Packaging To be determined Packaging may encourage sharing [5, 39] Looks like “medicine” thus may
discourage sharing [5, 39]
Local production capacity Unknown None [5] None
Cost To be determined.
Goal is <US$0.10/day
Less expensive than peanut-based
RUSFs if produced locally [18], but
also have to consider logistics, time
to treat, relapse [39]
Very cheap to produce at
US$0.025/daily dose [11],
but also have to consider
logistics
*RUSF daily serving size depends on the child’s age, i.e. 6-8 m – 4 pieces, 40 g; 9-11 m – 6 pieces, 60 g; 12-17 m – 11 pieces, 110 g
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Ministry of Health. Small villages that are close to each
other may merged into one site, or large villages split into
multiple sites, in order to create sites of similar sizes. Sites
will then be randomised to one of the arms.
Thus, participants will not be individually randomised.
All subjects in a given site will be in the same intervention
group to avoid potentially confounding social interaction,
such as inter-household sharing of different foods, and to
ensure better compliance [44]. Sites will be randomly allo-
cated to one of the foods, using an Excel random number
table and a randomised incomplete block design. The
principal researcher will generate the allocation sequence.
At least three sites will be allocated to each food.
Sample size
The main outcome of interest is anthropometric status
(WHZ, WAZ and L/HAZ), calculated through changes
in weight and length/height for the novel RUSF in com-
parison to the CSB++, Sprinkles, and the control after
six months of the interventions. An overall required sam-
ple size of 424 subjects, or 106 subjects per group, was
calculated, based on the assumptions of a difference in
mean z-scores of 0.1 between the groups (95%CI), an SD
= 0.8, and an assumption that subjects provide five mea-
surements (out of a possible total of seven), with a preci-
sion of 0.05, power of 0.8. This is in keeping with similar
effectiveness studies which have aimed to detect a differ-
ence in mean z-scores of 0.16 between groups, assuming
SD = 0.8 [45], or a difference in mean z-scores of 0.1 and
SD = 0.8 [20]. Therefore, detection of difference in mean
z-scores of 0.1 between groups is reasonable.
In similar studies, retention has been high at [22, 28, 35].
Therefore, we can assume a maximum attrition of 25%
with confidence. The total number of subjects enrolled will
therefore be 530, or approximately 133 children in each
group. This will be rounded up to 135 children/group for a
total of 540 subjects, which should be adequate. See Fig. 1
for the planned site selection, recruitment and enrolment
of children.
Eligibility criteria
Children must be between six to eleven months of age at
enrolment. It is expected that there will be approximately
equal numbers of female and male children. Subjects must
be normally nourished or only moderately malnourished
(mid-upper arm circumference, MUAC> 115 mm, WHZ
score > − 3), and healthy. Their iron status should be
normal or only moderately anaemic; children with severe
anaemia (haemoglobin, Hb < 70 g/l) will be referred for
treatment. Any children who have been using Sprinkles or
CSB++, are regularly consuming or receiving other food
or micronutrient supplementation, are enrolled in any
other research or supplementary feeding program, or have
received therapy for acute malnutrition within one month
prior to recruitment, will be excluded. Children with
Fig. 1 Site selection, recruitment and enrolment of children
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known food intolerances will also be excluded. Caregivers
must be healthy, and must give informed signed consent
for their children to be included.
Recruitment, Enrolment and Consent
Village Health Support Group members (local health
volunteers) will assist with recruitment, initially by invit-
ing potential caregivers and children to participate in the
trial. The data collection team will use a screening form
to assess initial eligibility of participants. Some participants
may be excluded at this point (e.g. on the basis of age or
unwillingness to participate). Those who are excluded
for severe acute malnutrition, anaemia or illness will be
referred for treatment.
Those who are eligible will be provided with written
and verbal information about the trial in Khmer lan-
guage. If the participant is willing to continue, they will
be asked to provide their verbal and signed (or finger-
printed) consent for them and their children to partici-
pate. It will be made clear that potential participants
have the option of not joining the study. If they consent
to participate, it will be made clear that they can ask
questions, make complaints, or withdraw at any time.
Data collection
After informed consent and enrolment, baseline data will
be collected. This will include demographics, morbidity,
anthropometry (weight, height, MUAC, skinfolds), bio-
chemical samples (blood, stool), dietary data (breast-
feeding, food frequency and dietary diversity), and
developmental milestone achievement. Participants may
still be excluded if they are malnourished (MUAC<
115 mm, WHZ score < − 3) or severely anaemic.
Participants in the intervention groups will then be
provided with a one-month supply of the food to which
their site has been allocated. Thereafter, participants will
be provided with food on a monthly basis, and they will
continue to consume the food over a six-month period.
Data will be collected monthly (anthropometry, morbidity,
developmental milestones), and/or at endline (biochemical).
Staff will inform the Village Health Support Group
members in advance of monthly data collection sessions,
and the latter will arrange for participants to be present.
If caregivers are not present, they will be followed up by
mobile phone and/or by the Village Health Support
Group members and home visits will be conducted.
Anthropometric data
Anthropometric measurements will include weight to the
nearest 0.1 kg, recumbent length to the nearest 0.1 cm,
skinfolds to the nearest 1 mm, and MUAC to the nearest
1 mm. Weight will be measured with a SECA scale, length
will be measured on wooden UNICEF height boards,
MUAC will be measured with a flexible UNICEF insertion
tape and skinfolds will be measured with a standard cali-
per (Holtain, United Kingdom). Anthropometry will be
measured monthly. Children with MUAC < 115 mm and
WHZ < − 3 at enrolment or at any time during the study
will be excluded from the study and referred to the health
centre for treatment.
Morbidity data
Data on diarrhoea and respiratory infections will be
collected at the beginning of the study and monthly
thereafter. Children with serious illnesses or severe malnu-
trition will be excluded from the study and referred to the
health clinic for treatment.
Biochemical samples
Blood samples (4mls) will be drawn at baseline and end-
line by trained nurses who are skilled and experienced in
taking paediatric blood samples. One to two drops will
be used immediately to measure haemoglobin (using a
HemoCue HB301 photometer). Of the remaining blood,
2mls will be placed in a trace element sodium heparin
vacuette for further micronutrient analysis. The remaining
blood will be placed in Ethylenediamine tetraacetic acid
(EDTA) tubes for fatty acid analysis, then 40 μl will be
pipetted onto pre-treated chromatography paper to be
analysed as a dried blood spot. Blood samples will be
stored, transported and analysed appropriately to avoid
contamination and deterioration. Analysis will be con-
ducted for micronutrient status including haemoglobin
(g/l), ferritin (μg/l), transferrin receptor (mg/l), retinol-
binding protein (vitamin A status) (μmol/l), zinc (μmol/l),
C reactive protein (mg/l), using internationally accepted
indicators [46].
Stool samples will be taken and tested for parasites. Stool
containers will be distributed to caregivers and collected
the following day. Analysis will be conducted using
FLOTAX method.
Cognitive data and developmental milestones
The mental and motor development and behaviour of
the participants will be tested monthly using the Bayley
Scales of Infant Development (BSID), an internationally
recognised standard of determining children’s develop-
mental progress. In addition, a more detailed assessment
will be conducted at endline.
Compliance data
Data on consumption, sharing, and adherence will be gath-
ered monthly. Subjects will be provided with a month’s
supply of food at this time.
Dietary data
Dietary data including breastfeeding status, food frequency
and dietary diversity for caregivers and children will be
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collected monthly, using the Cambodian Demographic and
Health Survey (CDHS) questionnaires as a model.
Endline data
Endline data will be collected on infants aged twelve to
seventeen months at the end of the study.
Timeline
The study will take place in 2016–2017 (see Table 3).
Statistical analysis
All data will be double-entered in Excel. Data will be
analysed in the statistical software required by the PhD
candidates’ respective universities. Thus, anthropometric
data will be analysed by one PhD candidate in the statis-
tical software STATA version 13.1, and biochemical and
cognitive/developmental data will be analysed by another
PhD candidate in SPSS and R.
Since most of the measures being taken are repeated
on a monthly basis, the assumption of independence is
not satisfied. Therefore, a mixed effect model, which is
appropriate for repeated measurements, will be used.
Predictor variables will be checked for normality and lin-
earity, and manipulated and recoded as necessary. Out-
come variables will be manipulated and recoded if
necessary to deal with non-normality and/or for easier
interpretation. Initial univariate screening will be conducted
at p ≤ 0.2 level using simple logistic regression to screen for
variables that could have an effect, and collinearity assump-
tions will be checked, in order to determine which covari-
ates to include in the model. A complete mixed effects
logistic regression will then be fit to the data. Significance
levels will be considered p < 0.05. Any missing data will be
treated as “missing at random” and accounted with the
mixed effect model.
Anthropometric status
The main outcome of interest is change in anthropometric
status. The independent variables are the food, sex and
age, and the dependent variables are the mean weight-
for-height (WHZ), height/length-for-age (H/LAZ) and
weight-for-age (WAZ). Anthropometric indices for chil-
dren will be calculated using World Health Organisa-
tion (WHO) 2006 standards (ANTHRO version 3.2.2
January 2011) and expressed as z-scores for weight-for-
height (WHZ), height/length-for-age (H/LAZ) and
weight-for-age (WAZ). Thus, multiple means will be
compared, and changes will be analysed using a mixed
effects model to determine whether there are statisti-
cally significant changes in WHZ, H/LAZ and WAZ of
participants consuming the different foods.
Body composition
A second outcome is body composition measured by
skinfold thickness. The independent variable is the food
and the dependent variable will be the mean of skinfold
thickness. The data will be analysed using a mixed ef-
fects model to determine whether there is a statistically
significant difference in the body composition of partici-
pants eating the different foods.
Enrolment data
Enrolment data describing the characteristics of the re-
cruited participants (e.g. sex, age, anthropometric and
biochemical status, morbidity, breastfeeding status) will
be reported as means ± SD for continuous measures.
Ethics and consent
Ethics approval was received from the University of
Queensland Medical Research Ethics Committee and the
National Ethics Committee for Health Research (NECHR)
Table 3 Schedule of enrolment, interventions and assessments
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT Feb 2016 Feb 2016 Feb 2016 Mar-Sept 2016 Oct 2016 Early 2017
ENROLMENT: X
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Baseline X
Monthly data collection X
Endline X
DOCUMENTATION:
Anthropometry X
Micronutrients X
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in Cambodia. Written informed consent will be obtained
from all the caregivers or parents of the participating
children before recruitment into the study. Based on
the experience of similar trials [20, 22, 28, 45], and
given the inclusion and exclusion criteria, no harm is
expected from trial participation. However, morbidity
data will be collected every month, and this will record
any harm (nausea, etc.) that could come from participa-
tion in the trial.
Discussion
The development and comparison of new supplementary
foods with current fortified blends and existing RUSFs in
terms of their potential for preventing growth faltering
and malnutrition responds to a need noted by various
researchers [5, 22, 47–49] as well as to a programmatic
need. Such products need to be affordable, effective, and
acceptable in terms of preparation as well as taste [23].
The novel RUSF has proved acceptable and this trial will
test its effectiveness, in terms of the main outcomes,
namely, anthropometric measures, body composition
and biochemical status.
Six months is sufficient time to see changes in the
main outcome, that is, in anthropometric measures. Simi-
lar effectiveness studies (considering weight and length
outcomes) have ranged from as little as four weeks [20],
with many studies taking twelve weeks to compare three to
eight food supplementation regimes [18, 22, 29, 32, 33, 50],
and others taking six months [39]. The INCAP study in
Guatemala provided supplementary food to children for up
to seven years, but nevertheless noted a detectable differ-
ence after three and six months of supplementation [10].
With respect to linear growth, healthy infants grow ap-
proximately 1.25 cm each month from six to eleven
months [51]. Golden notes that although the maximum
rate of height gain is as yet unknown, catch-up growth
can easily be three times the rate of normal growth.
Thus, a malnourished child less than one year of age
can gain one z-score in two to four weeks if receiving
adequate nutrition [4]. The mean HAZ-score for a
Cambodian child of six months is − 0.5, for twelve to
seventeen month-olds is − 1.3 and for eighteen to twenty-
three month-olds is − 1.8 [2]. Therefore, s/he loses around
0.8 z-score in six to eleven months, or approximately 0.07
z-score per month. In our trial, if the intervention stops or
slows growth faltering, we could see a difference in HAZ-
scores of up to 0.42 over six months between intervention
and control groups.
Since it is not uncommon nowadays to find stunted
but overweight individuals [4], a recent Cochrane review
recommended that future research report results on body
composition [49]. Among stunted, non-wasted children,
prevention is preferable to treatment [5]. In either treat-
ment or prevention of malnutrition, the aim is to increase
non-fat mass (bones, muscles) in preference to fat mass,
and one should therefore see linear growth as well as in-
creased weight, since linear growth is a better indicator of
nutritional recovery than weight gain [4]. Therefore, body
composition will also be an important outcome of our
trial.
The effectiveness trial of our novel RUSF will determine
how a ready-to-use, fish-based, supplementary food com-
pares with CSB++, Sprinkles, and an unsupplemented diet
in terms of preventing of growth faltering and improving
micronutrient status. This trial will contribute much-
needed data on the effectiveness of supplementary foods
with an animal-source food other than milk, by comparing
a supplementary food with fish (the RUSF) and one with
milk (CSB++). Moreover, it will deepen the understanding
of the impact of multiple micronutrients provided with or
without macronutrients, by comparing the RUSF and CSB
++, which combine macronutrients with multiple micro-
nutrients, and Sprinkles, which contains no macronutri-
ents. Moreover, most studies on supplementary foods are
from Africa, so this research will be an important contri-
bution to the body of evidence from Asia [49].
There are two limitations of this trial. First, the data
on consumption and compliance is based on self-
reporting, and therefore risks response bias. It could be
expected that any response bias would favour over-
reporting of consumption, which may suggest lower ef-
fectiveness of the interventions. Similarly, sharing of foods
with family members would likely be under-reported,
again leading to underestimation of effectiveness. The sec-
ond limitation is related to the generalisability of the find-
ings to non-urban Cambodian populations, and to other
South East Asian populations. Rural areas of Cambodia
experience higher levels of malnutrition and poorer infant
and young child feeding practices than urban [2]. There-
fore, in rural settings, it would be difficult to predict if the
interventions would appear more efficacious, or less.
From a programmatic point of view, if the novel RUSF
proves successful, not only would it provide an accept-
able, effective product for preventing childhood malnu-
trition. It might also simplify interventions in maternal
and child nutrition in Cambodia and in countries where
similar products could be produced, since, because of its
composition, it could be used with pregnant and lactat-
ing women as well as children aged six months to two
years.
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Departures from effectiveness protocol  
The trial was conducted for the most part according to the protocol, with departures indicated below.  
Sample size 
The required sample size was 424 subjects, or 106 subjects per group.  Assuming an attrition of 
approximately 25%, we aimed to recruit 540 subjects or 135 children/group.  In fact, recruitment proved 
more difficult than expected, and a second round of recruitment was conducted.  Ultimately, 485 
subjects were recruited, with 128, 127, 124 and 106 subjects in the control, RUSF, CSB++ and MNP 
groups respectively. 
Duration of trial 
The planned duration of the trial was six months or 182 days.  In some cases, scheduling constraints 
(usually due to weekends or public holidays) reduced or extended this duration.  The shortest period 
that any child was in the trial was 168 days and the longest was 220 days. 
Inclusion/exclusion criteria - age 
Two children were recruited at only five completed months of age.  One was five months and twenty-
seven days, and the other was five months and thirty days.  At the point that the error was discovered, 
the children had already completed baseline data collection, including anthropometry and blood 
collection.  Therefore, it was decided that it was not ethical to exclude them. 
At the end of the trial, nine children were less than one full year of age (ranging from 350 to 364 days 
old).  Six children were older than eighteen months (by one to eleven days).  
Inclusion/exclusion criteria – WHZ and MUAC 
Children with a WHZ ≤ -3 or ≥ 3 were excluded and the former were referred for treatment.  Children 
with a MUAC < 11.5cm were excluded and referred for treatment.  In the field, the data collectors 
responsible for anthropometric measurements used the paper-based WHO simplified field tables for 
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WHZ for boys and girls aged birth to two years (z-scores).  When children seemed very close to a WHZ 
of ±3, the researcher checked the WHZ, using a z-score calculator smartphone app (S-Cubus, Inc.)  
However, when WHZ was calculated using weight, height, age, and sex in the database, two children 
had a WHZ of less than -3 (-3.61 and -3.09 respectively) and one child had a WHZ of 3.32.  One child 
with MUAC 11.45cm was also enrolled.  It is unclear how these errors occurred.   
At the same time as our RUSF trial, a trial was being conducted on the ready-to-use therapeutic food 
(RUTF) version of the food.  This trial was having difficulty recruiting children with WHZ ≤-3 and 
began recruiting children with WHZ ≤-2.8 and below.  Our project began referring children with WHZ 
≤-2.8 and below to that project. 
Inclusion/exclusion criteria - MNP 
Some participants were familiar with MNP.  However, MNP had not been distributed or used 
systematically.  Therefore, it was decided to include rather than exclude those participants.  
Loss of one cluster 
Cluster 24 recruited only one participant who dropped out after baseline, resulting in twenty-seven 
instead of twenty-eight clusters at endline. 
Data collection format and data entry 
Baseline data collection was paper-based.  However, from the first month of follow up, data collection 
was shifted to hand-held tablets, using KoBo Toolbox (http://www.kobotoolbox.org/).  Therefore, only 
the baseline data was double entered in Excel.  All other data was entered directly in KoBo Toolbox. 
Post hoc analysis of consumption 
Post hoc analysis of consumption was conducted, with children who ate less than 75% of the monthly 
food supplied being considered to have low consumption, and those who ate 75% or more having high 
consumption. 
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Chapter 7: Results of the effectiveness trial 
Part of this chapter has been accepted for publication as: 
o Borg B, Sok D, Mihrshahi S, Griffin M, Chhoun C, Berger J, Laillou A, Roos N, Wieringa FT.
Effectiveness of a locally-produced ready-to-use supplementary food (RUSF) in preventing growth 
faltering and improving micronutrient status for children under two years in Cambodia: a
randomised controlled trial.  Maternal & Child Nutrition. 2019;(forthcoming).
This chapter describes the justification, results, contribution, and implications of the effectiveness trial. 
It begins by discussing the justification for an effectiveness trial.  Then it goes on to describe the main 
results, and to outline what the trial adds to the literature.  The final section is the current proof of the 
forthcoming publication. 
Justification for the effectiveness trial 
The main objective of the broader project, as articulated by the Cambodian Ministry of Health (MoH), 
was to develop a locally-produced ready-to-use therapeutic food (RUTF) as an alternative to the existing 
therapeutic product that was being used to treat severe acute malnutrition (SAM), namely BP-100™.  
The development and testing of a ready-to-use supplementary food (RUSF) for the prevention of 
undernutrition was a secondary objective, made more pressing when the World Food Program (WFP) 
ceased distribution of their standard supplementary food for children aged six months to two years, 
Corn-Soy Blend Plus Plus (CSB++).  
As described in Chapter 6, the literature at the time focused on treating severe and moderate acute 
malnutrition (SAM and MAM) with lipid-based nutrient supplements (LNSs) or fortified blends, in 
food insecure settings in Africa (1-4).  Little had been published about prevention of childhood 
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undernutrition, particularly in representative populations that included non-MAM children in food 
secure settings (2, 5).  
Main results 
Our six-month trial enrolled 485 children aged six to eleven months compared the RUSF to CSB++, 
micronutrient powders (MNP), and an unsupplemented control group.  Figure 7.1 shows a monthly 
supply of each of the intervention products. 
Growth continued to falter in all groups from baseline to endline.  In adjusted analysis, high and low 
consumers of RUSF had increased mid-upper arm circumference (MUAC) in comparison to the control, 
as did high and low consumers of CSB++, and high consumers of MNP.  Low consumers of RUSF had 
increased weight-for-age z-scores (WAZ) in comparison to the control, as did high consumers of 
CSB++ and MNP.  Low consumers of RUSF also had increased weight-for-height z-scores (WHZ) 
compared to the control, as did high and low consumers of CSB++.  Height-for-age z-scores (HAZ) 
decreased in all groups, especially amongst low consumers of CSB++.  
Thus, the results of our trial, as others, are mixed.  RUSF and CSB++ protected against the wasting and 
underweight experienced by the control group, but none of the interventions protected against stunting. 
Figure 7.1: A monthly supply of the intervention products.  Left to right:  CSB++ (1 bag, 3kg, 100g/day), MNP (~35 
sachets, 35g, 1g/day), RUSF (box of 120-380 pieces, 1.2-3.8kg, 4-11 pieces/day depending on child’s age). 
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Interestingly, low doses of RUSF seem to be effective, which indicates that future trials with small 
quantities of the RUSF may be warranted.  Overall, however, the impact was of limited clinical 
significance, highlighting the importance of considering additional factors and strategies for prevention 
of undernutrition in Cambodian children. 
What this trial contributes to the literature 
There have been some important changes in the five years since the study was designed, particularly 
with respect to the use and effectiveness of small quantity LNSs (SQ-LNSs) (6-8) and the inclusion of 
unsupplemented controls.  However, the focus has tended to remain on Africa, on moderately acutely 
malnourished children in food insecure settings, and on comparing specially formulated food products 
to each other rather than to other food or non-food interventions, such as dietary improvement with 
unprocessed foods, or nutritional counselling (9-13).  Our effectiveness trial provides evidence from a 
representative population of children, including an unsupplemented control, in a food secure setting in 
South-East Asia.  In that respect, it contributes significantly the literature on prevention of childhood 
undernutrition.  
Our trial shows that fish is a potential replacement for milk in specially formulated supplementary food.  
It has proved consistent with the finding that in the absence of adequate macronutrients, micronutrients 
do not contribute to growth (14-20).  In our trial as in others, WAZ, WHZ and MUAC increased for 
some one of the interventions, whereas HAZ was less likely to improve (21-23).  Our trial, like others, 
found that the impact of supplementary feeding interventions on undernutrition has been slight, mixed, 
or of limited clinical significance.  This suggests that specially formulated supplementary food may 
play only a small role in undernutrition prevention programming among a representative population of 
children in food secure settings. 
The following proof of the forthcoming publication describes the results of the effectiveness trial in 
detail. 
102
OR I G I N A L A R T I C L E
Effectiveness of a locally produced ready-to-use
supplementary food in preventing growth faltering for children
under 2 years in Cambodia: a cluster randomised controlled
trial
Bindi Borg1 | Daream Sok2,4 | Seema Mihrshahi1 | Mark Griffin1,3 |
Chhoun Chamnan4 | Jacques Berger5 | Arnaud Laillou6 | Nanna Roos2 |
Frank T. Wieringa5
1School of Public Health, Faculty of Medicine,
University of Sydney, Sydney, Australia
2Department of Nutrition, Exercise and Sports,
Faculty of Science, University of Copenhagen,
Copenhagen, Denmark
3School of Public Health, University of
Queensland, Brisbane, Australia
4Department of Fisheries Post-Harvest
Technologies and Quality Control, Fisheries
Administration, Ministry of Agriculture,
Forestry and Fisheries, Phnom Penh,
Cambodia
5UMR-204 Nutripass, Institut de Recherche
pour le Développement, IRD/UM/SupAgro,
Montpellier, France
6Child Survival and Development Section,
UNICEF, Phnom Penh, Cambodia
Correspondence
Bindi Borg, School of Public Health, Faculty of
Medicine, University of Sydney, Sydney,
Australia.
Email: bindi_borg@yahoo.com.au
Funding information
Cambodian Ministry of Health; DFPTQ; IRD;
UNICEF Cambodia
Abstract
This cluster randomised controlled trial tested the effectiveness of a locally produced,
fish-based, ready-to-use supplementary food (RUSF) to prevent growth faltering
(decline in z-scores). Cambodian infants (n= 485), aged 6 to 11 months, were
randomised by site to receive the RUSF, Corn-Soy Blend++ (CSB++), micronutrient
powders (MNP), or no supplement (control). The intervention was for 6 months. In
unadjusted analysis, the control group had statistically significantly decreased
weight-for-age z-scores (WAZ; -0.02, 95%CI = -0.03 - -0.01, P= 0.001) and height-
for-age z-scores (HAZ; -0.07, 95%CI = -0.09 - -0.05, P < 0.001), and increased mid-
upper arm-circumference (MUAC; 0.02cm, 95%CI = 0.01 - 0.04, P = 0.010), but no
statistically significant change in weight-for-height z-scores (WHZ). The RUSF group
did not differ significantly from the control for WAZ, HAZ or WHZ (in other words,
WAZ and HAZ decreased and WHZ did not change), but had increased MUAC in
comparison to the control (0.04cm, 95%CI = 0.01 - 0.06, P = 0.008). There were no
statistically significant differences between the RUSF group and the CSB++ or MNP
groups with respect to WAZ, HAZ, WHZ or MUAC. Interestingly, in adjusted analysis,
low consumers of RUSF had increased WAZ, WHZ and MUAC (0.03, 95%CI =
0.01-0.06, P = 0.006; 0.04, 95%CI = 0.01-0.08, P = 0.026; and 0.05cm, 95%CI =
0.02-0.09, P = 0.004, respectively) compared with the control. The novel RUSF, par-
ticularly in small quantities, protected against ponderal growth faltering, but the
improvements were of limited clinical significance.
K E YWORD S
childhood malnutrition, fish, growth faltering, lipid-based nutrient supplement (LNS), ready-to-
use supplementary food (RUSF)
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1 | BACKGROUND AND RATIONALE
Undernutrition contributes to almost half of all deaths in children
under 5 years (Black et al., 2013). In Cambodia, despite impressive
economic growth, high rates of undernutrition persist (NIS et al.,
2015). In the 2014 Cambodian Demographic and Health Survey
(DHS), almost one-third (32%) of children under 5 years were stunted,
10% were wasted and 24% were underweight (NIS et al., 2015). The
majority of growth faltering, indicated by a decline in z-scores
(Victora, de Onis, Hallal, Blössner, & Shrimpton, 2010) in Cambodia
occurs from 6 to 20 months (Dewey & Huffman, 2009; NIS et al.,
2015). Poor complementary feeding practices are often implicated in
the growth faltering observed in low- and middle-income countries
(Ferguson et al., 2018). Borbor (white rice porridge, the traditional
weaning food in Cambodia) has inadequate energy and micronutrient
nutrient density to sustain adequate growth velocity in the first
2 years of life (Black et al., 2008; Ferguson et al., 2018). Nutrition-
specific interventions aimed at improving complementary feeding
seem warranted (Black et al., 2013; Pham et al., 2012). High energy,
nutrient dense specialised foods can be used to prevent growth falter-
ing and promote improved linear growth and weight gain among chil-
dren (Bhutta et al., 2013; Pee & Bloem, 2009; Golden, 2009).
The development of affordable, acceptable and effective spe-
cialised foods, and their comparison with existing products in terms of
their potential for preventing growth faltering responds to a need
noted by researchers (de Pee & Bloem, 2009; Lazzerini, 2013). In
Cambodia prior to 2013, various supplementary or therapeutic foods
had been used or trialled. Corn-Soy Blend Plus Plus (CSB++, also
called SuperCereal Plus, the standard supplementary food that WFP
provides to children aged 6 months to 2 years to prevent undernutri-
tion), BP-100™ and Plumpy'Nut™ had limited acceptability or effec-
tiveness (Boudier, 2009; WFP, 2014; Wieringa, 2014). Micronutrient
powders (MNP), while acceptable and effective at improving micronu-
trient status, did not have any impact on growth (Jack et al., 2012).
Therefore, in mid-2013, UNICEF engaged the French National
Research Institute for Sustainable Development (IRD), and the
Cambodian Department of Fisheries Post-harvest Technologies and
Quality (DFPTQ), to develop a locally produced ready-to-use supple-
mentary food (RUSF). The aim was to develop an RUSF that would be
more acceptable, effective and affordable than previously tested or
used products (Sigh et al., 2018).
Many specialised foods, including CSB++, use milk or whey pow-
der as the animal-source food (Adu-Afarwuah, Lartey, Zeilani, &
Dewey, 2011; Nga et al., 2013), but in Cambodia, milk is an expensive,
imported ingredient. Thus, it was decided to replace milk with fish,
which is inexpensive, readily available and highly acceptable in Cam-
bodia (Vilain, Baran, Gallego, & Samadee, 2016). It had previously
been demonstrated that fish protein supported linear growth to the
same extent as milk protein in a locally produced complementary food
in Cambodia (Skau et al., 2015). Since lipid-based nutrient supple-
ments (LNSs) are particularly promising (de Pee & Bloem, 2009; de
Pee, Manary, & Ashorn, 2011), the novel ready-to-use supplementary
food (RUSF) was formulated as an LNS snack. In June 2015, the RUSF
was tested for acceptability in comparison to CSB++ and MNP. The
acceptability trial demonstrated that children would eat the RUSF and
that caregivers ranked it highly (Borg et al., 2019). Here, we report on
the effectiveness of the RUSF in preventing growth faltering for chil-
dren aged 6 to 17 months, in comparison to CSB++, MNP, and an
unsupplemented control group. The main outcomes of interest are
weight-for-age z-score (WAZ), height -for-age z-score (HAZ), weight-
for-height z-score (WHZ), and mid-upper arm circumference (MUAC).
2 | METHODS
2.1 | Study design and setting
The design and methods are detailed in the published protocol (Borg
et al., 2017) and briefly described here. The trial took place from
February to October 2016. It was a prospective, non-blinded, cluster
randomised controlled trial among infants that were 6 to 11 months
of age at inclusion. It aimed to establish the superiority of the novel
RUSF, using CSB++, and MNP as active comparators and the standard
diet as a control. The trial was conducted in peri-urban Phnom Penh
(Mekong Operational District), which has a large population of urban
poor. Peri-urban children under 5 years experienced higher rates of
underweight (36%) and stunting (29%) than the 25% and 19%
reported for Phnom Penh, respectively (UNICEF & People In Need,
2014; NIS et al., 2011). Twenty-eight sites were allocated to one of
the RUSF, CSB++, MNP, or control groups.
2.2 | RUSF formulation
The RUSF was based on the recommended nutritional guidelines for
ready-to-use therapeutic foods (Dewey, 2009; FAO/WHO, 2016). It
was produced locally, using local ingredients including small freshwa-
ter fish, soy, mung beans and coconut. The RUSF paste was piped into
hollow, cylindrical wafers which are a popular Cambodian snack. All
processing was conducted in certified facilities, and microbiological
safety testing was conducted regularly. The ingredients of the RUSF
and the comparators are detailed in Tables A1 and A2, and in the
acceptability and effectiveness protocols (Borg et al., 2017; Borg
et al., 2018). The RUSF was provided as a medium quantity supple-
mentary food, that is, providing 50-100% of the child's daily energy
requirements (i.e. 250 to 500 kcal) excluding breastfeeding (Gera,
Pena-Rosas, Boy-Mena, & Sachdev, 2017). This was 40-110g of RUSF
per day, depending on the child's age. The nutrient profiles of all the
supplements were similar in terms of multiple micronutrients. The
RUSF and CSB++ were similar in terms of energy, protein, carbohy-
drate, and lipid content.
2.3 | Outcomes and their measurement
The main outcomes of interest were anthropometric indicators calcu-
lated using World Health Organisation (WHO) 2006 standards
(ANTHRO version 3.2.2 January 2011) and expressed as z-scores,
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namely WAZ, HAZ, and WHZ, along with MUAC in centimetres (cm).
Data was collected by a dedicated anthropometrist, supported by a
dedicated anthropometric data collector, both of whom received ini-
tial and follow up training.
2.4 | Randomisation and allocation concealment
Participants were not individually randomised. Randomisation of the
interventions occurred at site level to ensure better compliance by
avoiding potentially confounding social interaction, such as inter-
household sharing of different foods (Van Hoan, Van Phu, Salvignol,
Berger, & Trèche, 2009). Using UNICEF data on health centre cover-
age, potential sites and their populations were listed. Sites were then
randomly allocated to one of the foods, using an Excel random num-
ber table and a randomised incomplete block design. The principal
researcher generated the allocation sequence. Seven sites were allo-
cated to each arm, for a total of 28 sites. One site yielded only one
participant, who dropped out, leaving 27 sites at the end of the study.
2.5 | Sample size
Based on the assumptions of a difference in mean z-scores of 0.1
between the groups (95%CI), a standard deviation (SD) of 0.8, and of
children providing five measurements (out of a possible total of
seven), with a precision of 0.05 and power of 0.8, an overall required
sample size of 424 children, or 106 children per group, was calculated.
We assumed an attrition of 25%, for a total sample of 530 or 133 chil-
dren per group. This sample size was comparable to similar effective-
ness studies (Jack et al., 2012; Kuusipalo, Maleta, Briend, Manary, &
Ashorn, 2006; Lin, Manary, Maleta, Briend, & Ashorn, 2008; Nga
et al., 2013; Pham et al., 2012).
2.6 | Eligibility criteria, recruitment, enrolment and
consent
Healthy singletons aged 6 to 11 months were enrolled. Village health
volunteers invited potential caregivers and children to participate. The
data collection team used a screening form to assess initial eligibility
(e.g. based on age, singleton status, and willingness to participate).
Most caregivers had a birth certificate or immunisation card with the
child's date of birth, or if not, they were asked if they knew the child's
birthdate or age. Children who were ill, severely acutely malnourished
(WHZ <-3 and/or MUAC<11.5cm), obese (WHZ >3), severely anaemic
(Hb<70g/l), or had known food intolerances, were excluded and
referred for treatment as necessary. Caregivers of eligible participants
signed or fingerprinted consent for their children to participate.
2.7 | Data collection
Baseline data including demographics; morbidity; anthropometric
measures; biochemical samples (blood, stool); dietary data; and devel-
opmental milestone achievement was collected. Baseline and monthly
follow up data were collected at community sites (e.g. health volun-
teers' homes, pagodas) or health centres by a team of trained data col-
lectors. Participants in the intervention groups were provided with a
1-month supply of the food or supplement to which their site has
been allocated. Thereafter, data collection and food distribution were
conducted monthly for 6 months. Anthropometric measurements
included weight to the nearest 0.1 kg (SECA scale), recumbent length
to the nearest 0.1 cm (wooden UNICEF height board), and mid-upper
arm circumference (MUAC) to the nearest 1mm (flexible UNICEF
insertion tape).
Caregivers were given incentives to participate, including cost of
transport, and/or a small gift such as a towel or baby item. Health pro-
motion messaging was not an explicit part of the project. Every
month, at the end of data collection, all caregivers were reminded to
continue if breastfeeding; to feed their baby normally, three to five
times daily; and to maintain adequate hygiene (safe stool disposal,
handwashing after defaecation and before eating/feeding). Caregivers
in the intervention arms were reminded to feed their baby the supple-
ment or supplementary food in the recommended dosage. Caregivers
in the RUSF and CSB++ groups were reminded that the supplemen-
tary foods were an extra snack in addition to regular feeding.
2.8 | Statistical analysis
Data was analysed in STATA version 13.1. Comparisons between
food types for children enrolled at baseline (n = 485) were made using
one-way ANOVA for continuous variables (reported as mean and SD),
Kruskal-Wallis rank test for non-normally distributed continuous vari-
ables (reported as median and interquartile range, IQR), and chi-
squared for categorical variables, (reported as n and %). These results
are reported in Table 1.
Comparisons between baseline and endline anthropometric mea-
sures for the different food types for children with baseline and
endline data (n = 292) were made using one-way ANOVA for continu-
ous variables, and Kruskal-Wallis rank test for continuous variables for
which homogeneity of variance was not observed. Changes in propor-
tion from baseline to endline (%) were calculated by subtracting base-
line proportion from endline proportion, and P-values were calculated
using Pearson's chi-squared test. These results are reported in
Table 2.
A mixed effects linear regression model was fit for each anthro-
pometric outcome for children who had baseline and endline data to
determine whether there were statistically significant differences in
the changes in anthropometric outcomes from baseline to endline for
the interventions compared to each of the other groups. The model
adjusted for clustering by person and site, and month as an interaction
term to  account  for  monthly follow-up  measures. Baseline values were
account for in the mode within each food group. The model included
parameters for the slope of the line in the control group with respect
to time, and the change in the slope between the intervention
versus the control group. Children who ate less than 75% of the monthly
food supplied were considered to have low consumption, while 75%
or more was high consumption. These results are reported in Table 3.
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3 | RESULTS
Of 514 children who were screened as eligible, 485 were recruited.
Among 29 children excluded, one was excluded due to food intoler-
ances, one due to severe anaemia, and 27 due to severe acute malnu-
trition (MUAC <11.5 and/or WHZ < -3) or overnutrition (WHZ > 3).
Excluded children were referred for treatment as appropriate. See
Fig. 1 for the site selection, recruitment and enrolment of children,
and trial completion.
A total of 192 children (39.7%) did not attend endline. Loss to fol-
low up ranged from 24.5% in the MNP group to 52.0% in the CSB++
group. There were differences in loss to follow up between the
groups. The MNP group had the lowest loss, while the control, CSB++
and RUSF groups had significantly higher loss to follow up. Older chil-
dren had slightly higher odds of being lost to follow up. Children
whose caregivers had attended high school or higher had lower odds
of being lost to follow up, as did children whose family were poor card
holders. Details on loss to follow up can be found in Tables A3a
and A3b.
3.1 | Baseline characteristics
Table 1 describes the baseline characteristics of children and care-
givers. For most characteristics, there were no significant differences
between groups. However, the control and MNP groups had signifi-
cantly more females. The CSB++ and MNP groups had significantly
lower HAZ at baseline (however, the histogram showed sufficient
overlap for the mixed effect model to account for this baseline differ-
ence). Infant feeding indicators were poor. Prevalence of prelacteal
feeding was high, but lower than the Phnom Penh prevalence in the
2014 DHS (NIS et al., 2015). The prevalence of bottle feeding was
very high while prevalence of continued breastfeeding at baseline was
very low in comparison to the national prevalence (NIS et al., 2015).
Rates of low birthweight (<2.5kg) were high in comparison to the
national prevalence (NIS et al., 2015). Most children were iron replete,
i.e. ferritin concentrations corrected for inflammation ≥ 15μg/L
(Thurnham et al., 2010) at baseline. One-third of children had experi-
enced diarrhoea in the past 2 weeks. Unsafe disposal of children's fae-
ces (left in the open or thrown in a drain or the garbage) was very
high and was significantly different between groups.
3.2 | Anthropometric outcomes
Table 2 shows the change in anthropometric measures from baseline
to endline for children with baseline and endline measurements (n =
292). There were no statistically significant differences between the
groups for any of the anthropometric changes. Mean height increased
between 6.4-6.7cm for all groups. Mean weight increased between
1.20 and 1.30kg for all groups. Mean WAZ, HAZ and WHZ decreased
overall and for each group. Mean MUAC increased overall and for
each group. The proportion of children underweight at endline wasT
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variable; it was unchanged in the RUSF group, increased in the CSB++
and MNP groups, and decreased in the control group. The proportions
of children stunted and wasted increased in all groups. The proportion
of children with low MUAC at endline compared with baseline
decreased for the RUSF group, whereas for the other groups it
increased or remained unchanged. There were no statistically signifi-
cant differences between any of the changes in anthropometric mea-
sures. Figure A1 graphs the change in monthly mean anthropometric
measures from baseline to endline.
A linear mixed effects model that took into account measures at
each follow-up was fitted for each anthropometric measure. The
results of these models are shown in Table 3.
In unadjusted analysis, the control group had statistically signifi-
cantly decreased WAZ and HAZ, and increased MUAC, but no statisti-
cally significant changes in WHZ. The RUSF group did not differ
significantly from the control for WAZ or HAZ but had increased
MUAC in comparison to the control. There were no statistically signif-
icant differences between the RUSF group and the CSB++ or MNP
groups with respect to WAZ, HAZ, WHZ or MUAC. The CSB++ group
did not differ significantly from the control for WAZ, HAZ or WHZ,
but had a statistically significantly increased MUAC. The MNP group
did not differ significantly from any group for WAZ, HAZ, WHZ
or MUAC.
In the adjusted model, missing data in the covariates resulted in a
smaller n (n = 235). The control group (Month) had statistically signifi-
cantly decreased WAZ, HAZ, and WHZ, and no statistically significant
change in MUAC. High consumers of RUSF did not differ significantly
from the control for WAZ, HAZ or WHZ, but had statistically signifi-
cantly increased MUAC. There were no significant differences
between high consumers of RUSF and the CSB++ or MNP groups
with respect to WAZ, HAZ, WHZ or MUAC. In comparison to the
control, low consumers of RUSF had statistically significantly
increased WAZ, WHZ and MUAC, but no statistically significant dif-
ference in HAZ. In comparison to the CSB++ group, low consumers of
RUSF had statistically significantly increased HAZ, but no differences
in other anthropometric measures. There were no statistically signifi-
cant differences between low consumers of RUSF and the MNP
group.
High consumers of CSB++ had statistically significantly increased
WAZ, WHZ and MUAC in comparison to the control group, increased
WHZ in comparison to the RUSF group, and increased WAZ and
WHZ in comparison to the MNP group. Low consumers of CSB++
had statistically significantly increased WHZ and MUAC in compari-
son to the control, but decreased HAZ in comparison to all groups.
High consumers of MNP had statistically significantly increased WAZ
and MUAC in comparison to the control. Low consumers of MNP had
no significant differences to the control for any anthropometric out-
come but had decreased WAZ and WHZ in comparison to the RUSF
and CSB++ groups.
Sex, birthweight, iron status, and diarrhoea significantly affected
anthropometric status. Bottle feeding and maternal body mass index
(BMI) were also significant. Age at baseline, iron repleteness at base-
line, prelacteal feeding, cessation of exclusive breastfeeding beforeT
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3 months, age of commencing complementary feeding, continued
breastfeeding, dietary diversity, caregiver's education, and living in a
household that holds a poor card or shares a toilet did not have a sig-
nificant effect on anthropometric outcomes.
4 | DISCUSSION
In our trial, a locally produced, fish-based RUSF slowed but did not
prevent ponderal growth faltering in Cambodian children aged
between 6 and 17 months. However, the impact was of limited clinical
significance. The RUSF did not prevent linear growth faltering. Nor
did CSB++ and MNP prevent growth faltering, or slow it to any clini-
cally significant extent. This is consistent with studies elsewhere and
in Cambodia, which have demonstrated the difficulty in preventing
undernutrition in a representative population with moderately acutely
malnourished (MAM) and non-MAM children using specialised
products.
4.1 | Few trials in a representative, food secure
population
Despite the consensus that prevention is essential, most specialised
foods have been tested with MAM children (WHZ -3 to -2, and/or
MUAC 11.5 to 12.5cm). Few prevention studies exist (Kennedy,
Branca, Webb, Bhutta, & Brown, 2015), especially with non-MAM
children receiving a preventative specialised food in comparison to an
unsupplemented control group. The children in our study ranged from
MAM to overweight, i.e. WHZ 2 to 3 (WHO, 2006). In Cambodia, as
in most countries, there is no treatment of children with MAM. Our
sample of children had a similar prevalence of MAM as the general
population of Cambodian children aged 6 to 17 months (NIS et al.,
2015). It can therefore be considered representative of the general
population that might be targeted for undernutrition prevention pro-
gramming, in that this population includes some moderately acutely
malnourished children and mostly children that range from WHZ >-2
to <3 with MUAC > 12.5cm. This is not to say that the results can be
generalised. One systematic review used the concept of food security
and by their definition (Lassi, Das, Zahid, Imdad, & Bhutta, 2013), our
population could be considered to be in a food secure, non-
emergency context.
4.2 | Do specialised products prevent
undernutrition?
In our trial, specialised products had limited effect on reducing growth
faltering, as seen in Tables 2 and 3. To some extent, all the specialised
products in our trial, especially the RUSF and CSB++ protected
against ponderal growth faltering, but none protected against linear
growth faltering. The RUSF afforded more protection than MNP, but
not more than CSB++. In comparable trials, the impact of supplemen-
tary feeding on undernutrition has often been similarly slight, mixed,
or nonsignificant. In those trials, WAZ, WHZ and MUAC usually
increased for at least one of the intervention groups, whereas HAZ
was less likely to improve and sometimes declined (Dewey & Adu-
Afarwuah, 2008; Iannotti et al., 2014; Lin et al., 2008; Lutter et al.,
2008; Ruel et al., 2008; Sguassero, de Onis, Bonotti, & Carroli, 2012;
Skau et al., 2015; Thakwalakwa et al., 2012; Tomedi et al., 2012). One
study, like ours, found HAZ decreased more for the CSB++ group than
for the control (Mangani et al., 2015). However, it is worth noting that
HAZ was already significantly lower in the CSB++ group at baseline.
Therefore, most interventions providing supplements or spe-
cialised foods did not prevent stunting, and some did not even pre-
vent wasting. Hence, that the interventions in our study did not
prevent growth faltering, and only had a small impact on anthropome-
try in comparison to the control was not unprecedented. A forthcom-
ing Cochrane Review (see the protocol by Das, Salam, Weise Prinzo,
Sadiq Sheikh, & Bhutta, 2017) will assess the effects of preventive
lipid-based nutrient supplements given with complementary foods to
infants and young children. This will contribute greatly to the under-
standing of the effects of specially formulated supplementary foods.
4.3 | Diarrhoea
One possible explanation for the continued growth faltering
observed in our study is that the nutrients from both the standard
F IGURE 1 Trial profile-site selection,
recruitment, enrolment of children and
trial completion
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diet and the interventions provided may not have been well
absorbed. Children who had had diarrhoea in the past 2 weeks had
decreased WAZ, WHZ and MUAC. The prevalence of diarrhoea in
our study population (32% overall) was much higher than the prev-
alence of diarrhoea in children under 5 years in Phnom Penh (17%)
or nationally to children aged 6 to 11 months or twelve to
23 months (20% and 19%, respectively). However, it was similar to
the prevalence of diarrhoea (40% of children under 5 years) in a
comparable survey amongst urban poor in Phnom Penh (UNICEF &
People In Need, 2014). Thus, high rates of diarrhoea may have con-
tributed to continued growth faltering.
4.4 | Sex
Another explanation may be related to sex. In our trial, female children
had increased WAZ, HAZ and WHZ compared with male children.
The control and MNP groups had significantly more females. Since
gender has been found to have a differential impact on MUAC and
WHZ, particularly in the presence of stunting (Fiorentino et al., 2016;
Wieringa et al., 2018), this may explain why a greater difference was
not seen between the outcomes for the RUSF and CSB++ groups
compared with the control and MNP groups.
4.5 | Potential displacement of breastmilk
and food
Another possible explanation for the lack of effect on prevention of
growth faltering may be that RUSF and CSB++ may have displaced
children's normal intake of food and breastmilk rather than
actually supplementing the existing diet (Dewey & Adu-Afarwuah,
2008; Mangani et al., 2015). The quantities of RUSF and CSB++
given in our study (between 40-110g/day) were relatively large
and could conceivably have displaced breastmilk and other
family foods (Dewey & Arimond, 2012). However, analysis thus far
on the displacement of breastmilk and family food does not reveal
any difference between dietary intakes across the groups (see
Table A4).
4.6 | Other explanations for growth faltering
In our trial, children with higher birthweight had significantly greater
increase in WAZ, HAZ, WHZ and MUAC from baseline to endline.
Children of underweight mothers (BMI < 18.5 at baseline) had
decreased WHZ. This highlights the multifactorial causes of child
undernutrition. Additional factors, including birthweight, maternal
BMI, iron status, and diarrhoea which contribute to poor anthropo-
metric outcomes, must be taken into consideration, along with inter-
ventions to address them, such as maternal supplementation and
adequate antenatal care, delayed cord clamping, and diarrhoeal pre-
vention and treatment (Bhutta et al., 2013).
4.7 | Non-milk animal source foods
Daily consumption of animal-source foods is recommended for pro-
viding the protein, energy, and micronutrients needed for healthy
micronutrient status, linear and ponderal growth (Manary, 2012;
Michaelsen, Grummer-Strawn, & Begin, 2017; Neumann et al., 2013;
PAHO/WHO, 2002). Most RUFs use milk or whey; non-milk supple-
mentary foods using meat, fish or eggs have rarely been compared
with milk-based products (Anderson, Bediako-Amoa, & Steiner-
Asiedu, 2014; Bogard et al., 2015; Gera et al., 2017; Kuusipalo et al.,
2006; Pachón, Domínguez, Creed-Kanashiro, & Stoltzfus, 2007; Skau
et al., 2014). However, the evidence on whether milk or other animal
source foods are more effective in preventing undernutrition is mixed.
Two efficacy studies have involved fish-based supplementary foods.
In Malawi, a study comparing a corn porridge fortified with fish pow-
der to a peanut/soy spread found that children had similar linear and
ponderal growth (Lin et al., 2008). In Cambodia, Winfood, based on
rice and fish, was compared with CSB++ (containing milk) and CSB+
(containing no milk). Both Winfood and CSB++ promoted linear
growth better than CSB+ (Skau et al., 2015). One study that compared
milk and meat found meat had a greater impact (Grillenberger et al.,
2003). In our trial, both the fish-based RUSF and the milk-based CSB+
+ provided some protection against ponderal growth faltering, demon-
strating that fish has the potential to replace milk in specialised foods.
4.8 | Micronutrients and macronutrients
Our study is consistent with trials that found that in the absence of
adequate macronutrients, micronutrients alone do not contribute to
growth (Adu-Afarwuah et al., 2007; Dewey & Adu-Afarwuah, 2008;
Dewey, Yang, & Boy, 2009; Imdad, Sadiq, & Bhutta, 2011; Jack et al.,
2012; Rivera & Habicht, 2002; Zlotkin, 2009). Children in the high
consuming MNP group had increased WAZ and MUAC compared
with the control in a similar magnitude to the RUSF and CSB++
groups. Low consumers of MNP had no significant differences to the
control for any anthropometric outcome, and had poorer outcomes
for WAZ, HAZ and WHZ than children in the RUSF and CSB++
groups. Since MNP is added to food, these results may be interpreted
as children who are high consumers of MNP actually eating more
food, thus receiving the necessary macronutrients along with the
MNP micronutrients.
4.9 | High and low consumption
In our trial, low rather than high consumers of RUSF experienced a
protective effect against faltering of WAZ, WHZ and MUAC. This sug-
gests that the RUSF, even in small quantities, actually supplements
the existing diet as intended. Other researchers who have worked on
small quantity LNSs (20-50g/day) have found that in small quantities,
LNSs may improve growth (Dewey et al., 2017; Hess et al., 2015).
They may also improve appetite (Arimond et al., 2015; Lesorogol,
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Jean-Louis, Green, & Iannotti, 2015), something which caregivers in
our acceptability trial remarked upon (Borg et al., 2018). This finding
warrants a trial of the RUSF in small quantities.
That most plausible interpretation of the increased weight-related
anthropometric measures (WAZ, WHZ and MUAC) among high con-
sumers of CSB++ and MNP in comparison to the control group is that
high consumers are eating more food generally. Hence it would be
expected that their growth would falter less than the control group.
4.10 | Strengths and limitations
This study had two main strengths. First, this is one of few undernutri-
tion prevention trials that has compared a novel specially formulated
supplementary food to an unsupplemented control group, as well as
to CSB++ and MNP which are widely used specialised products. Use
of an unsupplemented control enables the assessment of the clinical
and programmatic significance of the results. It informs programming,
by making it possible to compare the provision of specialised products
to no intervention (Gera et al., 2017). Second, our study generated
much needed evidence in a geographic and social context other than
Africa (Gera et al., 2017; Kennedy et al., 2015; Lazzerini, 2013).
There are four main limitations of this trial. First, the high and dif-
ferential loss to follow up may have introduced bias. Second, self-
reporting on compliance favours over-reporting of consumption,
which may lead to underestimation of effectiveness. Third, our find-
ings may not be generalisable to non-urban Cambodian populations.
Since rural areas of Cambodia experience higher levels of undernutri-
tion and poorer infant and young child feeding practices (NIS et al.,
2015), it would be difficult to predict if the interventions would
appear more or less effective. Finally, subgroup analysis of the effect
of the specialised products specifically on MAM children was not
undertaken due to low sample size.
5 | CONCLUSION
Our trial contributes to the limited literature on the supplementa-
tion of a population sample of children in a food secure, non-
emergency setting. This makes it useful for programming, which has
had to rely on findings from studies that focus specifically on MAM
children or food insecure settings. In this trial, the most important
finding is that the locally produced, fish-based RUSF, consumed in
small quantities, was superior to a standard diet. In small quantities,
the RUSF protected against the wasting and underweight seen in
the control group, with improved outcomes for WAZ, WHZ and
MUAC. However, the magnitude of improvements was of limited
clinical significance
There were few significant differences between the RUSF and
the CSB++ or MNP groups. None of the specialised products protec-
ted against stunting. The RUSF was not superior to CSB++. Both the
RUSF and CSB++ groups performed better than low consumers of
MNP, which confirms earlier findings that micronutrients in the
absence of macronutrients do not improve growth. However, once
again, the magnitude of improvements was of limited clinical
significance.
Further research is warranted to explore the potential role, if any,
of supplements and specially formulated supplementary foods in
preventing undernutrition in a representative population of Cambo-
dian children. With respect to the RUSF, future trials with MAM chil-
dren, and with small quantities of the RUSF may be warranted. All
future studies should include a control with a standard,
unsupplemented diet. Programming for the prevention of childhood
undernutrition in Cambodia will need to consider other approaches
and address additional important factors. These findings should assist
programmers in selecting nutrition interventions.
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* RUSF daily serving size depends on the child's age, i.e. 6-8m –
4 pieces, 40g; 9-11m – 6 pieces, 60g; 12-17m – 11 pieces, 110g.
Comparators
The RUSF was compared with:
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dard supplementary food that WFP provides to children aged six
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Appendix Table 3 a: Loss to follow up across the arms from base-
line to endline.
P-value was computed using Pearson chi squared. Asterisks high-
light significant p-values: * <0.05, ** < 0.01, ***<0.001.
Appendix Table 3 b: Loss to follow up from baseline to endline.
Odds ratios, standard errors P-values, and 95% Confidence Inter-
vals were computed using mixed effects regression models. Asterisks
highlight significant p-values: * <0.05, ** < 0.01, ***<0.001.
All subjects (N=485) attended baseline. Thereafter, subjects
attended 60-75% of data collection sessions. Loss to follow up refers
to subjects who failed to attend the endline data collection (n = 192),
regardless of how many other data collection points they attended.
There were significant differences in loss to follow up between the
groups. The MNP group had significantly lower odds of being lost to
follow up. Comparisons of the odds of dropping out between the
other groups were not statistically significant.
In comparison to the MNP group, subjects in the control group
had more than twice the odds of dropping out (OR = 2.37; 95% CI =
1.03, 5.44; p = 0.042), while RUSF subjects had almost four times the
odds (OR = 3.89; 95% CI = 1.71, 8.88; p = 0.001), and CSB++ subjects
had almost five times the odds of dropping out (OR = 4.84; 95% CI =
2.08, 11.29; p <0.001). In comparison to the control group, subjects in
the RUSF and CSB++ groups had about twice the odds of dropping
out (OR = 1.65; 95% CI = 0.76, 3.55; p = 0.204; and OR = 2.05; 95%
CI = 0.92, 4.57; p = 0.081 respectively) although these were not sta-
tistically significant. In comparison to the RUSF group, subjects in the
CSB++ groups had slightly greater odds of dropping out (OR = 1.24;
95% CI = 0.57, 2.72; p = 0.585) although this was not statistically
significant.
For every additional month that a subject stayed in the study,
their odds of dropping out decreased by approximately half (OR =
0.58; 95% CI = 0.54, 0.62; p<0.001). Subjects who were older at
baseline had slightly higher odds of dropping out (OR = 1.12; 95%
CI = 1.04, 1.01; p=0.002). Subjects whose caregiver had had
attended high school or higher had lower odds of dropping out
(OR = 0.64; 95% CI = 0.41, 0.99; p=0.047). Subjects whose family
were poor card holders had half the odds of dropping out (OR =
0.51; 95% CI = 0.34, 0.77; p=0.001). Sex, primary school education
and having diarrhoea in the past two weeks did not make a statisti-
cally significant difference.
Appendix Table 4: Change in dietary intake from baseline to
endline
P-values were computed by comparison of different food types
using chi-squared.
There were no statistically significant differences between the
groups in breastfeeding, dietary diversity, or amount eaten at each
meal at baseline or endline. This suggests that the specialised foods
did not displace breastmilk or food.
There was a statistically significant difference in meal frequency
at baseline. More children in the control and MNP groups ate infre-
quently (1-2 times/day). At endline, there was no difference between
groups. A possible explanation for the difference is that caregivers in
the RUSF and CSB++ groups did not consider the specialised food a
meal, and did not “count” them in answering the question at endline.
If this were the case, it would mean that RUSF and CSB++ replaced
meals. However, further analysis would be necessary to confirm that
interpretation.
There was a statistically significant difference in consumption of
snacks at baseline. Less children in the control group and more chil-
dren in the MNP group ate snacks. At endline, there was no difference
between groups. The question did not ask specifically about commer-
cial snacks, so it cannot be confirmed whether parents in the RUSF or
CSB++ groups considered the specialised foods as snacks.
Appendix Figure 1 depicts the change in monthly mean anthropo-
metric measures from baseline to endline for the 292 children with
baseline and endline measurements. The graphs show that WAZ, HAZ
and WHZ decline and MUAC increases. The wide and overlapping
confidence intervals of the graphs indicate that there may be no sig-
nificant difference between the groups.
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CHARACTERISTIC RUSF CSB++ MNP
Daily serving size 40-110g* 100g dry CSB++ 1 sachet (1g)
Animal-source food Fish Milk -
Energy (kcal/100g) 484 410 -
Protein (g/100g) 13 16 -
Carbohydrates (g/100g) 52 67 -
Lipids (g/100g) 24 9 -
Fibre (g/100g) 1.6 3 -
Vitamin A 1,080 μg 540 μg 400 μg
Vitamin D 60 μg 4.6 μg 5 μg
Vitamin B1 (thiamine) 0.59 mg 0.47 mg 0.5 mg
Vitamin B2 (riboflavin) 0.89 mg 0.84mg 0.5 mg
Vitamin B6 0.84 mg 2.1 mg 0.5 mg
Phosphorus 474 mg 530 mg -
Calcium 366 mg 260 mg -
Pantothenic acid 1.75 mg 7.3 mg -
Copper 1.6 mg - 0.56 mg
Vitamin E 10.9 mg 9.8 mg 5 mg
Folic acid 230 μg 115 μg 150 μg
Iron 8 mg 8.9 mg 10 mg
Magnesium 137 mg -
Vitamin B3 (niacin) 9.63 mg 7.2 mg 6 mg
Vitamin C 53.4 mg 100 mg 30 mg
Zinc 8.4 mg 7.5 mg 4.1 mg
Potassium 806 mg 990 mg -
Vitamin B12 10 μg 2.3 μg 0.9 μg
Biotin 0.37 mg - -
Selenium 90 μg - 17 μg
Iodine - 60 mg 90 μg
Vitamin K 3 μg 115 μg -
Taste Fishy Creamy, sweet, smooth (Skau, Sok &
Wieringa, 2012)
Should not have a taste (Salam,
Macphail, Das, & Bhutta, 2013)
Preparation No 10 mins cooking No
Acceptability in Cambodia Yes (Borg et al., 2019) Acceptable in trial (Skau, Sok &
Wieringa, 2012), but not in practice
(WFP, 2014)
Yes (Jack et al., 2012)
Effectiveness in reducing
malnutrition
To be tested Not inferior to peanut-based RUSFs,
which are the most effective in
promoting linear growth and weight
gain (LaGrone et al., 2012; Manary &
Chang, 2012.)
Improves micronutrient status but not
linear growth or weight gain
(de Pee & Bloem, 2009; Dewey &
Adu-Afarwuah, 2008; Jack et al.,
2012)
Intra-household sharing Unknown Yes (LaGrone et al., 2012) None noted (Jack et al., 2012)
Packaging Unknown Packaging may encourage sharing
(de Pee & Bloem, 2009; Nackers et al.,
2010)
Looks like “medicine” thus may
discourage sharing (de Pee & Bloem,
2009; Nackers et al., 2010)
Local production capacity Unknown None (de Pee & Bloem, 2009) None
Cost To be determined. Goal is
<US$0.10/day
Less expensive than peanut-based
RUSFs if produced locally (Manary &
Chang, 2012.), but also have to
consider logistics, time to treat,
relapse (Nackers et al., 2010)
Very cheap to produce at US$0.025/
daily dose (Zlotkin, 2009), but also
have to consider logistics
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Total (N=485) Control (n=127, 26%) RUSF (n=128, 26%) CSB++ (n=123, 25%) MNP (n=106, 22%) P-value
Loss to follow
up, n (%)
192 (39.7%) 50 (38.4%) 52 (40.6%) 64 (52.0%) 26 (24.5%) < 0.001***
Odds ratio 95% CI P value
Loss to follow up
MNP vs control 2.37 1.03, 5.44 0.042*
MNP vs RUSF 3.89 1.71, 8.88 0.001**
MNP vs CSB++ 4.84 2.08, 11.29 <0.000***
Control vs RUSF 1.65 0.76, 3.55 0.204
Control vs CSB++ 2.05 0.92, 4.57 0.081
RUSF vs CSB++ 1.24 0.57, 2.72 0.585
Adjusted for:
Month of study 0.59 0.54, 0.63 <0.000***
Sex 0.90 0.70, 1.17 0.443
Age at baseline 1.12 1.04, 1.20 0.002**
Caregiver attended
• primary school 1.28 0.84, 1.96 0.252
• high school or higher 0.64 0.41, 0.99 0.047*
Poor card holder 0.51 0.34, 0.77 0.001**
Diarrhoea 0.87 0.66, 1.14 0.305
Random effects 0.42 0.19, 0.94
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Change in dietary intake from
baseline to endline
Total
(N=292)
Control
(n=77, 26%)
RUSF
(n=76, 26%)
CSB++
(n=59, 20%)
MNP
(n=80, 27%) P-value
Breastfeeding
At baseline, n (%) 187 (64.5%) 51 (66.2%) 47 (66.1%) 39 (62.7%) 50 (63.3%) 0.955
At endline, n (%) 144 (49.7%) 41 (54.0%) 33 (43.4%) 30 (50.9%) 40 (50.6%) 0.614
Minimum dietary diversity in past 24hrs
At baseline, n (%) 81 (27.7%) 19 (24.7%) 24 (31.6%) 19 (32.2%) 19 (23.8%) 0.544
At endline, n (%) 256 (87.7%) 63 (81.8%) 68 (89.5%) 55 (93.2%) 70 (87.5%) 0.226
Meal frequency in past 24hrs at
baseline, n (%)
1-2 times 75 (26.8%) 24 (32.9%) 16 (21.9%) 9 (15.3%) 26 (34.7%) 0.004
3-4 times 200 (71.4%) 49 (67.1%) 57 (78.1%) 46 (78.0%) 48 (64.0%) 0.004
> 5 times 5 (1.8%) 0 (0.0%) 0 (0.0%) 4 (6.8%) 1 (1.3%) 0.004
Meal frequency in past 24hrs at endline,
n (%)
1-2 times 22 (7.5%) 7 (9.1%) 8 (10.5%) 2 (3.4%) 5 (6.3%) 0.812
3-4 times 262 (89.7%) 67 (87.0%) 66 (86.8%) 56 (94.9%) 73 (91.3%) 0.812
> 5 times 6 (2.1%) 2 (2.6%) 2 (2.6%) 1 (1.7%) 1 (1.3%) 0.812
Amount eaten at each meal at baseline,
n (%)
<2 tablespoonfuls each time 73 (26.0%) 19 (26.0%) 19 (25.7%) 15 (25.4%) 20 (26.7%) 0.866
2-3 tablespoonfuls each time 79 (28.1%) 25 (34.3%) 18 (24.3%) 13 (22.0%) 23 (30.7%) 0.866
< 1/2 bowl each time 78 (27.8%) 18 (24.7%) 22 (29.7%) 18 (30.5%) 20 (26.7%) 0.866
about 1 bowl each time 45 (16.0%) 9 (12.3%) 13 (17.6%) 13 (22.0%) 10 (13.3%) 0.866
>1 bowl each time 6 (2.1%) 2 (2.7%) 2 (2.7%) 0 (0.0%) 2 (2.7%) 0.866
Amount eaten at each meal at endline, n
(%)
<2 tablespoonfuls each time 19 (6.5%) 5 (6.5%) 4 (5.3%) 4 (6.8%) 6 (7.5%) 0.584
2-3 tablespoonfuls each time 81 (27.7%) 22 (28.6%) 19 (25.0%) 13 (22.0%) 27 (33.8%) 0.584
< 1/2 bowl each time 35 (12.0%) 12 (15.6%) 8 (10.5%) 8 (13.6%) 7 (8.8%) 0.584
about 1 bowl each time 150 (51.4%) 36 (46.8%) 41 (54.0%) 33 (55.9%) 40 (50.0%) 0.584
>1 bowl each time 6 (2.1%) 1 (1.3%) 4 5.3%) 1 (1.7%) 0 (0.0%) 0.584
Consumed sweet or salty snacks (eg chips, cakes, candies) in the past 24hrs
At baseline, n (%) 86 (29.5%) 12 (15.6%) 26 (34.2%) 17 (28.8%) 31 (38.8%) 0.010
At endline, n (%) 249 (85.3%) 62 (80.5%) 63 (82.9%) 52 (88.1%) 72 (90.0%) 0.316
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F IGURE A1 Mean anthropometric measures and confidence intervals monthly from baseline to endline for children with baseline and
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Chapter 8:  Process analysis and lessons learned 
Chapter 8 examines the process taken in developing the ready-to-use supplementary food (RUSF).  Part 
of this chapter has been published as: 
o Borg B, Mihrshahi S, Laillou A, Sigh S, Sok D, Peters R, Chhoun C, Berger J, Prak S, Roos N,
Griffin M, Wieringa FT. Development and testing of locally-produced ready-to-use therapeutic
and supplementary foods (RUTFs and RUSFs) in Cambodia:  Lessons learned.  BMC Public
Health. 2019; 19(1).
This chapter describes the process and context in which the ready-to-use supplementary food (RUSF) 
was conceived and developed.  It begins by explaining the rationale for documenting the process.  Then 
it briefly describes the lessons learned from the process.  It goes on to outline what the process paper 
adds to the literature on the development of specially formulated supplementary foods and the 
implications for potential developers of such products.  The last section is the submitted manuscript, 
revised based on the reviewers’ comments. 
Rationale for documenting the process 
In the past ten years, there has been growing interest in the development and testing of locally-produced 
specially formulated foods.  Invaluable knowledge and experience have been shared in relation to 
ingredients, ration size, nutrient content, safety and quality concerns, and packaging (1) and relative 
costs (2).  However, there is limited published sharing of lessons learned around the process of making 
the policy and programmatic decision to develop a local specially formulated food in a given context, 
despite the recognition of the importance of understanding decision-making processes (3).  These 
lessons can seldom be gleaned from the published protocols and papers.  Developing a locally-produced 
specially formulated food requires considerable funding, physical and human resources, and time, all 
of which are easily underestimated.  It is therefore essential to make an informed decision before 
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embarking on the process.  Building on the experience of preceding projects can improve decision-
making and optimise efficiency at all stages of the process.  Projects like ours offer opportunities for 
learning and exchange between research, policy, and program actors, both within and between 
countries, which often go untapped.   
Lessons learned 
The research, policy, advocacy, and programming environment in Cambodia in 2013-14 created an 
expressed need and opportunity for this project, which built on the earlier experience of creating a 
specially formulated food in Vietnam.  The project subsequently contributed to improved nutrition 
policy and to new programming options.  Rigorous project planning, management, and documentation, 
as well as sound stakeholder collaboration, project administration and resourcing, are vital.  A dedicated 
project manager is desirable in order to keep abreast of the literature and experiences elsewhere, identify 
and articulate needs and interests, and adhere to programming, policy, advocacy, and communication 
goals and guidelines in order to optimise opportunities.   
What this paper contributes to the literature 
Programmatic, policy, and decision-making lessons often remain hidden in grey literature or not 
documented at all.  In publishing the lessons we learned, we hope to help others who are considering 
developing locally-produced specially formulated foods to clarify their objectives and avoid some of 
the challenges in order to maximise their contribution to preventing undernutrition in their setting. 
The following publication describes the process and lessons learned in detail. 
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Abstract
Background: Rates of childhood undernutrition are persistently high in Cambodia. Existing ready-to-use supplementary
and therapeutic foods (RUSFs and RUTFs) have had limited acceptance and effectiveness. Therefore, our project
developed and trialled a locally-produced, multiple micronutrient fortified lipid-based nutrient supplement (LNS)
with therapeutic and supplementary versions. This ready-to-use food (RUF) is innovative in that, unlike many RUFs, it
contains fish instead of milk. Development began in 2013 and the RUF was finalised in 2015. From 2015 until
the present, both the RUTF and the RUSF versions were trialled for acceptability and effectiveness.
Methods: This paper draws on project implementation records and semi-structured interviews to describe the
partnership between the Cambodian Ministries of Health and Agriculture, Forestry and Fisheries, UNICEF,
the French National Research Institute for Sustainable Development (IRD), universities, and Vissot factory. It
discusses the project implementation and lessons learned from the development and trialling process, and
insights into positioning nutrition on the health agenda in low and middle-income countries.
Results: The lessons learned relate to the importance of project planning, management, and documentation
in order to seize opportunities in the research, policy, advocacy, and programming environment while
ensuring adequate day-to-day project administration and resourcing.
Conclusions: We conclude that projects such as ours, that collaborate to develop and test novel, locally-produced
RUTFs and RUSFs, offer an exciting opportunity to respond to both local programmatic and broader research needs.
Keywords: Ready-to-use supplementary food (RUSF), Ready-to-use therapeutic food (RUTF), Lipid-based nutrient
supplement (LNS), Locally-produced, Childhood malnutrition, Process, Lessons learned
Background
There is a longstanding recognition that undernutrition
is not only an individual problem but has ramifications
for economic development in many lower and middle
income countries, including Cambodia [1, 2]. This has
raised the profile of undernutrition, resulting in a body
of evidence and agreed frameworks for addressing the
problem [3]. Despite rapid economic development in
Cambodia, rates of childhood undernutrition remain un-
acceptably high. There were significant improvements in
nutrition between Cambodia’s first and second Demo-
graphic and Health Surveys (CDHS) in 2000 and 2005.
In that period, the prevalence of stunting in children
under 5 years dropped from 50 to 43%, wasting de-
creased from 17 to 8%, and underweight dropped from
39 to 28% [4, 5]. By 2010, progress in combatting child
undernutrition had stalled, with prevalences of stunting,
wasting and underweight in children under 5 years at
40, 11, and 28% respectively [6]. Cambodia was not on
track to meet its Millennium Development Goal targets.
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In 2014, almost one-third (32%) of all children under 5
years were stunted, 10% were wasted, 24% were under-
weight, and 2% were severely acutely malnourished, with a
weight-for-height z-score (WHZ) of less than − 3 [7]. This
can mostly be attributed to sub-optimal infant and young
child feeding practices [8, 9], as well as infection [10], that
result in inadequate energy and nutrient intakes to achieve
optimal growth and micronutrient status from 6 to 23
months. Our project, a nutrition-specific intervention for
treating and preventing malnutrition, grew out of that
context.
Over the past two decades, various products and ap-
proaches for the prevention and treatment of childhood
undernutrition have been developed and tested. Special
nutritious foods can be used to prevent and treat under-
nutrition [11–13]. Some of these energy-dense foods
require preparation e.g. fortified blended products, such
as Corn-Soy Blend++ (CSB++, now called Supercereal
Plus), that is cooked with water to make a porridge. Al-
ternatively, they may be ready to eat. These include
compressed bars or biscuits, such as BP-5™ or BP-100™.
Increasingly, ready-to-use foods are lipid-based nutrient
supplements (LNSs) which are often pastes, such as the
peanut-based Plumpy’Doz™ or Plumpy’Nut®. These LNSs
are proving effective, thanks to their relatively higher en-
ergy content, longer shelf life, and greater convenience
[13, 14]. The WHO/UNICEF protocols for the compos-
ition of ready-to-use therapeutic foods (RUTFs) and their
use in the treatment of severe acute malnutrition (SAM)
have demonstrated their effectiveness [15–19]. As yet, no
such standardised approach exists for the formulation of
ready-to-use supplementary foods (RUSFs), or for
approaches to prevention of undernutrition [15, 20].
WHO and various researchers have recommended the
development of new therapeutic and supplementary foods
that are affordable, acceptable and effective, and their
comparison with existing products in terms of their po-
tential for preventing growth faltering and undernutrition
[13, 15, 17, 20–25]. A number of existing RUSFs and
RUTFs and other supplements have been used or trialled
in Cambodia, but to date, their success has been limited
by low acceptability and effectiveness. Thus, the develop-
ment of novel ready-to-use foods (RUFs) also responds to
Cambodia’s particular programmatic need [12].
UNICEF is mandated to support the Ministry of Health
(MoH) to treat SAM, and to date, that had included pay-
ing for the majority of imported therapeutic product and
in-patient treatment of SAM. The long-term objective,
however, was that the MoH would purchase the thera-
peutic product themselves. Until then, the therapeutic
food used to treat SAM had been BP-100™, which had
limited acceptability [26]. Plumpy’Nut® had been trialled
in Cambodia in 2009 and was poorly accepted [27], as
elsewhere in the region [28]. In 2013, the MoH indicated
that they would be more willing and able to commit to
procuring therapeutic food if a cheaper, more acceptable
(thus more effective) product could be purchased locally.
UNICEF was familiar with the success of a locally-pro-
duced specialised food that had been developed in
Vietnam. In 2009, the Vietnamese National Institute of
Nutrition, in collaboration with UNICEF and the French
National Research Institute for Sustainable Development
(IRD) had developed a food called HEBI (High Energy
Bar for IMAM – Integrated Management of Acute Mal-
nutrition) [28]. HEBI contained mostly local ingredients
(rice, soy, and mung beans) and imported milk powder.
It was formulated to resemble “mooncake”, a delicacy
eaten to celebrate the Vietnamese Mid-Autumn Festival,
also known as the Children’s Festival. HEBI proved more
acceptable than, and as effective as, Plumpy’Nut® and be-
came widely and successfully used in Vietnam in IMAM
programming [29, 30]. It was determined that a similar
project could be undertaken in Cambodia. Since milk
powder is expensive and has to be imported, it was
decided that the novel product should replace milk with
fish, which is inexpensive, readily available, and more
adapted to local tastes.
Therefore, UNICEF solicited IRD’s assistance to develop
a locally-produced RUTF. IRD had worked with the
Department of Fisheries Post-Harvest Technologies and
Quality Control (DFPTQ) in the Fisheries Administration
of the Ministry of Agriculture, Forestry and Fisheries on
previous nutrition research projects, including the deve-
lopment of a locally-produced complementary food [31].
In addition to their research capacity, DFPTQ could
contribute its expertise with fish processing.
Around the same time, in June 2014, the United Na-
tions World Food Program (WFP) in Cambodia phased
out its distribution of CSB++ to children under 2 years
and pregnant and lactating women. WFP Cambodia was
experiencing budget constraints, and moreover, CSB++
had not been as acceptable or effective as expected [12].
Sprinkles micronutrient powders (MNP) had been dis-
tributed through the public health system, and although
they proved effective in trial [32], in practice, coverage
has been limited, and they have not been shown to con-
tribute to improvements in linear growth [33–38]. Thus,
there arose a gap in programming for the prevention of
undernutrition, which is traditionally WFP’s mandate.
Recognising an opportunity for creating a supplementary
version of the RUF to prevent undernutrition, UNICEF
also engaged WFP. In 2014, a letter of agreement was
signed between UNICEF, MoH, WFP, IRD, and DFPTQ
to develop products for prevention and treatment of un-
dernutrition. The aim was to create a ready-to-use food
(RUF) in RUTF and RUSF versions, that would prove
more acceptable, effective, and cheaper than the existing
products.
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Methods
Aim
This paper aims to share the lessons learned and
challenges faced in developing and trialling locally-
produced RUSFs and RUTFs in a low to middle-in-
come country, Cambodia, where unacceptable rates of
child undernutrition persist, despite robust economic
growth. By describing the partners involved, the de-
velopment and trialling process, and the opportunities
for positioning nutrition on the health agenda, we
hope that this paper will prove useful to others en-
gaging in a similar process of local RUSF and RUTF
development.
Design
This paper draws on project implementation records
and semi-structured interviews. The project has been
implemented in stages over 5 years, and is ongoing, as
shown in Fig. 1. All of the trials in the project were
carried out in Phnom Penh. Details on each of the trials
are included under the relevant sub-headings. The trials
were registered at ClinicalTrials. Gov (LNS-CAMBIN-
FANTS, NCT02257437; LNS-CAMB-INFANTS-EFF,
NCT02257762; FLNS_SAM, NCT02907424).
Formative acceptability testing
In July 2013, IRD carried out a taste trial of CSB++, BP-
100™, HEBI, and eeZeePaste™ (a peanut-based RUTF
from GC Rieber Compact). Both HEBI and eeZeePaste™
proved far more acceptable than CSB++ and BP-100™ in
terms of organoleptic qualities, which confirmed that the
development of a locally-produced RUF adapted to the
tastes of Cambodian children was warranted.
Initial product development
In 2014, the first version of the RUF was developed [29].
Rice, small freshwater fish, soy, and mung beans - all
important elements of the current Cambodian diet - were
Fig. 1 Project implementation. * Borbor: white rice porridge, the traditional Cambodian weaning food
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considered optimal ingredients, along with oil, sugar, and
multiple micronutrients. The product was made by a local,
quality-certified food factory, Vissot. Pre-tasting was
conducted with Cambodian project and factory staff.
Initial acceptability trial
In June 2014, an acceptability trial was held in a Phnom
Penh preschool with 61 children aged 2 to 7 years. The trial
was a 2 × 2 non-randomised, nonblinded crossover design.
Children ate the novel RUF and BP-100™ for 2 weeks each.
Neither the RUF nor BP-100™ were very well accepted, in
terms of the amount consumed. In organoleptic scoring (of
sensory qualities, e.g. taste and smell), BP-100™ scored
slightly higher. Therefore, the RUF was modified to reduce
the fishy taste and smell. Details on the initial product
development and acceptability trial have been reported
elsewhere [29].
Product refinement
From late 2014 to early 2015, the product went through
various refinements. Coconut powder was added to mask
the fishy taste and smell. The form of the RUF, originally
a paste, also changed. Snack consumption is ubiquitous in
Cambodia, even amongst young children [12, 39, 40]. In
an attempt to create a form that would be more accept-
able [28], we took a well-known Cambodian snack, a
wafer, and piped in the RUF paste. The final product was
a wafer that is a hollow cylinder between 8.5-9 cm long
with an internal diameter of 0.5 cm, filled with RUF paste.
RUTF and RUSF versions were created, the main differ-
ences being the micronutrient premixes, and the oil and
fibre contents. The RUFs were tested regularly for micro-
biological safety.
RUSF trials
The RUSF trials included acceptability testing with chil-
dren and with pregnant and lactating women in mid-2015.
Effectiveness among children was tested from February to
October 2016. The trials were organised with the collabor-
ation of the staff and health volunteers of the Mekong
Health District in peri-urban Phnom Penh.
RUSF acceptability trial – pregnant and lactating women
A non-blinded crossover study was conducted with 98 preg-
nant and lactating women, comparing the RUSF snack to
high energy biscuits (provided by UNICEF). The women ate
each food at home for 3 days, then responded to organolep-
tic testing. Both foods were considered highly acceptable. A
planned effectiveness trial with pregnant and lactating
women did not proceed, due to limited funding.
RUSF acceptability trial – children
A two-week, non-blinded, randomised 4 × 4 crossover
trial was conducted, with 95 children aged 9–23 months.
It compared the acceptability of the novel RUSF, pre-
sented as the filled wafer snack or the snack mixed into
borbor (white rice porridge), compared to CSB++ and
MNP mixed with borbor. Children at 4 sites ate the 4
foods for 3 consecutive days over 12 days. Although chil-
dren consumed more of the MNP-borbor, the RUSF as a
snack or mixed with borbor provided two to three times
more kilocalories. Caregivers reported that their children
had the highest preference for MNP, but that they also
liked the RUSF snack. Most importantly, caregivers
ranked the RUSF snack highest, and focus group discus-
sions confirmed this. Therefore, the research team felt
confident to proceed to a six-month trial to test the
RUSF’s effectiveness. Details on the children’s accept-
ability trial are described elsewhere [41, 42].
RUSF effectiveness trial – children
A six-month prospective, cluster randomised, non-blinded
controlled trial with a 1:1 allocation ratio was conducted
with 485 healthy, non-severely acutely malnourished chil-
dren aged 6 to 11 months. The aim was to establish the
novel RUSF’s superiority to CSB++, MNP, and a control
group. Twenty-eight sites were randomly allocated to one
of the four arms. Data collection and food distribution
were conducted monthly until endline. The main outcome
was anthropometric status, and secondary outcomes were
children’s body composition, biochemical status, and cog-
nitive development. In addition, long-term acceptability
was assessed. The RUSF was not as effective as expected.
All groups continued to experience growth faltering,
although the RUSF group faltered at a lower rate. Details
on the effectiveness trial are described elsewhere [43], and
results are forthcoming [44].
Cambodian Health and Nutrition Monitoring Study
The RUSF is being utilised in the Cambodian Health
and Nutrition Monitoring Study. Pregnant women with
a mid-upper arm circumference (MUAC) < 23 cm are
deemed malnourished and provided with RUSF. While
the study does not aim to trial the RUSF, it may provide
additional information on the implementation, accept-
ability, and effectiveness of the RUSF in a programmatic
setting. Results have yet to be analysed and reported.
RUTF trials
The RUTF trial from 2015 to 2017 included taste testing
to finalise the RUTF, followed by effectiveness and long-
term acceptability testing with children presenting to the
National Paediatric Hospital in Phnom Penh. The trial
was conducted with the cooperation of the hospital staff.
RUTF taste testing and long-term acceptability testing
In October 2015, 52 children aged 6 months to 17 years
and their caregivers participated in a taste test. These
Borg et al. BMC Public Health         (2019) 19:1200 Page 4 of 9
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children were visiting the outpatient department for
various reasons and were not necessarily malnourished.
The crossover design compared BP-100™ with the RUTF
paste, and the RUSF wafer. The RUTF paste was consid-
erably less acceptable, while BP-100™ and the RUSF
wafer were equally acceptable. As a result, the paste
form of the RUF was abandoned, and the RUTF was
finalised as a filled wafer, like the RUSF.
In the subsequent effectiveness trial (described below),
long-term acceptability was assessed with severely acutely
malnourished children. Both products were highly
acceptable, with BP-100™ slightly more so. Accept-
ability of the RUTF increased over the treatment
period, while acceptability of BP-100™ varied. More
details on the RUTF acceptability testing are reported
elsewhere [45].
RUTF effectiveness trial
Effectiveness was tested in a single-blinded, randomised
control trial conducted from September 2015 and January
2017. A total of 121 children with uncomplicated SAM
aged 6 months to 5 years were randomised to receive either
the novel RUTF or BP-100™ for home consumption for a
period of 8 weeks. Anthropometric measures were assessed
at baseline and fortnightly until endline at the eighth week.
No statistically significant differences between the two
products were found for changes in anthropometric status.
This suggests that the locally-produced fish-based RUTF
performed as well as BP-100™ and is a potential alternative
to the latter for SAM treatment in Cambodia. Details on
the RUTF effectiveness trial are reported elsewhere [46].
Results
This section describes the lessons learned from imple-
mentation of the locally-produced Cambodian RUF pro-
ject. The project has provided useful insights into the
opportunities and challenges of getting nutrition into
the broader health and development platform in low and
middle-income countries. These opportunities and chal-
lenges arise before, during and after project implementa-
tion, and emphasise the importance of having a broad
overview of the project from the outset. Even before the
project begins, there needs to be a deep understanding
of the facilitators and obstacles in the research and policy
environment, and of the experience of similar projects
elsewhere. At every stage, it is vital that opportunities for
uptake, advocacy, and for influencing policy or
process are recognised and seized. This requires com-
munication on multiple levels. Stakeholders must be
identified, and their roles and responsibilities outlined
clearly, while maintaining the balance between their
respective objectives. Throughout, consistent project
planning, management, resourcing, and documen-
tation are essential.
Research and policy environment
The global and national nutrition research, policy, and
programming environment around 2010–14 gave impetus
to this project. The 2010 and 2014 CDHSs [6, 7] had
shown that malnutrition rates in Cambodia were not
improving. WHO’s 2013 SAM guidelines had emphasised
the need for research in Asia on the effectiveness of
RUTFs using different ingredients, compared to existing
therapeutic foods [17]. The Cambodian Fast Track Road
Map for Improving Nutrition 2014–2020 acknowledged
that SAM treatment needed to be expanded and acceler-
ated and committed to developing and testing “new
innovative nutrition-specific interventions, which are
tailored specifically to the Cambodian context …. to
improve the current strategies for the treatment and the
prevention of severe malnutrition” [47]. In mid-2014,
Cambodia joined the Scaling Up Nutrition (SUN) move-
ment, thus declaring its commitment to reducing child
undernutrition on the global stage. The project took
advantage of this momentum.
In its turn, the project has influenced Cambodian nutri-
tion policy by encouraging the MoH to focus on treating
SAM and enabling them to do so with the novel RUTF.
The existence of a locally-produced RUTF persuaded the
MoH to agree to put therapeutic foods on the essential
medicines list of 2017. Cambodia’s new guidelines for
management of acute malnutrition (comprised of the in-
patient, outpatient, and community handbooks) state that
any available therapeutic product, including the locally-
produced RUTF, can be used for SAM treatment, and for
the management of moderate acute malnutrition [48].
On a broader level, the existence of just one RUF could
rationalise integrated management of acute malnutrition.
At community level, early detection could lead not only to
referral of SAM children, it could also result in moderately
acutely malnourished children receiving the RUSF or a
low dose of the RUTF. The RUF could be either provided
freely through nongovernmental organisation (NGO) pro-
grams or sold at the market. A middle model, which care-
givers favour, would be for community health volunteers
to sell RUF [44]. This kind of public/private production
and distribution model should be explored further. Any
models of distribution to non-severely acutely mal-
nourished children must avoid inadvertently increasing
the risk of overweight and obesity [49].
The project has also received attention from else-
where in the region, specifically, Laos, Indonesia and
Papua New Guinea, countries which are exploring
options for developing and using their own locally-
produced RUFs.
Strategy and advocacy
The RUFs were brought to the attention of high-level
Cambodian policy and decision makers in the Fill the
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Nutrient Gap process and report, convened by WFP [50].
By bringing together multiple ministries under the direc-
tion of the inter-ministerial Council for Agricultural and
Rural Development (CARD), the process has helped to
place nutrition more firmly onto the broader government
agenda. This may also facilitate nutrition-sensitive
programming across sectors.
That said, at the outset, there was no clear strategy
and advocacy plan for the project. Ad hoc opportunities
through UNICEF events, conferences, and media were
taken as they arose. Ideally, opportunities and strategies
for advocacy would be identified in the planning phases
of the project.
Project communication
The project needs to be communicated to the broader
group of stakeholders, especially when actors have different
backgrounds, goals, and roles. Too often, research is com-
municated in conferences that may not be attended by a
wide range of actors. The National Nutrition Program
Working Group provided a forum for project communica-
tion. Events such as project launch meetings that bring to-
gether a range of actors can also facilitate communication
between multiple actors and across multiple levels. An
important part of effective communication, especially in
hierarchical societies, entails negotiating cultural differ-
ences and protocol. On multiple levels, project communi-
cation is essential and needs to be an explicit part of the
project plan.
Stakeholders
The original group of core stakeholders comprised of
UNICEF, MoH, WFP, IRD and DFPTQ provided a com-
plementary set of skills, experience, and opportunities
for developing, promoting, or utilising the RUFs. The
various partners also had a history of collaboration. With
respect to undernutrition, the primary mandate of
UNICEF and the MoH is treating SAM, while WFP’s
mandate is preventing undernutrition, including by pro-
viding supplementary food. IRD and DFPTQ provided
the research skills and experience to implement the
project.
It is important to be explicit about the needs and pres-
sures on all actors, about what prerogatives are privileged
or steer the project, as well as how those priorities are
reconciled, and how communication will be ensured and
conducted. However, the letter of agreement between the
stakeholders was very general and did not outline roles or
responsibilities, including resourcing. In 2015, when
WFP’s funding for Cambodia decreased, and with it, the
likelihood that WFP would provide supplementary food
for the prevention of undernutrition in the foreseeable
future, they withdrew from the project. This was a signifi-
cant loss, given WFP’s expertise in the development of
specialised foods. A letter of agreement that clearly out-
lined the roles of each stakeholder in greater detail might
have assisted in the selection of the stakeholder group.
Moreover, a more binding agreement might have avoided
the resourcing and planning issues that impeded the
project’s early progress.
Research versus policy and program implementation
There can be tension between research and policy or
program goals and timelines [51], particularly when
there is a large a variety of actors (researchers and
research students, national and international institutions
as well as NGOs, multiple ministries and their staff and
volunteers). Researchers may not appreciate the policy
and implementation demands that program people face,
while the latter may expect research to deliver results
too quickly or definitively. On a broader level, the re-
search that is needed to satisfy program requirements
may not be the research that is considered necessary in
the academic community. This project did connect uni-
versities and research agencies to UN and government
agencies, but perhaps could have negotiated the complex
space between research and programming more effectively
by explicitly acknowledging the stakeholders’ various
objectives and timelines.
Programming
The RUTF can now be used by hospitals and health cen-
tres that provide SAM treatment, as well as by NGOs
that support community-based treatment. Vissot (a cer-
tified Cambodian food manufacturer that complies with
the relevant Cambodian food safety and labelling stan-
dards) is also planning to make RUF available for sale to
the public.
Currently, the RUTF is being piloted on a small scale
by an NGO doing community-based SAM treatment,
but it is not yet being used in the health system. A major
difference between HEBI and the Cambodian RUF pro-
ject is that the Vietnamese government were driving the
development, production, and utilisation of HEBI. Once
HEBI was demonstrated to be acceptable and effective,
the Vietnamese government phased out BP-100™ and
began using HEBI. Thus, a green light for HEBI uptake
was built into the Vietnamese process. On the other
hand, in Cambodia, the government was not driving the
process. Private sector production will depend on gov-
ernment commitment to purchase. Therefore, a green
light or trigger for agreeing to procure the RUTF for use
in the hospitals and health centres should have been
identified and agreed upon at the early stages, either in
the stakeholder letter of agreement or a project planning
document.
All new business ventures face the chicken and egg
dilemma – without consumers, producers find it difficult
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to invest, and without a product, consumers find it diffi-
cult to commit to purchasing. This project was no excep-
tion – while there was a great deal of interest in the
product, including from NGOs who could use it, until the
product was finalised and tested (at least for acceptability),
there was no way of knowing what the demand would be,
nor of knowing Vissot’s capacity to meet demand. Simi-
larly, although there is a target price which aims to make
the RUFs’ cost competitive with alternative supplementary
foods, that can only be confirmed once the factory is
producing at scale. Without a guaranteed demand, it was
impossible to invest in the machinery and staff that would
have helped the project progress in a timelier fashion.
Again, a green light and procurement commitment in the
stakeholder agreement may have helped to mitigate this
problem.
Lessons learned are that formative research, which is
seldom well-resourced, is vital. In the case of the RUF
project, this would have involved project mapping which
included cost analyses, and a survey or estimate of demand
from NGOs as well as MoH. The National Nutrition
Program Working Group comprised of government,
UN agencies, researchers and NGOs working in nutri-
tion in Cambodia, and convened by the MoH’s National
Nutrition Program, could have been drawn upon to
facilitate this.
Project management
A project such as this, spanning several years, and en-
gaging a variety of institutional stakeholders and individ-
ual actors, requires meticulous attention to daily and
long-term management. It needs to continuously review
the project’s clarity of purpose and roles, expected
outcomes, financial and human resources, and duration.
Particularly in an environment of indeterminate and
multiple potential sources of funding, organisational
support and staffing, the project’s plan, budget, and
timing need to be defined at the outset, in order to
manage expectations of all the actors. This requires
an identified project manager, or if project ma-
nagement roles are shared, a clear division of
responsibilities.
This long, multi-agency, multi-staff project also experi-
enced challenges in project documentation, partly due to
staff turnover and informal decision making. An identified
project manager would be responsible for collaborating
with all stakeholders to ensure thorough project docu-
mentation, including an initial project plan and regular
reporting. Project documents need to outline activities, a
timeline, and resources in detail. They also need to
describe the research and policy context in which the
project was conceived and opportunities for influencing
policy, and to formulate an advocacy strategy. Decisions
taken, and options excluded must be recorded.
Project resourcing
The project team had an admirably “can-do” attitude,
which yielded a high ratio of benefits for resource inputs
(at least in terms of funding). The use of doctoral
students (who undertook the research as part of their
PhDs) reduced costs, and the embedding of the project
in a government department allowed the achievement of
results that went beyond what may have been achieved
if roles had been too sharply defined. Conversely, the
“pitch in” approach left gaps in terms of responsibilities
for tasks. Similarly, a dependence on ad hoc funding that
was not clearly dedicated in advance - while allowing the
project to happen at all - meant that some parts (such as
the effectiveness trial with pregnant and lactating women)
had to be abandoned when the expected funding did not
materialise.
It is essential to consider human resources and to
acknowledge strengths and gaps in expertise and compe-
tence. Again, it is vital to have a defined project manager
who can be responsible for tying the threads together –
for calling meetings, documenting decisions, and flag-
ging resource gaps. A project manager need not be the
most senior person. Indeed, the skills of senior people
and experts are too often wasted by expecting them to
also do project management. Such senior people are best
used as a steering committee. One of their tasks is to
identify the responsibilities of the project manager, and
to ensure that the manager and team members are col-
laborating effectively. In this way, the willingness of team
members can be optimised, while ensuring that adequate
documentation and project administration happen.
Discussion
This project has responded both to a programmatic need
articulated by the Cambodian MoH and to identified
gaps in the current understanding of RUFs for the
prevention and treatment of undernutrition. Engaging
numerous actors over multiple years, it experienced
challenges and successes. Most importantly, it seized an
opportunity created by a combination of new research
and policy and drew on similar experiences in neigh-
bouring Vietnam. In turn, it encouraged greater commit-
ment to sound nutrition programming and policy.
Specifically, it contributed to improved guidelines for
SAM treatment and created new options for nutrition
programming.
The challenges could have been mitigated to a great
extent by improved project planning, management, and
documentation. Stakeholder agreements would have
benefited from being more detailed and binding, which
would have contributed to stakeholder collaboration.
More rigorous project planning could have anticipated
and perhaps resolved some of the dilemmas around
demand, capacity, and cost of the RUFs. It would also
Borg et al. BMC Public Health         (2019) 19:1200 Page 7 of 9
133
have clearly articulated the desired policy and program
outcomes, resolved tensions between research and pro-
gramming, and included green lights for ensuring that
the RUTF was taken up in hospitals and health clinics
treating SAM. More rigorous project planning would
have identified specific policy, advocacy and communi-
cation goals and opportunities in advance, rather than in
an opportunistic and ad hoc fashion, thus maximising
the likelihood of exploiting opportunities. At a more
quotidian level, improved project management – and
specifically, a designated project manager - would have
mitigated some of the administrative and resourcing
challenges and enabled the project to unfold more
smoothly. Improved documentation would have made it
easier to learn and share lessons both within the project
and outside it.
Conclusion
This collaborative project developed and tested novel,
locally-produced RUTFs and RUSFs. Projects like this
one can be rich and exciting in their contributions to
both literature and programming. They offer fruitful op-
portunities for learning and exchange between research,
policy, and program actors, which often go untapped.
Future similar projects should focus on project planning,
management and documentation that addresses both
strategic (policy and advocacy) and administrative levels.
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Chapter 9:  Discussion 
This chapter summarises the outcomes of the trials, and the implications for undernutrition prevention.  
It begins by discussing the acceptability and effectiveness trials and how they address some of the gaps 
in the literature.  It goes on to note the possible disadvantages of specially formulated supplementary 
foods.  The next section considers some of the potential strategies and concerns for undernutrition 
prevention arising from our trial.  Finally, the strengths and limitations of this research, and the lessons 
learned are outlined. 
What does the acceptability trial contribute to the literature? 
There have been few studies on the acceptability of supplementary foods in Cambodia (1-5).  This trial 
design was similar to that used in other short duration acceptability trials of supplementary foods in 
Cambodia and elsewhere in terms of sample size (1, 6-17), trial duration (18-20), study objectives, 
design, subjects (1, 3, 7, 10-12, 14, 20), and outcomes (6, 10, 12-14, 20). 
Use of ranking rather than preference scales 
A strength of this trial in comparison to others was the use of ranking.  Ultimately, caregivers determine 
whether a child will be given a particular food and will eventually develop a taste for it (20-23).  The 
use of ranking compelled caregivers to choose between test foods.  This result is more conclusive than 
preference scales and may help to mitigate the socially acceptable responding encountered in other 
studies (8, 18).   
Comparison with other supplementary foods and traditional weaning food 
In our trial we were able to compare the relative acceptability of the novel ready-to-use supplementary 
food (RUSF) containing fish to Corn-Soy Blend Plus Plus (CSB++) which contains milk, and the 
traditional Cambodian weaning food, borbor (white rice porridge) fortified with micronutrient powders 
(MNP).  Many trials have not made such extensive comparisons and in some cases have only tested the 
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intervention food.  Caregivers ranked the novel RUSF highest, which suggests that a fish-based product 
is more acceptable than a milk-based one, and even more acceptable than the familiar weaning food. 
Format of the food – a paste-filled wafer snack 
Caregivers reported that they appreciated the familiarity of the wafer.  They said that the shape 
encouraged children to hold the snack themselves, and consequently, to eat more.  In this respect, our 
product was well developed (24), and acceptable in a context where snacking is common (25).   Whether 
this would encourage more frequent feeding, or less attentive feeding practices, could be explored in 
future.   
Caregivers noticed that the large diameter of the wafer meant more paste in each bite.  The paste tended 
to stick to the children’s palate, and caregivers worried that children might choke, an issue which has 
been noted with other snacks (26).  To mitigate this risk, the wafer diameter was reduced.   
Volume versus energy in an acceptability trial 
The various test foods compared in our trial made it possible to consider the implications of foods with 
quite different volume and calorific content.  Many acceptability studies have compared foods that were 
inherently or volumetrically isocaloric (9, 11, 12, 14), hence few have considered energy consumption 
as an outcome (6, 11).  However, porridges require larger volumes than lipid-based nutrient 
supplements (LNSs) to deliver equivalent calories (18, 27).  Even consumed in smaller quantities, our 
novel RUSF provided more energy than CSB++ porridge or borbor fortified with MNP.   
Given the limited gastric volume of young children, smaller portions of more nutrient dense foods are 
preferable in order to avoid displacement of breastmilk and local foods that enhance dietary diversity, 
including animal-source foods, fruits, and vegetables (28, 29).  This is the rationale for trialling small-
quantity small quantity lipid-based nutrient supplements (SQ-LNSs).  Future studies would do well to 
consider the volume versus energy of test foods. 
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Effect on children’s appetite 
Our trial showed that the RUSF might improve appetite, with some caregivers reporting that, after eating 
the RUSF snack, their children ate more of the food that was offered at home.  This observation was 
made in previous research involving LNSs (30).  In small quantities, LNSs may actually improve 
appetite, potentially contributing to increased intake from other family foods (31).   
Cost and willingness to pay 
Our trial was able to assess the acceptability of the food for families from an economic perspective.  As 
in other studies (9, 13, 32), caregivers expressed a willingness to pay.  They indicated that they would 
pay between 300-1000 riel (US$0.07-0.25) for the RUSF snack, which is comparable to what they 
currently pay for snacks (25, 33).  A recent study of locally-produced supplementary foods has not 
found them competitive with imported products in terms of cost (34).  No thorough cost analysis has 
been conducted on the RUSF snack, but these results suggested that if the following effectiveness trial 
proved successful, the use of the product could be successfully scaled up. 
Confirming field observations of the low acceptability of CSB++ in this context 
In the quantitative questionnaire and the Focus Group Discussions (FDGs), caregivers ranked CSB++ 
very low.  This confirms the field observations that CSB++ had low acceptability (35), which is relevant 
for future programming. 
Conclusion 
Given that effectiveness is predicated on acceptability, the acceptability trial was an important 
foundation for the effectiveness trial.  The acceptability trial confirmed that fish is a promising 
alternative to milk in a locally-produced supplementary food.  It also provided feedback that allowed 
the format of the food to be refined and made more acceptable.  This improvement reduced potential 
bias in the effectiveness trial.  Since most specially formulated foods are developed and tested in Africa, 
the trial contributes to the literature on the food preferences of children and caregivers in Cambodia and 
South-East Asia.   
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What does the effectiveness trial contribute to the literature? 
Non-milk animal-source foods are as effectiveness as milk-based foods 
The few trials of the effectiveness of specially formulated foods using non-milk animal-source foods 
have had mixed outcomes.  Two Cambodian studies that compared milk- to fish-based products found 
no significant difference in anthropometric outcomes between groups (36, 37).  Another study 
comparing a peanut/soy spread to a fish-fortified porridge found that the former was slightly more 
effective (38).  In this trial, the RUSF (containing fish) appeared less effective than CSB++ (containing 
milk) at protecting against decreases in weight-for-age z-score (WAZ), weight-for-height z-score 
(WHZ), and mid-upper arm circumference (MUAC) amongst high consumers, but equally or more 
effective amongst low consumers, but the differences were marginal.  Thus, this trial suggests that non-
milk animal-source foods are as effective as milk-based foods (37). 
Evidence on the effectiveness of supplementary foods in South-East Asia 
This study helps fill a gap in the research pertaining to the effectiveness of supplementary foods in Asia 
generally, and in Cambodia and South-East Asia in particular.  South-East Asia is generally 
underrepresented in the research on prevention of childhood undernutrition.  While there are a number 
of studies on micronutrient supplementation from South and South-East Asia (39-44) including 
Cambodia (45-49), there are relatively few studies on the use of supplementary foods.  Most studies on 
supplementary foods originate in Africa (50), and much of the research in that region has been 
conducted in Malawi (38, 51-60).  Our research is important because it provides much-needed evidence 
on the effectiveness of supplementary foods in South-East Asia.   
Micronutrients without adequate macronutrients have limited impact on growth  
Our trial has reiterated the importance of ensuring that children consume adequate macronutrients as 
well as micronutrients.  In this trial, high consumers of MNP had increased WAZ and MUAC compared 
to the control group in adjusted analysis.  There was no significant difference between MNP and the 
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other products.  Since MNP is added to food after cooking, high consumers of MNP were likely to have 
an increased intake of all foods.  This would suggest that adequate food consumption with MNP, and 
not MNP alone, explains the increased ponderal growth of the high consumers of MNP in comparison 
to the control group.  This concurs with the finding that micronutrients are more likely to achieve growth 
outcomes only if they are combined with adequate macronutrients (47, 61-70). 
Supplementing with readily available foods may be more effective than specially formulated foods 
Our trial, and our review of similar trials, suggested that specially formulated supplementary foods had 
an inconclusive or modest impact on undernutrition prevention.  Amongst the supplementary feeding 
trials that were most successful in improving anthropometric outcomes were two that used readily 
available foods.  In a recent study comparing supplementation of children’s diets with one egg a day to 
an unsupplemented control, eggs were found to greatly increase WAZ and height-for-age z-score (HAZ) 
(71).  In another, a mixed food basket including meat was found to increase WAZ and WHZ (72).  This 
suggests that where supplementary feeding interventions are used, food-based approaches, using 
readily-available local foods, such as eggs, may be preferable to supplementing with specially 
formulated supplementary foods.   
Impact of providing supplementary food to a representative population 
Our trial tested the impact of providing supplementary foods to a representative population.  Providing 
supplementary foods to representative populations has not been done in very many trials, even though 
it is widely agreed that prevention of undernutrition is preferable to avoid children reaching the 
recognised cut-offs for stunting or wasting (73-75).  Our sample could be considered representative, in 
that it included some moderately acutely malnourished (MAM) children (WHZ > -3 to <-2 and MUAC 
11.5 - 12.5cm), some non-MAM (WHZ > -2 and MUAC > 12.5cm), and some overweight children 
(WHZ 2 to 3) (76).  Approximately 5% of the children in our study were MAM at baseline, which is 
comparable with prevalences in the general population (77).  A small number of studies were found 
(see Table 2.5) that appeared to include MAM and non-MAM children, although exclusion criteria were 
not always clear (36, 38, 71, 78-83).   
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Impact of providing supplementary food to a food secure population 
To date, there is no clear evidence that food supplementation prevents growth faltering in food secure 
settings (84, 85).  Our trial contributes to the limited literature on undernutrition prevention in food 
secure settings. 
Much of the evidence on the use of supplementary foods is from food-insecure or emergency contexts. 
Yet most undernutrition occurs in non-emergency settings, many of which could be considered 
relatively food secure, including Cambodia (50, 86).  Definitions of food security are multiple and vary 
in their analysis from country to household level.  For the purposes of determining whether our study 
population was food in/secure, we used two criteria.  First, Blanket Supplementary Feeding 
Programmes (BSFP) entailing the distribution of supplementary foods to prevent undernutrition is 
recommended when MAM prevalence rates exceed 15 - 20% (87).  This was not the case for our study 
population (see Table 2.1).  Second, Cambodia’s Identification of Poor Households Program, IDPoor 
(88), classified only 10% of the households in the study site as poor or very poor.  Based on these two 
criteria, the study population was considered food secure.   
Comparison of test food with an unsupplemented control 
This trial contributes to the evidence on provision of supplementary products compared to an 
unsupplemented control.  There have been many studies that have compared supplementary foods to 
each other but not to an unsupplemented control (89, 90).   
Did the trial interventions prevent undernutrition? 
None of our interventions prevented growth faltering.  Mean anthropometric measures decreased in all 
groups from baseline to endline.  HAZ decreased by 0.24 to 0.37; WAZ decreased by 0.03-0.14; WHZ 
decreased by 0.03-0.15.  MUAC increased by 0.1-0.3cm.  Therefore, the none of the interventions 
prevented undernutrition.  
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However, the RUSF and CSB++ did slow ponderal growth faltering with respect to the control group.  
As in similar trials, WAZ, WHZ and MUAC increased in comparison to the control group for at least 
one of the interventions, (28, 36, 38, 66, 72, 78-81, 90-93).  In our trial, low consumers of the RUSF 
and high consumers of CSB++ showed the most improvement. 
 
In similar trials, impact on HAZ was mixed (28, 36, 72, 79, 94, 95).  None of the interventions in our 
trial improved linear growth with respect to the control group.  In our study, and in at least one other, 
HAZ declined more for the CSB++ group than it did for the control (96).   
 
Thus, in this trial, as in others, none of the supplementary foods prevented undernutrition, although the 
RUSF and CSB++ provided limited protection.   
 
Are the outcomes clinically significant? 
From a programmatic point of view, it is important to question whether our outcomes were clinically 
significant.  In this trial, as in others, the magnitude of the impact of supplementary feeding on growth 
appears small to negligible (90, 94, 97), and the impact on linear growth is particularly mixed (28).  To 
date, there is insufficient evidence to recommend routine provision of supplementary foods for the 
prevention of undernutrition in representative populations of children in food secure settings (98). 
 
Conclusion  
Neither the novel RUSF, nor either of the other interventions, prevented undernutrition.  The RUSF and 
CSB++ slowed ponderal growth faltering with respect to the control group, but the impact was of 
limited clinical significance.  None of the interventions had a significant impact on linear growth 
faltering.  That said, the fish-based RUSF worked as well as CSB++, the gold standard, milk-based 
supplementary food that is widely provided to children aged six months to two years to prevent 
undernutrition.   
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Potential disadvantages of supplementary foods 
A number of researchers have pointed out the potential long-term risks of using specially formulated 
supplementary foods (97, 99-101).  These include possible undesirable effects; suboptimal patterns of 
growth; displacement of breastmilk and healthy family foods; disempowering caregivers and replacing 
traditional foods; encouraging consumption of non-nutritious commercial snacks; and diverting 
resources from other, potentially effective nutrition interventions.   
Potential undesirable effects 
Although interest in locally-produced supplementary foods has been growing for at least ten years, there 
is an acknowledged lack of data on potential adverse effects of these products (50, 90, 102).  What 
research exists has tended to focus on immediate adverse effects such as toxic doses, morbidity related 
to food hygiene and displacement of breastmilk, and use of iron-rich foods in high malaria settings (64, 
66).  
Suboptimal patterns of growth 
There is very little evidence on the potential long-term effects of provision of specially formulated 
supplementary foods on patterns of growth (99).  Ideally, weight gain should be balanced, favouring 
lean tissue over fat (27, 103).  A potential risk of the use of supplementary foods, especially LNSs, is 
rapid weight gain and obesity (100) particularly among stunted children (103).  For this reason, WHO 
cautions against routine provision of supplementary foods to moderately wasted or stunted children to 
avoid inadvertently increasing the risk of the risk of overweight and obesity, particularly in the context 
of the dual burden of malnutrition (104), which Cambodia, like many other low- and middle-income 
countries, is facing (105).   
Others question this recommendation, citing a lack of evidence that supplementary foods can contribute 
to overweight and obesity compared to clear evidence of the risks of not treating MAM, especially when 
it is concurrent with stunting (106).  A recent trial which provided MAM children with supplementary 
foods for twelve weeks found that most of the weight gained (94%) was fat free mass (107).  It is 
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recommended that future studies include measures of body composition to help resolve this question 
(50, 102).   
 
Displacement of breastmilk and healthy family foods 
Another possible unintended effect of supplementary foods is the displacement of breastmilk and 
healthy family foods, which risks decreasing dietary diversity, and food frequency.  Reduction in 
breastmilk consumption, in addition to the loss of nutritional quality, also exposes children to increased 
pathogens, and decreases potential breastmilk-mediated immune protection (66, 96, 108).  Dewey and 
Brown caution that a focus on only complementary feeding risks undermining breastfeeding and 
reiterate that feeding interventions that promote optimal breastfeeding and complementary feeding are 
more likely to result in appropriate growth (109).  For this reason, the International Lipid-Based Nutrient 
Supplements (iLiNS) Project have specifically designed small quantity LNSs (SQ-LNSs) to avoid the 
displacement of breastmilk and to allow consumption of diverse family foods (29).   
 
The quantities of RUSF provided in our trial (between 40-110g/day) could conceivably have displaced 
breastmilk and other family foods (108).  This may have been the case for high consumers of RUSF, 
whereas low consumption of RUSF may have supplemented the existing diet (66, 96).  However, 
analysis thus far on the displacement of breastmilk and family food does not reveal any difference 
between dietary intake across the groups.   
 
Disempowering caregivers and replacing traditional foods 
Specially formulated supplementary foods may be disempowering and deskilling for caregivers (73, 
100, 101) in terms of their food preparation skills and feeding practices.  It may also create the belief 
that processed foods are superior to breastmilk and family foods (89, 110).   
 
Encouraging consumption of non-nutritious commercial snacks  
In Cambodia, which has weak regulatory system for food production and marketing, and where there 
is high consumption of commercially produced snack foods of low nutritional quality (25, 111, 112), 
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commercialisation of supplementary foods could unintentionally encourage an increase in the 
consumption of processed foods and a decrease in the consumption of healthier foods (25, 85, 89, 100, 
101).  This may contribute to the rapid nutrition transition which Cambodia is experiencing (105).  In 
addition, if the RUSF snack proves successful, it may be counterfeited in a way that looks similar but 
is not as healthy.   
 
Diverting resources from other interventions 
A reliance on supplementary foods could divert funding from other potentially effective interventions 
for undernutrition prevention.  It is unclear whether the impact of supplementary foods is sustained, 
since very few trials have followed up over the long term, and those that have suggest that benefits have 
not persisted (28, 50, 89, 97, 100-102).  Furthermore, the use of supplementary foods does not address 
other immediate causes of undernutrition such as inadequate breastfeeding and complementary feeding 
practices, hygiene, and infection, let alone underlying and basic causes (89, 97, 101).  There is a need 
for trials that evaluate the effectiveness and long-term impact of supplementary foods compared to other 
types of nutrition-specific and nutrition-sensitive interventions (50, 85, 89, 97, 102).   
 
Potential strategies and considerations for undernutrition prevention arising from our trial 
This trial suggests that a supplementary food, as a stand-alone nutrition-specific intervention, has a 
limited impact on undernutrition prevention.  A number of possible future directions for reflection and 
research have arisen from the trial. 
 
Trialling the RUSF in small quantities 
The RUSF was given in medium quantities, that is, between 40-110g/day providing 250–500 kcals, or 
50–100% of required energy coming from foods other than breast milk.  In smaller quantities, the RUSF 
would be less likely to displace breastmilk and other family foods, or to negatively impact caregiver 
feeding practices and skills.  Given that low consumers of the RUSF had more positive anthropometric 
outcomes than high consumers, providing the RUSF in small quantities seems a promising strategy.   
146
The RUSF should be trialled in daily doses of approximately 20g, or 110 kcal, which is less than 50% 
of the energy required from foods other than breast milk per day (29).   
 
Interventions in addition to supplementary foods 
The results of this trial highlight the potential role of other factors such as maternal body mass index 
(BMI) and iron status pre-conception, low birthweight, and diarrhoea, that must also be addressed in 
programming aimed at prevention of undernutrition.  Evidence-based interventions targeting pre-
pregnancy, peri-natal and antenatal periods, such as optimising adolescent health and nutrition, 
including age at first pregnancy; maternal micronutrient and macronutrient supplementation; delayed 
cord clamping; neonatal vitamin supplementation; kangaroo mother care; early, exclusive, and 
continued breastfeeding; improved dietary diversity and complementary feeding; as well as diarrhoea 
prevention and management, are all elements of an integrated strategy for undernutrition prevention 
(113).   
 
Establishing standards for undernutrition prevention  
Building an evidence base for the role of supplementary foods in undernutrition prevention is stymied 
by a lack of standards, goals, and guidelines on clinical significance.  In severe acute malnutrition, 
recovery is clearly defined (WHZ is ≥ –2, MUAC is ≥ 12.5 cm and there has been no oedema for at 
least two weeks) (114).  No clear standard exists for prevention of undernutrition.  This is, in part, due 
to a lack of agreed terminology (74, 97).  Clear conceptualisation of expected outcomes is also lacking 
– is prevention of undernutrition equivalent to successful treatment of SAM or of MAM?  Is it achieving 
WHZ ≥ –1, which is the upper limit of mild wasting (WHZ ≥ –2 and < -1) and the lower limit of normal 
(103)?  Clearer terminology, standards, goals, and guidelines are required. 
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Strengths of the research  
 
Strengths of both trials  
The acceptability and effectiveness trials had two strengths in common.  First, they filled important 
gaps in the literature related to the use of animal-source foods other than milk in supplementary foods.  
Second, they provided much-needed evidence on the acceptability and effectiveness of supplementary 
foods in a geographic and social context other than Africa, specifically, in South-East Asia.   
 
Robust design and methodology of the acceptability trial  
The acceptability trial had a robust design and methodology.  The large sample size in comparison to 
other trials and the high rate of retention increased the likelihood of representativeness.  The crossover 
design reduced the risk of confounding, since each caregiver-child dyad served as its own control.  The 
use of ranking forced caregivers to choose between the test foods, thus providing more conclusive 
results than preference scales, and mitigating against socially acceptable responding.  
 
Robust design and methodology of the effectiveness trial 
The effectiveness trial was a cluster randomised controlled trial, which provides the strongest level of 
evidence for the effectiveness of an intervention.  It was one of relatively few undernutrition prevention 
trials that have compared supplementary interventions to an unsupplemented control group.  In addition, 
a concerted attempt was made to use validated tools and questions, especially from the Cambodian 
Demographic and Health Survey (DHS).   
 
Contribution to programmatic decision-making 
The use of an unsupplemented control enabled the assessment of the outcomes in comparison to doing 
nothing, rather than in comparison to providing another supplementary food.  This challenges the 
assumption that underlies many prevention studies and programs, namely, that any intervention is better 
than none.  It allows programmers to evaluate the relative benefits of supplementary foods compared to 
other interventions.   
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 In addition, unlike most prevention studies that have been conducted with MAM children in food 
insecure settings, this trial provides evidence on a representative population in a food secure setting.  
This enables better assessment of possible outcomes in that setting, which is extremely useful for 
programmatic decision-making.   
 
Limitations of the research 
 
Generalisability in both trials 
Both trials were conducted in peri-urban Phnom Penh.  The results may not be generalisable to rural 
Cambodian populations or to other South-East Asian populations.  With respect to the acceptability 
trial, this may be less problematic, as food preferences – particularly for rice and freshwater fish – are 
similar across the country.  However, it may be a bigger issue for the effectiveness results, given that 
rural areas of Cambodia experience higher levels of undernutrition and poorer infant and young child 
feeding practices.  In rural areas, it would be difficult to predict if the interventions would be more or 
less effective. 
 
Bias in the acceptability trial 
Despite attempting to avoid bias toward any of the foods, unintentional interviewer and respondent bias, 
as well as socially acceptable responding, may have favoured the RUSF in the acceptability trial.  
Forcing caregivers to rank the foods may have mitigated against this. 
 
Bias in the effectiveness trial 
First, self-reporting may have favoured over-reporting of consumption and compliance, which may lead 
to an underestimation of effectiveness.  Second, high and differential loss to follow up may have 
introduced bias, and potentially reduced the power of the study  Multiple channels of contact (directly 
to the caregiver, through community health volunteers, and through other caregivers) were not able to 
mitigate loss to follow up in this highly mobile population. 
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Lessons learned 
Amount of data collected 
In the acceptability trial, it only became apparent after the data collection that the rankings provided 
sufficient information, and that collecting information on caregiver preferences in terms of organoleptic 
qualities (taste, colour, smell, etc.) was unnecessary.  This was possibly because the supplementary food 
had already gone through a number of iterations based on earlier acceptability tests and was in its 
penultimate form by the time the RUSF acceptability trial was conducted.  That said, the data collection 
on organoleptic qualities was not particularly taxing or time consuming for data collectors or 
respondents. 
In the effectiveness trial, on the other hand, much more data was collected than could be analysed.  This 
placed high demand on respondents, in terms of time.  It may also have contributed to respondent and 
data collector fatigue and habituation, and thus to poorer quality data.  Ultimately, it may have 
contributed to loss to follow up.   
Small quantity doses 
The results of the iLiNS Project’s research on the effectiveness of SQ-LNSs had not yet been published 
when our effectiveness trial was designed (29, 108, 115-117).  In hindsight, given the promising results 
for low consumers of our RUSF, it would have been useful for our trial to include an arm receiving a 
small dose of the RUSF.   
Conclusion 
The acceptability and effectiveness trials demonstrated that a novel, fish-based RUSF was acceptable 
in Cambodia, and as effective as the gold-standard CSB++.  As such, they fill a gap in research on 
supplementary foods in South-East Asia.   
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In the effectiveness trial, none of the interventions prevented undernutrition, although they slowed 
ponderal growth faltering in comparison to the control.  However, the clinical significance of this impact 
was modest.  Since there are potential risks to the use of supplementary products, especially in medium 
quantities, trialling the RUSF in small quantities could be a promising approach.   
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Chapter 10:  Conclusion and recommendations 
In Cambodia, the prevalence of undernutrition remains unacceptably high.  It is crucial to implement 
effective strategies for undernutrition prevention.  One possible strategy is provision of specially 
formulated supplementary foods.  This project developed and trialled the acceptability and effectiveness 
of a locally-produced, ready-to-use supplementary food (RUSF).  This chapter summarises the key 
findings of the trials, and possible future directions based on the findings. 
Key findings 
The novel RUSF is acceptable 
The acceptability trial contributed new data on taste preferences of Cambodian caregivers and children 
and demonstrated that fish is a promising substitute for milk in a locally-produced RUSF.   
The RUSF was not as effective as expected 
In the subsequent effectiveness trial, the RUSF provided in medium quantities to a representative, food 
secure population, was not as effective as expected.  None of the interventions prevented undernutrition.  
The RUSF performed as well as Corn-Soy Blend Plus Plus (CSB++) in slowing ponderal growth 
faltering, but the magnitude of the effect was small and may not be clinically significant.   
Future research  
Future research exploring the potential role - if any - of specially formulated supplementary foods in 
preventing undernutrition in among Cambodian children should consider the following.   
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Trial provision of small quantities of the RUSF 
The evidence base for provision of small quantity lipid-based nutrient supplements (SQ-LNSs) is 
growing.   Given that the RUSF had the most consistently positive effect amongst low consumers, a 
study on the RUSF used in small quantities is recommended.   
Compare specially formulated supplementary foods with “real” food 
Future studies in Cambodia should consider comparing supplementation with specially formulated 
foods to supplementation with common family foods such as eggs, or the widely used Cambodian fish 
paste, prahok.  Similarly, in other international studies, specially formulated supplementary foods 
should be compared with common family foods. 
General design features of future studies 
Comparability of studies is complicated by different research designs, varying combinations and 
content of products or interventions, children’s baseline nutritional status, and anthropometric outcomes 
assessed.  Future studies should aim to use definitions, outcome measures and statistical approaches 
which are comparable with existing literature.  They should, where possible, include an unsupplemented 
control group, if that can be done in an ethically sound manner.  The nutritional status of the study 
population should be clearly identified e.g. as moderately acutely malnourished or representative 
(including moderately acutely malnourished and non-malnourished children) using weight-for-age z-
scores (WAZ), height-for-age z-scores (HAZ), weight-for-height z-scores (WHZ) and mid-upper arm 
circumference (MUAC).  Likewise, the setting should be identified as food secure or food insecure 
using the best available data.   
Establish standards, goals, and guidelines for undernutrition prevention  
Further progress in undernutrition prevention research and practice urgently requires consensus on 
terminology, standards, goals, and guidelines on clinically significant outcomes. 
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Conclusion and contribution to policy, practice, and research 
Over the past ten years, interest in the development and testing of locally-produced specially formulated 
supplementary foods has grown.  However, it is important to bear in mind that these products are not a 
silver bullet.  Our locally-produced RUSF slowed but did not prevent undernutrition.  The prevention 
of childhood undernutrition in Cambodia and elsewhere will require a combination of nutrition-specific 
and nutrition-sensitive interventions that address the immediate, underlying, and basic causes of 
undernutrition.  The findings of the two trials should give pause when planning future research, selecting 
nutrition interventions, and developing nutrition policies.   
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Appendix 2.1:  Definitions of malnutrition 
Malnutrition is a broad term that refers both to undernutrition (in energy, protein, or micronutrients) 
and overnutrition, that is, an excess of energy with or without micronutrient deficiency (1).   
This dissertation deals with anthropometric indices of growth and nutrition, based on the 2006 WHO 
growth standards (2) that use weight and height measurements combined with sex and age to develop 
z-score curves.  These anthropometric indices– weight-for-age (WAZ), length or height-for-age 
(LAZ/HAZ), weight-for-height (WHZ), and mid-upper arm circumference (MUAC) - are the most 
widely used and reported measures of growth and nutritional status in children aged six to twenty-three 
months.  The standards use the terms moderate and extreme to refer to z-scores that are, respectively, 
more than 2 or 3 z-scores below the median on the relevant anthropometric scale (2).   
Stunted children experience linear growth faltering.  In other words, they are short for their age. 
Moderate stunting is a HAZ > -3 and < -2 and severe stunting is a HAZ <-3.  Stunting is often considered 
an indicator of chronic or long-term undernutrition.  Wasted children have ponderal growth faltering; 
they are thin.  Wasting may occur suddenly, as a result of illness or food shortage, which may be 
seasonal.  Moderate wasting is WHZ > -3 and <-2 and severe wasting is <-3, respectively.  Underweight 
children, who have a low WAZ, may be wasted, stunted, or both.  Underweight is relatively easy to 
measure and is a simple and useful indicator for detecting growth faltering, whether linear or ponderal. 
In the past decade, MUAC has also grown in prominence as a reliable indicator for undernutrition (3).  
MUAC measurement requires only simple, inexpensive equipment (a flexible measuring tape, ideally 
colour-coded), is relatively easy to measure, does not require any calculation, and may be used by 
illiterate and/or innumerate measurers (4).  MUAC has been shown to predict mortality better than 
WHZ (5).  A range of 11.5-12.5cm is considered a moderately low MUAC <11.5cm is a severely low 
MUAC (6).  
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Moderate acute malnutrition is WHZ > -3 and <-2 and/or MUAC of 11.5-12.5cm, and severe acute 
malnutrition is WHZ <-3 and/or MUAC of <11.5-cm.  
Overweight children have a WHZ > 2 and < 3 z-scores above the median, and obese children have a z-
score > 3.  There are no validated MUAC cut-offs to indicate overweight or obesity (7).  It is important 
to note that children can be both stunted and overweight, which may indicate micronutrient deficiency 
(8). 
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Appendix 3.1: Energy and nutrient profile of novel RUSF 
Recommended daily serving size 40-110g depending on age of child 
Ingredients (g/100g) Rice 13.2 
Soy and mungbeans 21.8 
Fish  5.9 
Sugar 26.8 
Oil/shortening 18.1 
Micronutrient mix  0.9 
Coconut  8.7 
Rice bran  2.2 
Egg 2.5 
Flavouring 0.1 
Nutrients (g/100g) 
Energy (kcal/100g) 484 
Protein (g/100g) 13.1 
Carbohydrates (g/100g) 51.6 
Lipids (g/100g) 24.4 
Fibre (g/100g) 1.6 
Added multiple micronutrients per 100g 
Vitamin A 1,080 µg 
Vitamin D 58.4 µg 
Vitamin B1 (thiamine) 0.28 mg 
Vitamin B2 (riboflavin) 0.78 mg 
Vitamin B6 0.65 mg 
Phosphorus 246 mg 
Calcium 302 mg 
Pantothenic acid 0.75 mg 
Copper 0.75 mg 
Vitamin E 10.7 mg 
Folic acid 94.2 µg 
Iron 6.0 mg 
Magnesium 48.4 mg 
Vitamin B3 (niacin) 7.3 mg 
Vitamin C 52.8 mg 
Zinc 7.5 mg 
Potassium 194.8 mg 
Vitamin B12 10.7 µg 
Biotin 105.6 µg 
Selenium 89 µg 
Data sources: 2007 Vietnamese food composition tables, micronutrient manufacturer 
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Appendix 4.1-4.5:  Acceptability trial data collection forms 
The acceptability data collection forms in Appendices 4.1-4.5 are in English and Khmer languages.  The 
Khmer translations were originally typed using various Khmer fonts.  Some of the fonts are no longer 
available, nor are they compatible with newer fonts.  The text in the obsolete fonts appears in Latin 
fonts, usually as phonetic renderings of the Khmer, while the text in the current fonts appears correctly 
in Khmer script.  This has resulted in less attractive layout than in the original data collection forms.  
The English is all original and correct.   
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): 
kumar   (Child´s ID, CHID):   (Form ID, FORMID) 
Form 1&2: Acceptability trial – recruitment and exclusion form; participant information and consent sheet 1/7 
0 1 
ទ្រមងទ់១ី៖ ការសិក្សោសាកល្បង -- ទ្រមងស់្រមាប់េ្រជើសេរ�សការចូលរួម និងសំណួរស្រមាប់មនិទទួលយកការសកិ្សោ 
Form 1: Acceptability Trial – recruitment form and exclusion questions 
eQµaHkumar  Name of child 
eQµaHmþaykumar Name of the 
caregiver  
PUmi Village 
សង‌� ត់ Sangkat
កាលបរ�េច�ទ Date
ៃថ� Day ែខ Month ឆា� ំ  Year
្របាប់េ�អណ‌ព្យោបាល៖
Tell caregivers: 
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ េយងខ�ុំកំពុងេធ�ករជាមួយនឹងគេ្រមាងផលិតនំ្រតី។ 
េយងកំពុងេធ�ករសិក្សោេលគេ្រមាងផលិតនំ្រតីែដល្រត�វបានករឧបត�ម�និងគំា្រទេដយអង�ការយូនីេសហ� (UNICEF) កម�វ�ធីឣ‍ហារូបត�ម�ថ‌� ក់ជ‌តិៃន្រកសួងសុខាភិបាល 
ន‌យកដ‌� នបេច�េកវ�ទ្យោែកៃច�នងិគុណភាពៃនរដ�បាលជលផលៃន្រកសួងកសិកម� រុកា� ្របមាញ់និងេនសាទ និងវ�ទ្យោសា� ន្រសាវ្រជ‌វនិងអភិវឌ្ឍន៍របស់រ្របេទសបារ‌ំងែដលេ�កាត់ថ‌IRD។ 
េហយគេ្រមាងេនះនឹងេធ�ករសិក្សោេនក�ុងសង� ត់េនះ។ ពួកេយើងមានឣ‍ហារថ�ីែដលជួយឲ្យសុខភាពល� និងការលូតលាស់របស់កុមារ។ ពួកេយើងនងឹេធ�ើការសិក្សោេដ‌យឲ្យកុមារភ�ក់ឣ‍ហារក��ងរយៈេពល២សបា� ហ៍
េហើយេធ�ើការចាប់េផ�ើមពីៃថ�ទី១៩ែខមថិុន‌ រហូតដល់ៃថ�ទី០៣ែខកក�ដ‌ ឆា� ំ២០១៥។  
Hello, my name is _________________________.  I am working with the Num Trey Project. Num Trey Project.  The Num Trey 
Project is supported by UNICEF, National Nutrition Program of Ministry of Health, Department of Fisheries Post-Harvest 
Technologies and Quality Control, Fisheries Administration of the Ministry of Agriculture, Forestry and Fisheries, and IRD.    The Num 
Trey Project is doing a study in this commune.  We have some new foods that help maintain good health and growth for children. 
We will test the foods over two weeks, starting 19 June – 3 July 2015. 
េយើងនងឹបេ្រមើនូវឣ‍ហារខុសៗគា� េ�ទតីាងំសិក្សោែដលេ�ជតិផ�ះរបសអ់�កចូលរួម។ អណ‌ព្យោបាលនងិកុមារនងឹេ�កែន�ងសិក្សោេន‌ះជ‌េរៀងរ‌ល់ៃថ� ស្រមាបរ់យៈេពល២សបា� ហ។៍ 
We will serve different foods at a nearby test-feeding site.  Caregivers and children will go to the site every day for about two weeks.  
េយើងនងឹេធ�ើការស�ង់េមើលថ‌េតើកុមារចូលចតិ�ឣ‍ហារនិមយួៗប៉ុណ‌� ។ ពួកេគនងឹសួរអ�កអំពកីារយល់េឃើញរបស់អ�កពីឣ‍ហារេផ្សងៗគា� ។ ពកួេគនឹងនូវ្របមូលនវូព៌តមានអំពសីខុភាពរបសក់ូនអ�កនិងសុខភាពរបស់អ�ក កម�ស់នងិទម�ន។់
ព៌តមានែដល្របមូលបានទាងំអស់នងឹទកុជ‌ការសមា� ត់។ 
We will measure how much your child likes each food.  They will ask you about your opinion of the different foods.  They will collect 
information about your child’s and your health, height and weight.  All information collected will be kept private and confidential.   
វ‌នងឹមនិមានហានភិ័យអ�ីេកើតេឡើងក��ងការសិក្សោេនះេទ។ ការចូលរួមរបសអ់�កគឺជ‌ជេ្រមើសរបស់អ�កទាងំ្រស�ង។
There are no risks to this study.  Your participation is entirely your choice. 
ការចំណ‌យេ�េលើេសាហុយេធ�ើដេំណើរស្រមាបអ់�កនិងកូនរបស់អ�កេយើងនងឹផ�ល់ជនូសរុបអ�កជ‌សបា� ហ។៍
Your transport for you and your baby will be reimbursed every 7-8 days.  
េតើអ�កមានចណំ‌បឣ់‍រម�ណ៍និងមានេពលទំេនរស្រមាបច់ូលរួមេទ? 
Would you be interested and available to participate?  បាទ/ចាស�  Yes   េទ �No  
េបើសិនជ‌មាន សមូអនុ��ត�ិឲ្យ ខ��សំួរនូវសនំួរមួយចំននួេដើម្ីបដឹងថ‌អ�កនិងកនូអ�កមានលក�ណៈ្រគប់្រគានស់្រមាបច់ូលរួមក��ងការសកិ្សោេនះ។
0 6 2 0 1 5 
Appendix 4.1 Forms 1 & 2: Recruitment and exclusion; participant information and consent  
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): 
kumar   (Child´s ID, CHID):   (Form ID, FORMID) 
Form 1&2: Acceptability trial – recruitment and exclusion form; participant information and consent sheet 2/7 
0 1 
If yes, please let me ask some questions to see if you and your child are suitable participants. Ask the following questions: 
Variable 
name 
សូមសួរេ�អ�កេមើលែថកុមារ 
PLEASE ASK THE CAREGIVER 
ចេម�ើយ
RESPONSE 
 សកម�ភាព
 ACTION
កូដ
Code 
EXDOB 1. េត(េឈ� ះេនះ)សំបុ្រតកំេណ ត
េសៀវេភេលឿងឬឯកសរេផ្សងេទៀតមកជាមួយឬ
េទ?
េបមិនមាន សូមរលំងេទសំនួរទី៥។
Does (name) have a birth certificate, immunisation card, or
some other document?) If no, go to question 2.
បាទ/ចាស  
Yes   
េបើជ‌បាទ/ចាស សូមសរេសរនូវកាលបរ�េច�ត 
If yes, write the date: 
1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
Go to question 2
0 
EX1AGE េបើសិនជ‌មាន សមូសរេសរៃថ�កំេណើតេ�េលើឯកសារ េបើសិនៃថ�កេំនើតមនិែមនេ�ចេន‌� ះ19/6/13 and
19/9/14េទ សមូនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចលូរួមរបស់អ�ក។ 
ែតគរួឲ្យសា� យែដលអ�កនងិកូនរបស់អ�កមនិមានលក�ណៈ្រគប់្រគានស់្រមាបច់ូលរួមក��ងការសកិ្សោេទ េដ‌យសារេឈា� ះ( 
) ឣ‍យុតិច/េ្រចើនជ‌ងឣ‍យុែដល្រត�វសកិ្សោ។  មនិទទួលយកការចូលរួម នងិប��បស់ំនួរ។
If yes, write the date on document If date is not between 19/6/13 
and 19/9/14, say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate 
because (name) is too young/old. EXCLUDE/END QUESTIONNAIRE 
េបើជ‌បាទ/ចាស សូមសរេសរនូវកាលបរ�េច�ត 
If yes, write the date on document: 
   éf  Day        Ex  Month             qñaM  Year     
មិនទទលួយកការចលូរួម EXCLUDED      99 
EX2AGE 2. េតើកូនរបសអ់�កមានឣ‍យុពី ៩េ�២៣ែខែមនេទ?
ប�� ក់៖ កមុារេកើតេ�ចេន‌� ះៃថ�ទ1ី5/6/13 នងិ15/9/14
Is this child aged between 9-23 months, i.e. was your baby
born between 19/6/13 and 19/9/14?
បាទ/ចាស  
Yes   
 បន�េ សំនួរបន‌� ប់
Go to next question
1 
េទ   
No   
 មិនយក
Exclude.
0 
EX1TWIN 3. េតើកូនរបស់អ�កេនះជ‌កូនេភា� ះឬ?
Is this child a twin or multiple?
បាទ/ចាស  
Yes   
 មិនយក
Exclude.
1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
Go to next question
0 
EX1CF3M 4. ចាប់តាងំព៣ីែខមុនេតើកនូរបសអ់�កឣ‍ចញ‌� ឣំ‍ហារេផ្សងៗែដរឬេទ?
Has this child been eating borbor or other solid foods for at
least 3 months?
បាទ/ចាស  
Yes   
 បន�េ សំនួរបន‌� ប់
 Go to next question
1 
េទ   
No   
 មិនយក
Exclude.
0 
EX1ILL 5. េតើកូនរបសអ់�កកំពងុមានជងំឺធ�នធ់�រឬេទ?ដចូជ‌ជងំឺេអដស៍ ឬរេបង។ល។
Does this child have any major illness right now (e.g. HIV, TB,
etc)?
បាទ/ចាស  
Yes   
 មិនយក
Exclude.
1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
Go to next question.
0 
EX1ALRGY 6. េតើកូនរបសអ់�កធា� ប់មាន្របតិកម�ជ‌មួយឣ‍ហារអ�ខី�ះ? (ឧ. ញ‌� ំេហើយេធ�ើឲ្យពបិាកក��ងការដកដេង�ើម 
ឬមានកន��លរមាស់េ�េពលញ‌� ឣំ‍ហារណ‌មួយ)
Does this child have allergies or intolerances to any food (e.g.
difficulty breathing or a rash if they eat certain foods).
បាទ/ចាស  
Yes   
 មិនយក
 Exclude.
1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
 Go to next question.
0 
EX1STUDY 7. េតើកូនរបសអ់�កកំពងុចលូរួមេធ�ើការសិក្សោជ‌មួយគំេរ‌ងឬការសិក្សោដ៏ៃទេទៀតេទ?
Is this child currently participating in any other test /study?
បាទ/ចាស  
Yes   
 មិនយក
 Exclude.
1 
2 0 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): 
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0 1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
 Go to next question.

0 
EX1MUM 8. េតើអ�ក(ឬមា� យកុមារ)កពំុងមានជំងធឺ�ន់ធ�រឬេទ? (ឧ. ដូចជ‌៖ ជំងឺេអដស៍ ឬរេបង។ល។)
Do you (or the mother) have any major illness right now (e.g.
HIV, TB, etc)?
បាទ/ចាស  
Yes   
 មិនយក
 Exclude.
1 
េទ   
No   
 បន�េ សំនួរបន‌� ប់
 Go to next question.
0 
EX1AVBL 9. េតើអ�កនងិកូនរបស់អ�កឣ‍ចមានេពលជ‌េរៀងរ‌ល់្រពកឹ/លា� ចស្រមាប់ចូលរួមការសិក្សោក��ងរយៈេពល១៥ៃថ�េដ‌យចាប់េផ�ើមេ�ៃថ�១៩
ែខមិថុន‌ រហូតដល់ៃថ�ទី៣ ែខកក�ដ‌ ឆា� ំ២០១៥ ។ េបើសិនគាត់មិនទំេនរេទ កុំប���លគាត់ក��ងការសិក្សោ។
Will you and your child be available every morning/ afternoon for 
the full 15 days of the study, 19 June – 3 July 2015?  If no, exclude. 
បាទ/ចាស  
Yes   
 បន�េ សំនួរបន‌� ប់
 Go to next question
1 
េទ   
No   
 មិនយក
 Exclude.
0 
EX1AMPM 10. េតើអ�កទំេនរេពលណ‌?េពល្រពកឹឬលា� ច? (គូសចេម�ើយ១ ឬឣ‍ចគូសទាំង២)
Are you available morning and/or afternoon (tick one or both)? 
្រពឹក Morning    1 
លា� ច Afternoon   2 
EX1YES 11. េតើអ�កនងិកនូរបសអ់�កស�្រគច័ិត�ចូលរួមេធ�ើការសកិ្សោជ‌មយួេយើងេទ?
Are you willing for you and this child to participate in the study? 
បាទ/ចាស  
Yes   
 កត់េឈា� ះ
Write down name
1 
េទ   
No   
 មិនយក
 Exclude.
0 
េបើអ�កទទួលបាននវូចេម�ើយែដលមិនទទួលយកការចូលរួមរបស់អ�កែថកុមារេទ េន‌ះសូមនិយ‌យថ‌៖
If you get an answer that excludes the caregiver, please say:  
អរគុណចំេពាះឆន�ៈែដលចង់ចលូរួមក��ងការសិក្សោជ‌មួយពួកេយើង ែតគួរឲ្យេសាកសា� យែដលអ�ក និងកនូរបស់អ�កមនិមានលក�ណៈ្រគប់្រគាន់េដើម្បីចូលរួមក��ងការសិក្សោ េដ‌យសារែត [្របាប់នូវមូលេហតុដូចេ�ក��ងទ្រមង់មិនទទួលយកការចូលរួមរបស់គាត់ ឧ. កុមារមិនមានឣ‍យុចាប់ពី៩ែខ 
េ�២៣ែខ]។
Thank you for your willingness to participate.  Unfortunately, you and your child are not eligible to participate because [give the reason from the exclusion form that 
they were excluded, e.g. the child was not aged between 9-23 months, etc].. មិនប���លគាត់ក��ងការសិក្សោExcluded   
េបើសិនជ‌អ�កសួរ្រគប់សំនួរេហើយអ�កែថកុមារេន‌ះមានលក�ណៈ្រគប់្រគាន់ក��ងការចលូរួម និងមានឆន�ៈចូលរួមេន‌ះសូមនិយ‌យថ‌៖
If you ask all the questions and the caregiver is eligible and willing to participate, please say:  
អរគុណស្រមាបឆ់ន�ៈចូលរួមរបស់អ�ក េយើងនឹងសេសរេឈា� ះអ�កទុក។ ការសិក្សោនឹងចាប់េផ�ើមចាប់ពៃីថ�សុ្រកទ១ី៩ ែខមិថុន‌ ឆា� ំ២០១៥។ សូមអេ��ើញេ�កែន�ងសិក្សោជ‌មួយកូនរបស់អ�កេ�កែន�ងផ�ល់ឣ‍ហារ(..............................) េ�េវលាេម៉ាង៩្រពឹក ឬេម៉ាង២:៣០លា� ច។ 
សូមអ�កយកបណ� ័េលឿង ឬបណ� ័ប�� ក់អត�ស�� ណេផ្សងេទៀតរបស់កុមារមកជ‌មួយេដើម្បីប�� ក់ពៃីថ�ែខឆា� ំកំេណើតរបស់កុមារ។
Thank you for your willingness to participate.  I will write your name down.  The study will begin tomorrow on Friday  19 June.  Please go with your baby to (test-
feeding site) at X o’clock in the morning/afternoon.  Please bring your baby’s yellow card. 
េយើងនឹងផ�ល់នូវការចំណ‌យេលើការេធ�ើដំេណើរពីផ�ះមកកែន�ងផ�ល់ឣ‍ហារដល់អ�កនិងកូនរបស់អ�ក េហើយថរ�ការេន‌ះនឹងផ�ល់ឲ្យអ�កចំនួន4០០០េរៀលក��ងមយួៃថ� េហើយេយើងនឹងេបើកថវ�ការសរុបជ‌េរៀងរ‌ល់ៃថ�ទី៧ ឬទី៨ៃនការសិក្សោ។
Your transport for you and your baby will be reimbursed at $1/day every 7-8 days.  
េបើសិនជ‌អ�កសួរនវូ្រគប់សំណួរេហើយ េហើយអណ‌ព្យោបាលេន‌ះមាន្រគប់លក�ណៈសម្បត�ិ្រគប់្រគាន់នងិមានឆន�ៈក��ងការចូលរមួ សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈែដលចូលរួម។ ឥឡ�វេនះេយើងនឹង្របាបអ់�កលម�ិតអំពីការសិក្សោនិងសំុការយល់្រពមពីអ�កក��ងការចូលរួម។ 
បន�េ�ពាក្យចូលរួម។ 
If you ask all the questions and the caregiver is eligible and willing to participate, please say:  Thank you for your willingness to participate.  Now I am going to tell you 
more about the study and ask for your consent to participate.  Go to consent form. 
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0 1 
ទ្រមងទ់២ី៖ ការសកិ្សោសាកល្បង -- ព៌តមានស្រមាបអ់�កចូលរួមនងិពាក្យយល់្រពម
Form 2: Acceptability trial - participant information and consent sheet 
ភាពទទួលយកបាននូវឣ‍ហារបំប៉នែផ�កេលើលីពីតមានលាយប���លមី្រក�សារជ‌តិចំរុះស្រមាប់កុមារែដលមានឣ‍យុេ្រកាម២ឆា� ំក��ង្របេទសកម��ជ‌ 
Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two Years in Cambodia 
ចូរអនពក្យយល់្រពមេនះេទកន់អ�កចូលរមួ:
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ ។ 
ខ�ុំបាទ/នាងខ�ុំេធ�ករងរជាមួយគេ្រមាងែដលមានេឈ� ះថានំ្រតី។
Hello, my name is _________________________ and I work with the Num Trey Project.  
េនៃថ�េនះ េយងកំពុងេធ�ករសិក្សោេលគេ្រមាងផលិតនំ្រតីែដល្រត�វបានករឧបត�ម�និងគំា្រទេដយអង�ការយូនេីសហ� (UNICEF)
កម�វ�ធឣី‍ហារូបត�ម�ថ‌� កជ់‌តិៃន្រកសងួសុខាភិបាល ន‌យកដ‌� នបេច�េកវ�ទ្យោែកៃច�និងគុណភាពៃនរដ�បាលជលផលៃន្រកសងួកសិកម� រុកា� ្របមាញន់ិងេនសាទ និងវ�ទ្យោសា� ន្រសាវ្រជ‌វនងិអភិវឌ្ឍន៍របសរ់្របេទសបារ‌ំងែដលេ�កាត់ថ‌IRD។ 
អង�ការេនះែចកចាយនូវឣ‍ហារបបំន៉េ�ដល់កុមារនិងមា� យេដើម្ីបការពារជំងកឺង�ះឣ‍ហាររូបត�ម�។ ពួកេគចង់េធ�ឲ្យផលិតផលរបស់េគឲ្យមានករ្របេសរេឡង
ដូេច�ះពួកេគមានចណំ‌បឣ់‍រម�ណ៍ចងដ់ឹងថ‌េតើឣ‍ហារមួយណ‌ែដល្របជ‌ជនកម��ជ‌ចលូចតិ�ខា� ងំជ‌ងេគ។ ពួកេយើងចង់េធ�ើការសិក្សោឣ‍ហារេដ‌យេ្រប�បេធៀបឣ‍ហារចនំនួ៤្របេភទែដលមានមី្រក�សារជ‌តចិំរុះែដលលជយួរក្សោនូវសខុភាពល�នងិការលតូលាសល់�។  
ពួកេគចង់េ្រប�បេធៀបឣ‍ហារទាងំេនះជ‌មយួនងឹបបរធម�តា។ តាមរយៈការចូលរួមរបសអ់�កនិងកូនរបសអ់�ក 
វ‌នងឹឣ‍ចជួយេយើងឲ្យផលតិនូវឣ‍ហារបំបន៉ឲ្យកាន់ែតល�្របេសើរនងិេថ‌កែដលឣ‍ចជយួដលម់ា� យនងិកុមារេ�ទទូាំង្របេទសកម��ជ‌ឲ្យមានសា� នភាពឣ‍ហារូបត�ម�ល�និងមានសខុភាពល�។ ការសកិ្សោេនះនងឹ្រត�វបានអនុវត�េដ‌យក��  Bindi Borg
មកពីសកលវ�ទ្យោលយ័ Queensland និង Dr Frank Wieringaមកពី IRD។
Today, we are doing a study for the Num Trey Project.  The Num Trey Project is supported by UNICEF, National Nutrition Program of 
Ministry of Health, Department of Fisheries Post-Harvest Technologies and Quality Control, Fisheries Administration of the Ministry 
of Agriculture, Forestry and Fisheries, and IRD.  These agencies distribute supplementary food to children and mothers to prevent 
malnutrition.  They want to improve their products, so they are interested in knowing which food Cambodians like best.  They want 
to test four foods that contain multiple micronutrients which help maintain good health and growth.  They would like to compare 
these foods.  Through your participation, you and your child will be helping us to make better and cheaper supplementary food that 
can help Cambodian mothers and children to be better nourished and healthier.  The study is being conducted by Ms Bindi Borg 
from the University of Queensland and Dr Frank Wieringa from IRD.   
េយើងនងឹបំេរ�ជនូនូវបបរចំននួ៤្របេភទខសុគា� េ�ទីតាងំេនះ ក��ងរយៈេពល១២ៃថ�បន�បន‌� ប។់ េយើងសមូអេ��ើញអ�កមកទីេនះ េហើយអ�កនងឹប���កឣ‍ហារ រយៈ៣ៃថ�ដលក់ូនអ�កស្រមាបឣ់‍ហារមួយ្របេភទ មុននឹងចាប់េផ�ើមប���កឣ‍ហារមួយ្របេភទេទៀត។ 
េយើងនងឹថ�ងឹថ‌េតើកនូអ�កបានញ‌� ំឣ‍ហារអសប់៉ុន‌� ន េហើយថ‌េតើពកួេគចលូចតិ�ឣ‍ហារទាងំេន‌ះឬយ៉‌ងណ‌។បន‌� បព់១ី២ៃថ�េន‌ះ េយើងនឹងអេ��ើញ អ�កឲ្យមកទីេនះេហើយេយើងនឹងសួរអំពីេយ‌បលរ់បសអ់�កេ�េលើឣ‍ហារទាំងេន‌ះ។ 
េបើសិនជ‌ឣ‍ចេយើងចងឲ់្យអ�កមកែតមា� ក់ឯងេ�ក��ងៃថ�េន‌ះ។ 
We will serve four different foods on this site for the next 12 days.  We ask you to come here and feed your child with each food for 
three days each, before passing onto the next food.  We will measure how much your child ate of each food and how they liked 
each food.  After the 12 days, we ask you to come to this site and then we will ask you about your opinion of the four different 
foods.  If it is possible we will like you to come alone on that day.  
េយើងនងឹេធ�ើការ្របមូលពត៌មានអពំកីនូរបសអ់�កនងិសខុភាពកនូរបស់អ�ក ដចូជ‌កម�ស ់ ទងំន ់ និងរបបឣ‍ហាររបស់េគ។ ពត៌មានែដល្របមលូបានទាងំអសន់ឹង្រត�វទកុជ‌ការសមា� តន់ងិជ‌លក�ណៈឯកជនស្រមាបអ់�ក។ 
អ�កនិងកូនរបសអ់�កនឹងមិនឣ‍ច្រត�វបានេគកំណត់អតស�� ណបានេឡើយ។ េយើងនងឹ្រតលប់មកកែន�ងសិក្សោេនះម�ងេទៀតេដើម្ីបែចកចាយនូវលទ�ផលជ‌មយួអ�កេ�េពលែដលលទ�ផលេន‌ះបានេបាះពមុ�េចញេហើយ។ 
លទ�ផលៃនការសិក្សោនងឹ្រត�វេបាះពុម�និងែចកចាយជ‌មួយអ�កណ‌ែដលចងជ់ួយមា� យនងិទារកឲ្យមាន សា� នភាពឣ‍ហាររូបត�ម�ល�នងិសខុភាពល�។ 
ទ្រមង់ៃនការយល់្រពមនិងព៌តមានចូលរួមេនះគឺស្រមាប់អណ‌ព្យោបាលកុមារែដលមានឣ‍យុ៩ 
េ�២៣ែខែដល្រត�វបានអេ��ើញឲ្យចូលរួមក��ងការសិក្សោេលើភាពទទួលយកបាននូវឣ‍ហារបំប៉នែដលឣ‍ចបរ�េភាគបានភា� មេដ‌យមិនចាំបាច់េរៀបចំ/ចម�ិនបែន�ម
This participant information and consent form is for the caregivers of children aged 9-23 months who have been invited to 
participate in an acceptability trial of a locally produced ready-to-use-supplementary food. 
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0 1 
We will collect information about your child’s and your health, height, weight and diet.  All information collected will be kept private 
and confidential.  You and your child will not be identifiable.  We will return to this testing site to share the results with you when 
they are available.  The results of the study will be published and shared with others who want to help mothers and children to be 
better nourished and healthier. 
វ‌គា� នេ្រគាះថ‌� កអ់�ីទាងំអស់េ�ក��ងការចូលរួមក��ងការសិក្សោ។  ការចូលរួមរបស់អ�កគឺជ‌ជំេរ�សរបសអ់�កទាំង្រស�ង។ ថ‌េតើអ�កេ្រជើសេរ�សចលូរួម ឬកអ៏ត់ វ‌នងឹមនិប៉ះប៉ាលដ់ល់ការទទួលេសវ‌កម�េផ្សងៗរបសអ់�កនិង្រគ�សាររបសអ់�កេទ ពី មណ� លសខុភាព ឬសា� បន័
រដ�េផ្សងៗ។ េបើេទាះេយើងបានសង្ឹឃមថ‌អ�កនឹងបន�ចលូរួមជ‌មយួ ការសកិ្សោសំ រ‌ប់រយៈេពល១២ៃថ�ក៏េដ‌យ ក៏អ�កឣ‍ចប�្ឈប់ការចលូរួមរបស់អ�កេពលណ‌ក៏បានក��ងកឡំ�ងេពលសកិ្សោេនះ។ េយើងដងឹថ‌េពលេវលារបស់អ�កគមឺានតំៃល ដូេច�ះអ�កនងឹទទលួ
បានវត��អនសុ្សោរ�យម៍ួយសំរ‌ប់ការចលូរួមរបស់អ�កេ�េពលែដលអ�កេ�ចូលរួមជ‌មយួពកួេយើងរហូតដលច់ុងប��ប់ៃនការសិក្សោ 
េហើយេយើងនឹងជូននូវថវ�ការសរំ‌ប់េធ�ើដំេណើរេ�កែន�ងទទួលឣ‍ហារចំននួ៤០០០េរៀលក��ងមួយៃថ�េដ‌យេយើងនឹងេធ�ើការេបើជនូជ‌េរៀងរ‌ល់ៃថ�ទ៧ី ឬទ៨ីៃនការសិក្សោនូវទឹក្របាកស់រុបៃនចំននួ៧ឬ៨ៃថ�េន‌ះ។  
There are no risks to this study.  Your participation is entirely your choice.  Whether you choose to participate or not, it will not 
affect other services you and your family receive from the health centre, village health support group, or other government 
authorities.  Although we hope you will continue with the study for the full 12 days, you can stop participating at any time during 
the study.  We realize that your time is valuable, so you will receive a gift for your participation if you complete the 12 days.  The 
cost of travel will be reimbursed at $1/day every 7-8 days.   
ការសិក្សោេនះ្រត�វបានទទលួការយល់្រពមឲ្យេធ�ើការសកិ្សេដ‌យសាកលវ�ទ្យោល័យ Queensland ក��ង្របេទសអូ្រសា� ល ីនងិគណៈកម�ការ្រកមសីលធមជ៌‌តសិ្រមាបក់ារ្រសាវ្រជ‌វសុខភាពរបស់្រកសួងសុខាភិបាល្របេទសកម��ជ‌។ 
េតអ�កមានសំណួរែដរឬេទ? ្របសិនេបេនេពលណាមួយក�ុងកំឡុងេពលសិក្សោអ�កមាន សំណួរ 
េនាះអ�កអចទូរសព�័េទកន់ក�� ដេរៀមែដលមានេលខទូរសព�័ ០៩២ ៧៧០៦៧៨។
This study has been approved in ethical reviews by The University of Queensland in Australia and the National Ethics Committee for 
Health Research of the Cambodian Ministry of Health.  If you have any questions or if you would like to discuss your participation in 
this study, you can talk to the project staff, or you can call this number: Daream 092 770 678 
េយងចង់សួរអ�កអំពីករចូលរមួរបស់អ�កក�ុងករសិក្សោឥឡូវេនះ។ េបសិនជាអ�កយល់្រពមចូល 
រមួជាមួយកូនរបស់អ�កក�ុងករសិក្សោ សូមចុះហត�េលខ ឬផ�ិតេមៃដក�ុង្របអប់ខងេ្រកមេនះ។ 
Do you understand what I have told you?  Do you have any questions?  Would you like to participate in the study?  If you agree for 
you and your child to participate in the study, please sign or fingerprint in the box below.  
eQµaHkumar  
Name of the child 
eQµaHmþaykumar 
Name of the caregiver 
ហត�េលខ 
ឬស� មេមៃដរបស់អ�កែថកុមារ 
Signature or thumbprint of the caregiver 
េលខកំណត់អត�ស�� ណកុមារ   
Child´s ID 
ខ�ុំបានអនពក្យយល់្រពមទំងអស់ដល់អ�កែថកុមារ។ 
I have read the consent form in its entirety to the caregiver of the child. 
េឈ� ះអ�ក្របមូលទិន�ន័យ 
Name of the data collector 
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ហត�េលខអ�ក្របមូលទិន�ន័យ 
Signature of data collector 
kalbriecäTRbmUlTinñn½y  
Date of data collection  
ៃថ� Day ែខ Month ឆា� ំ  Year
េបសិនជាអ�កែថរេក�ង/អណាព្យោបាលមិនយល់្រពមចូលរមួេទ សូមនិយាយថា៖ អរគុណ 
ស្រមាប់េពលេវលរបស់អ�ក។ អ�កអច្រតលប់េទផ�ះបាន។  
If the caregiver does not agree to participate, say:  Thank you for your time.  You are free to leave now. 
្របគល់ពក្យយល់្រពមមួយច្បោប់េទអ�កែថេក�ង។ គូសរង�ង់េនេលេលខទូរសព�័េនេល្រកដស់ េនាះេដម្ប ី
្របាកដថាពួកគាត់ដឹងថាគាត់អចទូរសព�័មកេលខណាសំរប់សួរព័តមានបែន�ម។ 
េបសិនជាអ�កែថរេក�ង/អណាព្យោបាលយល់្រពមចូលរមួេទ 
្របគល់ពក្យចូលរមួេទឲ្យអ�កែថរេក�ង/អណាព្យោបាល។ សូមគូសរង�ង់េនេលេលខទូរសព�័េនេលទំព័រ។ 
និយាយថា៖ ព៌តមានេនះគឺស្រមាប់អ�ក អ�កអចទូរសព�័េទេលខេនះ ០៩២ ៧៧០៦៧៨។ 
If the caregiver agrees to participate, tear off and leave the next page with the caregiver.  Circle the telephone number on the page. 
Say:  This information is for you.  If you want more information, you can call this number, 092 770 678.   
ឥឡ�វេនះខ��ំសូមសួរនូវសំណួរខ�ះអពំកីូនរបស់អ�ក។ េ្របើ “ការសិក្សោការទទួលយកបាន ទ្រមង់្របមូលទនិ�ន័យមលូដ‌� ន”
I am now going to ask you some questions about your child. Administer “Acceptability trial, baseline data collection form.”  
0 6 2 0 1 5
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្របគល់ទំព័រេនះេ�អ�កចូលរួម GIVE THIS PAGE TO PARTICIPANT
ភាពទទលួយកបានៃនឣ‍ហារបបំន៉ែដលដ‌ក់ប���លនវូម្ីរក�សារជ‌តេិ្រចើននងិសបំរូលពីតីស្រមាបក់មុារេ្រកាមឣ‍យ២ុឆា� ំក��ង្របេទសកម��ជ‌ 
Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two Years in Cambodia 
្របាប់េ�អណ‌ព្យោបាល៖
Tell caregiver: 
អ�កបានយល់្រពមចូលរួមក��ងការសិក្សោនូវការទទួលយកបានៃនឣ‍ហារបំប៉នែដលឣ‍ចញ‌� ំបានែតម�ងេដ‌យមិនបាច់ចម�ិនេហើយផលិតក��ង្រស�ក។ សូមអេ��ើញមកជ‌មួយកូនរបស់អ�កេដ‌យយកពាក្យយល្់រពមេនះមកជ‌មួយ 
េហើយសូមយកបណ� ៍េលឿងឬសំបុ្រតកំេណើតមកជ‌មួយអ�កផង ។ 
You have agreed for you and your child to participate in an acceptability trial of a locally produced ready-to-use-supplementary 
food.  Please come with your child.  Please bring this paper and your child’s yellow card or birth certificate. 
ព៌តមានទាំងអស់ែដលបាន្របមូលនឹង្រត�វរក្សោេដ‌យសមា� ត់។ វ‌នឹងមិនមានហានិភ័យអ�ីទាំងអស់។ 
All information collected will be kept private and confidential.  There are no risks to this study.  
ការចួលរួមគឺជ‌ជេ្រមើសរបស់អ�ក។ េយើងសង្ឃឹមថ‌អ�កនឹងបន�ការចូលរួមក��ងការសិក្សោស្រមាប់រយៈេពល១២ៃថ� បុ៉ែន�អ�កឣ‍ចមានសិទ�ិឈប់ចូលរួមក��ងការសិក្សោបាន្រគប់េពល។ េយើងដឹងថ‌េពលេវលារបស់អ�កគឺមានតំៃល 
ដូេច�ះអ�កនឹងទទយលបាននូវវត��អនុស្សោរ�យ៍មួយស្រមាប់ការចូលរួមរបស់អ�កេបើអ�កេ�បន�ការចូលរួមរបស់អ�ករហូតដល់ចប់ការសិក្សោ។ 
េយើងនឹងជូននូវថវ�ការសំរ‌ប់ការេធ�ើដំេណើរេ�កែន�ងទទួលឣ‍ហារចំនួន៤០០០េរៀលក��ងមួយៃថ�េដ‌យេយើងនឹងេធ�ើការេបើជូនជ‌េរៀងរ‌លៃ់ថ�ទី៧ ឬទី៨ៃនការសិក្សោនូវទឹក្របាក់សរុបៃនចំនួន៧ឬ៨ៃថ�េន‌ះ។ 
Your participation is your choice.  We hope you will continue with the study for the full 12 days, but you are free to stop 
participating at any time.  We realize that your time is valuable, so you will receive a gift for your participation if you complete the 
full 12 days.  The cost of travel will be reimbursed at $1/day every 7-8 days.   
េបើសិនជ‌អ�កមានសំណួរ ឬេបើអ�កចង់ពិភាក្សោអំពីការចូលរួមរបស់អ�កក��ងការសិក្សោេនះ អ�កឣ‍ចនិយ‌យេ�កាន់បុគ�លិកគេ្រមាងក�� ដ‌េរៀមែដលមានេលខទូរសព�័ ០៩២ ៧៧០៦៧៨។ 
If you have any questions or if you would like to discuss your participation in this study, you can talk to the project staff, or you can 
call Ms Sok Daream on this number:092 770678 
eQµaHkumar  Name of the child  
eQµaHmþaykumar Name of the caregiver 
ហត�េលខ ឬស� មេមៃដៃនអ�កែថកុមារ 
Signature or thumbprint of the caregiver 
េលខកំណត់អត�ស�� ណកុមារ   
Child´s ID 
ទីកែន�ងស្រមាប់ផ�ល់ឣ‍ហារ៖ Test feeding site:
េពលេវលា Time:
ទីកាលបរ�េច�ទ៖19/06-03/07/2015
Dates: 19/06-03/07/2015 
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0 3 
ទ្រមង់ទ៣ី៖ ទ្រមង់ប��ីសំនួរ្របមូលទិន�ន័យមលូដ‌� ន – ស្រមាប់កុមារ ៃថ�០ Form 3:  Acceptability trial, baseline data collection form – children 
Variable name េលខកូដ
សង‌� ត់
Sangkat (SANGKAT) 
ទួលសែង�Tuol Sangkae   1 គីឡ�ែម៉្រតេលខ៩Kiloumaetr Lekh 9   3 
ឬស្ីសែកវRuessei Kaev   2 ្រចាងំចំេរះChrang Chamreh Pir   4 
PUmi 
Village (VILLAGE) 
VILLAGE2 (other village) 
Kleang Sangឃា� ំងសាఄំង   1 Phum Kha 2ខ២   8 
Boeng Salangបឹងសាఄឡ‍ង   2 Phum Khorឃ   9 
Boeng Chhukបឹងឈូក   3 Phsar Touchផ្សោរតូច   10 
Spean Khposសាఄ� នខ�ស់   4 Tuol Sangkaeទួលសែង�   11 
Kroal Kouេ្រកាលេគា  5 Tuol Koukទួលេគាក   12 
Phum Kaក   6 Meattakpheapមិត�ភាព   13 
Phum Kha 1ខ១   7 Sammeakkiសាఄមគ�ី   14 
ទីកែន�ងផ�ល់ឣ‍ហារ
Test-feeding site (SITE) 
Site 1 Sokly’s house  1 
Site 2 Sopha & Nath’s house  2 
Site 3 Leang Sok’s house  3 
Site 4 Thearith’s house  4 
kalbriecäTRbmUlTinñn½y 
Date of data collection (DATE3) 
ៃថ� Day ែខ Month ឆា�  ំ Year
ការ្របមូលទិន�ន័យបានទាងំអស់
Data collection completed (COMPLETE3) 
េទNo   1 
បាទ/ចាសYes   2 
េឈ� ះអ�កដឹកនំា្រក�ម 
Team leader name (SPVSR) 
 Kunthea   1 
Phanna    2 
កលបរេិច�ទៃនករពិនិត្យរបស់អ�កដឹកនំា្រក�ម 
Date checked by team leader (CHEKDATE3) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈា� ះអ�ក្រគប់្រគងក��ងការ�យ‌ល័យ
Office supervisor name (OFFICE3) 
ប៊�នឌីBindi   1 
កាលបរ�េច�ទពនិិត្យេដ‌យអ�ក្រគប់្រគងក��ងការ�យ‌ល័យ
Date checked by office supervisor (OFFDATE3) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ 
Data entry person 1 name (ENTERER1_3) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ Data entry person 1 name  
កលបរេិច�ទប��ូ លទិន�ន័យទី១ 
Date entered (ENTDATE1_3) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ 
Data entry person 2 name (ENTERER2_3) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ Data entry person 2 name  
កលបរេិច�ទប��ូ លទិន�ន័យទី២ 
Date entered (ENTDATE2_3) 
ៃថ� Day ែខ Month ឆា�  ំ Year
eQµaHkumar 
Name of child  (NAMECH3) 
eQµaHmþaykumar 
Name of the caregiver (NAMECG3) 
0 6 2 0 1 5 
0 6 2 0 1 5 
0 6 2 0 1 5 
0 2 0 1 5 
0 2 0 1 5 
Appendix 4.2 Form 3:  Baseline questionnaire 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME3):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID3):
kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 2/10 
0 3 
Variable 
name 
Question  Response កដូ
Code 
RSHP 
RSHPOTH 
1. etIGñkmanTMnak;TMngGVICamYynwgkumarenH? 
What is your relationship to (name)?
sUmKUsrgVg;ykcMelIyEtmYy
Select ONLY ONE answer
មា� យបេង�ើតBiological mother   1 
មា� យចុងStepmother   2 
ជីដូនGrandmother   3 
ឪពុកFather   4 
បង្រសីSister   5 
េផ្សងៗ(ពិព៌ណន‌)Other (describe)       7 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
CARE2W 2. etIGñkman)anTTYlxusRtUvkñúgkarEfTaMkumarenH ya:gticNas;
2s)þah¾cugeRkayenHb¤eT?
Have you had responsibility for taking care of (name) for at least the
last two weeks?)
sUmKUsrgVg;ykcMelIyEtmYy
Select ONLY ONE answer 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
SEX 3. etI kumarenH ePTRbus b¤Rs
Is (name) a male or female?
sUmKUsrgVg;ykcMelIyEtmYy
Select ONLY ONE answer 
្រប�សMale   1 
្រសីFemale   2 
DOB2 4. េត(េឈ� ះេនះ)សំបុ្រតកំេណ ត
េសៀវេភេលឿងឬឯកសរេផ្សងេទៀតមកជាមួយឬេទ? 
េបមិនមាន សូមរលំងេទសំនួរទី៥។
Does (name) have a birth certificate, immunisation card, or some
other document?)
If no, go to question 5.
េទNo       0 
បាទ/ចាសYes       1 
AGE2 
AGE2EX 
េបើសិនជ‌មាន សូមសរេសរៃថ�កំេណើតេ�េលើឯកសាఄរ េបើសិនៃថ�កំេនើតមិនែមនេ�ចេន‌� ះ19/6/13 and 19/9/14េទ សូមនិយ‌យថ‌៖ 
អរគុណស្រមាប់ឆន�ៈចូលរួមរបស់អ�ក។ ែតគួរឲ្យសាఄ� យែដលអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគាន់ស្រមាប់ចូលរួមក��ងការសិក្សោេទ េដ‌យសាఄរេឈា� ះ(  
) ឣ‍យុតិច/េ្រចើនជ‌ងឣ‍យុែដល្រត�វសិក្សោ។ 
មិនទទួលយកការចូលរួម និងប��ប់សំនួរ។
If yes, write the date on document If date is not between 19/6/13 and 
19/9/14, say: Thank you for your willingness to participate.  Unfortunately, 
you and your child are not eligible to participate because (name) is too 
young/old. 
EXCLUDE AND END QUESTIONNAIRE 
េបើជ‌បាទ/ចាស សូមសរេសរនូវកាលបរ�េច�ត
If yes, write the date on document: 
   éf  Day        Ex  Month             qñaM  Year           
មិនទទួលយកការចូលរួម EXCLUDED      
99 
2 0 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME3):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID3):
kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 3/10 
0 3 
AGE 
AGEEX 
5. etIkumarmanGayub:unñan
េបសិនជាកុមារអយុេ្រកម៩ែខ ឬេលស២ឆា� ំ 
សូមនិយាយថាអរគុណស្រមាប់ឆន�ៈចូលរមួរបស់អ�ក 
ែតគួរឲ្យេសកស� យែដលអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈស្រមាប់
ករចូលរមួេទ 
េ្រពះអយុកូនរបស់អ�កមិនស�ិតេនចេនា� ះអយុែដល្រត�វសិក្សោ។ 
មិនទទួលយកករចូលរមួ េហយប�� ប់សំនួរ 
How old is (name)?  
If < 9 months or > 2yrs, say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate because 
(name) is too young/old.. 
EXCLUDE AND END QUESTIONNAIRE 
GayuKitCaEx ......................................... 
Age in months 
មិនទទួលយកការចូលរួម EXCLUDED      99 
BFG 6. េតអ�កកំពុងបំេបកូនឬ? (េបអ�កែថកុមារេនាះជាមា� យ)
េបសិនជាអ�កែថរក្សោកុមារមិនែមនជាមា� យ ្រត�វសួរ៖ េតកុមារ 
(េឈ� ះ)កំពុងែតេបេដះឬ?
If caregiver is mother, ask: Are you still breastfeeding (name)? 
If caregiver is not mother, ask: Is (name) still being breastfed? 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME3):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID3):
kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 4/10 
0 3 
CF 
CFEX 
7. េតកូនរបស់អ�កបានចប់េផ�មញុាអំហរេផ្សង
េទៀតេទេ្រកពីេបេដះមា� យ?
េបសិនជាចេម�យថា បាទសូមបន�េទសំនួរទី៨ 
េបសិនជាចំេលយេទសំរប់សំនួរេនះ–សូមនិយាយថាសូមអរគុណ 
េហយប�� ប់ប�� ីសំនួរ។ 
Does (name) have foods or drinks other than breastmilk?  
If Yes, go to question 8. 
If No, Refused to respond, or Don’t know – Say: Thank you for your 
willingness to participate.  Unfortunately, you and your child are not 
eligible to participate because (name) is not yet eating foods or drinks 
other than breastmilk. 
EXCLUDE AND END QUESTIONNAIRE  
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទួលយកការចូលរួម EXCLUDED      99 
AGECF 8. េតើេ�ឣ‍យុប៉ុន‌� នែដលកុមារ (េឈា� ះ) បានចាប់េផ�ើមញ‌� ំឣ‍ហារ ឬផឹកទឹកែដលមិនជ‌ទឹកេដ‌ះមា� យ?
At about what age did (name) start having foods or drinks other than 
breastmilk?
At <3mths េ�ឣ‍យុតិចជ‌ង៣ែខ   1 
At <6mths  េ�ឣ‍យុតិចជ‌ង៦ែខ  2 
At >6mths  បន‌� ប់ពីឣ‍យុជ‌ង៦ែខ  3 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
EATS 9. េតកុមារ (េឈ� ះ) បានអ�កញុាំអហរ
ឬផឹកទឹកអ�ីខ�ះចប់តំងពីេគេចះញុាំអហរមក?
គូសនូវចេម�យខងស� ំេនះ 
What foods or drinks does (name) usually eat or drink since they began 
solids? 
Tick all that apply 
EATS/1 ឣ‍ហារហ�័មយូឡ‍របស់កុមារ ឬទឹកេដ‌ះេគាេផ្សងៗ   
Infant formula or other milk  
1 
EATS/2 សាఄរធាតុរ‌វដូចជ‌ទឹក ែត ទឹកែផ�េឈើ សូដ‌។ល។   
Liquids such as water, tea, juice, soda, etc     
2 
EATS/3 បបរ បាយ គុយទាវ/មី នំបុ័ង     
Borbor, rice, noodles, or bread  
3 
EATS/4 ែផ�េឈើ ឬបែន�  
Any fruit or vegetables   
4 
EATS/5 ឣ‍ហារ្របេភទសាఄច់ដូចជ‌ សុ៊ត សាఄច់ ្រតី  
Any animal food such as eggs, meat, fish     
5 
EATS/6 បែង�ម ឬឣ‍ហារញ‌� េំលងៃ្រប   
Sweet or salty snacks   
6 
EATS/7 េផ្សងៗ(ពិព៌ណន‌)  
Any other food or drink (describe)    
EATSOTH 
7 
EATS/8 បដិេសធមិនេឆ�ើយRefused to respond    8 
EATS/9 មិនដឹងDon’t know      9 
IMPBB 10. េតកុមារេនះមានញុាំបបរខប់្រគប់េ្រគ�ង (បបរែដលដំជាមួយបែន�
េ្របង និងសច់សត�ដូចជា ពងទ/ពងមាន់ សច់ ឬ្រតី?
េបមិនមាន បន�េទសំនួរ១៣។ 11
Does this child eat improved borbor (borbor with vegetables, oil and an 
animal food such as eggs, meat, or fish? 
If no, go to question 11. 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
IMPBB2 េបើសិនជ‌មាន េតើចម�ិនញឹកញ‌ប់ប៉ុណ‌� ?
If yes, how often does this child eat improved borbor? 
២េ�៣ដងក��ងមួយៃថ�2-3 times/day   2 
ម�ងដងក��ងមួយៃថ�Once a day   3 
ពីរបីៃថ�ម�ងOnce every few days   4 
Seldom   5 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME3):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID3):
kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 5/10 
0 3 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
SUPPS 11. េតើកូនរបស់អ�កធា� ប់បានញ‌� ំឣ‍ហារបំប៉នផ�ល់ឲ្យេដ‌យអង�ការណ‌ឬេទ (ដូចជ‌ឣ‍ហារ �ស�ីងខល សីុេអសប៊�េផ�ើសេផ�ើស។ល។)?
េបើមានអ�កឣ‍ចបង‌� ញក��ប់បានែដរឬេទ?
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ13
Has this child ever used Sprinkles, CSB++ or similar supplementary foods 
or supplements/vitamins?  Tick all that apply.  (show packages or 
examples of foods). 
If No to this question – jump to question 13 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
SUPPS2 12. េតើឣ‍ហារបំប៉នមួយណ‌ ឬឣ‍ហារបែន�មណ‌/វ�តាមីនណ‌ែដលកូនរបស់អ�កបានេ្របើ? សូមគូសចំេពាះឣ‍ហារេនះេបើបានញ‌� ំចំេពាះចេម�ើយេ�ខាងសាఄ� ំ។
(បង‌� ញក��ប់ ឬគំរូៃនឣ‍ហារ)
Which supplementary foods or supplements/vitamins has the child used?  
Tick all that apply.  (show packages or examples of foods).  
SUPPS2/2 ្រស�ីងខលSprinkles    2 
SUPPS2/3 សីុេអសប៊�ផ�ឺសផ�ឺសCSB++    3 
SUPPS2/4 ឣ‍ហារបំប៉នេផ្សងេទៀតេបើមាន េហើយសូមេរៀបរ‌ប់Other 
supplementary foods (describe)        
SUPPFOOD_____________________ 
4 
SUPPS2/5 េ្រគ�ងបែន�មេផ្សងេទៀតOther supplements 
(describe)        
SUPPSOTH_____________________     
5 
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Form 3:  Acceptability trial, baseline – children 6/10 
0 3 
ILL3D 13. េតើ៣ៃថ�មុនេនះ កុមារ(េឈា� ះ)មានឈឺេទ?
(គូសចេម�ើយែតមួយ)
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ19
In the past 3 days, has (name) been ill? (Tick ONLY ONE answer) 
If No to this question – jump to question 19 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ILLRATE3 
ILLRATEX 
14. ជ‌គំនិតរបស់អ�ក េតើកុមារ(េឈា� ះ) មានជំងឺធ�ន់ មធ្យម ឬ្រសាఄល?
េបើសិនជ‌ជំងឺធ�ន់ សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈែដលចង់ចូលរួម។ 
ប៉ុែន�សូមេទាសេដ‌យអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគាន់ក��ងការចូលរួមេដ‌យសាఄរ(េឈា� ះ)មានជំងឺធ�ន់តាងំពី៣ៃថ�មុន។
េយើងផ�ល់េយ‌បល់ឲ្យអ�កេ�មណ� លសុខភាព ឬគ�ីនិកេដើម្ីបពិនិត្យ។
មិនយកេហើយប��ប់សំនួរ
In your opinion , was (name’s) illness serious, moderate or slight? 
If Serious – Say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate because 
(name) has been seriously ill in the last 3 days.  We suggest that you visit a 
health care provider or clinic. 
EXCLUDE AND END QUESTIONNAIRE  
ជំងឺធ�ន់ Serious       1 
មធ្យមModerate    2 
្រសាఄលSlight    3 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទួលយកការសិក្សោEXCLUDED      99 
FEVER3D 15. េតើកុមារ(េឈា� ះ)មានេ�� ខ��នេទចាប់តាងំពី៣ៃថ�?
Has (name) been ill with a fever at any time in the past 3 days? 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ARI3D1 16. េតើកុមារ(េឈា� ះ)មានក�កេទចាប់តាងំពី៣ៃថ�?
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ19
Has (name) had an illness with a cough at any time in the past 3 days? If 
No to this question – jump to question 19 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ARI3D2 17. េ�េពលកុមារ(េឈា� ះ)ជងំឺក�ក េតើេគមានដកដេង�ើមញ‌ប់ជ‌ងធម�តាេដ‌យដង�ក់ ដកដេង�ើយញឹក ឬមានការពិបាកក��ងការដកដេង�ើម?
េបើសិនចេម�ើយេទ សូមរ�លងេ�សំនួរ19
When (NAME) had an illness with a cough, did  he/she breathe faster than 
usual with short, fast breaths or had difficulty breathing?). If No to this 
question – jump to question19 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
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kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 7/10 
0 3 
ARI3D3 
ARIOTHER 
18. មានការដកដេង�ើយញឹក ឬមានការពិបាកក��ងការដកដេង�ើមេដ‌យមានប�� េ�េដើម្រទ�ង ឬមានស�ះេ�្រចមុះ?
Was the fast or difficult breathing due to a problem in the chest or a 
blocked nose?) 
េដើម្រទ�ងChest only   1 
្រចមុះNose only   2 
ទាងំ២Both   3 
េផ្សងេទៀត ចូរេរៀបរ‌ប់Other (describe)        7 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
DIAR3D1 19. េតើកុមារមានរ‌គេទចាប់ពី៣ៃថ�មុន?
ឧ. បេន‌� របង់៣េ�៤ដងក��ងរយៈេពលល២៤េម៉ាង
េបើមាន បន�េ�សំនួរ 20
េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរ21
Has (name) had had diarrhoea in the past 3 days? i.e.  3 or more loose 
stools during 24 hours  If Yes – go to question 20. If No, Refused, Don’t 
know – go to question 21 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
DIAR3D2 
DIAREX 
20. េតើកុមារមានបេន‌� របង់េដ‌យមានឈាមជ‌ប់លាមកេទ?
េបើមាន សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក��ងការចូលរួម 
េដ‌យសាఄរកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម ែដលប�� ក់ថ‌គាតម់ានជំងឺធ�ន់ចាប់តាងំពី៣ៃថ� មុន។ េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មណ� លសុខភាព 
ឬគ�នីិក។ 
េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរ21
Was there any blood in the stools? 
If Yes – Say: Thank you for your willingness to participate.  Unfortunately, 
you and your child are not eligible to participate because (name) has had 
blood in their stools, which indicates a serious illness, in the last 3 days.  
We suggest that you visit a health care provider or clinic. 
EXCLUDE AND END QUESTIONNAIRE  
If No, Refused, Don’t know – go to question 21 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទួលយកការសិក្សោEXCLUDED      99 
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0 3 
VOMIT3D 21. េតើកុមារមានក��តេទចាបព់ី៣ៃថ�មុន?
Has (name) vomited in the past 3 days? 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
APPET1W 22. េតើកុមារ(េឈា� ះ)ញ‌� ំឣ‍ហារជ‌ធម�តា ឬេ្រចើនជ‌ងធម�តា ឬតិចជ‌ងធម�តាេ�ក��ងសបា� ហ៍មនុ?
Has (name) been eating normally, more than usual, or less than usual in 
the past week?
ធម�តាNormally       0 
េ្រចើនជ‌ងធម�តាMore than usual        1 
តិចជ‌ងធម�តាLess than usual        2 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
RASH3D 23. េតើកុមារ (េឈា� ះ)មានេឡើងកន��លេលើែស្បកេទតាងំពី៣ៃថ�មុន?
Has (name) had a skin rash in the past 3 days?
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
SYMPT3D 
SYMPOTH 
24. េតើកុមារមានេរ‌គស��  ឬជំងឺអ�ីេផ្សងេទៀតែដលខ��ំមិនបានសួរតាងំពី៣ៃថ�មុន?
Has (name) had any other sickness or symptoms that I have not asked 
about in the past 3 days? 
េបើមាន សូមប�� ក់ 
If yes - Please specify. 
េទNo       0 
បាទ/ចាសYes      
េបើសិនជ‌មាន េតើេរ‌គស��  ឬជំងឺអ�ីែដរ 
If yes, what sickness or symptoms? 
1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
េបើសិនជ‌អ�កទទួលបានចេម�ើយែដលមនិទទួលយកការចូលរួមរបស់អ�កែថរកុមារេទ សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសាఄរ[ផ�ល់នូវមូលេហតុែដលទទួលដូចេ�ក��ងប��ីសំនួរខាងេលើ] 
េបើសិនជ‌ប�� េន‌ះពាក់ពន�័ជ‌មួយនឹងប�� សុខភាព សូម្របាប់គាត់ថ‌ឲ្យគាត់យកកូនរបស់គាត់េ�មណ� លសុខភាព/មន�ីរេពទ្យ។ 
If you get an answer that excludes the caregiver, say:  Thank you for your willingness to participate.  Unfortunately, you and your child are not 
eligible to participate because [give the reason].  [If health related reason, say] We suggest that you take your child to the health clinic.   
េបើសិនជ‌អ�កសួរនូវសំនួរទាងំអស់េហើយ េហើយអ�កែថរកុមារ/កុមារេន‌ះមានលក�ណៈ្រគប់្រគាន់ក��ងការចូល រួម សូមនិយ‌យថ‌៖ អរគណុស្រមាបច់េម�ើយរបស់អ�ក។ សូមយកប��ីសំនួរេន‌ះេហើយអេ��ើញេ�តុបន‌� ប់ េដើម្ីបឲ្យបុគ�លិករបស់េយើងេធ�ើការវ‌ស់កូនរបស់អ�ក។ 
If you ask all the questions and the caregiver is eligible to participate, say:  Thank you for answering these questions.  Please take this questionnaire 
and go to the next station to have your child measured. 
WT 25. ទំងន់ជាគីឡូ្រកម(ក្រមិតលេម� ង0.1kg)?
ថ�ឹងទម�ន់មា� យ េហយចុចជ�� ឹងឲ្យេទ០ 
េហយហុចកុមារឲ្យេទមា� យ 
េហយកត់្រតនូវទម�ន់កុមារែដលបង� ញេលជ�� ីង 
Weight in kilograms to the closest 0.1kg?  
Weigh mother, zero, pass child to mother, record weight. 
ទម�ន់(kg) 
Weight (kg) 
បដិេសធMother refused     8 
េផ្សងៗ   Other        9 
HT 26. ្របែវងជាសង់ទីែម៉្រត(ក្រមិតលេម� ង0.1cm)? 
វ‌ស់េដ‌យដ‌ក់កុមារឲ្យេដកចុះ
គណន‌រក WHZ េបើ<-3 វ‌ស់ម�ងេទៀតេដើម្ីបពនិិត្យ។ ផ�ល់ដំណងឹេ�អ�ក្រគប់្រគង
េបើ<-3 សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ 
្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសាఄរកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម ែដលប�� ក់ថ‌គាត់មានជំងឺធ�ន់ចាប់តាងំពី៣ៃថ� មុន។ 
េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មន�រីេពទ្យេមគង�។ 
មិនទទួលយកការចូលរួម ប��ប់សំនួរ 
Length in centimetres to the closest 0.1cm? Measure lying down 
្របែវង(cm)
Length (cm) 
បដិេសធMother refused     8 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME3):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID3):
kumar   (Child´s ID, CHID3):  (Form ID, FORMID) 
Form 3:  Acceptability trial, baseline – children 9/10 
0 3 
WHZEX 
Calculate WHZ.  If <-3 measure again to check.  Inform supervisor.  If 
<-3 – say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate 
because (name) is severely malnourished.  This is very serious.  You 
need to take your child to the Mekong hospital.  We will give you 
money to go to the hospital. 
EXCLUDE AND END QUESTIONNAIRE  
េផ្សងៗ   Other        9 
មិនទទួលយកការសិក្សោEXCLUDED     99 
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0 3 
MUAC 
MUACEX 
27. ្របែវងរង�ង់កំភួនៃដ(MUAC)គិតជា cm ែដលខិតេ�ជិត0.1cm?
េបើប៉ះចចំំណុចព៌ណេលឿង វ‌ស់ម�ងេទៀតេដើម្ីបពិនិត្យ។ ផ�ល់ដំណឹងេ�អ�ក្រគប្់រគង 
េបើ្រកហម សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ 
្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសាఄរកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម ែដលប�� ក់ថ‌គាត់មានជំងឺធ�ន់ចាប់តាងំពី៣ៃថ� មុន។ 
េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មន�រីេពទ្យេមគង�។ 
មិនទទួលយកការចូលរួម ប��ប់សំនួរ 
Mid upper arm circumference (MUAC) in cm closest 0.1cm?  
If yellow– measure again to check.  Inform supervisor. 
If red– say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate 
because (name) is severely malnourished.  This is very serious.  You 
need to take your child to Mekong hospital.  We will give you money 
for transport to go to the hospital if necessary . 
EXCLUDE AND END QUESTIONNAIRE  
MUAC (cm)   
បដិេសធMother refused     8 
េផ្សងៗ   Other        9 
មិនទទួលយកការសិក្សោEXCLUDED    99 
េបើសិនជ‌អ�កទទួលបានចេម�ើយែដលមនិទទួលយកការចូលរួមរបស់អ�កែថរកុមារេទ សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសាఄរកុមារ (េឈា� ះ) មានជំងឺកង�ះឣ‍ហាររូបត�ម�្រស�ច្រសាఄវ វ‌ជ‌ជំងធឺ�ន់ធ�រ។ 
អ�ក្រត�វែតយកកូនរបស់អ�កេ�មន�ីេពទ្យេមគង�។ េយើងនឹងផ�ល់្របាក់ដល់អ�កស្រមាប់ការចំណ‌យេលើការេធ�ើដំេណើរក��ងការយកកូនរបស់អ�កេ�មន�ីេពទ្យេបើសិនជ‌ចាបំាច់។ 
If you get an answer that excludes the caregiver, say:  Thank you for your willingness to participate.  Unfortunately, you and your child are not 
eligible to participate because your child is severely malnourished.  This is very serious.  You need to take your child to the Mekong hospital.  We will 
give you money for transport to go to the hospital if necessary. 
េបើសិនអ�កបានសួរ្រគបសំ់ណួរេហើយ េហើយអ�កែថរកុមារ/កុមារមានលក�ណៈ្រគប់្រគាន់ក��ងការចលូរួម សូមនិយ‌យថ‌សូមអរគុណស្រមាប់ចេម�ើយទាងំអស់។ សូម្រតលបម់កម�ងេទៀតេ�ទីេនះេ�ៃថ�ែស�ក េ�េវលាេម៉ាង............................េដើម្ីបេធ�ើការផ�កឣ់‍ហារ។ 
If you ask all the questions and the caregiver is eligible to participate, say:  Thank you for answering these questions.  Please come back here 
tomorrow at XXX o’clock to test the food. 
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ទ្រមង់ទី4៖ ទ្រមងប់��ីសំនួរ្របមូលទិន�ន័យ្របចំាៃថ� – ស្រមាបក់ុមារ ៃថ�ទី១េ�ៃថ�ទ១ី២ 
Form 4:  Acceptability trial, daily data collection form – children, days 1-12 
Variable name េលខកូដ
សង‌� ត់
Sangkat (SANGKAT4) 
Svay Pakសា� យប៉ាក 1 
SANGKAT4_2 Other (describe) េផ្សងៗ(ពិព៌ណន‌) ___________________      7 
PUmi 
Village (VILLAGE4) 
Phum Svay Pakសា� យប៉ាក 1 
Phum Louលូ 2 
Phum La Kamboarឡកំេបា 3 
VILLAGE4_2 Other (describe) េផ្សងៗ(ពិព៌ណន‌) ___________________      7 
ទីកែន�ងផ�ល់ឣ‍ហារ
Test-feeding site (SITE4) 
Site 1 Sokly’s house  1 
Site 2 Sopha & Nath’s house  2 
Site 3 Leang Sok’s house  3 
Site 4 Thearith’s house  4 
kalbriecäTRbmUlTinñn½y  
Date of data collection (DATE4) 
ៃថ� Day ែខ Month ឆា�  ំ Year
ការ្របមូលទិន�ន័យបានទាងំអស់
Data collection completed (COMPLETE4) 
េទNo   1 
បាទ/ចាសYes   2 
េឈ� ះអ�កដឹកនំា្រក�ម 
Team leader name (SPVSR4) 
 Kunthea   1 
Phanna    2 
កលបរេិច�ទៃនករពិនិត្យរបស់អ�កដឹកនំា្រក�ម 
Date checked by team leader (CHEKDATE4) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈា� ះអ�ក្រគប់្រគងក��ងការ�យ‌ល័យ
Office supervisor name (OFFICE4) 
ប៊�នឌីBindi   1 
កាលបរ�េច�ទពនិិត្យេដ‌យអ�ក្រគប្់រគងក��ងការ�យ‌ល័យ
Date checked by office supervisor (OFFDATE) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ 
Data entry person 1 name (ENTERER1_4) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ Data entry person 1 name   
កលបរេិច�ទប��ូ លទិន�ន័យទី១ 
Date entered (ENTDATE1_4) ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ 
Data entry person 2 name (ENTERER2_4) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ Data entry person 2 name   
កលបរេិច�ទប��ូ លទិន�ន័យទី២ 
Date entered (ENTDATE2_4) ៃថ� Day ែខ Month ឆា�  ំ Year
0 6 2 0 1 5 
0 6 2 0 1 5 
0 6 2 0 1 5 
0 2 0 1 5 
0 2 0 1 5 
Appendix 4.3 Forms 4, 5, & 6:  Daily data collection; consumption record days 1-12; preference ranking,
days 3-6-9-12
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eQµaHkumar  Name of child
(NAMECH4) 
eQµaHmþaykumar Name of 
the caregiver (NAMECG4)
Variable 
name 
សំនួរ Question ចេម�ើយ
Response 
កដូ
Code 
BFGDAILY 1. េតអ�កកំពុងបំេបកូនឬ? (េបសិនអ�កែថកុមារជាមា� យ)
េបសិនជាអ�កែថកុមារមិនែមនជាមា� យ ្រត�វសួរ៖ េតកុមារ 
(េឈ� ះ)កំពុងែតេបេដះឬ?
េបើសិនេទ សូមរ�លងេ�សំនួរ3
If caregiver is mother, ask: Are you still breastfeeding (name)?  If 
the caregiver is is not the mother, ask: 
Is (name) still being breastfed? 
If No – please jump to question 3 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
LASTBF 2. េតើកុមារ(េឈា� ះ)បានេ�េដ‌ះចុងេ្រកាយេពលណ‌? គូសចេម�ើយែតមួយ)
When did (name) last breastfeed? 
 (Tick ONLY ONE answer) 
តចិជ‌ង១េម៉ាងមុន      < 1 hour ago     1 
េ្រចើនជ‌ង១េម៉ាងមនុ> 1 hour ago     2 
បដិេសធមនិេឆ�ើយ  Refused to respond      8 
មិនដឹង  Don’t know      9 
LASTEAT 3. េតកុមារកំពុងេបេដះឬ (ឧ. បាទ/ចសជាមួយសំនួរទី១ Q1)?
សួរថា៖ េតកុមារ(េឈ� ះ)បានញំុាអ�ីចុងេ្រកយេ្រកពីេបេដះ?
េបកុមារឈប់េបេដះេហយ (ឧ. បាទ/ចសជាមួយសំនួរទី១ Q1)? 
សួរថា៖ េតកុមារ(េឈ� ះ)បានញំុាអ�ីចុងេ្រកយេ្រកពីេបេដះ? 
គូសចេម�ើយែតមួយ) 
If child is still breastfeeding (i.e. yes to Q1), ask: When did (name) 
last eat or drink something other than breastmilk? 
If child is no longer breastfeeding (i.e. no to Q1), ask: When did 
(name) last eat or drink something? 
 (Tick ONLY ONE answer) 
តិចជ‌ង១េម៉ាងមុន     < 1 hour ago       1 
េ្រចើនជ‌ង១េម៉ាងមុន  > 1 hour ago      2 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ILL24H 4. េតើក��ង២៤េម៉ាងមុនេនះ កុមារ(េឈា� ះ)មានឈឺេទ?
(គូសចេម�ើយែតមយួ)
េបើេទ សូមរ�លងេ�សំណួរ៨
េបើមាន សូមបន�េ�សំនួរ5
In the past 24hrs has (name) been ill?  (Tick ONLY 1 answer) 
If No– go to question 8 
If Yes– go to question 5 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ILLRATE 5. ជ‌គំនតិរបស់អ�ក េតើកមុារ(េឈា� ះ) មានជងំធឺ�ន់ មធ្យម ឬ្រសាល?
េបើសិនជ‌ជងំឺធ�ន់ សូមនិយ‌យថ‌៖ អរគណុស្រមាប់ឆន�ៈែដលចងច់ូលរួម។ 
ជំងឺធ�ន់ Serious       1 
មធ្យមModerate    2 
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ILLRATEX 
ប៉ុែន�សមូេទាសេដ‌យអ�កនងិកនូរបសអ់�កមនិមានលក�ណៈ្រគប្់រគា䴰ន់ក��ងការចូលរួមេដ‌យសារ(េឈា� ះ)មានជងំឺធ�ន់តាងំព២ី៤េម៉ាងមនុ។ 
េយើងផ�ល់េយ‌បល់ឲ្យអ�កេ�មណ� លសុខភាព ឬគ�នីិកេដើម្ីបពិនតិ្យ។ 
មិនយកេហើយប��ប់សនំួរ 
In your opinion, was (name’s) illness serious, moderate or slight?  If 
Serious – Say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate 
because (name) has been seriously ill in the last 24hrs.  We suggest 
that you visit a health care provider or clinic.  EXCLUDE AND END 
QUESTIONNAIRE  
្រសាលSlight    3 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទួលយកស្រមាប់ការសិក្សោEXCLUDED      99 
FEVER24H 6. េតើកុមារ(េឈា� ះ)មានេ�� ខ��នេទចាប់តាំងពី២៤េម៉ាងមុន?
Has (name) been ill with a fever in the past 24 hours? 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ARI24H1 7. ក��ងកំឡ�ងេពល២៤េម៉ាងមុនរហូតដល់ឥឡ�វេតើកុមារ(េឈា� ះ)មានក�កេទ?
Has (name) had an illness with a cough in the past 24 hours? 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
DIAR24H1 8. ក��ងកំឡ�ងេពល២៤េម៉ាងមុនរហូតដល់ឥឡ�វេតើកុមារមានរ‌គេទ?
ឧ. បេន‌� របង់ចាប់ពី៣ដងក��ងរយៈេពល២៤េម៉ាង
េបើមាន បន�េ�សំនួរ 9 
េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរទី10
Has (name) had had diarrhoea in the past 24 hours, i.e. 3 or more 
loose stools during 24hr? 
If Yes – go to question 9 
If No, Refused, Don’t know – go to question 10 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
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DIAR24H2 
DIAR24HEX 
9. ក��ងកំឡ�ងេពល២៤េម៉ាងមុនរហូតដល់ឥឡ�វេតើកុមារមានបេន‌� របង់េដ‌យមានឈាមជ‌ប់លាមកេទ?
េបើមាន សមូនិយ‌យថ‌៖ អរគណុស្រមាបឆ់ន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក 
និងកូនរបសអ់�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគា䴰នក់��ងការចូលរួម េដ‌យសារកុមារ (េឈា� ះ) មានបន‌� របងឈ់ាម 
ែដលប�� ក់ថ‌គា䴰តម់ានជងំធឺ�នច់ាបត់ាំងព២ី៤េម៉ាងមុន។ េយើងឲ្យេយ‌បលថ់‌អ�កគួរែតេ�ពិនតិ្យេ�មណ� លសខុភាព 
ឬគ�នីិក។ 
ប��បស់ំនួរ េហើយមិនទទលួការចលូរួម 
េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរទី10 
Was there any blood in the stools in the past 24hrs? 
If Yes – Say: Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to 
participate because (name) has had blood in their stools, 
which indicates a serious illness, in the last 24hrs.  We suggest 
that you visit a health care provider or clinic. 
EXCLUDE AND END THE QUESTIONNAIRE 
If No, Refused, Don’t know – go to question 10 
 េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទួលយកស្រមាប់ការសិក្សោEXCLUDED      99 
VOMIT24H 10. េតើកុមារ(េឈា� ះ)មានក��តេទចាបត់ាំង២៤េម៉ាងមនុ?
Has (name) vomited in the past 24 hours? 
 េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
RASH24H 11. េតើកុមារ(េឈា� ះ)មានេឡើងកន��លេលើ ែស្បកេទចាប់តាងំពី២៤េម៉ាងមុន?
Has (name) had a skin rash in the past 24 hrs? 
 េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
APPET24H 12. េតើកុមារ(េឈា� ះ)ញ‌� ំឣ‍ហារជ‌ធម�តា ឬេ្រចើនជ‌ងធម�តា ឬតិចជ‌ងធម�តាេ�ក��ង24េម៉ាងមនុ?
Has (name) been eating normally, more than usual, or less 
than usual in the past 24 hrs?  
ធម�តាNormally       0 
េ្រចើនជ‌ងធម�តាMore than usual      1 
តិចជ‌ងធម�តាLess than usual        2 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer(IVNAME4):________________________GñkRbmUlTinñn½y (Interviewer ID, IVID4):  
kumar   (Child´s ID, CHID4):     (Form ID, FORMID)  
 
Form 4, 5, 6:  Acceptability trial, daily data collection form and consumption record days 1-12; preference ranking, days 3-6-9-12 5/7 
  0 6 
SYMPT24H 
 
 
 
 
 
SYMP24H2 
13. េតើកុមារមានេរ‌គស�� អ�ីេផ្សងេទៀតែដលខ��មំិនបានសួរតាំងព2ី4េម៉ាងមុន? 
 
េបើមាន សមូប�� ក ់
 
Has (name) had any other symptoms that I have not asked 
about in the past 24 hours? 
If yes - Please specify. 
 
 
េទNo       0 
បាទ/ចាសYes       
េបើសិនជ‌មាន េតើេរ‌គស�� អ�ីែដរ 
If yes:  
What symptoms? 
 
 
 
1 
បដិេសធមនិេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
 
េបើសិនជ‌មិន្រត�វបានេ្រជើសេរ�សឲ្យចូលរួមេដ‌យសារជំងឺ សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ បុ៉ែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគា䴰ន់ក��ងការចូលរួម េដ‌យសារកុមារ (េឈា� ះ) 
មានជំងឺធ�ន់។ េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មណ� លសុខភាព ឬគ�ីនិក។ 
If excluding due to illness, say:  Thank you for answering these questions.  Unfortunately, your child is not eligible to participate 
because  they have a serious illness.  We suggest that you visit a health care provider or clinic. 
 
េបើសិនជ‌្រត�វបានេ្រជើសេរ�ស សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ការផ�ល់ចេម�ើយ។ សូមអេ��ើញេ�កែន�ងបន‌� ប់ េហើយេយើងនឹងចាប់េផ�ើមបេ្រមើឣ‍ហារដល់អ�កភា� ម។ 
If not excluding, say:  Thank you for answering these questions.  Please go to the next station and we will soon serve the food. 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer(IVNAME4):________________________GñkRbmUlTinñn½y (Interviewer ID, IVID4): 
kumar   (Child´s ID, CHID4):     (Form ID, FORMID)
Form 4, 5, 6:  Acceptability trial, daily data collection form and consumption record days 1-12; preference ranking, days 3-6-9-12 6/7 
  0 6
ទ្រមង់ទ៥ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី១ – កំណតញ់‌� ំ្របចំាៃថ� ពីៃថ�ទី១េ�ៃថ�ទ១ី២
Form 5: Acceptability trial, sub-study 1 (child) – daily consumption record, days 1-12 
eQµaHkumar  Name of child
eQµaHmþaykumar 
Name of the caregiver 
Variable Question Response Code 
PRODWT ផលិតផល
Product 
បបរជ‌មួយ LNS    LNS +Borbor   1 
LNSជ‌នំញ‌� ំេលងLNS snack   2 
បបរជ‌មួយCSB++   3 
បបរជ‌មួយSprinkles    4 
EATDAY ៃថ�របស់ឣ‍ហារ
Day on this food:  
ៃថ�ទី១1st    1 
ៃថ�ទី២2nd    2 
ៃថ�ទី៣3rd   3 
PREWT 1. ទម�ន់សរុបរបស់ចាន សា� ប្រពា ្រកដ‌ស់ជូតមាត់ និងឣ‍ហារមុនេពលញ‌� ំ(g)
Wt of bowl/spoon/napkins/food/product (100.0±1g to nearest 0.1g). 
POSTWT 2. ទម�ន់សរុបរបស់ចាន សា� ប្រពា ្រកដ‌ស់ជូតមាត់ និងឣ‍ហារេ្រកាយេពលញ‌� ំ(g)
Weight of bowl/spoon/napkins/remaining food after eating to 0.1g 
STARTIME 3. កត់្រតានូវេម៉ាងែដលកុមារចាប់េផ�ើមញ‌� ំឣ‍ហារ (េម៉ាង.ន‌ទី)
(រយៈេពលឲ្យញ‌� ំ្របែហលជ‌១៥ន‌ទី)
Record time that child started eating (hr.min). (Allow approximately 15mins.) េម៉ាង Hour ន‌ទី Minutes
ENDTIME 4. កត់្រតានូវេម៉ាងែដលកុមារ ប�្ឈប់ញ‌� ំឣ‍ហារ (េម៉ាង.ន‌ទី)
(រយៈេពលញ‌� ំ្របែហលជ‌១៥ន‌ទី)
Record time that child stopped eating (hr.min). (Should be approx 15mins.) េម៉ាង Hour ន‌ទី Minutes 
REFUSED 5. េតើកុមារមានបដិេសធមនិញ‌� ំេទ?  (អ�ក្របមូលទិន�ន័យ្រត�វសេង�តេដ‌យខ��នឯងចំេពាះសំនួរេនះ មនិ្រត�វសួរអ�កែថកុមារេទ)
Did the child refuse to eat? (Data collector observation– do not ask caregiver.)
េទNo   0 
បាទ/ចាសYes   1 
ការេគង Sleeping   2 
មិនដឹងDon’t know      9 
RELUCT 6. េតើកុមារមានអល់ឯកមនិចង់ញ‌� ំេទ?   (អ�ក្របមូលទិន�ន័យ្រត�វសេង�តេដ‌យខ��នឯងចេំពាះសំនួរេនះ មិន្រត�វសួរអ�កែថកុមារេទ)
Was child reluctant to eat?  (Data collector observation– do not ask caregiver.) 
េទNo   0 
បាទ/ចាសYes   1 
យំ Crying   2 
មិនដឹងDon’t know      9 
SPIT 7. េតើកុមារមានបដិេសធមនិញ‌� ំេទ?  (អ�ក្របមូលទិន�ន័យ្រត�វសេង�តេដ‌យខ��នឯងចំេពាះសំនួរេនះ មនិ្រត�វសួរអ�កែថកុមារេទ)
Did child spit the food out? (Data collector observation– do not ask caregiver.)
េទNo   0 
បាទ/ចាសYes   1 
មិនដឹងDon’t know      9 
FORCED 8. េតើមា� យមានបានបង�កំូនឲ្យញ‌� ំេទ?   (អ�ក្របមូលទិន�ន័យ្រត�វសេង�តេដ‌យខ��នឯងចេំពាះសំនួរេនះ មិន្រត�វសួរអ�កែថកុមារេទ)
Was mother forcing child to eat?  (Data collector obs– don’t ask mother) 
េទNo   0 
បាទ/ចាសYes   1 
មិនដឹងDon’t know      9 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer(IVNAME4):________________________GñkRbmUlTinñn½y (Interviewer ID, IVID4): 
kumar   (Child´s ID, CHID4):     (Form ID, FORMID)
Form 4, 5, 6:  Acceptability trial, daily data collection form and consumption record days 1-12; preference ranking, days 3-6-9-12 7/7 
  0 6
ទ្រមង់ទ៦ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី១ – ការឲ្យចំណ‌ត់ថ‌� ក់ពីការចូលចិត�េដ‌យមា� យ ៃថ�ទី៣ ទី៦ ទី៩ ទ១ី២ 
Form 6: Acceptability trial, sub-study 1 (child) – children’s preference ranking by mother, days 3-6-9-12 
eQµaHkumar   Name of
child  
eQµaHmþaykumar  
Name of the caregiver 
kalbriecäTRb
mUlTinñn½y  
Date of data collection 
(DATE) 
លខកដូ
Code 
ៃថ� Day ែខ Month ឆា� ំ  Year
ទីកែន�ងផ�ល់ឣ‍ហារ
Test-feeding site (SITE) 
Site 1 Sokly’s house  1 
Site 2 Sopha & Nath’s house  2 
Site 3 Leang Sok’s house  3 
Site 4 Thearith’s house  4 
ផលិតផល
Product 
(PRODUCT) 
បបរជ‌មួយ LNS       LNS +Borbor   1 
LNSជ‌នំញ‌� ំេលងLNS snack   2 
បបរជ‌មួយCSB++   3 
បបរជ‌មួយSprinkles    4 
ៃថ�របស់ឣ‍ហារ
Day on this food:  
(EATDAY) 
ៃថ�ទ១ី1st    1 
ៃថ�ទ២ី2nd    2 
ៃថ�ទ៣ី3rd   3 
្រត�វនិយ‌យថ‌៖ កូនរបសអ់�កបានញ‌� ឣំ‍ហារអសរ់យៈេពល៣ៃថ�េហើយ។ េតើអ�កគតិថ‌កូនរបសអ់�កចូលចិត�ឣ‍ហរេនះឬេទ? 
Say: Your child has been eating this food for 3 days.  How do you think your child liked this food? (Code: LIKE) 
1 =មិនចូលចិត�ទាល់ែតេសាះ
1 = Disliked a lot 
2 =មិនចូលចិត�តិចៗ
2 = Disliked a little 
3 =ធម�តា
3 = Neither liked nor disliked 
4 =ចូលចិត�តិចៗ
4 = Liked a little 
5 =ចូលចិត�ខា� ំង
5 = Liked a lot 
  
0 2 0 1 5 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 1/6 
0 7 
ទ្រមង់ទ៥ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី២ (អ�កែថកមុារ) – ការ្របមូលទិន�ន័យមូលដ‌� នេ�ៃថ�ទី១៣ 
Form 7: Acceptability trial, sub-study 2 (caregiver) – baseline data on day 13 
Variable name េលខកូដ
សង‌� ត់
Sangkat (SANGKAT7)  
Svay Pakសា� យប៉ាក 1 
(SANGKAT7_2) Other (describe) េផ្សងៗ(ពពិ៌ណន‌) ___________________      7 
PUmi 
Village (VILLAGE7) 
Phum Svay Pakសា� យប៉ាក 1 
Phum Louលូ 2 
Phum La Kamboarឡកំេបា 3 
(VILLAGE7_2) Other (describe) េផ្សងៗ(ពិព៌ណន‌) ___________________      7 
ទីកែន�ងផ�ល់ឣ‍ហារ
Test-feeding site (SITE7) 
Site 1 Sokly’s house  1 
Site 2 Sopha & Nath’s house  2 
Site 3 Leang Sok’s house  3 
Site 4 Thearith’s house  4 
kalbriecäTRbmUlTinñn½y 
Date of data collection (DATE7) 
ៃថ� Day ែខ Month ឆា� ំ  Year
ការ្របមូលទិន�ន័យបានទំាងអស់
Data collection completed (COMPLETE7) 
េទNo   1 
បាទ/ចាសYes   2 
េឈ� ះអ�កដឹកនំា្រក�ម 
Team leader name (SPVSR7) 
 Kunthea   1 
Phanna    2 
កលបរេិច�ទៃនករពិនិត្យរបស់អ�កដឹកនំា្រក�ម 
Date checked by team leader (CHEKDATE7) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈា� ះអ�ក្រគប់្រគងក��ងការ�យ‌ល័យ
Office supervisor name (OFFICE7) 
ប៊�នឌBីindi   1 
កាលបរ�េច�ទពនិិត្យេដ‌យអ�ក្រគប្់រគងក��ងការ�យ‌ល័យ
Date checked by office supervisor (OFFDATE7) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ 
Data entry person 1 name (ENTERER1_7) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ Data entry person 1 name   
កលបរេិច�ទប��ូ លទិន�ន័យទី១ 
Date entered (ENTDATE1_7) 
ៃថ� Day ែខ Month ឆា�  ំ Year 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ 
Data entry person 2 name (ENTERER2_7) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ Data entry person 2 name   
កលបរេិច�ទប��ូ លទិន�ន័យទី២ 
Date entered (ENTDATE2_7) ៃថ� Day ែខ Month ឆា�  ំ Year
0 7 2 0 1 5 
0 7 2 0 1 5 
0 7 2 0 1 5 
0 2 0 1 5 
0 2 0 1 5 
Appendix 4.4 Forms 7, 8, & 9: Caregiver baseline data; sensory test; and ranking day 13
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 2/6 
0 7 
eQµaHkumar   Name of child
(NAMECH7) 
eQµaHmþaykumar Name of the
caregiver (NAMECG7) 
Variable name  Question  Response លខកដូ
Code 
RSHP2 
RSHP2OTH 
1. etIGñkmanTMnak;TMngGVICamYynwgkumare
nH?
sUmKUsrgVg;ykcMelIyEtmYy
What is your relationship to (name)?
Select ONLY ONE answer
មា� យបេង�ើតBiological mother   1 
មា� យចុងStepmother   2 
ជីដូនGrandmother   3 
ឪពុកFather   4 
បង្រសីSister   5 
េផ្សងៗ(ពិព៌ណន‌)Other (describe)       7 
បដិេសធមិនេឆ�ើយRefused to respond   8 
មិនដឹងDon’t know      9 
CARE2W7 2. etIGñkman)anTTYlxusRtUvkñúgkarEfTaMkumar
enH ya:gticNas; 2s)þah¾cugeRkayenHb¤eT?
sUmKUsrgVg;ykcMelIyEtmYy
Have you had responsibility for taking care of (name) 
for at least the last two weeks?) 
Select ONLY ONE answer 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
AGEMUM 3. េតើអ�កឣ‍យុបុ៉ន‌� ន?
How old are you?  .............................................. 
Age in years          ឣ‍យជុ‌ឆា�  ំ
ETHNIMUM 
ETHNMUM2 
4. េតើអ�កកាន់សាសន‌អ�?ី
What religion do you identify with? 
(Tick ONLY ONE answer) 
្រពះពទុ� Buddhist   2 
មូស�ីមMuslim    3 
េផ្សងៗ សមូេរៀបរ‌បO់ther (describe)      
 
____________________________________________  
7 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 3/6 
0 7 
ILL1MUM 5. េតើ៣ៃថ�មុនេនះ អ�កមានឈឺេទ?
(ចូគូសចេម�ើយមួយ)
េបើេទ ប��ប់សំនួរ
In the past 3 days, have you been ill? 
 (Tick ONLY ONE answer) 
If No to this question – jump to end. 
េទNo   0 
បាទ/ចាសYes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
ILL2MUM 
ILLMUMEX 
6. ជ‌គំនិតរបស់អ�ក េតើអ�ក មានជំងឺធ�ន់ មធ្យម ឬ្រសាល?
េបើធ�ន់ធ�រ សូមនិយ‌យថ‌៖ សូមអរគុណស្រមាប់ឆន�ៈចូលរួម។ 
ែតគួរឲ្យសា� យែដលអ�កមនិមានលក�ណៈ្រគប់្រគាន់ស្រមាប់ចូលរួមក��ងការសិក្សោេដ‌យសារែតអ�កមានជំងឺធ�ន់ចាប់ពី៣
ៃថ�មុនមក។ េយើងសំណូរពរឲ្យអ�កេ�មណ� លសុខភាពឬគ�ីនកិ។ 
ប��ប់សំណួរ 
In your opinion , was your illness serious, moderate 
or slight? 
If Serious – Say: Thank you for your willingness to 
participate.  Unfortunately, you are not eligible to 
participate because you have been seriously ill in the 
last 3 days.  We suggest that you visit a health care 
provider or clinic. 
EXCLUDE AND END QUESTIONNAIRE 
ជំងឺធ�ន់ Serious       1 
មធ្យមModerate    2 
្រសាលSlight    3 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
មិនទទលួស្រមាប់ការសកិ្សោEXCLUDED      99 
េបើសិនជ‌មិនេ្រជើសេរ�សេដ‌យសារជំងឺ សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈចូលរួម។ បុ៉ែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសារកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម 
ែដលប�� ក់ថ‌គាត់មានជំងឺធ�ន់ចាប់តាំងពី៣ៃថ� មុន។ េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មណ� លសខុភាព ឬគ�ីនិក។ 
If excluding due to illness, say:  Thank you for answering these questions.  Unfortunately, you are not eligible to participate because 
of your illness.  We suggest that you visit a health care provider or clinic. 
េបើសិនជ‌្រត�វបានេ្រជើសេរ�ស សូមនិយយ‌យថ‌៖ អរគុណស្រមាប់ការផ�ល់ចេម�ើយ។ សូមបន�េ�តុបន‌� ប់ េហើយេយើងនឹងចាប់េផ�ើមបេ្រមើឣ‍ហារដល់អ�ក។ 
If not excluding, say:  Thank you for answering these questions.  Please go to the next station and we will soon serve the food. 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 4/6 
0 7 
ទ្រមង់ទ៥ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី២ (អ�កែថរកមុារ) – ការេធ�ើេតស�េដ‌យញ‌ណ ៃថ�ទី១៣ 
Form 8: Acceptability trial, sub-study 2 (caregiver) - sensory test, day 13 
eQµaHkumar  Name of child
eQµaHmþaykumar
Name of the caregiver 
េតើអ�កគតិយ៉‌ងេម៉ចចំេពាះផលិតផលទាំងេនះ?       What do you think of these products? 
Variable 
name 
LNS +បបរ
LNS + borbor 
ល�ណ‌ស(់1)
Very Good (1) 
ល�(2)
Good (2) 
ធម�តា(3)
Neutral (3) 
អន(់4)
Bad (4) 
អនខ់ា� ងំ(5)
Very Bad (5) 
 
SENLNSA រូបរ‌ង
Appearance 
SENLNSC ព៌ណ
Colour 
SENLNSS ក�ិន
Smell 
SENLNST រសជ‌តិ
Taste 
SENLNSX សាច់នំ
Texture 
SENLNSO សរុប
Overall 
Variable 
name 
CSB++ porridge 
CSB++ បបរ 
ល�ណ‌ស(់1)
Very Good (1) 
ល�(2)
Good (2) 
ធម�តា(3)
Neutral (3) 
អន(់4)
Bad (4) 
អនខ់ា� ងំ(5)
Very Bad (5) 
SENCSBA រូបរ‌ង
Appearance 
SENCSBC ព៌ណ
Colour 
SENCSBS ក�ិន
Smell 
SENCSBT រសជ‌តិ
Taste 
SENCSBX សាច់នំ
Texture 
SENCSBO សរុប
Overall 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 5/6 
0 7 
Variable 
name 
Sprinkles + borbor 
Sprinkles + បបរ 
ល�ណ‌ស(់5)
Very Good (1) 
ល�(4)
Good (2) 
ធម�តា(3)
Neutral (3) 
អន(់2)
Bad (4) 
អនខ់ា� ងំ(1)
Very Bad (5) 
SENSPA រូបរ‌ង
Appearance 
SENSPC ព៌ណ
Colour 
SENSPS ក�ិន
Smell 
SENSPT រសជ‌តិ
Taste 
SENSPX សាច់នំ
Texture 
SENSPO សរុប
Overall 
Variable 
name 
LNS Snack 
LNS ជ‌នំញ‌� ំេលង
ល�ណ‌ស(់5)
Very Good (1) 
ល�(4)
Good (2) 
ធម�តា(3)
Neutral (3) 
អន(់2)
Bad (4) 
អនខ់ា� ងំ(1)
Very Bad (5) 
SENSNKA រូបរ‌ង
Appearance 
SENSNKC ព៌ណ
Colour 
SENSNKS ក�ិន
Smell 
SENSNKT រសជ‌តិ
Taste 
SENSNKX សាច់នំ
Texture 
SENSNKO សរុប
Overall 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME7):________________________ GñkRbmUlTinñn½y (Interviewer ID, IVID7):
kumar   (Child´s ID, CHID7):   (Form ID, FORMID) 
Forms 7, 8, 9: Acceptability trial, sub-study 2 (caregiver) – baseline data, sensory test and ranking on day 13 6/6 
0 7 
ទ្រមង់ទ៥ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី២ (អ�កែថរកមុារ) – ការេធ�ើេតស�េដ‌យការឲ្យចំណ‌ត់ថ‌� ក់ ៃថ�ទី១៣
Form 9: Acceptability trial, sub-study 2 (caregiver) - ranking test, day 13 
eQµaHkumar  Name of child
eQµaHmþaykumar 
Name of the caregiver 
េតើអ�កគតិយ៉‌ងេម៉ចែដរចំេពាះផលិតផលេនះ? 
How did you like these products? 
Variable 
name 
Product 
ផលិតផល 
ចលូចិត�ខា� ំង
Like most (1) 
ចលូចិត�េលខេរៀងទ២ី
Like 2nd best (2) 
ចលូចិត�េលខេរៀងទ៣ី
Like 3rd best (3) 
មិនសវូចលូចតិ�
Like least (4) 
RANKLNS LNS +បបរ
LNS + ជ‌មួយបបរ
RANKCSB CSB++ ជ‌មួយបបរសរ
CSB++ porridge 
RANKSP Sprinkles ជ‌មួយបបរសរ
Sprinkles with borbor 
RANKSNK LNS snack 
LNS ជ‌នំញ‌� ំេលង 
RANKNO មា� យមិនឣ‍ចឲ្យចំណ‌ត់ថ‌� ក់បាន
The mother could not rank the products 
9 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:__Ung Sreymach_______________ GñkRbmUlTinñn½y (Interviewer ID, IVID): 
kumar   (Child´s ID, CHID):   (Form ID, FORMID) 
Form 10: Focus group discussion day 14 1/7 
3 
0 6 
ទ្រមង់ទ៥ី៖ ការសិក្សោសាកល្បង – ែផ�កសិក្សោទី២ (អ�កែថរកមុារ) – ្រក�មពិភាក្សោ ៃថ�ទី១៤
Form 10:  Acceptability trial, sub-study 2 (caregiver) – focus group discussion, day 14 
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ ។ ខ�ុំបាទ/នាងខ�ុំេធ�ករងរជាមួយគេ្រមាងផលិតនំ្រតី។ 
ពួកេគគឺជាសហកររីបស់ខ�ុំ (ែននំាពួកេគ) ែដលជាអ�កកត់្រតនិងជួយក�ុងករស្រមបស្រម�លក�ុងករពិភាក្សោ។ 
(ែននំាអ�កេផ្សងេទៀតែដលផ�ល់អហរ)។
Hello, my name is _________________________.   I am working with the Num Trey Project.  These are my colleagues (introduce 
them) who will be taking notes and helping to facilitate this discussion.  (Introduce anyone else who is observing). 
ៃថ�េនះេយើងនងឹនិយ‌យអពំីឣ‍ហារែដលអ�ក និងកនូរបស់អ�កបានភ�ក់ក��ងរយៈេពល២សបា� ហ៍មុន។ ក��ងន‌ម អ�កជ‌មា� យ សូមអ�កផ�ល់ឲ្យេយើងនូវព៌តមានសំខាន់ខ�ះ។ ព៌តមានទំាងេនះនងឹទកុជ‌ការសមា� ត់នងិឯកជន។ េយើងនឹងែននំ‌ខ��នពួកេយើង 
េហើយេយើងឣ‍ចេ�េឈា� ះគា� េ�វ�ញេ�មកបាន។ េ�មុនេពលេយើងចាប់េផ�ើម សូមេមតា� ឲ្យេយើងរ�លឹកនូវការែននំ‌ស្រមាប់ការពិភាក្សោេនះ។ 
Today we are going to talk about the foods that you and your child have tasted over the past two weeks.  As mothers, you can 
provide us with some important information.  This will be a private, confidential discussion.  We will only introduce ourselves and 
call each other by our first names.  Before we get started, let’s review the guidelines for this discussion. 
1. វគ�េនះនឹង្រត�វការរយៈេពល1-2េម៉ាង។ វគ�េនះនងឹ្រត�វការការថតសេម�ងេហើយេយើង ក៏្រត�វការអ�កកត្់រតាែដរ។
(កំណតស់មា� ល់ស្រមាប់អ�កស្រមបស្រម�ល៖ េបើអ�កមិនទានប់ានែណនំ‌ សូមេមតា� ែណ នំ‌ខ��នេ�សហការ�របស់អ�ក)។
This session will take 1-2 hours.  This session will be tape-recorded and we will have a note taker.  (If you haven’t already, please
introduce your colleague/s).
2. អ�កទំាងអស់គា� សូមេមតា� និយ‌យឲ្យបានលឺៗ
Everyone please speak clearly one at a time.
3. េយើងសូមឲ្យអ�កទំាងអស់គា� ចូលរួម ប៉ែុន�េបើអ�កមិនមានឣ‍រម�ណ៍ថ‌្រស�លក��ងការនិយ‌យេទ អ�កមិនចំាបាច់និយ‌យេទ។ ម្៉យោងវ�ញេទៀត សូមទុកឳកាសឲ្យអ�កដ៏ៃទនិយ‌យផង។
We would like everyone to participate, but if you do not feel comfortable talking you do not have to.  On the other hand, please
give each other a chance to speak.
4. វ‌មិនមានចេម�ើយណ‌ខុសឬ្រត�វេឡើយ។ អ�កគួរែតមានឣ‍រម�ណ៍្រស�លេដើម្បីបេ��ញនូវ អ�ីែដលអ�កគិត។
There are no right or wrong answers.  You should feel free to express whatever you are thinking.
5. ការចូលរួមរបស់អ�កនិងចេម�ើយរបស់អ�ក្រត�វបានទុកជ‌ការសមា� ត់ទំាង្រស�ង។ អ�កឣ‍ច ែណនំ‌េឈា� ះែដលអ�កចង់ឲ្យេគេ� វ‌មនិចំាបាច់ថ‌ជ‌េឈា� ះពិតរបស់អ�កក៏េដ‌យ។ េយើងនឹងមិនេ្របើេឈា� ះរបស់អ�កក��ងរបាយការណ៍ណ‌េទ។
Your participation and your answers are completely confidential.  You can introduce yourself with whichever name you want,
not necessarily your real name.  We will not use your name in any of our reports.
6. េតើអ�កទំាងអស់គា� យល់អំពេីគាលការណ៍ទំាងអស់គា� េហើយឬេ�? េតើមានអ�កណ‌មាន សំណួរអ�ីេទ?
Does everyone understand the rules?  Does anyone have any questions?
គិត្រតលប់េ�េពលែដលពួកគាត់បានភ�ក់ឣ‍ហារេ�២សបា� ហ៍មុន េតើឣ‍ហារណ‌ែដលកូនរបស់អ�កចូលចិត�បំផតុ? (LNS + បបរ, LNS ជ‌នំញ‌� ំេលង, CSB++ ជ‌មួយបបរ, sprinkles ជ‌មួយបបរ) 
Think back over the past two weeks.  Which food did your child like best? (LNS+borbor, LNS snack, CSB++, Sprinkles + borbor) 
LNS+borbor  6ន‌ក ់
LNS snack ៧ន‌ក់ 
CSB++  ៦ន‌ក ់
Sprinkles + borbor ៨ន‌ក ់
Comments: 
Lns+borbor: ពួកគាត់ទំាងអស់គា� យល់ថ‌lns+borborគួរេធ�ើមិចកុំេឣ‍យវ‌ខាប់េពកពិបាក់ប���កេក�ង
Csb++ ពួកគាត់យល់ថ‌វ‌សាបេពកពិបាក់ញ‌�ំ ។
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េតើេហតុអ�ីបានជ‌កនូអ�កចូលចិត�ឣ‍ហារេនះ?
• េផ�ើមេដ‌យ៖ េគញ‌� ំបានេ្រចើន មិនបដិេសធមិនញ‌� ំ  ចង់ញ‌� ំ មិនអល់ឯកក��ងការញ‌� ំ ខ��ំមិនបានបង�ំេគឲ្យញ‌� ំ េគញ‌� ំបានរហ័ស េគញ‌� ំយ៉‌ងសប្បោយ េធ�ើឲ្យេគសប្បោយ េធ�ើមុខឆា� ញ់/េផ្សងៗ
What makes you think your child liked this product?
S/he ate a lot 
S/he didn’t refuse to eat  
S/he wanted to eat, wasn’t reluctant to eat 
I didn’t force him/her to eat   
S/he ate quickly  
S/he was happy  
S/he made happy, yummy faces  
Other Comments: 
េតើឣ‍ហារមួយណ‌ែដលអ�កមិនសូវចូលចិត�? (LNS + បបរ, LNS ជ‌នំញ‌� ំេលង, CSB++ ជ‌មួយបបរ, springkles ជ‌មួយបបរ) 
Which food did your child like least? 
LNS+borbor 
LNS snack 
CSB++ ៥ន‌ក ់
Sprinkles + borbor ២ន‌ក់ 
Comments: 
េតើអ�ីែដលេធ�ើឲ្យអ�កគតិថ‌កូនអ�កមិនសូវចូលចិត�ឣ‍ហារេនះ?
• ចាប់េផ�ើមេដ‌យ៖ េគខា� ក់/្រព�សេចញវ�ញេ្រចើន បដេិសធមិនញ‌� ំ មិនចង់ញ‌� ំ អល់ឯកក��ងការញ‌� ំ ខ��ំបានបង�ំេគ ឲ្យញ‌� ំ េ្របើេពលយូក��ងការប���ក គាត់មិនសប្បោយចិត�/មួេ�៉ យំ េគេធ�ើមុខមិនសប្បោយចិត�/េផ្សងៗ
What makes you think your child didn’t like this product?
S/he spat/spilled a lot
S/he refused to eat/ didn’t want to eat, was reluctant to eat 
I had to force him/her to eat 
S/he took a long time to eat  
S/he was distressed/ unhappy/ crying  
S/he made unhappy faces  
Other Comments: 
ឥឡ�វេនះ ខ��ំនងឹេធ�ើការសួរអ�កឲ្យេរៀបរ‌ប់លម�តិអពំីឣ‍ហារនិមួយឲ្យខ��ំ េដ‌យរួមប���លទំាងរូបរ‌ង រសជ‌តិ ព៌ណ ក�ិន ភាពមិនែ្រប្រប�លរបស់នំ និងសាច់នំ ថ‌េតើអ�កវ‌យតៃម�វ‌យ៉‌ងណ‌?
- េតើឣ‍ចេរៀបរ‌ប់ពីLNSលាយជ‌មួយនឹងបបរសរធម�តា?
- េតើឣ‍ចេរៀបរ‌ប់ពី CSB++?
- េតើឣ‍ចេរៀបរ‌ប់ពី Sprinkles លាយជ‌មួយនឹងបបរសរធម�តា?
- េតើឣ‍ចេរៀបរ‌ប់ពបីបរសរធម�តា?
Now, I am going to ask you to describe each food for me, including its appearance, taste, colour, smell, consistency, how you find it 
overall. 
- Can you please describe LNS with borbor?
៧ន‌ក់និយ‌យថ‌lns ក�និដូចចំនីមាន់ ពណ៍ក៏អត់សា� ត ែតសំរ‌បរ់ស់ជ‌ត់ឆា� ញ់ មានរស់ជ‌ត់ែផ�ម េមើលេ�ដូចជ‌សូកូឡ‍ែតក��ងេន‌ះហាក់មានក�ិនឈ��យតិចៗែដរ និយ‌យជ‌រមួឣ‍ចេឣ‍យេក�ងញ៉‌�� បាន។ 
- Can you please describe CSB++?
៧ន‌ក់បាននិយ‌យថ‌វ‌ដូចជ‌បបរធម�តាែដរ េហើយក�ិនវ‌ល� េហើយរ‌វល�ម ង‌យ្រស�លេឣ‍យកូនញ‌�ំ ។ 
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ប៉ុែន�មាន១ន‌ក់និយ‌យថ‌ បបរេនះវ‌រ‌ងសាបេពក ដូចជ‌អត់មានែ្របអេីសាះ អត់មានជ‌តិេ� េហើយរ‌ងសា� តៗក៏េ�េពលញ‌�ំ ។ 
- Can you please describe Sprinkles with borbor?
៩ន‌ក់និយ‌យថ‌ពណ៍វ‌សា� ត់  
៨ន‌ក់ថ‌រស់ជ‌តិវ‌ល� ក�ិនល�(ដូចគា� ជ‌មួយបបរធម�តា) 
១ន‌ក់បាននិយ‌យថ‌ពណ័អត់សា� តេហើយេភ� វ 
- Can you please describe LNS snack?
១០ន‌ក់រស់ជ‌តឆិា� ញ់(ក��ងេន‌ះវ‌មានរស់ជ‌ត់ែផ�ម េហើយរស់ជ‌ត់ែបបេនះទាក់ទាញ់កូនេក�ង)
ឥឡ�វេនះ ខ��ំនងឹសួរអ�កថ‌េតើឣ‍ហារមួយណ‌ែដលអ�កចូលចិត�បផំតុ (សួរមា� យ)?េតើេហតុអ�ី?
- ឣ‍ហារមួយណ‌អ�កចលូចិត�ជ‌ងេគ? (សួរមា� យ)
- េហតុអ�បីានជ‌អ�កចូលចិត�ឣ‍ហារេនះជ‌ងេគ? (សួរមា� យ)
- េហតុបានជ‌វ‌មានភាព្របេសើរជ‌ងឣ‍ហារមួយេទៀត? (សួរមា� យ)
Now I’m going to ask you which food you (the mother, not the child) liked best and why. 
Which food did you (the mother, not the child) like best? 
Why is it better that the other ones? 
Why do you (the mother, not the child)  like this food best? 
LNS+borbor 
LNS snack 
១០ន‌ក់និយ‌យថ‌គាត់ចូលចិត� េ្រពាះវ‌ឆា� ញ់ រស់ជ‌ត់ប៉ុន�ឹងល�ម ឈ��យ ង‌យ្រស�លញ‌�ំ  វ‌មានរស់ជ‌ត់ែផ�មតិចៗ េហើយរូបរ‌ងសា� ត គួរេឣ‍យទាក់ទាញទំាងខាងក��ងនិងខាងេ្រ� េហើយនំខាងក��ងដូចសូកូឡ‍ េហើយសំបកនំខាងេ្រ�ជ‌នុំែដរេក�ងចូល ចិត�ញ‌�ំ ។ 
CSB++ 
Sprinkles + borbor 
ឥឡ�វេនះ ខ��ំនងឹសួរអ�កថ‌េតើឣ‍ហារមួយណ‌ែដលអ�កមិនសូវចូលចិត�(សួរមា� យ)?េតើេហតុអ�ី?
- ឣ‍ហារមួយណ‌អ�កមិនសូវចូលចិត�? (សួរមា� យ)
- េហតុអ�ីបានជ‌អ�កមិនសូវចូលចិត�ឣ‍ហារេនះ?
- េហតុបានជ‌វ‌មានអន់ជ‌ងឣ‍ហារមួយេទៀត?
Now I’m going to ask you which food you the mother, not the child) liked least and why. 
Which food did you the mother, not the child) like it least?  
Why do you find this food the least acceptable / less acceptable than the other foods? 
LNS+borbor 
LNS snack 
CSB++ 
៨ន‌ក់គាត់យល់ថ‌វ‌េភ� វេពក សាបេពក រស់ជ‌តិអត់ឆា� ញ់ ែតសំរ‌ប់ក�ិនឣ‍ចទទួលយកបាន។ 
Sprinkles + borbor 
ឥឡ�វេនះ ខ��ំនងឹសួរអ�កេបើសិនជ‌អ�កមានសំេណើរអ�ីស្រមាប់ការេធ�ើឲ្យឣ‍ហារេនះ្របេសើរេឡើង។
េតើមានមេធ្យោបាយអ�ែីដលេធ�ើឲ្យឣ‍ហារែដលអ�កចូលចិត�បំផុត្របេសើរជ‌ងេនះេទ? ឧ. េតើមានអ�ីែដលអ�កចងប់ែន�មេដើម្បីេធ�ើឲ្យវ‌កាន់ែត្រត�វបានចូលចិត�ញ‌� ំ?
េហតុអ�ី? ឧ. េតើេធ�ើដូចេម�ចេដើម្បីេធ�ើឲ្យវ‌្របេសើរេឡើង
Now I’m going to ask you if you have any suggestions for improving the foods. 
Is there any way to improve (the food they liked best)?  Prompt: is there anything you would add or take out to make it more 
appetising? 
Why? i.e. how would that improve it 
ពួកគាត់មួយចំនួននិយ‌យថ‌សំុកុំេឣ‍យសំបកខាងេ្រ�រ�ងេពក េហើយេបើឣ‍ចសំុេឣ‍យសំបកវ‌្រស�យជ‌ងេនះបន�ិច។ េហើយមានមា� ក់និយ‌យថ‌ សំកុំេឣ‍យស��លខាងក��ងរមួតេពកេ្រពាះវ‌ង‌យេឣ‍យស�ិតក៏ េហើយនំេនះែផ�មចឹងេពលញ‌�ំ  គឺឆាប់ែឆ�ត។ 
សំរ‌បរូបរ‌ង្របែវងទំហំ ឣ‍ចទទួលយកបានេហើយប៉ុន�ឹង។ 
មាន១ន‌កចង់េឣ‍យរស់ជ‌ត់ចាស់ជ‌ងេនះ ប៉ុែន�ក��ងេពលហ�ឹងែដរមាន៦ន‌ក់និយ‌យថ‌រស់ជ‌ត់ប៉ុន�ឹងសមរម្យេហើយេ្រពាះ កាលណ‌រស់ជ‌តិចាស់េពកឣ‍ចបណ‌� ល់េឣ‍យេក�ងឆាប់េ�� ខ��ន។ 
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េបើសិនជ‌ឣ‍ហារេន‌ះមិនែមនជ‌LNS អ��ឹងសួរថ‌៖ េតើមានមេធ្យោបាយអ�ីេដើម្បីេធ�ើ ឲ្យឣ‍យូេអហ�្របេសើរេឡើង (បង‌� ញពួកេគពីឣ‍ហារេន‌ះ)?
ឧ. េតើមានអ�ីែដលអ�កចងប់ែន�មេដើម្បីេធ�ើឲ្យវ‌កាន់ែត្រត�វបានចូលចតិ�ញ‌� ំ?
េហតុអ�ី? ឧ. េតើេធ�ើដូចេម�ចេដើម្បីេធ�ើឲ្យវ‌្របេសើរេឡើង
If that food wasn’t the LNS, then ask:   
Is there any way to improve the LNS (show them that food)?  Prompt: is there anything you would add or take out to make it more 
appetising? 
Why? i.e. how would that improve it 
េតើជ‌ទូេ�អ�កជ‌អ�កប���កកនូរបស់អ�ក? ចាប់េផ�ើម៖ េតើជ‌ទូេ�អ�កជ‌អ�កប���កកនូរបស់អ�ក ឬក៏អ�កណ‌ េផ្សងជ‌អ�កប���ក? 
Who usually feeds your child?  Prompt: do you usually feed your child or does someone else usually feed your child? 
មា� យបេង�ើតBiological mother 
មា� យចុងStepmother 
ជីដូនGrandmother 
ឪពុកFather 
បង្រសីSister 
េផ្សងៗ(ពពិ៌ណន‌)Other (describe)     
េតើអ�ក (ឬក៏អ�កដ៏ៃទេទៀតែដលប���កកូនអ�ក) នឹងទនំងជ‌ប���កកូនអ�កនូវឣ‍ហារទំាងេនះជ‌្របចំាឬេទ? (ឧ. ៣ដងក��ងមួយៃថ�)? េតើឣ‍ហារមួយណ‌ែដលអ�កចង់ប���ក?
- េហតុអ�ី?
- េហតុអ�ីមិនចង់?
- េតើមានអ�ឣី‍ចេធ�ើឲ្យអ�កចងប់���កឣ‍ហារេនះេ�កុមារជ‌្របចំាែដរឬេទ(ឧ. ៣ដងក��ងមួយៃថ�)?
Would you (or the other person who feeds the child) be likely to serve any of these foods to your children on a regular basis (e.g. 3 
times a day)?   
Which one/s?  Why?  Why not?   
LNS+borbor 
LNS snack 
ពួកគាត់និយ‌យថ‌ឣ‍ចប���ក២េ�៣ដងក��ង១ៃថ�គេឺពល្រពឹកនិងលា� ច គឺេឣ‍យេក�ងញ‌�ំ ែលងបន‌� ប់ពីញ‌�ំ បាយ។ េហើយ្របែហលជ‌ឣ‍ចេឣ‍យរ‌ល់ៃថ� ។ 
CSB++ 
Sprinkles + borbor 
What might make you want to feed this food to your children on a regular basis (e.g. 3 times a day)?  
LNS+borbor 
LNS snack 
CSB++ 
Sprinkles + borbor 
េបើមិនែមនជ‌LNS អ��ឹងសួរថ‌៖
េតើអ�ក (ឬកអ៏�កដ៏ៃទេទៀតែដលប���កកូនអ�ក) នឹងទនំងជ‌ប���កកូនអ�កនូវឣ‍ហារLNSជ‌្របចំាឬេទ? (ឧ. ៣ដងក��ងមួយៃថ�)?
- េហតុអ�ី?
- េហតុអ�ីមិនចង់?
- េតើមានអ�ឣី‍ចេធ�ើឲ្យអ�កចងប់���កឣ‍ហារេនះេ�កុមារជ‌្របចំាែដរឬេទ(ឧ. ៣ដងក��ងមួយៃថ�)?
If that food wasn’t the LNS, then ask:  Would you (or the other person who feeds the child) be likely to serve the LNS to your 
children on a regular basis (e.g. 3 times a day)?   
Why?  
Why not?  
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What might make you want to feed the LNS to your children on a regular basis (e.g. 3 times a day)?  
េបើLNS មានរូបរ‌ងែបបេនះ(បង‌� ញនំ)? េតើអ�កនឹងដ‌កវ់‌ចលូក��ងបបរេដើម្បីប���កកនូរបស់អ�ក ឬឲ្យញ‌� ំជ‌នំែតម�ង?
- េតើេហតុអ�ីបានជ‌អ�កដ‌ក់ក��ងបបរេហើយប���ក? េតើេហតុអ�ីបានជ‌អ�កមិនឲ្យញ‌� ំជ‌នំ?
- េតើេហតុអ�ីបានជ‌អ�កឲ្យញ‌� ំជ‌នំ?  េតើេហតុអ�ីបានជ‌អ�កមនិឲ្យញ‌� ំេដ‌យដ‌ក់ក��ងបបរ?
េតើជ‌ទូេ�អ�កឲ្យនំអ�ដីល់កូនរបស់អ�កញ‌� ំេ�េពលៃថ�?  
The LNS comes in this form [show the LNS bar] and it can also be mixed into borbor?  Would you be more likely to give it to your 
child in borbor, or as a snack? 
Why would you give it in borbor?  Why wouldn’t you give it as a snack?  
គាត់និយ‌យ ថ‌ េ្រកាមមយួឆា� ំឣ‍ចលាយជ‌មួយបបរេ្រពាះពិបាក់កាន់ញ‌�ំ ែតេបើេលើសព១ីឆា� ំកាន់ញ‌�ំ ល�ជ‌ង។ 
Why would you give it as a snack?  Why wouldn’t you give it in borbor?   
េ្រពាះេក�ងចង់កានន់ំញ‌�ំ ែលងែតសំរ‌ប់ែតេក�ងេលើលពី១ឆា� ំេទើបកាន់ញ‌�ំ បាន។ 
What are the usual snacks that your child eats during the day?   
៤ន‌ក់និយ‌យថ‌នំសាគឺរ‌�  េក�ងៗចូលចិត�ញ‌�ំ េ្រពាះវ‌្រស�យ ែផ�ម រស់ជ‌តិដូចដំឡ�ង មានជ‌តិទឹកេដ‌ះេគា េក�ងខ�ះញ‌�ំ កាេរ�ម នំៃ្រប េហើយ៤ន‌ក់េទៀតេឣ‍យែផ�េឈើ។ 
េតើអ�កបាននទំំាងេនះមកពីណ‌?ចាប់េផ�ើមេដ‌យ៖ អ�កដំ‌វ‌េ�ក��ងផ�ះ (ឧ.ែផ�េឈើ) អ�កេធ�ើវ‌េ�ផ�ះ ឬទិញេគ?  
Where do you get these snacks?ទិញពីផ្សោរ កែន�ងលក់នុ ំ
Grow them at home (e.g. fruit),  
make them at home,  
buy them,? 
other  
េតើជ‌ទូេ�អ�កចំណ‌យប៉ុន‌� នស្រមាប់នំទំាងេន‌ះ? ចាប់េផ�ើមេដ‌យ៖ ឧ. េបើសិនជ‌អ�កទិញវ‌ េតើជ‌មធ្យមអ�កចំណ‌យអស់ប៉ុន‌� ន?
េតើជ‌ទូេ�អ�កចំណ‌យប៉ុន‌� នស្រមាប់ទិញនំញ‌� ំេលងទំាងេន‌ះស្រមាប់កូនរបស់អ�ក(កមុារែដលបានភ�ក់ឣ‍ហាររបស់េយើង)? ចាប់េផ�ើមេដ‌យ៖ ឧ. េបើសិនជ‌អ�កទញិវ‌ េតើជ‌មធ្យមអ�កចំណ‌យអស់ប៉ុន‌� ន?
How much do you usually pay per snack? Prompt: for example, if you buy them, how much do you pay on average? 
ពួកគាត់និយ‌យថ‌១ក��ប់១០០េរៀល ៥០០ ២០០  
How much do you usually spend on snacks each day for your child (the one who tested the food)? 
េហើយក��ង១ៃថ�ចំន‌យ្របែហល២០០០ ឬ ៣០០០េរៀលក��ង១ៃថ�។ 
ឥឡ�វេនះ ខ��ំនងឹសួរអ�កឲ្យេ្រប�បេធៀបអំពីLNS េ�នឹងនំែដលកូនអ�កញ‌� ំ. េតើអ�កេធ�ើការេ្រប�បេធៀបLNSយ៉‌ងេម៉ច? 
- េតើអ�កគតិថ‌កនូរបស់អ�កនងឹមានឣ‍រម�ណ៍ថ‌មានLNSឪជ‌រស/រសជ‌តិ/ឣ‍ចទទួលយកបានដូចនំែដលញ‌� ំជ‌្របចំាែដរឬេទ?
Now I’m going to ask you to compare the LNS to the usual snacks that your child eats.  How does the LNS compare? 
ទំាងអស់គា� គិតថ‌វ‌ល�ជ‌ងនំែដលេក�ងៗចូលចិត�ទិញញ‌�ំ  េ្រពាះlnsវ‌មានគុណភាពល�ជ‌ង េដ‌យសារេក�ងេពលញ‌�ំ នlំnsហ�ឹងេហើយេពលេ�ផ�ះញ‌�ំ បាយេ្រចើនជ‌ងមុន េហើយេដ‌យថ‌ខាងអង�ការចុះមកចងឹយកមក្របាកដជ‌ឣ‍ហារបំប៉នសំរ‌ប់េក�ងៗេដើម្បី េឣ‍យេក�ងៗមានសុខភាបល�។ 
េហើយសំរ‌ប់េក�ងៗវ‌ចូលចិត�ញ‌�ំ នំែតេបើមា� យចង់េឣ‍យជ‌នំអីេ្រសចែតេ�េលើមា� យ។ 
៤ន‌ក់បាននិយ‌យថ‌េក�ងភាគេ្រចើនទាល់ែតមានបន�បខ់�ះម�ងេយើងេឣ‍យនំេនះម�ងេយើងេឣ‍យនំេន‌ះចឹងេទើបេក�ងៗវ‌ចូលចិត�។ 
Do you think that your child would find the LNS as palatable/tasty/acceptable as the usual snacks? 
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េដ‌យេធ�ើការេ្រប�បេធៀបជ‌មួយនឹងនំធម�តា េតើអ�កនងឹទំនងជ‌ ឬមិនសូវចង់ ឬឣ‍ចផ�ល់តំៃលេស�ើនឹងេ្រជើស េរ�សLNSយកមកេធ�ើជ‌នំស្រមាប់កូនរបស់អ�កែដរឬេទ?
- េហតុអ�ី?
- េហតុអ�ីមិនចង់?
- េតើេហតុអ�ីបានជ‌េធ�ើឲ្យអ�កេ្រជើសេរ�សLNSេធ�ើជ‌នំស្រមាប់កុមារជ‌្របចំា?
In comparison to your child’s usual snack, would you be more likely, less likely, or equally to choose the LNS as a snack for your 
child? 
Why? Why not? 
more likely, ១០ន‌ក់បាននិយ‌យថ‌ឣ‍ចទញិេឣ‍យកូនញ‌�ំ បាន 
េ្រពាះបាល�សំរ‌ប់កុមារ។ 
less likely 
equally 
likely 
Don’t know 
What might make you want to choose the LNS as a snack for your child on a regular basis?  
េ្រពាះវ‌ល�ជ‌ងនំេក�ងញ‌�ំ េផ្សងៗ 
េដ‌យេធ�ើការេ្រប�បេធៀបជ‌មួយនឹងនំធម�តា េតើអ�កនងឹទំនងជ‌ ឬមិនសូវចង់ ឬឣ‍ចផ�ល់តំៃលេស�ើនឹងទិញLNS យកមកេធ�ើជ‌នំស្រមាប់កូនរបស់អ�កែដរឬេទ?
In comparison to your child’s usual snack, if you had to pay for the LNS, would you be more likely, less likely, or equally to buy the 
LNS as a snack for your child? 
• more likely,
សំរ‌ប់នំ្រតីវ‌គឺល�ជ‌ងនំធម�តាចឹងេហើង្របាកដណ‌ថ‌ឣ‍ចទិញបានេឣ‍យេក�ងៗញ‌�ំ េបើេទាះបីជ‌េពលខ�ះៃថ�ជ‌ងតិចតចួក៏េដ‌យ។ 
• less likely,
• equally likely
េបើអ�ក្រត�វែតចំណ‌យស្រមាប់LNS េតើតៃម�ប៉ុន‌� នែដលអ�កមានឆន�ៈក��ងការចំណ‌យេដើម្បទីិញLNSទំហំប៉ុន១ដុំេនះស្រមាបក់ូនរបស់អ�ក (បង‌� ញLNS)? 
- ចាប់េផ�ើមេដ‌យ៖ េតើវ‌េថ‌កជ‌ង ឬៃថ�ជ‌ងនំែដលអ�កទិញមកឲ្យកនូអ�កញ‌� ំជ‌ទូេ�?
- េបើសិនជ‌ៃថ�ជ‌ង េតើេហតុអ�ីបានជ‌អ�កសុខចិត�ចំណ‌យ?
- េបើសិនជ‌េថ‌កជ‌ង េតើេហតុអ�ីបានជ‌អ�កសុខចិត�ចំណ‌យតិច ឬេតើេហតុអ�ីបានជ‌អ�កស�្រគ័ចិត�ចំណ‌យេស�ើនឹងតៃម�នំទេូ�ែដលអ�កទិញមកឲ្យកូនរបស់អ�កញ‌� ំ?
- េបើសិនជ‌តៃម�ដូចគា�  េតើេហតអុ�ីបានជ‌អ�កស�្រគ័ចតិ�ចំណ‌យតៃម�េស�ើនឹងនំទូេ�ែដលអ�កទិញមកឲ្យកនូអ�កញ‌� ំ?
If you had to pay for the LNS, how much would you be willing to pay for a piece/bar this size as a snack for your child [show the LNS 
package]? 
ពួកគាត់៥ន‌ក់ និយ‌យថ‌ឣ‍ចនំ១តំៃល៣០០េរៀលឬ២តំៃល៥០០េរៀលឬ ឣ‍ចដល់១០០០េរៀល េ្រពាះេពលខ�ះនំេក�ងៗឣ‍ចដល់តៃំលប៉ុន�ឹងក��ងមួយក��ប់។ 
Is that more, less or the same as you pay for your child’s usual snack? 
more, 
less 
same 
If more, why would you be willing to pay more? 
If less, why would you be willing to pay less OR why wouldn’t you be willing to pay as much as you pay for your child’s usual snack? 
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If the same, why would you be willing to pay the same as you pay for your child’s usual snack? 
េតើមានអ�ីខ�ះែដលអ�កចងន់ិយ‌យ/េរៀបរ‌បអ់ំពឣី‍ហារែដលអ�កបានភ�ក់កន�ងមក?
Is there anything else that you would like to say about any of the foods you tasted? 
ពួកគាត់ចង់េឣ‍យដ‌ក់លក់ឆាប់ៗ។ 
េតើមានអ�ីេផ្សងេទៀតេទែដលអ�កចង់និយ‌យជ‌ពិេសសអំពី LNS?
Is there anything else that you would like to say particularly about the LNS? 
ការដ‌ក់េឈា� ះមាន៦ន‌ក់និយ‌យថ‌ 
១. នំ្រតី(េ្រពាះវ‌ធកំ�ិន្រតី) 
២. នំ្រតីស��លែផ�ម 
៣. នំ្រតីឆ��យឆា� ញ់ 
៤. នំ្រតីវ�តាមីនសំរ‌ប់កុមារ 
៥. នំ្រតីវ�តាមីនសំរ‌បក់ុមារនិយមា� យ 
េហើយពួកគាត់េស�ើរសំុេឣ‍យសរេសរពត៍មានអំពីផល្របេយ‌ន៏ៃនការបរ�េភាគនំ្រតីេ�េលើក��ប់េដើម្បីេឣ‍យអ�កេផ្សងយល់។ 
េហើយសំបកក��ប់ សំុេឣ‍យដ‌ក់រូបកុមារ េហើយពណ៍សំេឣ‍យសា� តជ‌ងហ�ឹងបន�ិចឬក៏ឣ‍ចដ‌កដ់ចូរូបេ�េលើក��ប់sprincalេហើយឣ‍ចដ‌ក់ពណ៏ទឹក្រក�ច។ 
មាន៦ន‌ក់បាននិយ‌យថ‌កាែបងែចកលក់េ�េលើទីផ្សោរជ‌ការល�ង‌យ្រស�លទិញ េហើយេបើឣ‍ចសំុដ‌ក់េ�មណ� លសុខភាព ឬកែន�ងលកថ‌� ំេពទ្យ េហើយ៣ន‌ក់េទៀតនិយ‌យថ‌កាលណ‌ដ‌ក់េ�េពទ្យេពទ្យែនណំ‌េឣ‍យេ្របើ និង្របាប់េឣ‍យេ្របើវ‌ជ‌ការល�។ 
៥ន‌ក់បាននិយ‌យថ‌ េបើេយើងលក់េ�តូបលក់នំតូចៗជ‌ការល�ង‌យ្រស�លទិញ។ 
េហើយេបើេ្រប�បេធៀបហ�ឹងនេំក�ងៗញ‌�ំ ធម�តាគាត់្របាកដជ‌ទិញនេំនះេឣ‍យេក�ងៗញ‌�ំ ។ 
េហើយេបើេគលកម់�ងមួយក��ប់ធំមិន្របាកដថ‌មានលុយទញិេទេ្រពាះេពលខ�ះមានេពលខ�ះអត់លុយ។ 
ចំណ‌យេពលអស់(៥៤:៥៣) 
សូមអរគុណស្រមាប់ការនិយ‌យជ‌មួយពួកខ��ំ។ ការចូលរួមរបស់អ�កគឺបានជួយយ៉‌ងខា� ំងក��ងការេធ�ើឲ្យ្របេសើរេឡើងនូវការទទួលយកបានៃនឣ‍ហារែដលេធ�ើឲ្យសុខភាពល�ែដលេយើងនឹងផលិតស្រមាប់កមុារនិងមា� យ។
Thank you for talking with us.  Your input is helpful in improving the acceptability of the healthy foods that we develop for children 
and mothers. 
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Appendix 5.1-5.5:  Effectiveness trial data collection forms 
The effectiveness data collection forms in Appendices 5.1-5.5 are in English and Khmer languages. 
The Khmer translations were originally typed using various Khmer fonts.  Some of the fonts are no 
longer available, nor are they compatible with newer fonts.  The text in the obsolete fonts appears in 
Latin fonts, usually as phonetic renderings of the Khmer, while the text in the current fonts appears 
correctly in Khmer script.  This has resulted in less attractive layout than in the original data collection 
forms.  The English is all original and correct.   
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):   
Form 1: Efficacy trial – recruitment and exclusion form 1/5 
0 2
ទ្រមង់ទី១៖ ្របសិទ�ភាពនំ្រតីរបស់ការសិក្សោ-- ទ្រមង់ស្រមាប់េ្រជើសេរ�សការចូលរួម និងសំណួរស្រមាប់មិនទទួលយកការសិក្សោ 
Form 1: Efficacy Trial – recruitment and exclusion 
eQµaHkumar Name of child 
eQµaHអ�កេមើលែថកុមារ  Name of caregiver
PUm សង‌� ត ់Village, Sangkat
កាលបរ�េច�ទ Date
ៃថ� Day ែខ Month ឆា� ំ  Year
្របាប់េទអ�កេមលែថកុមារ ៖ 
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ 
េយងខំុ�កំពុងេធ�ករជាមួយនឹងគេ្រមាងផលិតនំ្រតី។ 
�
(UNICEF) 
រុក� ្របមាញ់និងេនសទ 
េយងកំពុងេធ�ករសិក្សោេលគេ្រមាងផលិតនំ្រតីែដល្រត�វបានករឧបត�ម�និងគំា្រទេដយអង�ករយូនីេសហ 
កម�វ ធីិអហរបូត�ម�ថា� ក់ជាតិៃន្រកសួងសុខភិបាល 
នាយកដ� នបេច�េកវទិ្យោែកៃច�និងគុណភាពៃនរដ�បាលជលផលៃន្រកសួងកសិកម� 
និងវទិ្យោស� ន�សវ្រជាវនិងអភិវឌ្ឍន៍របស់រ្របេទសបារងំែដលេហកត់ថាIRD។ 
េហយគេ្រមាងេនះនឹងេធ�ករសិក្សោេនក�ុងទី្រក�ងភ�ំេពញ។េយងចង់េធ�ករតមដនសុខភាពនិងកររកីលូតលស់របស់កុមារែដល
មានអយុេលសពី៦ែខ េដយចប់េផ�មពីៃថ�ទី ២២ ែខកុម�ៈ និងប�� ប់េនៃថ�ទី ៣០ ែខក�� ឆា� ំ ២០១៦។ 
Tell caregivers: 
Hello, my name is _________________________.  I am working with the Num Trey Project. The Num Trey Project is supported by UNICEF, National Nutrition 
Program of Ministry of Health, Department of Fisheries Post-Harvest Technologies and Quality Control, Fisheries Administration of the Ministry of Agriculture, 
Forestry and Fisheries, and IRD.    The Num Trey Project is doing a study around Phnom Penh.  We want to follow the health and growth of children over 6 months, 
starting 22 February and ending 30 September 2016. 
ក�ុងមួយែខម�ងេនាះអ�កនឹង្រត�វអេ�� ញមកចូលរមួ េដម្ីបឲពួកេយងសួរសំណួរដល់អ�ក។ េយងនឹង្របមូលព៌តមានរបស់អ�កនិង 
កូនរបស់អ�កអំពីសុខភាព កម�ស់និងទម�ន់។ េយងនឹង្រត�វបូមយកឈមនិងលមករបស់កូនអ�កេនៃថ�េនះ និង 
ៃថ�ប�� ប់ៃនករសិក្សោេនះ។ ពត៏មានទំងអស់ែដល្របមូលបាននឹង្រត�វបានរក្សោទុកេដយែឡកនិងរក្សោសមា� ត់។ 
Once a month, you would need to come for us to ask you questions.  We will collect information about your child’s and your health, height and weight.  Two times, at 
the beginning and the end of the study, we will take blood and stool samples from your baby.  All information collected will be kept private and confidential.   
វនឹងមិនមានហនិភ័យអ�ីេកតេឡងក�ុងករសិក្សោេនះេទ។ ករចូលរមួរបស់អ�កគឺជាជេ្រមសរបស់អ�កទំង�ស�ង។ 
ករចំណាយេទេលេសហុយេធ�ដំេណ រស្រមាប់អ�កនិងកូនរបស់អ�កេយងនឹងផ�ល់ ជូនម�ង$1 េហយនឹងអំេណាយតិចតួច 
រល់េពលែដលអ�កអេ�� ញមក ចូលរមួករសិក្សោេនះ។ 
េតអ�កមានចំណាប់អរម�ណ៍និងមានេពលទំេនរស្រមាប់ចូលរមួែដរឬេទ? បាទ/ចស    េទ  
No   
There are no risks to this study.  Your participation is entirely your choice. 
Your transport for you and your baby will be reimbursed at $1 and you will receive a small gift every time you come.  
Would you be interested and available to participate?          Yes   
េបសិនជាមាន សូមអនុ��ត�ិឲ្យ 
ខ�ុំសួរនូវសំនួរមួយចំនួនេដម្ីបដឹងថាអ�កនិងកូនអ�កមានលក�ណៈ្រគប់្រគាន់ស្រមាប់ចូលរមួក�ុងករសិក្សោេនះែដរឬេទ។ 
សួរសំនួរដូចខងេ្រកម 
2 0 1 6 
Appendix 5.1 Form 1:  Recruitment and exclusion
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):   
 
Form 1: Efficacy trial – recruitment and exclusion form 2/5 
0 2
If yes, please let me ask some questions to see if you and your child are suitable participants.  Ask the following questions: 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):   
Form 1: Efficacy trial – recruitment and exclusion form 3/5 
0 2
Variable 
name 
សូមសួរេ�អ�កេមើលែថកុមារ   PLEASE ASK THE CAREGIVER 
ចេម�ើយ    RESPONSE កូដ Code
EXDOB 1. េត(េឈ� ះេនះ)មានសំបុ្រតកំេណ ត
ប័ណ�េលឿងចក់វ៉ក់សុំឬឯកសរេផ្សងេទៀតមកជាមួយឬេទ?
េបមិនមាន សូមរលំងេទសំនួរទី២។
Does (name) have a birth certificate, immunisation card, or some other
document?)
េទNo       0 
បាទ/ចាសYes       1 
EX1AGE េបសិនជាមាន សូមសរេសរៃថ�កំេណ តមឯកសរចក់វ៉ក់សងំ
េបមិនមានសូមសរេសរតមករចងចំរបស់អ�កែថទំកុមារ
េបសិនៃថ�កំេនតមិនែមនេនចេនា� ះ……..… និង…….… េទ 
សូមនិយាយថា៖ អរគុណស្រមាប់ឆន�ៈចូលរមួរបស់អ�ក។ 
ែតគួរឲ្យស� យែដលអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគាន់ស
្រមាប់ចូលរមួក�ុងករសិក្សោេទ េដយសរេឈ� ះ(eQµaH)
អយុតិចេពក/េ្រចនជាងអយុែដល្រត�វសិក្សោ។
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។
If yes, write the date on document.  If no document but mother knows 
birthdate, write it.  If date is not between …… and …, say: Thanks for your 
willingness to participate.  Unfortunately, you and your child are not 
eligible to participate because (name) is too young/old.  EXCLUDE, END 
QUESTIONNAIRE, GO TO EXCLUSION STATEMENT 
éf  Day        Ex  Month             qñaM  Year 
EXCLUDED      99
EX2AGE 2. etIkumarmanGayub:unñan ?
េបសិនជាកុមារអយុេ្រកម8ែខ
ឬេលស10ែខសូមនិយាយថាអរគុណស្រមាប់ឆន�ៈចូលរមួរបស់អ�ក
ែតគួរឲ្យេសកស� យែដលអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគា
ន់ស្រមាប់ករចូលរមួេទ េ្រពះអយុកូនរបស់អ�កតិចេពក/េ្រចនជាង ។
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
How old is (name)? If < 8 months or > 10mths, say: Thank you for your 
willingness to participate.  Unfortunately, you and your child are not 
eligible to participate because (name) is too young/old. EXCLUDE AND 
END QUESTIONNAIRE AND GO TO EXCLUSION STATEMENT 
Ex Months       éf  Days មិនទទួលយកការចូលរួម
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1TWIN 3. េតើកូនេនះ�កូនេ�� ះ២ឬេ�� ះេ្រចើនឬេទ?
េបើកុ�រ�កូនេ�� ះ២ឬេ្រចើនសូមនិ�យ�:
អរគុណចំេ�ះឆន�ៈរបស់អ�កេដើម្ីបចូលរមួ។
ែតគួរឲ្យស� យអ�កនិងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់ចូលរមួ
េ�យ�រែត (េ�� ះ) គឺ�េ�� ះ។
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
Is this child a twin or multiple? 
If the child is a twin or multiple, say: Thank you for your willingness to 
participate.  Unfortunately, you and your child are not eligible to 
participate because (name) is a twin. EXCLUDE AND END QUESTIONNAIRE 
AND GO TO EXCLUSION STATEMENT 
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1ILL 4. េតើកូនរបស់អ�កកំពុង�នជំងឺធ�ន់ធ�រឬេទ?ដូច�ជំងឺេអដស៍ 
ឬរេបង។ល។េបើកុ�រ�នជំងឺធ�ន់ធ�រសូមនិ�យ�:
េទNo       0 
បាទ/ចាសYes       1 
2 0 1 5 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):   
Form 1: Efficacy trial – recruitment and exclusion form 4/5 
0 2
អរគុណចំេ�ះឆន�ៈរបស់អ�កេដើម្ីបចូលរមួ។ 
ែតគួរឲ្យស� យអ�កនិងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់ចូលរមួ
េ�យ�រែត (េ�� ះ)�នជំងឺធ�ន់ធ�រ។ 
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
Does this child have any major illness right now (e.g. HIV, TB, etc)?  If the 
child has a major illness, say: Thank you for your willingness to participate.  
Unfortunately, (name) is not eligible to participate because s/he has a 
major illness. EXCLUDE AND END QUESTIONNAIRE AND GO TO EXCLUSION 
STATEMENT  
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1ALRGY 5. េតើកូនរបស់អ�កធា� ប់មាន្របតិកម�ជ‌មួយឣ‍ហារអ�ីខ�ះ? (ឧ. ញ‌� ំេហើយេធ�ើឲ្យពិបាកក��ងការដកដេង�ើម 
ឬមានកន��លរមាស់េ�េពលញ‌� ំឣ‍ហារណ‌មួយ)េបើកុ�រ�ន្របតិកម�សូមនិ�យ�:
អរគុណចំេ�ះឆន�ៈរបស់អ�កេដើម្ីបចូលរមួ។ 
ែតគួរឲ្យស� យអ�កនិងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់ចូលរមួ
េ�យ�រែត (េ�� ះ)�ន្របតិកម� �រ។ 
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
Does this child have allergies or intolerances to any food (e.g. difficulty 
breathing or a rash if they eat certain foods).  If the child has food 
intolerances, say: Thank you for your willingness to participate.  
Unfortunately, (name) is not eligible to participate because s/he has food 
intolerances. EXCLUDE AND END QUESTIONNAIRE AND GO TO EXCLUSION 
STATEMENT  
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1STUDY 6. េតើកូនរបស់អ�កកំពុងចូលរមួេធ� ើ រសិក��មួយគំេ�ងឬ�រសិក�ដ៏ៃទ
េទៀតេទ?េបើកុ�រកំពុងចូលរមួេធ� ើ រសិក��មួយគំេ�ងឬ�រសិក�ដ៏ៃទ
េទៀត សូមនិ�យ�: អរគុណចំេ�ះឆន�ៈរបស់អ�កេដើម្ីបចូលរមួ។ 
ែតគួរឲ្យស� យអ�កនិងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់ចូលរមួ
េ�យ�រែត (េ�� ះ) 
កំពុងចូលរមួេធ� ើ រសិក��មួយគំេ�ងឬ�រសិក�ដ៏ៃទេទៀត។
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។
Is the child currently participating in any other study?  If the child is 
participating in another study, say: Thank you for your willingness to
participate.  Unfortunately, (name) is not eligible because s/he is 
participating in another study. EXCLUDE AND END QUESTIONNAIRE AND
GO TO EXCLUSION STATEMENT  
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1AVBL 7. េតើអ�កនិងកូនរបសអ់�ក�ច�នេពល
ស្រ�ប់ចូលរមួ�រសិក�ក� �ងរយៈេពល៦ែខេពញ, �ប់េផ�ើមពីេពលេនះ 
រហូតដល់ចុងែខក�� ឬេទ  ? េបើសិន��ត់
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
Will you and your child be available for the full 6 months of the study, 
from today until September 2016?  If no:  
EXCLUDE AND END QUESTIONNAIRE AND GO TO EXCLUSION STATEMENT  
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      
99 
EX1YES 8. េតើអ�កនិងកូនរបសអ់�កស� ្រគ័ចិត�ចូលរមួេធ� ើ រសិក��មួយេយើងេទ?
េបើសិន��ត់ទំេនរ
ប�� �ល�ត់ក� �ង�រសិក�។េបើសនិ��ត់មិនទទួលយកករចូលរមួ
ប�� ប់សំនួរ និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។
Are you willing for you and this child to participate in the study?
If yes, write down name.
If no, EXCLUDE AND END QUESTIONNAIRE AND GO TO EXCLUSION 
STATEMENT 
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      99 
228
េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):   
Form 1: Efficacy trial – recruitment and exclusion form 5/5 
0 2
សរចុងប�� ប់ៃនករមិនមិនទទួលយក 
េបើអ�កទទួល�ននូវចេម� ើយែដលមិនទទួលយក�រចូលរមួរបស់អ�កែថកុ�រេទ េ�ះសូមនិ�យ�៖ 
អរគុណចំេ�ះឆន� ៈែដលចង់ចូលរមួក� �ង�រសិក��មួយពួកេយើង ែតគួរឲ្យេ�ក�� យែដលអ�ក 
និងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់េដើម្ីបចូលរមួក� �ង�រសិក� េ�យ�រែត 
[្រ�ប់នូវមូលេហតុដូចេ�ក� �ងទ្រមង់មិនទទួលយក�រចូលរមួរបស់�ត់ ឧ. កុ�រមិន�ន�យុចេ�� ះព៨ី េ� ៩ែខ]។មិនប���លគាត់ក��ងការសិក្សោ 
EXCLUSION STATEMENT: If you get an answer that excludes the caregiver, please say:  Thank you for your willingness to participate.  
Unfortunately, you and your child are not eligible to participate because [give the reason from the exclusion form that they were 
excluded, e.g. the child was not aged between 8-9 months, etc].. 
Excluded   
េបើសិន�អ�កសួរ្រគប់សំនួរេហើយអ�កែថកុ�រេ�ះ�នលក�ណៈ្រគប់្រ�ន់ក� �ង�រចូលរមួ និង�នឆន�ៈចូលរមួេ�ះសូមនិ�យ�៖ 
អរគុណស្រ�ប់ឆន� ៈចូលរមួរបស់អ�ក េយើងនឹងសេសរេ�� ះអ�កទុក។  
េយើងនឹងផ�ល់នូវ�រចំ�យេលើ�រេធ� ើដំេណើរ ដល់អ�កនិងកូនរបស់អ�កចំនួន $1 េហយនឹងអំេណាយតិចតួច 
រល់េពលែដលអ�កអេ�� ញមក ចូលរមួករសិក្សោេនះ។ 
េបើសិន�អ�កសួរនូវ្រគប់សំណួរេហើយ េហើយអ�ព��លេ�ះ�ន្រគប់លក�ណៈសម្បត� ិ្រគប់្រ�ន់និង�នឆន� ៈក� �ង�រចូលរមួ
សូមនិ�យ�៖ អរគុណស្រ�ប់ឆន� ៈែដលចូលរមួ។ 
ឥឡ� វេនះេយើងនឹង្រ�ប់អ�កលម� ិតអំពី�រសិក�និងសុំ�រយល់្រពមពីអ�កក� �ង�រចូលរមួ។ បន�េ��ក្យយល់្រពមចូលរមួ ។ 
If you ask all the questions and the caregiver is eligible and willing to participate, please say:  Thank you for your willingness to participate.  I will write your name 
down.   
Your transport for you and your baby will be reimbursed at $1/day and you will receive a small gift every time you come.  
Now I am going to tell you more about the study and ask for your consent to participate.  Go to consent form. 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME2):________________ GñkRbmUlTinñn½y (Interviewer ID, IVID2):  (Form ID, FORMID) 
kumar   (Child´s ID, CHID2):  (Child´s BioID, CHBIOID):
 
Form 2A: Efficacy trial –participant information and consent sheet, control group  1/4 
0 2 
ទ្រមង់ទី២: ្របសិទ�ភាពនំ្រតីរបស់ការសិក្សោ-  ព៌តមានអ�កចូលរមួនិងពក្យយល់្រពម, ្រក�មេផ� ងផា� ត់
Form 2A:  Efficacy trial - participant information and consent sheet, control group  
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ ។ ខ�ុំបាទ/នាងខ�ុំេធ�ករងរជាមួយគំេរងផលិតនំ្រតី។ 
គំេរងផលិតនំ្រតីេនះទទួលបានករឧបត�ម�និងគំា្រទេដយអង�ករយូនីេសហ�(UNICEF) 
កម�វធីិអហរបូត�ម�ថា� ក់ជាតិៃន្រកសួងសុខភិបាល  
នាយកដ� នបេច�កវទិ្យោែកៃច�និងគុណភាពៃនរដ�បាលជលផលៃន្រកសួងកសិកម� 
រកុ� ្របមាញ់និងេនសទនិងវទិ្យោស� ន�សវ្រជាវនិងអភិវឌ្ឍន៍របស់រ្របេទសបារងំែដលេហកត់ថាIRD។
អង�ករេនះបានែចកចយនូវអហរបំប៉នេទដល់កុមារនិងមា� យេដម្ីបករពរ និង 
ព្យោបាលជំងឺកង�ះអហររបូត�ម�ក្រមិតមធ្យម។ ពួកេយងមានចំណាប់អរម�ណ៏ចង់ដឹងថា 
អហរមួយណាែដលល�បំផុតក�ុងករជំរុញឲមានសុខភាព និងករលូតលស់ល�។ 
េហតុេនះេហយបានជាេយងកំពុងេធ�ករសិក្សោេនតំបន់ជាយ្រក�ងភ�ំេពញ។ករសិក្សោេនះនឹង្រត�វបានអនុវត�េដយអ�ក�សី Bindi 
Borg មកពីសកលវទិ្យោល័យ Queensland អ�ក�សី Sok Daream មកពីសកលវទិ្យោល័យ Copenhagen និង Dr Frank Wieringa 
មកពីវទិ្យោស� ន�សវ្រជាវនិងអភិវឌ្ឍន៍របស់រ្របេទសបារងំែដលេហកត់ថា IRD  
Hello, my name is _________________________ and I work with the Num Trey Project.  The Num Trey Project is supported by UNICEF, National Nutrition Program of Ministry of Health, Department of Fisheries Post-
Harvest Technologies and Quality Control, Fisheries Administration of the Ministry of Agriculture, Forestry and Fisheries, and IRD. These agencies distribute supplementary food to children and mothers to prevent and 
treat moderate malnutrition.  We are interested in knowing which food is best at promoting good health and growth.  Therefore, we are conducting a study in peri-urban Phnom Penh.  The study will be conducted by Ms 
Bindi Borg from the University of Queensland, Ms Sok Daream from the University of Copenhagen, and Dr Frank Wieringa from IRD. 
េយងចង់ដឹងថាេតអហរមួយណាែដលជួយឱ្យកុមារធំលូតលស់និងមានសុខភាពល�។ 
េយងចង់េ្រប�បេធៀបអហរទំងេនះេទនឹងរបបអហរធម�តក�ុងរយៈេពល 6 ែខខងមុខេនះ។ េយងនឹងសំុឱ្យកូនរបស់អ�ក 
បរេិភាគ របបអហរធម�តឲបានេទៀងទត់ដូចជា បបរ  និងអហរ្រគ�សរ។  េយងនឹង្របមូលពត័មានេនេដម្រគា, អំឡុងេពល 
និង ចុងប�� ប់ៃនករសិក្សោ�សវ្រជាវ ។ 
We want to know which foods help children to grow and be healthy.  We would like to compare these foods to a regular diet over the next 6 months.  We would ask that your child eats its regular diet, such as borbor and 
family foods.  We will gather information at the beginning, end and during the study.   
េយងនឹងេធ�ករ្របមូលព៌តមានអំពីកូនរបស់អ�កនិង ខ�ួនអ�កផា� ល់ ដូចជាសុខភាព កម�ស់ ទំងន់ និងរបបអហរ ។ 
េនេពលចប់េផ�មនិងេនចុងប�� ប់ៃនករសិក្សោេនះ (6 ែខេ្រកយមក), 
េយងនឹង្រត�វបូមយកឈមកូនរបស់អ�កជាមួយនឹងម�ុលមួយ េដម្ីបឲេយងអចដឹងពីក្រមិតៃនវតីមីននិងសរធាតុែរ ៉
(ដូចជាជាតិែដក, វតីមីន A និងជាតិស័ង�សី) េនក�ុងរងកយរបស់គាត់ ។ េ្រកមករចូលរមួរបស់េលកអ�ក អ�កនិងកូនរបស់អ�ក 
នឹងជួយពួកេយងេដម្ីបេធ�ឱ្យមានភាពល�្របេសរេឡង និងេធ�ឲអហរបែន�មមានតៃម�េថាកជាងមុន 
ែដលអចជួយជំរុញឲកុមារកម�ុជាទទួលបានជីវជាតិ្រគប់្រគាន់និងមានសុខភាពល�្របេសរជាងមុន។ 
វគា� នហនិភ័យអ�ីទំងអស់េនក�ុងករចូលរមួក�ុងករសិក្សោេនះ។ េបេទះបីជាករបូមឈមអចនឹងមាន ករឈឺចប់បន�ិចក�ី 
្រពមទំងអចបង�ឱ្យមានស� មជំាមួយចំនួន វ្រគាន់ែតជាអករៈបេណា� ះអសន�បំុ៉េណា� ះ។  
We will collect information about your child’s and your health, height, weight and diet.  At the beginning of the study and at the end of the study (6 months later), we will take your child’s blood with a needle , so that we 
can know the levels of vitamins and minerals (such as iron, vitamin A, and zinc) in his/her body.  Through your participation, you and your child will be helping us to make better and cheaper supplementary food that can 
help Cambodian children to be better nourished and healthier. 
There are no risks to this study, although taking blood may be a little painful temporarily and may cause some bruising.   
ព៌តមានែដល្របមូលបានទំងអស់នឹង្រត�វទុកជាករសមា� ត់និងេដយែឡកពីគា� ។ 
អ�កនិងកូនរបស់អ�កនឹងមិនអច្រត�វបានេគកំណត់អត�ស�� ណបានេឡយ។ 
េយងនឹង្រតលប់មកកែន�ងសិក្សោេនះម�ងេទៀតេដម្ីបែចកចយនូវលទ�ផលជាមួយអ�កេនេពលែដលលទ�ផលេនាះបានេបាះពុម�េច
ទ្រមង់ៃនករយល់្រពមនិងព៌តមានចូលរមួេនះគឺស្រមាប់អ�កែថទំ កុមារែដលមានអយុ៨ េទ
៩ែខែដល្រតវបានអេ�ញឲ្យចលរមកងករសិក្សោេលភាពទទលយកបាននវអហរបំប៉នែដលអចបរេិភាគបានភាមេដយមិន
Appendix 5.2 Form 2A : Participant information and consent, control &
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ញេហយ។ លទ�ផលៃនករសិក្សោនឹង្រត�វេបាះពុម�និងែចកចយជាមួយអ�កណាែដលចង់ជួយមា� យនិងទរកឲ្យមាន 
ស� នភាពអហររបូត�ម�ល�និងសុខភាពល�។ 
All information collected will be kept private and confidential.  You and your child will not be identifiable.  We will return to this testing site to share the results with you when they are available.  The results of the study 
will be published and shared with others who want to help children to be better nourished and healthier. 
ករចូលរមួរបស់អ�កគឺជាជំេរ សរបស់អ�កទំង�ស�ង។ ថាេតអ�កេ្រជសេរ សចូលរមួ ឬក៏អត់ 
វនឹងមិនប៉ះប៉ាល់ដល់ករទទួលេសវកម�េផ្សងៗរបស់អ�កនិង្រគ�សររបស់អ�កេទ ពី មណ� លសុខភាព 
អ�កស�័្រគចិត�្រទ្រទង់សុខភាពភូមិ ឬស� ប័ន រដ�េផ្សងៗ។ េបេទះជាយាងណាក៏េដយ 
ក៏េយងសង្ឹឃមថាអ�កនឹងបន�ចូលរមួជាមួយករសិក្សោរបស់េយងសំរប់រយៈេពល៦ែខេពញ។ 
អ�កអចប�្ឈប់ករចូលរមួរបស់អ�កេពលណាក៏បានក�ុងកំឡុងេពលសិក្សោេនះ។ េយងដឹងថាេពលេវលរបស់អ�កមានតំៃល 
ដូេច�ះេហយេយងនឹងផ�ល់ជូននូវថវកិរសំរប់េធ�ដំេណ រ 
ចំនួន៤០០០េរៀលនិងអំេណាយតិចតួចជាេរៀងរល់េពលែដលអ�កអេ�� ញមកកែន�ងសិក្សោេនះ។ 
Your participation is entirely your choice.  Whether you choose to participate or not, it will not affect other services you and your family receive from the health centre, village health support group, or other government 
authorities.  Although we hope you will continue with the study for the full 6 months, you can stop participating at any time during the study.  We realize that your participation is valuable, so you will receive $1 for 
transport and a small gift each time you come.   
ករសិក្សោេនះ្រត�វបានអនុម័ត និងពិនិត្យេឡងវញិ�សបតម្រកមសិលធម៍វជិា� ជីវៈេដយសកលវទិ្យោល័យៃនរដ� Queensland 
ក�ុង្របេទសអូ�ស� លីនិងគណៈកមា� ធិករ្រកមសិលធម៍ជាតិ ស្រមាប់ករ�សវ្រជាវសុខភាពៃន្រកសួងសុខភិបាលកម�ុជា។ 
្របសិនេបអ�កមានសំណួរណាមួយឬ 
អ�កចង់ពិភាក្សោអំពីករចូលរួមរបស់អ�កេនក�ុងករសិក្សោេនះអ�កអចនិយាយេទកន់បុគ�លិកគេ្រមាងេនះឬអ�កអចទូរសព�័េទក
ន់េលខេនះ: ០១១៥៦៤៨០១ 
This study has been approved in ethical reviews by The University of Queensland in Australia and the National Ethics Committee for Health Research of the Cambodian Ministry of Health.  If 
you have any questions or if you would like to discuss your participation in this study, you can talk to the project staff, or you can call this number: 011 564 801 
េតអ�កយល់ពីអ�ីែដលខ�ុំបាន្របាប់អ�កេទ? េតអ�កមានសំណួរណាមួយេទ? េតអ�កចង់េទចូលរមួក�ុងករសិក្សោេនះេទ? 
្របសិនេបអ�កបានយល់្រពមស្រមាប់កូនរបស់អ�កេដម្ីបចូលរមួក�ុងករសិក្សោេនះ, 
សូមចុះហត�េលខឬផ�ិតេមៃដក�ុង្របអប់ខងេ្រកមេនះ។ 
Do you understand what I have told you?  Do you have any questions?  Would you like to participate in the study?  If you agree for your child to participate in the study, please sign or fingerprint in the box below.  
eQµaHkumar  Name of the child  (CHNAME2) 
េឈ� ះអ�កែថទំកុមារ Name of caregiver (CGNAME2)
ហត�េលខ ឬស� មេមៃដរបស់អ�កែថទំកុមារ 
Signature or thumbprint of the caregiver (CGSIGNED)  
េលខកំណត់អត�ស�� ណកុមារ   Child´s ID (CHID2) 
ខ�ុំបានអនពក្យយល់្រពមទំងអស់ដល់អ�កែថកុមារ។  I have read the consent form in its entirety to the caregiver of the child.  
េឈ� ះអ�ក្របមូលទិន�ន័យ Name of data collector 
ហត�េលខអ�ក្របមូលទិន�ន័យ Signature of data collector
(IVSIGNED) 
kalbriecäTRbmUlTinñn½y  Date of data collection 
(DATE2) 
ៃថ� Day ែខ Month ឆា� ំ  Year
2 0 1 6
231
េឈា� ះអ�កសមា� សន៍ Name of interviewer (IVNAME2):________________ GñkRbmUlTinñn½y (Interviewer ID, IVID2):  (Form ID, FORMID) 
kumar   (Child´s ID, CHID2):  (Child´s BioID, CHBIOID):
Form 2A: Efficacy trial –participant information and consent sheet, control group  3/4 
0 2 
េបសិនជាអ�កែថរេក�ង/អណាព្យោបាលមិនយល់្រពមចូលរមួេទ សូមនិយាយថា៖ អរគុណ ស្រមាប់េពលេវលរបស់អ�ក។ 
អ�កអច្រតលប់េទផ�ះបាន។ If the caregiver does not agree to participate, say:  Thank you for your time.  You are free to leave now.  
េបសិនជាអ�កែថរទំេក�ង/អណាព្យោបាលយល់្រពមចូលរួម ្របគល់ពក្យយល់្រពមមួយច្បោប់េទគាត់។ 
គូសរង�ង់េលេលខទូរសព�័េនេល្រកដស់ រចួ្របាប់គាត់ថា ព័តមានេនះគឺស្រមាប់អ�ក។ ្របសិនេបអ�កចង់ដឹងព័តមានបែន�ម, 
េនាះអ�កអចទូរសព�័មកកន់េលខេនះបាន(០១១៥៦៤៨០១)។  
If the caregiver agrees to participate, tear off and leave the next page with the caregiver.  Circle the telephone number on the page.  Say:  This information is for you.  If you want more 
information, you can call this number, 011 564 801.   
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្របគល់ទំព័រេនះេទអ�កចូលរួម GIVE THIS PAGE TO PARTICIPANT 
ភាពទទួលយកបានៃនឣ‍ហារបំប៉នែដលដ‌ក់ប���លនូវមី្រក�សារជ‌តិេ្រចើននិងសំបូរលីពីតស្រមាប់កុមារេ្រកាមឣ‍យុ២ឆា� ំក��ង្របេទសកម��ជ‌ 
Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two Years in Cambodia 
្របាប់េទអណាព្យោបាល៖ 
Tell caregiver: 
អ�កបានយល់្រពមចូលរមួក�ុងករសិក្សោនូវករទទួលយកបានៃនអហរបំប៉នែដលអចញំុាបានែតម�ងេដយមិនបាច់ចម�ិនេហយផ
លិតក�ុង�ស�ក។ សូមអេ�� ញមកជាមួយកូនរបស់អ�កេដយយកពក្យយល់្រពមេនះមកជាមួយ 
េហយសូមយកប័ណ�េលឿងឬសំបុ្រតកំេណ តមកជាមួយអ�កផង ។ 
You have agreed for you and your child to participate in an acceptability trial of a locally produced ready-to-use-supplementary food.  Please come with your child.  Please bring this paper 
and your child’s yellow card or birth certificate each time. 
ព៌តមានទំងអស់ែដលបាន្របមូលនឹង្រត�វរក្សោេដយសមា� ត់។ វនឹងមិនមានហនិភ័យអ�ីទំងអស់។ 
All information collected will be kept private and confidential.  There are no risks to this study.  
ករចូលរមួរបស់អ�កគឺជាជំេរ សរបស់អ�កទំង�ស�ង។ 
េយងសង្ឃឹមថាអ�កនឹងបន�ចូលរមួជាមួយករសិក្សោរបស់េយងសំរប់រយៈេពល៦ែខេពញ បុ៉ែន� 
អ�កអចប�្ឈប់ករចូលរមួរបស់អ�កេពលណាក៏បានក�ុងកំឡុងេពលសិក្សោេនះ។ 
េយងដឹងថាេពលេវលរបស់អ�កមានតំៃល ដូេច�ះេហយអ�កនឹងទទួលបានអំេណាយ្របសិនេបអ�កចូលរមួ 
ក�ុងរយះេពល៦ែខេពញ។ មិនែតបុ៉េណា� ះ េយងនឹងផ�ល់ជូននូវថវកិរសំរប់េធ�ដំេណ រ 
ចំនួន៤០០០េរៀលនិងអំេណាយតិចតួចជាេរៀងរល់េពលែដលអ�កអេ�� ញមកកែន�ងសិក្សោេនះ។ 
Your participation is your choice.  We hope you will continue with the study for the full 6 months, but you are free to stop participating at any time.  We realize that your time is valuable, so 
you will receive a gift for your participation if you complete the full 6 months.  We realize that your participation is valuable, so you will receive $1 for transport and a small gift 
each time you come.   
េបសិនជាអ�កមានសំណួរ ឬេបអ�កចង់ពិភាក្សោអំពីករចូលរមួរបស់អ�កក�ុងករសិក្សោេនះ 
អ�កអចនិយាយេទកន់បុគ�លិករបស់គេ្រមាងេនះ ឬអ�កអចទូរសព�័មក េលខ:០១១ ៥៦៤៨០១ 
If you have any questions or if you would like to discuss your participation in this study, you can talk to the project staff, or you can call this number: 011 564 801.   
eQµaHkumar  
Name of the child  
េឈ� ះអ�កែថទំកុមារ 
Name of caregiver 
ហត�េលខ ឬស� មេមៃដៃនអ�កែថកុមារ 
Signature or thumbprint of caregiver 
េលខកំណត់អត�ស�� ណកុមារ    Child´s ID
ទីកែន�ងផ�ល់អហរ 
Data collection site: 
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ទ្រមង់២B:  ្របសិទ�ភាពនំ្រតីរបស់ការសិក្សោ- ព៏តមានអ�កចូលរមួ និង ពាក្យយល្់រពមចូលរមួ, ្រក�មអន�រ‌គមន ៍
Form 2B:  Efficacy trial - participant information and consent sheet, intervention groups  
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ ។ ខ�ុំបាទ/នាងខ�ុំេធ�ករងរជាមួយគំេរងផលិតនំ្រតី។
គំេរងផលិតនំ្រតីេនះទទួលបានករឧបត�ម�និងគំា្រទេដយអង�ករយូនីេសហ�(UNICEF)
កម�វធីិអហរបូត�ម�ថា� ក់ជាតិៃន្រកសួងសុខភិបាល  
នាយកដ� នបេច�កវទិ្យោែកៃច�និងគុណភាពៃនរដ�បាលជលផលៃន្រកសួងកសិកម� 
រកុ� ្របមាញ់និងេនសទនិងវទិ្យោស� ន�សវ្រជាវនិងអភិវឌ្ឍន៍របស់រ្របេទសបារងំែដលេហកត់ថាIRD។
អង�ករេនះបានែចកចយនូវអហរបំប៉នេទដល់កុមារនិងមា� យេដម្ីបករពរ និង 
ព្យោបាលជំងឺកង�ះអហររបូត�ម�ក្រមិតមធ្យម។ ពួកេយងមានចំណាប់អរម�ណ៏ចង់ដឹងថា 
អហរមួយណាែដលល�បំផុតក�ុងករជំរុញឲមានសុខភាព និងករលូតលស់ល�។ 
េហតុេនះេហយបានជាេយងកំពុងេធ�ករសិក្សោេនតំបន់ជាយ្រក�ងភ�ំេពញ។ករសិក្សោេនះនឹង្រត�វបានអនុវត�េដយអ�ក�សី Bindi 
Borg មកពីសកលវទិ្យោល័យ Queensland អ�ក�សី Sok Daream មកពីសកលវទិ្យោល័យ Copenhagen និង Dr Frank Wieringa 
មកពីវទិ្យោស� ន�សវ្រជាវនិងអភិវឌ្ឍន៍របស់រ្របេទសបារងំែដលេហកត់ថា IRD  
េយងចង់ដឹងថាេតអហរមួយណាែដលជួយឱ្យកុមារធំលូតលស់និងមានសុខភាពល�។ 
េយងចង់េ្រប�បេធៀបអហរទំងេនះេទនឹងរបបអហរធម�តក�ុងរយៈេពល 6 ែខខងមុខេនះ។ 
េយងនឹងផ�ល់ជូនអហរស្រមាប់កូនរបស់អ�ករយៈេពល 6 ែខខងមុខេទៀត។ េយងនឹងសំុឱ្យ កូនរបស់អ�កបរេិភាគអហរេនះ 
បែន�មេទេល របបអហរធម�តរបស់នាង/គាត់។ 
Hello, my name is ____________ and I work with the Num Trey Project.  The Num Trey Project is supported by UNICEF, National Nutrition Program of Ministry of Health, Department of Fisheries Post-Harvest Technologies 
and Quality Control, Fisheries Administration of the Ministry of Agriculture, Forestry and Fisheries, and IRD. These agencies distribute supplementary food to children and mothers to prevent and treat moderate 
malnutrition.  We are interested in knowing which food is best at promoting good health and growth.  Therefore, we are conducting a study in peri-urban Phnom Penh.  The study will be conducted by Ms Bindi Borg from 
the University of Queensland, Ms Sok Daream from the University of Copenhagen, and Dr Frank Wieringa from IRD.  We want to know which foods help children to grow and be healthy.  We would like to compare these 
foods to a regular diet over the next 6 months.  We will provide food for your child for the next 6 months.  We ask that your child eat that food every day in addition to his/her regular diet.   
េយងនឹងេធ�ករ្របមូលព៌តមានអំពីកូនរបស់អ�កនិង ខ�ួនអ�កផា� ល់ ដូចជាសុខភាព កម�ស់ ទំងន់ និងរបបអហរ ។ 
េនេពលចប់េផ�មនិងេនចុងប�� ប់ៃនករសិក្សោេនះ (6 ែខេ្រកយមក), 
េយងនឹង្រត�វបូមយកឈមកូនរបស់អ�កជាមួយនឹងម�ុលមួយ េដម្ីបឲេយងអចដឹងពីក្រមិតៃនវតីមីននិងសរធាតុែរ ៉
(ដូចជាជាតិែដក, វតីមីន A និងជាតិស័ង�សី) េនក�ុងរងកយរបស់គាត់ ។ 
ជាេរៀងរល់ែខេយងនឹងវស់ស�ង់ពីករធំលូតលស់របស់កូនអ�កនិងសួរសំណួរអំពីសុខភាព និង របបអហររបស់គាត់ ។ 
េ្រកមករចូលរមួរបស់េលកអ�ក អ�កនិងកូនរបស់អ�ក នឹងជួយពួកេយងេដម្ីបេធ�ឱ្យមានភាពល�្របេសរេឡង 
និងេធ�ឲអហរបែន�មមានតៃម�េថាកជាងមុន ែដលអចជួយជំរុញឲកុមារកម�ុជាទទួលបានជីវជាតិ្រគប់្រគាន់និងមានសុខភាពល�។ 
វនឹងគា� នេ្រគាះថា� ក់អ�ីទំងអស់ក�ុងករចូលរមួជាមួយករសិក្សោេនះ, េបេទះបីជាករបូមឈមអចនឹងមាន ករឈឺចប់បន�ិចក�ី 
្រពមទំងអចបង�ឱ្យមានស� មជំាមួយចំនួន វ្រគាន់ែតជាអករៈបេណា� ះអសន�បំុ៉េណា� ះ។ 
អហរទំងេនះ្រត�វបានពិេសធន៏ថាមានសុវត�ិភាពនិងេធ�ឲមានសុខភាពល� 
We will collect information about your child’s and your health, height, weight and diet.  At the beginning of the study and at the end of the study (6 months later), we will take your child’s blood with a needle, so that we 
can know the levels of vitamins and minerals (such as iron, vitamin A, and zinc) in his/her body.  Every month, we will measure your child’s growth, and ask questions about his/her health and diet.  Through your 
participation, you and your child will be helping us to make better and cheaper supplementary food that can help Cambodian children to be better nourished and healthier.   
There are no risks to this study, although taking blood may be a little painful temporarily and may cause some bruising.  The food has been tested and is healthy and safe.   
ព៌តមានែដល្របមូលបានទំងអស់នឹង្រត�វទុកជាករសមា� ត់និងេដយែឡកពីគា�  ។ 
អ�កនិងកូនរបស់អ�កនឹងមិនអច្រត�វបានេគកំណត់អតស�� ណបានេឡយ។ 
េយងនឹង្រតលប់មកកែន�ងសិក្សោេនះម�ងេទៀតេដម្បីែចកចយនូវលទ�ផលជាមួយអ�កេនេពលែដលលទ�ផលេនាះបានេបាះពុម�េចញេហ
ទ្រមង់ព៏តមានអ�កចូលរួម និង ពាក្យយល់្រពមចូលរួមេនះគឺស្រមាប់អ�កែថទំាកុមារែដលមានឣ‍យុពី ៨ េ� ៩ែខ
ែដល្រត�វបានអេ��ើញឲ្យចូលរួមក��ងការសិក្សោេលើ្របសិទ�ភាពសាកល្បង របស់ផលិផលក��ង្រស�កឣ‍ចញំ‌បានេដ‌យមិនចំាបាច់េរៀបចំ/ចម�ិនបែន�ម 
This participant information and consent form is for the caregivers of children aged 8-9 months who have been invited to participate in an efficacy trial of a locally produced ready-to-use-supplementary food. 
Appendix 5.2 Form 2B: Participant information and consent, intervention
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kumar   (Child´s ID, CHID):   
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យ។ លទ�ផលៃនករសិក្សោនឹង្រត�វេបាះពុម�និងែចកចយជាមួយអ�កណាែដលចង់ជួយមា� យនិងទរកឲ្យមាន 
ស� នភាពអហររបូត�ម�ល�និងសុខភាពល�។ 
All information collected will be kept private and confidential.  You and your child will not be identifiable.  We will return to this testing site to share the results with you when they are available.  The results of the study 
will be published and shared with others who want to help children to be better nourished and healthier. 
ករចូលរមួរបស់អ�កគឺជាជំេរ សរបស់អ�កទំង�ស�ង។ ថាេតអ�កេ្រជសេរ សចូលរមួ ឬក៏អត់ 
វនឹងមិនប៉ះប៉ាល់ដល់ករទទួលេសវកម�េផ្សងៗរបស់អ�កនិង្រគ�សររបស់អ�កេទ ពី មណ� លសុខភាព 
អ�កស�័្រគចិត�្រទ្រទង់សុខភាពភូមិ ឬស� ប័ន រដ�េផ្សងៗ។ េបេទះជាយាងណាក៏េដយ 
ក៏េយងសង្ឹឃមថាអ�កនឹងបន�ចូលរមួជាមួយករសិក្សោរបស់េយងសំរប់រយៈេពល៦ែខេពញ។ 
អ�កអចប�្ឈប់ករចូលរមួរបស់អ�កេពលណាក៏បានក�ុងកំឡុងេពលសិក្សោេនះ។ េយងដឹងថាេពលេវលរបស់អ�កមានតំៃល 
ដូេច�ះេហយេយងនឹងផ�ល់ជូននូវថវកិរសំរប់េធ�ដំេណ រ 
ចំនួន៤០០០េរៀលនិងអំេណាយតិចតួចជាេរៀងរល់េពលែដលអ�កអេ�� ញមកកែន�ងសិក្សោេនះ។ 
Your participation is entirely your choice.  Whether you choose to participate or not, it will not affect other services you and your family receive from the health centre, village health support group, or other government 
authorities.  Although we hope you will continue with the study for the full 6 months, you can stop participating at any time during the study.  We realize that your participation is valuable, so you will receive $1 for 
transport and a small gift each time you come.   
ករសិក្សោេនះ្រត�វបានអនុម័ត និងពិនិត្យេឡងវញិ�សបតម្រកមសិលធម៍វជិា� ជីវៈេដយសកលវទិ្យោល័យៃនរដ� Queensland 
ក�ុង្របេទសអូ�ស� លីនិងគណៈកមា� ធិករ្រកមសិលធម៍ជាតិ ស្រមាប់ករ�សវ្រជាវសុខភាពៃន្រកសួងសុខភិបាលកម�ុជា។ 
្របសិនេបអ�កមានសំណួរណាមួយឬ 
អ�កចង់ពិភាក្សោអំពីករចូលរួមរបស់អ�កេនក�ុងករសិក្សោេនះអ�កអចនិយាយេទកន់បុគ�លិកគេ្រមាងេនះឬអ�កអចទូរសព�័េទក
ន់េលខេនះ: ០១១ ៥៦៤ ៨០១ 
This study has been approved in ethical reviews by The University of Queensland in Australia and the National Ethics Committee for Health Research of the Cambodian Ministry of Health.  If you have any questions or if 
you would like to discuss your participation in this study, you can talk to the project staff, or you can call this number: 011 564 801 
េតអ�កយល់ពីអ�ីែដលខ�ុំបាន្របាប់អ�កឬេទ? េតអ�កមានសំណួរឬេទ? េតអ�កចង់ចូលរមួក�ុងករសិក្សោេនះឬេទ។ 
េបសិនជាអ�កយល់្រពមឲកូនរបស់អ�កចូលរមួជាមួយ ករសិក្សោេនះ សូមចុះហត�េលខ ឬផ�ិតេមៃដក�ុង្របអប់ខងេ្រកមេនះ។ 
Do you understand what I have told you?  Do you have any questions?  Would you like to participate in the study?  If you agree for your child to participate in the study, please sign or fingerprint in the box below.  
េឈ� ះកុមារ Name of the child
េឈ� ះអ�កែថទំកុមារ  Name of caregiver 
ហត�េលខ ឬស� មេមៃដរបស់អ�កែថកុមារ Signature or thumbprint of caregiver
េលខកំណត់អត�ស�� ណកុមារ   Child´s IDENTIFY 
ខ�ុំបានអនពក្យយល់្រពមទំងអស់ដល់អ�កែថទំកុមារ។ I have read the consent form in its entirety to the caregiver of the child.  
 
េឈ� ះអ�ក្របមូលទិន�ន័យ  Name of the data collector
ហត�េលខអ�ក្របមូលទិន�ន័យ  Signature of data collector 
kalbriecäTRbmUlTinñn½y  
Date of data collection  
ៃថ� Day ែខ Month ឆា� ំ  Year
2 0 1 6
235
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េបសិនជាអ�កែថរទំេក�ង/អណាព្យោបាលមិនយល់្រពមចូលរមួេទ សូមនិយាយថា៖ អរគុណ ស្រមាប់េពលេវលរបស់អ�ក។ 
អ�កអច្រតលប់េទផ�ះបាន។  If the caregiver does not agree to participate, say:  Thank you for your time.  You are free to leave now.  
េបសិនជាអ�កែថរទំេក�ង/អណាព្យោបាលយល់្រពមចូលរួម ្របគល់ពក្យយល់្រពមមួយច្បោប់េទគាត់។ 
គូសរង�ង់េលេលខទូរសព�័េនេល្រកដស់ រចួ្របាប់គាត់ថា ព័តមានេនះគឺស្រមាប់អ�ក។ ្របសិនេបអ�កចង់ដឹងព័តមានបែន�ម, 
េនាះអ�កអចទូរសព�័មកកន់េលខេនះបាន(០១១ ៥៦៤ ៨០១)  ្របគល់ពក្យយល់្រពមមួយច្បោប់េទឲអ�កែថរទំេក�ង។ 
គូសរង�ង់េលេលខទូរសព�័េនេល្រកដស់ េដម្ីបធានាថាពួកគាត់បានយល់ច្បោស់ ថាពួកគាត់អចទូរសព�័មកបានសំរប់ 
ព័តមានបែន�ម ។ 
If the caregiver agrees to participate, tear off and leave the next page with the caregiver.  Circle the telephone # on the page.  Say:  This information is for you.  If you want more information, you can call this number, 011 
564 801.  Leave a copy of the consent form with the caregiver.  Circle the telephone number on the page to ensure that they understand they can call for more information.  
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kumar   (Child´s ID, CHID):   
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្របគលទ់ំពរ័េនះេ�អ�កចលូរួម GIVE THIS PAGE TO PARTICIPANT 
ភាពទទួលយកបានៃនឣ‍ហារបំប៉នែដលដ‌ក់ប���លនូវមី្រក�សារជ‌តិេ្រចើននិងសំបូរលីពីតស្រមាប់កុមារេ្រកាមឣ‍យុ២ឆា� ំក��ង្របេទសកម��ជ‌ 
Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two Years in Cambodia 
្របាប់េ�អ�កែថទំាកុមារ៖ 
Tell caregiver: 
អ�កបាន្រពមេ្រព�ង ស្រមាប់អ�កនិងកូនរបស់អ�កក�ុងករចូលរមួក�ុងករសិក្សោមួយ 
ករទទួលយកបានៃនអហរបំប៉នែដលអចញុាបំានែតម�ងេដយមិនបាច់ចម�ិនេហយផលិតក�ុង�ស�ក។ 
សូមមកជាមួយនឹងកូនរបស់អ�ក។ 
សូមយក្រកដសេនះនិងកតេលឿងឬសំបុ្រតកំេណ តកូនរបស់អ�កមកជាមួយរល់េពល។ 
You have agreed for you and your child to participate in an acceptability trial of a locally produced ready-to-use-supplementary food.  Please come with your child.  
Please bring this paper and your child’s yellow card or birth certificate each time. 
ព៌តមានទំងអស់ែដលបាន្របមូលនឹង្រត�វរក្សោទុកេដយែឡក និង រក្សោសមា� ត់។ 
វនឹងមិនមានហនិភ័យអ�ីទំងអស់។ 
All information collected will be kept private and confidential.  There are no risks to this study.  
ករចូលរមួរបស់អ�កគឺជាជំេរ សរបស់អ�កទំង�ស�ង។ 
េយងសង្ឹឃមថាអ�កនឹងបន�ចូលរមួជាមួយករសិក្សោរបស់េយងសំរប់រយៈេពល៦ែខេពញ បុ៉ែន� 
អ�កអចប�្ឈប់ករចូលរមួរបស់អ�កេពលណាក៏បានក�ុងកំឡុងេពលសិក្សោេនះ។ 
េយងដឹងថាេពលេវលរបស់អ�កមានតំៃល 
ដូេច�ះេហយអ�កនឹងទទួលបានអំេណាយមួយស្រមាប់ករចូលរមួរបស់អ�ក 
េនចុងប�� ប់ៃនករសិក្សោ៦ែខេ្រកយ។ មិនែតបុ៉េណា� ះ េយងនឹងផ�ល់ជូននូវថវកិរសំរប់េធ�ដំេណ រ 
ចំនួន៤០០០េរៀលនិងអំេណាយតិចតួចជាេរៀងរល់េពលែដលអ�កអេ�� ញមកកែន�ងសិក្សោេនះ។ 
Your participation is your choice.  We hope you will continue with the study for the full 6 months, but you are free to stop participating at any time.  We realize that 
your time is valuable, so you will receive a gift for your participation if you complete the full 6 months.  We realize that your participation is valuable, so you will 
receive $1 for transport and a small gift each time you come.   
េបសិនជាអ�កមានសំណួរ ឬេបអ�កចង់ពិភាក្សោអំពីករចូលរមួរបស់អ�កក�ុងករសិក្សោេនះ 
អ�កអចនិយាយេទកន់បុគ�លិករបស់គេ្រមាងេនះ ឬអ�កអចទូរសព�័មក េលខ: ០១១ ៥៦៤ ៨០១ 
If you have any questions or if you would like to discuss your participation in this study, you can talk to the project staff, or you can call this number: 011 564 801.   
េឈ� ះកុមារ Name of the child
េឈ� ះអ�កែថទំកុមារ Name of the caregiver
ហត�េលខ ឬស� មេមៃដៃនអ�កែថទំកុមារ 
Signature or thumbprint of the caregiver  
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kumar   (Child´s ID, CHID):   
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េលខកំណត់អត�ស�� ណកុមារ    
Child´s ID 
ទីកែន�ងផ�ល់អហរ 
Data collection site: 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):
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0 3 
ទ្រមង់ទី៣៖ ្របសិទ�ភាពន្ំរតីរបស់ការសិក្សោ, ទ្រមង់ប��ីសំនួរ្របមូលទិន�ន័យមូលដ‌� ន – ្របជ‌សា�ស� 
Form 3A:  Efficacy trial, baseline data collection form - Demographics 
េឈា� ះអេថរ      Variable name លខកូដ
ខណ�  Khan (KHAN) ខណ�  ឬស្សីែកវ Khan Russey Keo   1 េ្រជ‌យចង‌�  Khan Chhroy ChhangVa   2 
សង‌� ត់
Sangkat 
(SANGKA
T) 
ទួលសែង�Tuol Sangkae   1 ្រចំាងចំេរះChrang Chamreh 2   5 ស.ក េ្រជ‌យចង‌� រ Chhroy ChhangVa   9 
ឬស្សីែកវRuessei Kaev   2 ស.ក សា� យប៉ាក Svay Pak   6 ស.ក ែ្រពកតាេសក Prek Tasek   10 
ស.ក ្រចំាងចំេរះ ១Chhrang Chamres 1   3 ស.ក ែ្រពកលាប Prek Leap   7 ស.ក េកាះដ‌ច ់Kos Dach   11 
ស.ក គីឡ�ែម៉្រត ៦ Km 6   4 ស.ក បាក់ែខង Bak Kheng   8 េផ្សងៗ(ពពិ៌ណន‌) Other      12
PUmi 
Village 
(VILLAGE
) 
Chhrang Chamres 1 Phum 1 ស.ក 
្រចំាងចំេរះ ១ 1   1 Tuol Koukទួលេគាក   16 Prek Leap ែ្រពកេលៀប   31 
Chhrang Chamres 1 Phum 2 ស.ក 
្រចំាងចំេរះ ១ 2   2 Mittapheap មិត�ភាព   17 Khean Khleang េគៀនឃា� ំង   32 
Chhrang Chamres 1 Phum 3 ស.ក 
្រចំាងចំេរះ ១ 3   3 Lor KomBor ឡកំេបា   18 Bak Kheng Le បាក់ែខងេលើ   33 
Chhrang Chamres 1 Phum 4 ស.ក 
្រចំាងចំេរះ ១ 4   4 Prek Tasek ែ្រពកតាេសក   19 Kdey Chhas ក�ីចាស់   34 
Chroy Changva Phum 1 េ្រជ‌យចង‌� រ  1   5 Prek Reang ែ្រពករ‌ំង  20 Chhom Bok Meas ចំបក់មាស   35 
Chroy Changva Phum 2 េ្រជ‌យចង‌� រ  2   6 Prek Takorng ែ្រពកតាគង់  21 Chhong Kos village ភូមិ ចុងេកាះ   36 
Chroy Changva Phum 3  េ្រជ‌យចង‌� រ  3
  
7 Doeum Kor េដើមគ   22 Lavea village ភូមិ លា�    37 
Boeng Chhukបឹងឈូក   8 Prek Tarath ែ្រពកតារ�ត�  23 Kabal Kos village ភូមិ ក្បោលេកាះ   38 
Spean Khposសា� នខ�ស់   9 Samki សាមគ�ី   24 Kos Dach  village ភូមិ េកាះដ‌ច ់  39 
Kroal Koេ្រកាលេគា  10 Kleang Sangឃា� ំងសំាង   25 Roneah ភូមិ រនះ   40 
Phum Korភូមិ ក   11 Boeng Salangបឹងសាឡ‍ង   26 Toul sangke ផ្សោរតូច   42 
Phum Khor 1ភូមិ ខ១   12 Doeum Kor េដើមគ   27 Svay Pak សា� យប៉ាក   43 
Phum Khor 2 ភូមិ ខ២   13 Khean Khleang  េគៀនឃា� ំង   28 Lu លូ   44 
Phum Khuor ឃ   14 Bak Kheng បាក់ែខង   29 េផ្សងៗ(ពពិ៌ណន‌) Other      41
Phsar Touch ផ្សោរតូច   15 KhaTor ខ�រ   30 
ទីកែន�ងផ�ល់ឣ‍ហារ
Data 
collectio
n site 
(SITE) 
Phsar Touchផ្សោរតូច   1 Kor & Khuor ភូមិ ក & ឃ   11 
Prek Leap/Khean Khleang ែ្រពកេលៀប &
េគៀនឃា� ំង   21 
Tuol Kouk 1ទួលេគាក 1   2 Boeng Salangបឹងសាឡ‍ង   12 Sangkat Bak Kheng ស.ក បាក់ែខង   22 
Tuol Kouk 2ទួលេគាក 2   3 Boeng Chhuk &Spean Khpos
បឹងឈូក & សា� នខ�ស់   13 
Chhong Kos/Roneah/Kos Dach
ភូមិ ចុងេកាះ &  ភូមិ េកាះដ‌ច់ &  ភមូិ រនះ  23 
Mittapheap មិត�ភាព   4 Lor KomBor ឡកំេបា   14 Kleang Sangឃា� ំងសំាង   24 
Samki សាមគ�ី   5 
Sangkat Prek Tasek  ស.ក 
ែ្រពកតាេសក  15 Boeng Chhukបឹងឈូក   26 
Doeum Kor/Khean Khleang េដើមគ &
េគៀនឃា� ំង   6 
Chroy Changva Phum 1 េ្រជ‌យចង‌� រ
 
16 Toul sangke ផ្សោរតូច   27 
Chhrang Chamres 1 Phum 1&2 ស.ក 
្រចំាងចំេរះ ១ 1&2   7 
Lavea/ Kabal Kos ភូមិ លា�  & ភូមិ ក្បោលេកាះ
  
17 Svay Pak សា� យប៉ាក   28 
Chhrang Chamres 1 Phum 3&4ស.ក 
្រចំាងចំេរះ ១ 3&4   8 
Chroy Changva Phum 2 េ្រជ‌យចង‌� រ
2   18 
Lu លូ   29 
Kroal Koេ្រកាលេគា  9 Chroy Changva Phum 3  េ្រជ‌យចង‌� រ
3   
19 េផ្សងៗ(ពពិ៌ណន‌) Other      25 
Khor 1& Khor 2 ភូមិ ខ១& ភមូិ ខ២   10 Bak Kheng/KhaTor បាក់ែខង & ខ�រ   20 __________________________________ 
Appendix 5.3 Form 3:  Baseline questionnaire 
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kumar   (Child´s ID, CHID):
Form 3: Demographics 2/3 
0 3 
2 0 1 6 
2 0 1 6 
2 0 1 6 
kalbriecäTRbmUlTinñn½y  
Date of data collection (DATE) 
ៃថ� Day ែខ Month  ឆា� ំ  
Year           
ការ្របមូលទិន�ន័យបានទំាងអស់ Data collection completed (COMPLETE) េទNo   1 
បាទ/ចាស  Yes   2 
កលបរេិច�ទៃនករពិនិត្យរបស់អ�កដឹកនំា្រក�ម 
Date checked by team leader (CHEKDATE) 
ៃថ� Day ែខ Month ឆា� ំ  Year
កាលបរ�េច�ទពិនិត្យេដ‌យអ�ក្រគប់្រគងក��ងការ�យ‌ល័យ
Date checked by office supervisor (OFFDATE) 
ៃថ� Day ែខ Month ឆា� ំ  Year
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ 
Data entry person 1 name (ENTERER1) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី១ Data entry person 1 name  
កលបរេិច�ទប��ូ លទិន�ន័យទី១ 
Date entered (ENTDATE1) 
ៃថ� Day ែខ Month ឆា� ំ  Year
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ 
Data entry person 2 name (ENTERER2) 
េឈ� ះអ�កប��ូ លទិន�ន័យទី២ Data entry person 2 name  
កលបរេិច�ទប��ូ លទិន�ន័យទី២ 
Date entered (ENTDATE2) 
ៃថ� Day ែខ Month ឆា� ំ  Year
eQµaHkumar  Name of child  (NAMECH) 
eQµaHអ�កេមើលែថកុមារ  Name of caregiver
(NAMECG) 
2 0 1 6 
0 2 0 1 6 
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Form 3: Demographics 3/3 
0 3 
CadMbUg ´sUmsYrGMBIB½t’manTUeTAmYycMnYnGMBIkumar 
(First, I will ask some general questions about the child)  
Variable 
name 
Question  Response Code 
RSHP 1. etIGñkmanTMnak;TMngGVICamYynwgkumarenH?
sUmKUsrgVg;ykcMelIyEtmYy
្របសិនេបើអ�កែថទំាមិនែមនជ‌ (េឈា� ះ) មា� យ, រ�លងេ�សំណួរទ២ី។
្របសិនេបើអ�កែថទំាគឺជ‌ (េឈា� ះ) មា� យ, រ�លងេ�សំណួរទ៣ី ។
What is your relationship to (NAME)? Select ONLY ONE
answer
If the caregiver is not (NAME’S) mother, go to question 2.
If the caregiver is (NAME’S) mother, go to question 3.
មា� យបេង�ើត Biological mother   1 
ជីដូន Grandmother   2 
ឪពុក Father   3 
បង្រសី Sister   4 
bgb¥ÚnRbus Brother   5 
េផ្សងៗ(ពពិ៌ណន‌) Other (describe)       7 
បដិេសធមិនេឆ�ើយ Refused to respond    8 
មិនដឹង Don’t know      9 
MOTHER 2. េតើមា� យ (ៃនេឈា� ះ) េ�ឯណ‌េពលេនះ?
sUmKUsrgVg;ykcMelIyEtmYy
Where is (NAME’S) mother now? Select ONLY ONE
answer
At work in PP   េ�កែន�ងេធ�ើការេ�ក��ងរ‌ជធានីភ�េំពញ   1 
At work outside PP េ�កែន�ងេធ�ើការេ�ខាងេ្រ�រ‌ជធានីភ�ំេពញ   2 
At work outside Cambodia   េ�កែន�ងេធ�ើការេ�េ្រ�្របេទសកម��ជ‌   3 
សា� ប់ Not alive   4 
េផ្សងៗ(ពពិ៌ណន‌) Other (describe)       7 
បដិេសធមិនេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
CAREGVR 3. េតើអ�កជ‌អ�កែថទំា របស់កូនេនះជ‌ប់លាបឬេទ?
sUmKUsrgVg;ykcMelIyEtmYy
Are you the child’s usual caregiver?  Select ONLY ONE
answer
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមិនេឆ�ើយ Refused to respond    8 
មិនដឹង Don’t know      9 
CARE2W 4. etI2s)þah¾cugeRkayenH GñkបានេមើលែថTaMkumarenH b¤eT?
sUmKUsrgVg;ykcMelIyEtmYy
Have you been looking after (NAME) for at least the last
two weeks?) Select ONLY ONE answer
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមិនេឆ�ើយ Refused to respond    8 
មិនដឹង Don’t know      9 
SEX 5. etI kumarenH ePTRbus b¤ ្រសី
Is (name) a male or female?
្រប�ស Male   1 
្រសី Female   2 
ឥឡ�វេនះខ��នំឹងសួរសំណួរមួយចំនួនអពំីអ�ក។ I will now ask some questions about you. 
AGECG 6. េតើអ�កឣ‍យុប៉នុ‌� ន?
How old are you?
Age in years       ឣ‍យុជ‌ឆា� ំ
ETHNICG 7. េតើអ�កកាន់សាសន‌អ�ី?
What religion do you identify with?  (Tick ONLY ONE answer)
្រពះពុទ�  Buddhist   1 
មូស�ីម Muslim    2 
្រគិស�Christian    3 
េផ្សងៗ សូមេរៀបរ‌ប់ Other (describe)     
____________________________________ 
7 
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ទ្រមង់ទី៣៖្របសិទ�ភាពនំ្រតីរបស់ការសិក្សោ, ទ្រមង់ប�� ីរសំនួរ្របមូលទិន�ន័យមូលដ� ន – កំេណ តនិងអ្រតជំងឺ Form 3B:  Efficacy trial, baseline data collection form – birth and morbidity 
្របសិនេបអ�កេមលែថទំកុមារគឺជាមា� យរបស់កុមារ្រត�វនិយាយថា: \LÚv´sUmkt;eQµaHkUnrbs;GñkTaMgGs; TaMgេនrs; TaMgsøab; cab;BIkUnTI 1 eTA  .
្របសិនេបអ�កេមលែថទំកុមារមិនែមនជាមា� យរបស់កុមារ្រត�វនិយាយថា: \LÚv´sUmkt;eQµaH; បងប�ូនរមួមា� យរបស់កុមារេនះTaMgGs;  TaMgេនrs; TaMgsøab; cab;BIkUnTI 1 eTA
kt;eQµaHkUnTaMgGs;kñúgbegÁal 212. កត់្រត កូនេភា� ះ២និងកូនេភា� ះ៣ េនេលជួរេដកដច់េដយែឡក។ (្របសិនេបផ�ល់កំេណ តកូនេ្រចនជាង ៣ េ្របសំណួរបែន�ម) ។ 
If the caregiver is the baby’s mother say: Now I would like to record the names of all your births, whether still alive or not, starting with the first one you had.  If the caregiver is not the baby’s 
mother say:  Now I would like to record the names of all of this child’s siblings from the same mother, whether still alive or not, starting with the first one. Record twins and triplets on separate 
rows. (If there are more than 3 births, use an additional questionnaire).  
BIRTH1 BIRTH2 BIRTH3 BIRTH4 BIRTH5 BIRTH6 BIRTH7 
BIRTH 
កំេណ ត
កូនទី
1. etIkUnTI1¼ kUn 
bnÞab;eQµaH
GVI ?
What name was 
given to your 
first/next baby?  
¬ eQµaH ¦ (NAME) 
2. etI kumarenH
ePT Rbus
b¤Rs 
Was that baby a 
male or female?   
3. etIkUnTaMg 
enHman ePøaH
b¤eT?
Were any of these 
births twins? 
4. e tI ¬eQµaH ¦ ekItExNa
qñaMNa ?  sYreyagrkéf¶xYb
kMeNItrbs ;eKebImincaMEx
sklsYr rkE xqñaMExµr
rYcbMElg .
In what month and year was 
(NAME) born? Probe: When is 
his/her birthday? 
5. etI ¬eQµaH¦ 
enArs; b¤ søab;?
Is (NAME) still alive? 
6. ebIenArs; ³ etI
¬eQµaH¦ rs;enACa
mYyGñk b¤ eT ?
IF ALIVE: Is (NAME) living 
with you? 
7. ebIsøab; ³ etI ¬ eQµaH ¦ søab; enA Gayub:unµan?
ebIsøab;enA Ga yu1qñaM sYreyag³ etI ¬eQµaH ¦ 
søab;enA Gayub:unµa nEx? kt;Rta Ca éf¶ebI Gayut
icC ag1Ex kt;CaEx ebIGayu ticCag 2qñaM kt;CaqñaM 
ebIG ayu cabBI 2qñaMeLIg
IF DEAD: How old was (NAME) when he/she died? IF '1 
YR', PROBE: How many months old was (NAME)? 
Record days if less than 1 month; months if less than 
two years; or years. 
01 
១
្រប�ស Male   1
្រសី Female   2 
មា� ក់; Single    1  
eRcInnak;; Multiple    
2 ែខ Month ឆា�  ំ Year
សា� បD់ead   0 
 8
េ�រស់Alive   1
េទ   No   0 
បាទ/ចាស  Yes   1
    éf  Days               ¶       Ex Months         
qñaM Years 
02 
២
្រប�ស Male   1
្រសី Female   2 
មា� ក់; Single    1  
eRcInnak;; Multiple    
2 
ែខ Month ឆា� ំ  Year
សា� បD់ead   0 
 8
េ�រស់Alive   1
េទ   No   0 
បាទ/ចាស  Yes   1
    éf  Days               ¶       Ex Months         
qñaM Years 
03 
៣
្រប�ស Male   1
្រសី Female   2 
មា� ក់; Single    1  
eRcInnak;; Multiple    
2 
ែខ Month ឆា� ំ  Year
សា� បD់ead   0 
 8
េ�រស់Alive   1
េទ   No   0 
បាទ/ចាស  Yes   1
    éf  Days              ¶       Ex Months         
qñaM Years 
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BIRTH8 8. etI\LÚvenHGñkmanépÞeBaHb¤eT? (ឬមា� យរបស់ទារកេនះ
្របសិនេបើអ�កេឆ�ើយតបគមឺិនែមនជ‌មា� យ)
្របសិនេបើetIGñkmanépÞeBaHb:unµanExehIy ?
kt;RtacMnYnExeBjelj.
Are you (or NAME’S mother, if respondant is not the
mother) pregnant now?  If yes, how many months
pregnant are you? Record the number of completed
months.
េទ   No   0 
បាទ/ចាស   Yes  
Ex  Months 
1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
BIRTH9 9. etIGñkNa)anCYybegáItkUn ¬eQµaH¦?
Who assisted with the delivery of (NAME)?
buKÁlikeBTü Health personnel 
evC¢bNÐit¼RKUeBTümFüm Doctor/medical assistant   1 
qµb Midwife   2 
Kilanub,dæak Nurse   3 
buKÁlepSgeTot Other person 
qµbbUraN Traditional birth attendant   4 
jatisNþan¼mitþP½k Relative/friend   5 
epSgeTot Other (specify)   
______________________________ 
6 
KµanGñkNaeT No one assisted   10 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
BIRTH10 10. េតើ(កូនេឈា� ះេនះ) េកើត្រគប់ែខឬេទ? (៣ សបា� ហ៍មុនឬ 2 សបា� ហ៍បន‌� ប់ពេីពលកំណត់្រគប់ែខ) ឆាប់េពកឬយឺតេពក?
Was (NAME THIS CHILD) born on time (3 weeks before or
2 weeks after the due date), too early, or too late?
្រគប់ែខOn time   0 
ឆាប់Early   1 
យឺតLate   2 
េតើទារកេកើតេ�ឣ‍យុប៉ុន‌� នែខ? At how many months/days was (NAME) 
born? 
3 
 Ex Months                  éf  Days           
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
BIRTH11 11. etI ¬eQµaH¦ ekItedayvHkat; mann½yfa
eK)anvHeBaHrbs;GñkedIm,IykkUnb¤ ?
Was (NAME) delivered by caesarean, that is, did they cut
your belly open to take the baby out?
េទ   No   0 
cas+ suMvH Yes, elective   1 
Yes, emergency/medically indicated cas+ RtUvvHbnÞan;  
  
2 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
BIRTH12 12. etI ¬eQµaH¦man)anføågeTenAeBlekIt?
្របសិនេបើគា� ន ឬ បដិេសធ ឬ មិនដងឹរ�លងេ�សំណួរទី 14
Was (NAME) weighed at birth?
If No, Refused, Don’t know skip to question 14
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
BIRTH13 13. etI ¬eQµaH¦manTMgn;b:unµan eBlekIt?
kt;RtaTMgn;CaKILÚRkamBIb½NÑ suxPaBebIman
្របសិនអត់b½NÑ សុខភាព កំណត់្រតាទម�ន់ជ‌គីឡ�្រកាមពកីារចងចំា។
How much did (NAME) weigh? Record weight in
kilograms from health card, if available.  If health card
not available, record weight in kilograms from recall.
KILÚRkamBIb½NÑ KG 
from card 
KILÚRkamBIkarcaM 
KG from recall  
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
IFA1 14. មុនeBlmanépÞeBaHenH etIGñk)anTTYl ឬ បាន TijfañM
្រគាបC់atiEdk Edrb¤eT?¤ បង‌� ញរូបភាពថ‌� ំជ‌តិែដក
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
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េបើអត់ សូមរ�លងេ�សំនួរទី16
Before this pregnancy with (NAME), were you given or 
did you buy any iron-folate tablets? Show tablets.  If no, 
go to 16 
មិនដឹង   Don’t know      9 
IFA2 15. មុនeBlmanépÞeBaHenH etIGñk)anelbfañMCatiEdk
cMnYnb:unµan្រគាប់?¤
Before the pregnancy with (NAME), how many iron-
folate tablets did you take?
ចំនួន្រគាប់ថ‌� ំ
Number of tablets 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
IFA2 16. kñúgGMLúgeBlmanépÞeBaHenH etIGñk)anTTYl ឬ បាន
TijfañM ្រគាបC់atiEdk Edrb¤eT?¤
េបើអត់ សូមរ�លងេ�សំនួរទី១8
During this pregnancy with (NAME), were you given or
did you buy any iron-folate tablets? Show tablets.  If no,
go to 18.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
IFA4 17. kñúgGMLúgeBlmanépÞeBaHenH
etIGñk)anelbfañMCatiEdk cMnYnb:unµan្រគាប់?¤
During the pregnancy with (NAME), how many iron-
folate tablets did you take?
ចំនួន្រគាប់ថ‌� ំ
Number of tablets 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
IFA5 18. េ្រកាយេពលសំរ‌លកូន (េឈា� ះ)etIGñk)anTTYl ឬ បាន TijfañM ្រគាប់CatiEdk
Edrb¤eT?¤
េបើអត់ សូមរ�លងេ�សំនួរទី20
After (NAME’s) birth, were you given or did you buy any
iron-folate tablets? Show tablets.  If no, go to 20.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
IFA6 19. េ្រកាយេពលសំរ‌លកូន (េឈា� ះ) etIGñk)anelbfañMCatiEdk
cMnYnb:unµan្រគាប់?¤
After (NAME’s) birth, how many iron-folate tablets did
you take?
ចំនួន្រគាប់ថ‌� ំ
Number of tablets 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
DEWORM 20. kñúgGMLúgeBlmanépÞeBaHenHetIGñk)an េលបថ‌� ំទមា� ក់្រព�ន ឬ
ដង��វេពាះេវៀនឬេទ?¤ ឲឧទាហរណ៍
During this pregnancy with (NAME), did you take any
drug for intestinal parasites? Show examples.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
MALARIA
1 
21. kñúgGMLúgeBlmanépÞeBaHenHetIGñkman)aneRbIfñaM
kar
BaCMgWRKuncajEdrb¤eT;?¤
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ23
During this pregnancy with (NAME), During this
pregnancy, did you take any drugs to keep you from
getting malaria?  If no, skip to question 23.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
MALARIA
2 
22. ; etIGñk)aneRbIfñaMGVI ?¤និងេ្របើប៉ុន‌� នដង?
sUmkt;Rtaral;cMelIyែដលបានេរៀបរ‌ប;។ បង‌� ញថ‌� ំ្រគ�នចាញ់។
fñaM eGsPI¼hVg;sIuda SP/FANSIDAR        
cMnYndg Times 
1 
fñaMkøÚrUKIn CHLOROQUINE        
cMnYndg Times 
2 
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What drugs did you take, and how many times? Record 
all mentioned. Show typical antimalarial drugs to 
respondent 
េផ្សងេទៀត ចូរេរៀបរ‌ប ់Other (describe)       cMnYndg Times
_________________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
ILL2W 23. េតើ២សបា� ហ៍ចុងេ្រកាយ េនះ កុមារ(េឈា� ះ)មានឈឺេទ?
(គូសចេម�ើយែតមយួ)
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ26
In the past 2 weeks, has (NAME) been ill? (Tick only one
answer)
If No to this question – jump to question 26
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
ILLRATE2 24. ជ‌គំនិតរបស់អ�ក េតើកុមារ(េឈា� ះ) មានជំងឺធ�ន់ មធ្យម ឬ្រសាល?  េបើសិនជ‌ជំងឺធ�ន់ធ�រ សូមរ�លងេ�សំនរួ25
In your opinion , was (NAME’S) illness serious, moderate
or slight?
If Serious go to question 25.
ជំងឺធ�ន់  Serious       1 
មធ្យម  Moderate    2 
្រសាល Slight    3 
បដិេសធមិនេឆ�ើយ  Refused to respond    8 
មិនដឹង  Don’t know      9 
ILLRATE3 25. េតើអ�កបានយក (េឈា� ះ) េ�ជួប្រគ�េពទ្យឬេទ?
្របសិនេបើបានេ�េវជ�បណ� ិត សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈែដលចង់ចូលរួម។
ប៉ុែន�សូមេទាសេដ‌យអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគាន់ក��ងការចូលរួមេដ‌យសារ(េឈា� ះ)មានជំងឺធ�ន់ធ�រកាលពី
២សបា� ហ៍មុនេនះ ។ មិនយកេហើយប��ប់សំនួរ
Did you take (NAME) to the doctor?  If yes, visited the
doctor – Say: Thank you for your willingness to
participate.  Unfortunately, you and your child are not
eligible to participate because (name) has been seriously
ill in the last 2 weeks.  EXCLUDE AND END
QUESTIONNAIRE
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ  Refused to respond    8 
មិនដឹង  Don’t know      9 
មិនទទួលយកការសិក្សោ  EXCLUDED      99 
FEVER2W 26. េតើកុមារ(េឈា� ះ)មានេ�� ខ��នេទ ក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (NAME) been ill with a fever at any time in the past 2
weeks?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
ARI2W1 27. េតើកុមារ(េឈា� ះ)មានក�កេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយេនះ? េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ៣០
Has (NAME) had an illness with a cough at any time in
the past 2 weeks? If No to this question – jump to
question 30
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
ARI2W2 28. េ�េពលកុមារ(េឈា� ះ)មានជំងឺក�ក េតើេគមានដកដេង�ើមញ‌ប់ជ‌ងធម�តាេដ‌យដង�ក់ ដកដេង�ើយញឹក
ឬមានការពិបាកក��ងការដកដេង�ើមឬេទ?
េបើសិនចេម�ើយេទ សូមរ�លងេ�សំនួរ30
When (NAME) had an illness with a cough, did he/she
breathe faster than usual with short, fast breaths or had
difficulty breathing?). If No to this question – jump to
question30
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
AR2W3 29. មានការដកដេង�ើយញឹក ឬមានការពិបាកក��ងការដកដេង�ើមេដ‌យមានប�� េ�េដើម្រទ�ង ឬមានស�ះេ�្រចមុះ?
Was the fast or difficult breathing due to a problem in
the chest or a blocked nose?)
េដើម្រទ�ងChest only   1 
្រចមុះNose only   2 
ទំាង២Both   3 
េផ្សងេទៀត ចូរេរៀបរ‌ប ់Other (describe)       
_______________________________________ 
7 
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បដិេសធមិនេឆ�ើយ Refused to respond    8 
មិនដឹងDon’t know      9 
DIAR2W1 30. េតើកុមារមានរ‌គេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
ឧ. បេន‌� របង់៣េ�៤ដងក��ងរយៈេពលល២៤េម៉ាង
េបើមាន បន�េ�សំនួរ 31 េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរ32
Has (NAME) had had diarrhoea in the past 2 weeks? i.e.
3 or more loose stools during a 24 hour period.  If Yes –
go to question 31. If No, Refused, Don’t know – go to
question 32
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
DIAR2W2 31. េតើកុមារមានបេន‌� របង់េដ‌យមានឈាមជ‌ប់លាមកេទ?
េបើមាន សូមនិយ‌យថ‌៖ អរគណុស្រមាប់ឆន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ
្រគប់្រគាន់ក��ងការចូលរួម េដ‌យសារកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម
ែដលប�� ក់ថ‌គាត់មានជំងឺធ�ន់ក��ងរយះេពល២សបា� ហ៍មុនេនះ។េយើងឲ្យេយ‌បល់ថ‌អ�កគួរែតេ�ពិនិត្យេ�មណ� លសុខភាព
ឬគ�ីនិក។
េបើេទ បដេិសធ មនិដឹង រ�លងេ�សំនួរ 32
Was there any blood in the stools?  If Yes – Say: Thank
you for your willingness to participate.  Unfortunately,
you and your child are not eligible to participate because
(name) has had blood in their stools, which indicates a
serious illness, in the last 2 weeks.  We suggest that you
visit a health care provider or clinic.  EXCLUDE AND END
QUESTIONNAIRE
If No, Refused, Don’t know – go to question 32
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
មិនទទួលយកការសិក្សោ  EXCLUDED      99 
VOMIT2
W 
32. េតើកុមារមានក��តេទ  រយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (name) vomited in the past 2 weeks?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
APPET2W 33. េតើកុមារ(េឈា� ះ)ញ‌� ំឣ‍ហារជ‌ធម�តា ឬេ្រចើនជ‌ងធម�តា ឬតិចជ‌ងធម�តាេ�ក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (name) been eating normally, more than usual, or
less than usual in the 2 weeks?
ធម�តាNormally       0 
េ្រចើនជ‌ងធម�តាMore than usual        1 
តិចជ‌ងធម�តាLess than usual        2 
បដិេសធមិនេឆ�ើយRefused to respond   8 
មិនដឹងDon’t know      9 
RASH2W 34. េតើកុមារ (េឈា� ះ)មានេឡើងកន��លេលើែស្បកេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (name) had a skin rash in the past 2 weeks?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
SYMPT2
W 
35. េតើកុមារមានេរ‌គស��  ឬជំងឺអ�ីេផ្សងេទៀតែដលខ��មំិនបានសួរក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
េបើមាន សូមប�� ក់
Has (name) had any other sickness or symptoms that I
have not asked about in the past 2 weeks?  If yes - Please 
specify.
េទNo       0 
បាទ/ចាសYes      
េបើសិនជ‌មាន េតើេរ‌គស��  ឬជំងឺអ�ីែដរ If yes, what sickness or symptoms?
______________________________________ 
1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
MEDS2W េតើកុមារ (េឈា� ះ)មានេលបថ‌� អំ�ីេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ? ្របសិនេបើេលប េតើបានេលបថ‌� អំ�ីខ�ះ? 
គូសនូវចេម�យទំងអស់ែដលទទួលបាន ្របសិនេបើេទ សូមរ�លងេ�សំនួរ36
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
MEDS2W
2 
Has (name) taken any medicine in the past 2 weeks? 
If yes, which medicines did (NAME) take? Tick all that apply.
If no, go to question 36. 
vItamIn Vitamins   1 
fµaMk¥Üt Anti-vomiting   2 
fµaMraK Anti-diarrhea   3 
fµaMk¥k Anti-cough   4 
fñaMbM)at;karQWcab; Painkillers   5 
fµaMbM)at;karrlak Anti-inflammatories   6 
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fµaMGg;TIb‘ÍyUTik Antibiotics   7 
Anti-malarial   11 
fµaMepSg²eTotEdleGayedayGñkCMnajxagsuxPaB  ពិព៌ណន‌  
_________________________________________________
______________ 
Other medicine supplied by health professionals (describe) 
12 
fµaMepSg²eTotEdleGayedayminEmnGñkmanCMnajxagsuxPaB
ពិព៌ណន‌  
_________________________________________________
______________ 
Other medicine supplied by non-health professionals 
(describe) 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
VITAMINA 36. kñúgGMLúgeBl 6Ex knøgmk etI ¬eQµaH¦ )anTTYlfñaM vItamIn 
Ga ឬeT? sUmbgðajfñaMRKab;vItamIn Ga
cMlgéf¶ Ex qñaM ទទួលfñaMBIb½NÑ
កត់្រតាកាលបរ�េច�ទៃនការេលបថ�ីបំផុតពបី័ណ� សុខភាព្របសិនេបើបាន។
Within the last six months, was (NAME) given a vitamin A dose 
like (this/any of these)? Show common types of capsules. Copy
date of most recent dose from Health Card if recorded.
េទ   No   0 
បាទ/ចាស   Yes  
If yes, write the date: េបើជ‌បាទ/ចាស សូមសរេសរនូវកាលបរ�េច�ត 
    éf¶  Day        Ex  Month             qñaM  Year           
1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
37. kñúgGMLúgeBl 6Ex knøgmk etI ¬eQµaH¦ )anTTYlfñaMប���ះRBUn 
Edrb¤eT ?
Was (NAME) given any drug for intestinal worms in the last six 
months?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
ឥឡ�វេនះខ��ចំង់សួរសំណួរមួយចំនួនអពំីសុខភាពរបស់អ�ក Now I would like to ask some questions about your health 
ILL1MU
M 
38. េតើអ�ក(ឬមា� យកុមារ)កំពុងមានជំងធឺ�ន់ធ�រឬេទ? (ឧ. ដូចជ‌៖ ជងំេឺអដស៍ ឬរេបង។ល។)
Do you have any major illness right now (e.g. HIV, TB, etc)?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
ILL2MUM 39. េតើក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយេនះ អ�កមានឈឺេទ?
(ចូគូសចេម�ើយមួយ) េបើេទ រ�លងេ�សំនួរប��ប់
In the past 2 weeks, have you been ill?  (Tick ONLY ONE answer).  If No –
jump to end
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
ILL3MUM 40. ជ‌គំនិតរបស់អ�ក េតើអ�ក មានជំងឺធ�ន់ មធ្យម ឬ្រសាល?
េបើធ�ន់ធ�រ សូមរ�លងេ�សំនួរ 41
In your opinion , was your illness serious, moderate or slight?
If Serious – go to question 41.
ជំងឺធ�ន់ Serious       1 
មធ្យម Moderate    2 
្រសាល Slight   3 
បដិេសធមិនេឆ�ើយ Refused to respond   8 
មិនដឹង   Don’t know      9 
ILL4MU
M 
41. េតើអ�កបានេ�ជួប្រគ�េពទ្យឬេទ?
Did you go to the doctor?
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ Refused to respond   8 
មិនដឹង  Don’t know      9 
េបើសិនជ‌អ�កទទួលបានចេម�ើយែដលមិនទទួលយកការចូលរួមBIkumar សូមនិយយ‌យថ‌៖ អរគុណស្រមាបឆ់ន�ៈចូលរួម។ ប៉ុែន�សូមេទាសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក��ងការចូលរួម 
េដ‌យសារ[ផ�ល់នវូមូលេហតុែដលទទួលដូចេ�ក��ងប��ីសំនួរខាងេលើ] េបើសិនជ‌ប�� េន‌ះពាក់ពន�័ជ‌មួយនឹងប�� សុខភាព សូម្របាប់គាត់ឬឲ្យគាត់យកកូនរបស់គាត់េ�មណ� លសុខភាព/មន�ីរេពទ្យ។
If you get an answer that excludes the child, say:  Thank you for your willingness to participate.  Unfortunately, you and your child 
are not eligible to participate because [give the reason].  [If health related reason, say] We suggest that you go to OR you take your 
child to the health clinic.  
2 0 1 
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ទ្រមង់ទី៣៖ ្របសិទ�ភាពៃនការសិក្សោសាកល្បង ទ្រមង់ប��ីសំនួរ្របមលូទិន�ន័យមលូដ‌� ន – េគាលេ�ការវ�វត�  ការវ�វត�មជ្ឈដ‌� ន 
Form 3C:  Efficacy trial, baseline data collection form – developmental milestones 
ឥឡ�វេនះខ��នំឹងសួរសំណួរមួយចំនួនអពំីឥរ�យ‌បទរបស់កូនេនះ។ Now I’m going to ask some questions about this child’s behaviour. 
Variabl
e 
name 
សូមសួរេ�អ�កេមើលែថកុមារ    PLEASE ASK THE CAREGIVER ចេម�ើយ  RESPONSE Code 
SMILE 1. щЗשּׂЇ уŪ ТщЛяБ Б сРъВТдщЙ=
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРщРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТБ Б сР �
&ОǾū РщВשּׂР▫рщКċשּׂйĈЇ уŪ ТщЧ שּׂЌ' � ў  
Does this child smile? 
Can we try to observe that? See if the child smiles (try to 
make it laugh). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
SOUND 2. щЗשּׂщЇ āЋщЛяŦ Лķ Ї Ї ǽУ ТМЧ єщЉщΌ ТЇ Ч ющЩЋдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?щРשּׂУ Ŗ щЗ שּׂЇ уŪ Т
щЛяŦ ЛъĉМЇ ǽУ ТМЧ єщЉщΌ ТЇ Ч ющЩЋдщЙ�
&А ТщΏ Орщĉį С Ї уŪ ТЛпЋĴ ℓЧ єĉŪ РыВ' � ў  
Does this child turn its head to sounds?  Can we try to 
observe that? See if the child turns its head to sounds (stand 
behind it and snap fingers ). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
SIGHT 3. щЗשּׂщЇ āЋщЛяŦ Лŏ РщРשּׂУ ЪċръВУ ĉМŗ Ї єЛсЋъП▪Ї ТМЧ єщЉдщЙ? �
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРщРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тŏ РщРשּׂУ �
&Ї ющТשּׂЇ ĉŪ РыВщΏ ОрРуЈ ъП▪Ї ТМЧ єщЉ� ' � ў  
Does this child follow things with its eyes? 
Can we try to observe that? See if the child follows (move 
fingers in front of eyes). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
HEAD 4. щЗשּׂЇ фЛщЛяſ ЌщЋשּׂМЇ ǽУ ТМЧ єщЉщЩשּׂЋŦ ЛщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРщРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌщЋשּׂМЇ ǽУ ТМЧ єщЉщЩשּׂЋ&Ч уюк Ъ▪Ї
ъИŗ юŊ Ї єЇ уŪ ТщЉЋŧ ◙МєРуЈ � ТхЌщУ שּׂЇ ыВĉЇ ФрщΏ ОрРуЈ щЇ āЋ�
щВשּׂР▫рк ĵ З єщЋשּׂМщРשּׂУ '  
Does this child hold its head up?  Can we try to observe that? 
See if the child holds its head up (ask caregiver to put child 
on tummy and wave to make it look up). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
ROLL 5. щЗשּׂЇ фЛщЛящЌяĉЇ ŷ МєщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРщРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌĉЇ ŷ МєŦ Л&Ч уюк Ъ▪Ї ъИŗ юŊ Ї єЇ у
Ū ТщЉЋŧ ◙МєРуЈ � щУ שּׂщŨ яЛпЋщУ שּׂЇ ЙсЇ ЌпЗ ″щВשּׂР▫рк ĉЇ ŷ Мє 
Does this child roll over? Can we try to observe that? Ask 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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caregiver to put child on tummy and encourage to roll. 
REACH 6. щЗשּׂЇ фЛщЛяŦ ЛщŅ ЋщΌ ĸ МєЪċрŦ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРщРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌщŅ ЋщΌ ĸ МєФЗ℅уЪċрРхС ъВУ щΏ Ор
РуЈ щЉў  
Does this child reach for things? Can we try to observe that? 
See if the child reaches for an object in front of it. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
TALK 7. щЗשּׂЇ фЛщЛяſ ЌНĊующУ ЋЙсЇ Ū З єŦ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРк Ū″С НĊующУ ЋЙсЇ Ū З єщΌ į ЛєЇ уŪ Т 
Does this child babble? 
Can we try to observe that? Ask caregiver to babble to child. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
TALK2 8. щЗשּׂЇ фЛщЛяſ ЌЛпū С МщЋ◙שּׂЗ ļ Ũ Ї ĈŦ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Ч фРк Ъ▪Ї ъИŗ юЛпū С � Ũ Ї ĈЇ уŪ Т 
Does this child form words? 
Can we try to observe that? Ask caregiver to “say” its words. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
TALK3 9. щЗשּׂЇ фЛщЛяſ ЌС У єŨ Ї ĈŦ ЛЈ Ċя� ъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
щРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяĉМЗ пЇ РāщЎĊשּׂС ЗМщΌ ЛсЋŨ Ї ĈРхС ЌюЛхЛ 
Can this child understand some words? 
Can we try to observe that? See if the child responds to 
some words. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
MOUTH10. щЗשּׂЇ фЛщЛяſ ЌŊ Ї єТМЧ єЌфУ Ї ▪уЋŪ З єъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
щРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяſ ЌŊ Ї єЧ ◙Тĉĵ МєЌфУ Ї ▪уЋŪ З є�
к Ч ◙Тĉĵ МєщΌ Ъ▪Ї ъИŗ ю� - � Р пЛщĉМשּׂщЩשּׂЋФпБ �  
Does this child bring things to its mouth? Can we try to 
observe that? See if the child brings a candy to its mouth – 
leave the candy with caregiver – do not reuse. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
SIT 11. щЗשּׂЇ фЛщЛящЌяЪЋ☻уС щŊ С Ū Лį ТЏхС �Ŧ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
щРשּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяſ ЌŊ Ї єЧ ◙Тĉĵ МєЌфУ Ї ▪уЋŪ З є�
к Ч ◙Тĉĵ МєщΌ Ъ▪Ї ъИŗ ю 
Can this child sit with support? Can we try to observe that? 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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See if the child can sit with  support (ask caregiver to sit child 
up). 
SIT2 12. щЗשּׂЇ фЛщЛяſ ЌЪЋ☻уС � щŊ С ĵ āЛЏюЛхС Ŧ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌЪЋ☻уС Ŧ ЛщŊ С Ū ЛЏюЛхС дщЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к ЪЋ☻уС '  
Can this child sit without support? Can we try to observe 
that? See if the child can sit without support (ask caregiver 
to sit child up). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
CRAWL 13. щЗשּׂЇ фЛщЛяſ ЌŲТ� щŊ С щĉМשּׂыВЛпЋ� ЏЋ☻ЋєŦ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌŲТ� щŊ С щĉМשּׂыВЛпЋ� ЏЋ☻ЋєŦ ЛдщЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к щЉЋŧ ◙МєРуЈ � ТхЌщΞ щЇ āЋ'  
Can this child crawl on its hands and knees? Can we try to 
observe that? See if the child can crawl on its hands and 
knees (ask caregiver to put child on tummy and call it to 
them). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
STAND 14. щЗשּׂЇ фЛщЛяſ ЌА Т� щŊ С Ū ЛЏюЛхС Ŧ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌА ТŦ ЛщŊ С Ū ЛЏюЛхС дщЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к А ТъНėЇ щỳ Ър'  
Can this child stand with assistance? Can we try to observe 
that? See if the child can stand with assistance (ask 
caregiver to stand child against chair). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
WALK 15. щЗשּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С Ū ЛЏюЛхС дщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С Ū ЛЏюЛхС дщЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А ТъНėЇ щỳ Ър� щШשּׂС щΞ Ї уŪ Т 
Can this child walk with assistance? Can we try to observe 
that? See if the child can walk with assistance (ask 
caregiver to stand child against chair and call it to them). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
STAND
2 
16. щЗשּׂЇ фЛщЛяſ ЌА Т� щŊ С ĵ āЛЏюЛхС Ŧ ЛъВТдщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌА ТŦ ЛщŊ С ĵ āЛЏюЛхС дщЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А Т�
Can this child stand without assistance? Can we try to
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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observe that? See if the child can stand without assistance 
(ask caregiver to stand child). 
WALK2 17. щЗשּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С ĵ āЛЏюЛхС дщЙ?
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ? �
щРשּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С ĵ āЛЏюЛхС дщЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А Т� щШשּׂС щΞ Ї уŪ Т 
Can this child walk without assistance? Can we try to 
observe that? See if the child can walk without assistance 
(ask caregiver to stand child and call it to them). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
LOOK 18. щЗשּׂЇ фЛщЛящЌяŏ РТЇ щРשּׂУ ТМЧ є� щОУ ъВУ щС שּׂЋŭ Ї єщУ Ћ�
ъВТдщЙ?  
щЗשּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙ЗщРשּׂУ Ŧ ЛъВТдщЙ?  
Мķ ĕБ ФЗ℅уРхС щΌ Ї уŪ Т�
Мŝ ℓМєРЇ ŭ Ї єФЗ℅ущŝ ящШשּׂС щРשּׂУ Ŗ щЗ שּׂЇ фЛŏ РТЇ щРשּׂУ �
ФЗ℅ущŝ ядщЙў  
Does this child look for things out of view? Can we try to 
observe that? Show the child an object, then hide the 
object and see if the child looks for it.  
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកុមារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјРпЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t 
observe    
4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
Лпū С Ŗ Ґ � ЪТЉуЖ Ч ĉŪ МєЌщРĊשּׂС ТМЧ єЪ▪Ї ў � Say:  Thank you for answering these 
questions.   
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Form 3: Dietary diversity 1/6 
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ទ្រមង់ទី៣៖ ្របសិទ�ភាពន្ំរតីរបស់ការសិក្សោ, � ទ្រមងប់��ីសំនួរ្របមលូទិន�ន័យមូលដ‌� ន – ទិន�ន័យរបបឣ‍ហារ  
Form 3D:  Efficacy trial, baseline data collection form – dietary data 
eQµaHkumar  Name of child  (NAMECH) 
eQµaHអ�កេមើលែថកុមារ Name of caregiver (NAMECG)
CadMbUg ´sUmsYrGMBIrbbGaharkumar Now I will ask some questions 
about the child’s diet 
PRELACT
1 
1. kñúgGMLúgeBl 3éf¶dMbUgeRkaysMraletI ¬eQµaH¦
RtUv)anpþl;GVImYysMrab;pwkeRkABITwkedaHmþay
b¤eT? េបើមាន សូមបន� េបើអត់ សូមរ�លងេ�សំនរួេលខ2
In the first three days after delivery, was (NAME) given
anything to drink other than breast milk?  If yes, continue.
If no go to question 2.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
PRELACT
2 
etIGñk)aneGayTwkGVIdl;kUn ¬eQµaH¦ sMrab;pwk?
manTwkGVIepSgeToteT ? kt;Rtaral;TwkEdl)aneGay5
(េបើសិនជ‌ចំាបាច់្រត�វបេង�ើបសំនួរ)
What was (NAME) given to drink?  Anything else? Tick all
that apply.
(Prompt if necessary)
Milk (other than breastmillk)TwkedaHeKaxab;  1 
Plain water  TwkFmµta   2 
Sugar or honey water  Twksár¼TwkXµúM   3 
Sugar –salt-water solution TwkGMbillaysár   4 
Coconut/fruit juice TwkdUg¼TwkEpøeQI   5 
Infant formula TwkedaHeKaemSA   6 
Herbal tea TwkEt   10 
Other (describe)      េផ្សងេទៀត ចូរេរៀបរ‌ប ់  7 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
EBF 2. េតកុមារ(េឈ� ះ)បានេបទឹកេដះមា� យែតមួយមុខគត់
ដល់អយុបុ៉នា� ន (អត់េបសូមបីែតទឹក)?
Until what age did (NAME) have only breastmilk, not even
water?
Never breastfed  
មិនបានេបទឹកេដះមា� យសូមបីែតបន�ិច  
0 
<3mths េនអយុតិចជាង៣ែខ   1 
<6mths  េនអយុតិចជាង៦ែខ   2 
>6mths  បនា� ប់ពីអយុជាង៦ែខ   3 
Refused to respond បដិេសធមិនេឆ�យ    8 
Don’t know    មិនដឹង   9 
BFG 3. េតកុមារ(េឈ� ះ)បានកំពុងេបទឹកេដះមា� យឬេទ?
េបមាន សូមបន�េទសំនួរេលខ៤ េបអត់
សូមរលំងេទសំនួរេលខ5
Is (NAME) still being breastfed? If yes go to question 4.  If
no, go to question 5
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
BFGFREQ 4. េតកុមារ(េឈ� ះ)បានេបទឹកេដះមា� យបុ៉នា� នដង
កលពីម្ិសលមិញ និង យប់មិញ ?
(ចេនា� ះ២៤េម៉ាងចុងេ្រកយ)
How many times did (NAME) breastfeed yesterday (last 24
hours) during the day and the night?
កលពីម្ិសលមិញ មិនបានេបទឹកេដះមា� យ   
Did not breastfeed yesterday 
0 
បានេបទឹកេដះមា� យ ១ េទ ២ដង  
Breastfed 1-2 times 
1 
បានេបទឹកេដះមា� យ ៣ េទ ៥ដង  
Breastfed 3-5 times 
2 
បានេបទឹកេដះមា� យ ៦ េទ ៨ដង  
Breastfed 6-8 times 
3 
បានេបទឹកេដះមា� យ េ្រចនជាង៨ដង  
Breastfed >8 times 
4 
បដិេសធមិនេឆ�យ   Refused to respond    8 
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មិនដឹង   Don’t know      9 
CF 5. េតកុមារ(េឈ� ះ) មានញំុាអហរេផ្សងេទៀតឬេទ
េ្រកពីេបទឹកេដះមា� យ? េបសិនជាចេម�យថា បាទ/ចស 
សូមបន�េទសំនួរទី៨
េបសិនជាចំេលយេទ េដយបដិេសធមិនេឆ�យ ឬ
េឆ�យថាមិនដឹង  –សូមនិយាយថាអរគុណ
ស្រមាប់ឆន�ៈចូលរមួរបស់អ�ក
ែតគួរឲ្យេសកស� យែដលអ�កនិងកូនរបស់អ�កមិនមានល
ក�ណៈស្រមាប់ករចូលរមួេទ
្រគប់្រគាន់ស្រមាប់ចូលរមួក�ុងករសិក្សោេទ
េដយសរេឈ� ះ(          ) មិនទន់េចះញំុាអហរ
ឬេភសជ�ៈេផ្សងេទៀត េ្រកពីេបទឹកេដះមា� យ។
មិនទទួលយកករចូលរមួ េហយប�� ប់ប�� ីសំនួរ។
Does (NAME) have foods or drinks other than breastmilk?
If Yes, go to question 8.  If No, Refused to respond, or
Don’t know – Say: Thank you for your willingness to
participate.  Unfortunately, you and your child are not
eligible to participate because (name) is not yet eating
foods or drinks other than breastmilk.EXCLUDE AND END
QUESTIONNAIRE
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
មិនទទួលយកការចូលរួម EXCLUDED      99 
AGECF 6. េតេនអយុបុ៉នា� នែដលកុមារ (េឈ� ះ)
បានចប់េផ�មញំុាអហរ
ឬផឹកទឹកែដលមិនែមនជាទឹកេដះមា� យ?
At about what age did (NAME) start having foods or drinks
other than breastmilk?
At <3mths េ�ឣ‍យុតិចជ‌ង៣ែខ   1 
At <6mths  េ�ឣ‍យុតិចជ‌ង៦ែខ  2 
At >6mths  បន‌� ប់ពីឣ‍យុជ‌ង៦ែខ  3 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
េទ   No   0 
BMS24H 7. etImSilmij b¤ yb;mij ¬eQµaH¦)anpwk
TwkGVImYyBIdbTwkedaHeKaEdrb¤eT ?
Did (NAME) drink anything from a bottle with a nipple
yesterday or last night?
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
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FOODGEN 
8. េតកុមារ (េឈ� ះ)
បានញំុាអហរ
ឬផឹកទឹកអ�ីខ�ះចប់តំងពី
េគេចះញំុាអហរមក?
គូសនូវចេម�យទំងអស់ែដ
លទទួលបាន
What foods or drinks 
does (NAME) usually eat 
or drink since they began 
solids? Tick all that apply 
Plain water  TwkFmµta    1 
Liquids such as tea, juice, soda, etc     សរធាតុរវដូចជាទឹកែត ទឹកែផ�េឈ ទឹកសូដ។ល។   2 
Soup  ទឹកសុ៊ប   3 
Milk (tinned, powdered, or fresh animal milk) TwkedaHeKa dUcCa TwkedaHeKakMb:ug 
emS:ATwkedaHeKab¤TwkedaHeKaRss;²    
4 
Infant formula.  júaM TwkedaHeKakUnekµg EdlpSMtamrUbmnþ dUcCa RhVg;ebeb Duymuic  
uImILak;> b¤eT ? ebIman³ etI ¬eQµaH¦   
5 
Any brand of commercially fortified baby food, e.g., Cerelac]? 
júaMGaharEdlbBa©ÚlBBYkmIRkUsarCatiEdlmanm:akeQµaHBaNiC¢kmµ dUUcCaesr:aLak; 
Edrb¤eT ?   
6 
júaM nMb½ug )ay nMbBa©úk¼mI bbr b¤GaharepSgeToteFVIBIRKab;FBaØCati ?  
Bread, rice, noodles, borbor or other food made from grain 
10 
Pumpkin, carrots, yellow or orange sweet potatoes  េ��  ការ�ុត ដំឡ�ងជ‌� ពណ័េលឿង ឬ ពណ័ទឹក្រក�ច  11 
White potatoes, white yams, manioc, cassava, roots  
júaM dMLÚgs Rtav dMLÚgmI éqfav b¤GaharepSgeTotEdlman emIm¼b¤s Edrb¤eT?   
12 
Dark green, leafy vegetables júaM bEnøébtgcas; bEnømansøwkeRcIn Edrb¤eT?   13 
Ripe mangoes, papayas? ស� យទំុ ល�ុងទំុ   14 
Any other fruit or vegetables  júaM EpøeQI b¤bEnøepSgeTot b¤eT ?   15 
Liver, kidney, heart or other organ meats? េថ�មសត�, 
្រកលន,េបះដូងសត�ឬេ្រគ�ងក�ុងសត�េផ្សងៗ ?   
16 
សច់សត�េផ្សងៗេទៀត ឧ. សច់េគា,សច់្រជ�ក, សច់េជៀម,សច់ពែព,សច់មាន់ឬសច់ទ    
Any other meat, e.g. beef, pork, lamb, goat, chicken, or duck      
17 
Eggs ពងមាន់   18 
Fresh or dried fish or shellfish   ្រតី�សស់ឬ្រតីេ្រគ�មឬខ្យងេខ�    19 
ចំណីអហរែដលផលិតពីសែណ� កេសៀង សែណ� កេហឡំាងតវ សែណ� កបាយ ឬ 
សែណ� កេផ្សងៗ  
Any foods made from beans, peas, lentils, or nuts      
20 
Yoghurt, cheese or any other food made from milk យាអួរ ឈឺស ឬ 
អហរដ៏ៃទេទៀតែដលផលិតពីទឹកេដះេគា 
21 
Any foods made with oil, fat, or butter ចំណីអហរណាែដលផលិតពីេ្របង ខ� ញ់ ឬប៊រ  22 
Any snake, snail, frog, rat, or insects ្របេភទពស់េផ្សងៗ, ខ្យង, កែង�ប, កណ�ុ រ, ឬសត�ល�ិត    23 
Sweet or salty snacks eg chips, cakes, candies   បែង�ម ឬអហរញំុាេលងៃ្រប ឧ. 
្របេភទនំ�ស�យៗ នំេខក ស�រ្រគាប់  
24 
Any other solid, semi-solid, or soft food? ្របេភទអហររងឹ េផ្សងៗ ្របេភទអហរ ្រជាយៗ 
ឬ្របេភទអហរទន់ៗ    
Other (describe)      េផ្សងេទៀត ចូរេរៀបរ‌ប ់________________________________________
7 
បដិេសធមិនេឆ�យRefused to respond    8 
មិនដឹងDon’t know      9 
FOOD24
H 
9. etIកុមារ ¬eQµaH¦ manjúaMGaharrwg GaharRCay
b¤GaharRទន់eTenAeBléf¶ b¤eBlyb; កលពីmSilmij?
្របសិនេបើមាន សូមបន�េ�សំនួរេលខ ១០
្របសិនេបើអត់  សូមបន�េ�សំនួរេលខ 13
Did (NAME) eat any solid,  semi-solid, or soft foods
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
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yesterday during the day or at night? If yes, go to 10.  If no, 
go to 13 
10. etI
កលពីម្ិសលមិញកុមារ¬eQµ
aH¦ )anjúaM ឬផឹកGVIខ�ះ? 
គូសនូវចេម�យែដលទទួល
បាន
What foods yesterday did 
(NAME) eat or drink
yesterday? Tick all that apply
Plain water  TwkFmµta    1 
Liquids such as tea, juice, soda, etc     សរធាតុរវដូចជាទឹកែត ទឹកែផ�េឈ ទឹកសូដ។ល។   2 
Soup  ទឹកសុ៊ប   3 
Milk (tinned, powdered, or fresh animal milk) TwkedaHeKa dUcCa TwkedaHeKakMb:ug 
emS:ATwkedaHeKab¤TwkedaHeKaRss;²   
If yes, how many times?ebIman³ etI ¬eQµaH¦ júa b:unµandg?  
4 
Infant formula.  júaM TwkedaHeKakUnekµg EdlpSMtamrUbmnþ dUcCa RhVg;ebeb Duymuic  uImILak;> 
b¤eT ? ebIman³ etI ¬eQµaH¦   
If yes, how many times? pwkTwkedaHeKakUnekµgb:unµandg? 
5 
Any brand of commercially fortified baby food, e.g., Cerelac]? 
júaMGaharEdlbBa©ÚlBBYkmIRkUsarCatiEdlmanm:akeQµaHBaNiC¢kmµ dUUcCaesr:aLak; Edrb¤eT ?   
6 
júaM nMb½ug )ay nMbBa©úk¼mI bbr b¤GaharepSgeToteFVIBIRKab;FBaØCati ?  
Bread, rice, noodles, borbor or other food made from grain 
10 
Pumpkin, carrots, yellow or orange sweet potatoes  េ��  ការ�ុត ដំឡ�ងជ‌� ពណ័េលឿង ឬ ពណ័ទឹក្រក�ច   11 
White potatoes, white yams, manioc, cassava, roots  
júaM dMLÚgs Rtav dMLÚgmI éqfav b¤GaharepSgeTotEdlman emIm¼b¤s Edrb¤eT?   
12 
Dark green, leafy vegetables júaM bEnøébtgcas; bEnømansøwkeRcIn Edrb¤eT?   13 
Ripe mangoes, papayas? ស� យទំុ ល�ុងទំុ  14 
Any other fruit or vegetables  júaM EpøeQI b¤bEnøepSgeTot b¤eT ?   15 
Liver, kidney, heart or other organ meats? េថ�មសត�, ្រកលន,េបះដូងសត�ឬេ្រគ�ងក�ុងសត�េផ្សងៗ ?   16 
សច់សត�េផ្សងៗេទៀត ឧ. សច់េគា,សច់្រជ�ក, សច់េជៀម,សច់ពែព,សច់មាន់ឬសច់ទ    
Any other meat, e.g. beef, pork, lamb, goat, chicken, or duck      
17 
Eggs ពងមាន់   18 
Fresh or dried fish or shellfish   ្រតី�សស់ឬ្រតីេ្រគ�មឬខ្យងេខ�    19 
ចំណីអហរែដលផលិតពីសែណ� កេសៀង សែណ� កេហឡាំងតវ សែណ� កបាយ ឬ សែណ� កេផ្សងៗ   
Any foods made from beans, peas, lentils, or nuts      
20 
Yoghurt, cheese or any other food made from milk យាអួរ ឈឺស ឬ 
អហរដ៏ៃទេទៀតែដលផលិតពីទឹកេដះេគា 
21 
Any foods made with oil, fat, or butter ចំណីអហរណាែដលផលិតពីេ្របង ខ� ញ់ ឬប៊រ  22 
Any snake, snail, frog, rat, or insects ្របេភទពស់េផ្សងៗ, ខ្យង, កែង�ប, កណ�ុ រ, ឬសត�ល�ិត    23 
Sweet or salty snacks eg chips, cakes, candies   បែង�ម ឬអហរញុាំេលងៃ្រប ឧ. ្របេភទនំ�ស�យៗ នំេខក 
ស�រ្រគាប់  
24 
Any other solid, semi-solid, or soft food? ្របេភទអហររងឹ េផ្សងៗ ្របេភទអហរ ្រជាយៗ 
ឬ្របេភទអហរទន់ៗ     
Other (describe)      េផ្សងេទៀត ចូរេរៀបរ‌ប់ ________________________________________
7 
បដិេសធមិនេឆ�យRefused to respond    8 
មិនដឹងDon’t know      9 
FF24H 11. etI ¬eQµaH¦ )anjúaMGaharrwg GaharRCaylµm b¤Gahar ១ េ� ២ ដង 1-2 times   1 
៣ េ� ៤ ដង 3-4 times  2 
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ទន់b:unµandgkalBImSilmij enAeBléf¶ b¤eBlyb;?
How many times did (NAME) eat solid, semisolid, or soft foods 
yesterday during the day or at night? 
៥ ឬ េ្រចើនជ‌ងេនះ  5 or more times   5 
បដិេសធមិនេឆ�ើយRefused to respond    8 
មិនដឹងDon’t know      9 
FOODAMT 12. កលពីម្ិសលមិញ អំឡុងេពលៃថ� និង េនេពលយប់
េតកុមារបានបរេិភាគអហររងឹ អហរ្រជាយ និង
អហរទន់បាន្របែហលបុ៉នា� នែដរ ?
Approximately how much solid, semisolid, or soft foods did 
(NAME) eat each time yesterday during the day or at night?
<2 tablespoonfuls each time  ម�ង <២ សា� ប្រពាបាយេពញ   ០
2-3 tablespoonfuls each time  ម�ង ២ េ� ៣ សា� ប្រពាបាយេពញ   1 
< 1/2 bowl each time ម�ងតិចជ‌ងកន�ះចានចង�ឺះ ម�ង< ១/២ ចានចង�ឺះ  2 
About 1 bowl each time ម�ងកន�ះ េ� មួយចានចង�ឺះ  3 
>1 bowl each time ម�ងេ្រចើជ‌ង១ចានចង�ឺះ  4 
បដិេសធមិនេឆ�យRefused to respond    8 
មិនដឹងDon’t know      9 
SUPPS 13. េតើកូនរបស់អ�កធា� ប់បានញុាំ �ស�ីងខល េហបី៊
សីុេអសបី៊េផ�សេផ�សឬអហរបំប៉ន�សេដៀងគា�
ឬអហរបំប៉នបែន�ម ឬ វតីមីនេផ្សងៗណាឬេទ ?
េបសិនជាចេម�យេទ សូមរលំងេទសំនួរចុងប�� ប់
Has (NAME) ever used Sprinkles, HEBs, CSB++ or similar
supplementary foods or supplements/vitamins?  If No to this
question – jump to end. 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
SUPPS2 14. េតើ��របំប៉នមួយ�
ឬ��របែន�ម�/វ � មីន�ែដលកូនរបស់អ�ក�នេ្របើ?
សូមគូស្រគីសចំេ�ះ��រ�ងំនុះ (ប�� ញក�� ប់
ឬគំរៃូន��រ)
េបើេ្របើ�ស�ីងខល បន�េទសំនួរទី ១៥។
េបសិនជាេហបី៊សូមរលំងេទសំនួរទី១៧។
េបសិនជាមិនេ្រប�ស�ីងខល ឬេហបី៊សូមប�� ប់សំនួរ។
េបើមិន�នេ្របើ�ស�ីងខលេទ សូមរលំងេទសំនួរចុងប�� ប់
Which supplementary foods or supplements/vitamins has
(NAME) used?  Tick all that apply.  (show packages or examples
of foods). If using Sprinkles, go to question 15.  If using HEBs go
to question 17. If not using Sprinkles or HEBs, go to end. 
�ស� ងីខលSprinkles    1 
សុីេអស� �ផ�ឺសផ�ឺសCSB++    2 
េហបី៊ HEBs    3 
��របំប៉នេផ្សងេទៀតេបើ�ន េហើយសូមេរៀប�ប់   
Other supplementary foods (describe)       
______________________________ 
4 
េ្រគ�ងបែន�មេផ្សងេទៀតOther supplements (describe)        
______________________________     
5 
SPRINKL
1 
15. េតើ កុ�រញុាំ�ស�ីងខល ញឹកញាប់បុ៉ណា� ?
How often does (NAME) have Sprinkles?
េស� ើែតមិនែដលញុាំេ�ះ Almost never   0 
ញុាំេស� ើែត�ល់ៃថ� Almost daily    1 
ញុាំ២ េទ ៣ ដងក�ុងមួយ 2-3 times/week    2 
១សបា� ហ៏ ញុាំម�ង Once a week    3 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
SPRINKL
2 
16. េតើកុ�រញុាំ�ស�ីងខល ម�ងបុ៉នា� នក�� ប់ក�ុងមួយៃថ�?
How many sachets of Sprinkles does (NAME) have each day?
១ក�� ប់ 1 sachet   0 
២ក�� ប់ 2 sachets   1 
Other (describe)      េផ្សងេទៀត ចូរេរៀបរ‌ប់   7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HEB1 17. េតើ កុ�រញុាេំហបី៊ញឹកញាប់បុ៉ណា� ?
How often does (NAME) eat HEBs?
េស� ើែតមិនែដលញុាំេ�ះ Almost never   0 
ញុាំេស� ើែត�ល់ៃថ� Almost daily    1 
ញុាំ២ េទ ៣ ដងក�ុងមួយ 2-3 times/week    2 
១សបា� ហ៏ ញុាំម�ង Once a week    3 
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បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HEB2 18. េតើកុ�រញុាំេហបី៊ម�ងបុ៉នា� នក�ុងមួយៃថ�?
How many HEBs does (NAME) have each day?
1-2 1 -2   0 
3-4 3-4   1 
Other (describe)      េផ្សងេទៀត ចូរេរៀបរ‌ប់   7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
េបើសិន�អ�កទទួល�នចេម� ើយែដលមិនទទួលយក�រចូលរមួរបស់អ�កែថរកុ�រេទ សូមនិយ�យ�៖ អរគុណស្រ�ប់ឆន� ៈចូលរមួ។ 
ប៉ុែន�សូមេ�សែដលអ�ក និងកូនរបស់អ�កមិន�នលក�ណៈសម្បត� ិ ្រគប់្រ�ន់ក� �ង�រចូលរមួ េ�យ�រ 
[ផ�ល់នូវមូលេហតុែដលទទួលដូចេ�ក� �ងប�� ីសំនួរ�ងេលើ]  If you get an answer that excludes the caregiver, say:  Thank you for your 
willingness to participate.  Unfortunately, you and your child are not eligible to participate because [give the reason].   
េបើសិន�អ�កសួរនូវសំនួរ�ងំអស់េហើយ េហើយអ�កែថរកុ�រ/កុ�រេ�ះ�នលក�ណៈ្រគប់្រ�នក់� �ង�រចូល រមួ សូមនិ�យ�៖ 
អរគុណស្រ�ប់ចេម� ើយរបស់អ�ក។ If you ask all the questions and the caregiver is eligible to participate, say:  Thank you for 
answering these questions.   
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ទ្រមងទ់៣ី៖ ្របសទិ�ភាពន្ំរតរីបស់ការសកិ្សោ, ទ្រមងប់��សីនំរួ្របមលូទនិ�នយ័មលូដ‌� ន – esdækic©sgÁm 
Form 3E:  Efficacy trial, baseline data collection form – socio-economic 
ឥឡ�វេនះខ��នំឹងសួរសំណួរមួយចំនួនអពំីអ�ក ្រគ�សាររបស់អ�ក និង សា� នភាពរស់េ�របស់្រគ�សារអ�ក រួមប���លទំាងសំណួរទាក់ទងពីកំរ�តវប្បធម៏ ទឹកសា� ត អន‌មយ័ និង្របាកច់ំណូល និងជ‌ហូែហរ។  
I will now ask some questions about you and about your household and your living situation, including questions about education, 
water and sanitation, income generation, and so on.  
eQµaHkumar Name of child  (NAMECH) 
eQµaHអ�កែថទំាkumar Name of caregiver
(NAMECG) 
Variabl
e name 
សនំរួ Question ការេឆ�ើយតប Response កដូ
ode 
EDMUM 1. េតើអ�ក�� ប់�នចូល��េរៀនឬេទ?
្របសិនេទ សូមរ�លងេ�សំនួរទ4ី
Have you ever attended school? If no, skip to question 4.
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
EDMU
M2 
2. etIGñkeronx<s;bMput)ankMritNa bzmsikSa GnuviTüal½y
ឬកំរ�តខ�ស់ជ‌ងviTüal½y
What is the highest level of school you attended: primary,
secondary, or higher?
បឋមសិក្សោ Primary   1 
អនុវ�ទ្យោល័យ Junior high school   2 
វ�ទ្យោល័យ Senior high school   3 
កំរ�តខ�ស់ជ‌ងviTüal½y  Higher   
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
EDMU
M3 
3. etIGñk)aneronចប់fñak;TIb:unµanenAkMritsikSaxagelI ?
ebIeron)anticCag mYyqñaMenAkMritsikSaenaH sUmkt;Rta  '00'
What is the highest (grade/form/year) you completed at that level? 
IF COMPLETED LESS THAN ONE YEAR AT THAT LEVEL, RECORD '00'. 
fñak;TI grade/form/year
1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HH 4. េតើជ‌ធម�តាមានសមាជិកប៉ុន‌� នន‌ក់ែដល េគងេ�ក��ងផ�ះជ‌េរៀងរ‌ល់យប់?
How many people usually sleep in this house each night? Number of people  cMnYnsmaCik . 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HHU5 5. ជ‌ធម�តា etImankumarGayueRkam 5 qñaM ប៉ុន‌� នន‌ក់ រស់េ�ក��ង្រគ�សាររបស់អ�ក?     (
rYmTaMងកុមារែដលកំពុងេធ�ើការសិក្សោ)
How many children under 5 years of age usually live in your
household? – (including the study child)
cMnYnkumarGayueRkam 5qñaM 
Number children < 5 years 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
1 
6. enArdUvR)aMgetIsmaCikRKYsarGñkeRbIR)as;RbPBTwkGVI
CasMxan;sMrab;pwk?
សូមគូសចេម�ើយែតមួយគត់
What is the main source of drinking water during the dry season
for members of your household? Circle ONLY ONE answer
hUrtambMBg;dl;kñúgpÞH Piped into dwelling
  1 
hUrtambMBgdl;kñúgrbgpÞH Piped to
yard/plot   2 
bMBg;dak;tamsaFarN³  Public tap/standpipe
  3 
bMBg;tBIGNþÚg Tube well or borehole   4 
TwkGNþÚgCIk  Dug well or spring   5 
ទឹកអណ�� ងស�ប់ Pumping well   6 
TwkePøóg  Rainwater   10 
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lk;tamLan b¤lk;enAtamtUb  Tanker truck/ cart
  11 
RbPBTwkelIdIdUcCaTenø TMnb; RtBaMg bwg
RbLay    
Surface water: river/ stream /dam/ /lake/ 
pond/ canal/ irrigation channel 
12 
Twkdb/កាដុង Bottled water   13 
epSgeTot Other specify  
_____________________________________
________________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
3 
7. េតើ្របភពទឹកសា� តក��ងអំឡ�ងរដូវវស្សោ និង ក��ងរដូវ្របំាង របស់សមាជិក ្រគ�សារអ�កដូចគា� េទ? ្របសិនេបើដូច សូមរ�លងេ�សំនួរទី៨ េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
4 
្របសិនេបើខុសគា�  etIអ�កeRbIR)as;RbPBTwkGVI
CasMxan;sMrab;pwk ?
សូមគូសចេម�ើយែតមួយគត ់
During the wet season, is the main source of drinking water for 
members of the household the same as during dry season?)  If 
YES, go to question 8 
If No, what is the main source of drinking water during the wet 
season? Circle ONLY ONE answer 
hUrtambMBg;dl;kñúgpÞH Piped into dwelling
  1 
hUrtambMBgdl;kñúgrbgpÞH Piped to
yard/plot   2 
bMBg;dak;tamsaFarN³  Public tap/standpipe
  3 
bMBg;tBIGNþÚg Tube well or borehole   4 
TwkGNþÚgCIk  Dug well or spring   5 
ទឹកអណ�� ងស�ប់ Pumping well   6 
TwkePøóg  Rainwater   10 
lk;tamLan b¤lk;enAtamtUb  Tanker truck/ cart
  11 
RbPBTwkelIdIdUcCaTenø TMnb; RtBaMg bwg
RbLay    
Surface water: river/ stream /dam/ /lake/ 
pond/ canal/ irrigation channel 
12 
Twkdb/កាដុង Bottled water   13 
epSgeTot Other specify  
_____________________________________
________________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
5 
8. េតើអ�កមានេធ�ើសមា� ប់េមេរ‌គក��ងទឹកេដ‌យេ្របើវ�ធសីា្រស�េផ្សងៗ េដើម្បីឲ្យទឹកមានសុវត�ភាពស្រមាប់ការទទួលទានឬេទ?
សូមគូសចេម�ើយែតមួយគត់
Do you treat your water in any way to make it safer to drink?
Circle ONLY ONE answer
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
6 
9. etIGñkេ្របើវ�ធសីា្រស� dUcemþcedIm,Iេធ�ើeGay ទឹក ;briePaKenaH
mansuvtßiPaB?
sUmKUsrgVg;ykcMelIyEdlBak;B½n§TaMgGs;
What do you do to the water to make it safer to drink?
(Circle ALL applicable answers)
Twkdb/កាដុង Bottled water   1 
ដំ‌ Boil   
ដ‌ក់ថ‌� ំសមា� តទកឹ ក�រ�ន ឬចាហួយ  
Add bleach, chlorine or Agar 
2 
សាច់ជូស White alum    3 
េ្រចាះេដ‌យ្រកណ‌ត ់Strain it through a cloth   4 
េ្របើឧបករណ៍ចេ្រមាះទឹក Use a water filter  5 
េ្របើពន�ឺ្រពះឣ‍ទិត្យសមា� ប់េមេរ‌គ Solar disinfection    6 
ទុកឲ្យវ‌រងេដ‌យខ��នវ‌ Let it stand and settle   10 
epSgeTot Other specify   
_____________________________________
_______________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
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មិនដឹង   Don’t know      9 
WATER
7 
10. េតើអ�កែតងែតសមា� ប់េមេរ‌គក��ងទឹក្រគប់េពលេដើម្បីឲ្យវ‌មានសុវត�ភិាពជ‌ងមុន ឬ្រគាន់ែតក��ងករណីពិេសស?
សូមគូសចេម�ើយែតមួយគត់
Do you always treat your water to make it safer or only in special
cases? Circle ONLY ONE answer
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
WATER
8 
11. េតើអ�កបានឲទកឹសា� ត មានសុវត�ិភាពដល់កូនរបស់អ�ក (េឈា� ះ)ឬេទ?
សូមគូសចេម�ើយែតមួយគត់
Do you give (NAME) water that has been treated to make it
safer?
Circle ONLY ONE answer
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HANDS
1 
12. េតើអ�កលាងៃដរបស់អ�កជ‌មួយនឹងសាប៊ូញឹកញ‌ប់b:uណña?
សូមគូសចេម�ើយែតមួយគត់
How often do you wash your hands with soap? Circle ONLY ONE
answer
If “almost never” jump to 15
េស�ើែតមិនែដលលាងេសាះ   Almost never   0 
តិចជ‌ងម�ងក��ង១សបា� ហ៏ <once/week    1 
២េ�៣ៃថ� លាងម�ង      Once every 2-3 days   2 
១ៃថ� ម�ង   1 time/day   3 
២-៣ដងក��ង១ៃថ�      2-3 times/day   4 
េ្រចើនជ‌ង៣ដងក��ង១ៃថ�   >3 times/day   5 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HANDS
2 
13. េតើអ�កលាងៃដ ជ‌មួយសាប៊ូេ�េពលណ‌?
សូមកុំបេង�ើបសំនួរ យកែតការេឆ�ើយតបរបស់អ�កចូលរួមប៉ុេន‌� ះ
sUmKUsrgVg;ykcMelIyEdlបានផ�ល់ឲ្យTaMgGs;
When do you wash your hands with soap?  Do not prompt – only
tick applicant responses.  Circle ALL answers given
េ�េពលែដលេគ្របលាក់ When they are dirty   1 
មុនេពលញំ‌បាយ Before eating   2 
េ្រកាយេពលញំ‌បាយ After eating   3 
េ្រកាយេពលបេន‌� បង់ After defecation   4 
េ្រកាយេពលេ្របើ្របាស់បង�ន់ After any toilet use   5 
មុនេពលប���កឣ‍ហារេក�ង Before feeding child    6 
េ្រកាយេពលកាន់សំរ‌ម After handling rubbish   10 
េ្រកាយេពលកាន់កន�បេក�ង/លាមក After handling baby’s
diaper/feces   
11 
មុនេពលេរៀបចំឣ‍ហារ Before preparing food   12 
After handling animals  េ្រកាយេពលកាន់ ឬប៉ះពាល់សត�   13 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
HANDS
3 
14. ជ‌ធម�តា េតើអ�កលាងសំឣ‍តៃដរបស់អ�កជ‌មួយសាប៊ូេ�កែន�ងណ‌?
សូមកុំេធ�ើការសា� ន យកែតការេឆ�ើយតបរបស់អ�កចូលរួមប៉ុេន‌� ះ
sUmKUsrgVg;ykcMelIyEdlទទួលបានTaMgGs;
;Where do you usually wash your hands with soap?
Do not prompt – only tick applicant responses.  Circle ALL
answers given
ជ‌ធម�តា មិនលាងៃដជ‌មួយសាប៊ូេទ 
Don’t usually wash hands with soap 
0 
លាងៃដេ�ក��ងផ�ះបាយ / េពលេរៀបចំឣ‍ហារ  
In the kitchen/food preparation area 
1 
េ�ក��ងបង�នអ់ន‌ម័យ In the latrine   2 
េពលេ�ជិតបង�នអ់ន‌ម័យ Near the latrine   3 
េពលេ�ជិត្របភពទឹក At the water source   4 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET 15. CaFmµta etIsmaCikRKYsarrbs;Gñkេ្របើ្របាស់បង�ន់្របេភទណ‌ែដ? bgÁn;cucTwkb¤cak;Twk Flush or pour flush 1 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):
Form 3: Socio-economic 4/7 
0 3 
1 KUsrgVg;cMelIyEtmYy  
ebIKµanbgÁn;eT sUmrMlgeTAsMnYrTI ១៨ 
What kind of toilet facility do members of your household usually 
use? Circle ONLY ONE answer 
If no facility bush/field to this question -  jump to question 18 
toilet   
bgÁn;reNþAmanKMrb Pit latrine with slab   2 
bgÁn;reNþAKµanKMrb   Pit latrine without 
slab/open pit   
3 
eRbIkenßar Bucket toilet   4 
bgÁn;elITwk Toilet over water   5 
គា� នបង�ន់/បេន‌� របង់េ�វ‌ល/ៃ្រព No facility bush/field   6 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
2 
16. etIGñkេ្របើbgÁn;rYmCamYyRKYsarepSgែដររ�េទ?
សូមគូសចេម�ើយែតមួយគត់ ebIKµanbgÁn;eT sUmrMlgeTAsMnYrTI១៨
Do you share this toilet facility with other households? Circle
ONLY ONE answer
If No to this question – jump to question 18
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
3 
17. េតើមានប៉ុន‌� ន្រគ�សារ ែដលេ្របើបង�ន់េនះ?
សូមគូសចេម�ើយែតមួយគត់
How many households use this toilet facility? Circle ONLY ONE
answer
តិចជ‌ង១០ Less than 10   0 
េ្រចើនជ‌ង១០ More than 10   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
4 
18. ជ‌ធម�តា េតើអ�កជ‌ន‌ក់ ជួយកុមារ(េឈា� ះ)ក��ងការbenÞarbg;?
ebIKµan sUmrMlgeTAsMnYrTI ១៩  
ebIman sUmrMlgeTAsMnYrTI 20
Are you usually the person who helps (NAME) defecate? If no
jump to question 19. If Yes,to question 20
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
5 
19. េតើនរណ‌ជ‌មនុស្សមា� កែ់ដលជ‌ធម�តាឣ‍ចជួយ (េឈា� ះ)ក��ងការbenÞarbង់?
KUsrgVg;cMelIyEtmYy
Who is the person who usually helps (NAME) defecate?
Circle ONLY ONE answer
មា� យបេង�ើត Biological mother   1 
ជីដូន Grandmother   2 
ឪពុក Father   3 
បង្រសី Sister   4 
bgb¥ÚnRbus Brother   5 
epSgeTot Other specify   7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
6 
20. ជ‌ធម�តាេតើ(េឈា� ះ)benÞarbង់េ�កែន�ងណ‌?
KUsrgVg;cMelIyEtmYy
What is the usual place that (NAME) defecates
Circle ONLY ONE answer
បង�ន់Toilet   1 
កេន‌� រ Potty    2 
ដីែក្បរគានផ�ះ Yard   3 
ដ‌ក់េខា ឬ កន�ប Cambodian diaper/underpants    4 
ដ‌ក់េខាទឹកេន‌ម Disposable diaper   5 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
7 
21. េតើអ�កេធ�ើយ៉‌ងដូចេម�ចចំេពាះលាមក(េឈា� ះ) េ្រកាយការbenÞarbង់ចុងេ្រកាយរបស់េគ?
KUsrgVg;cMelIyEtmYy
កុមារេ្របើបង�ន់ Child used toilet   1 
េចាលេ�ក��ងបង�ន់ Stools thrown in toilet    2 
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kumar   (Child´s ID, CHID):
Form 3: Socio-economic 5/7 
0 3 
The last time (NAME) defecated, what was done with the stools? 
Circle ONLY ONE answer 
Stools thrown in drain/ditch  េចាលេ�ក��ងលូ  3 
Stools thrown in garbage  េចាលេ�ក��ងធុងសំរ‌ម  4 
Stools buried  ដុតេចាល 
Stools left in open  ទុកេចាលហាេលវ‌ល 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
8 
22. េបើកុមារ (េឈា� ះ) មិនេ្របើបង�នឬ់ កេន‌�  េតើអ�កេលើកលាមកេ�េចាល េដ‌យរេបៀបណ‌?
KUsrgVg;cMelIyEtmYy
When (NAME) is NOT using a latrine/potty, how do you move the
stools?
Circle ONLY ONE answer
  េ្របើៃដ Hands   1 
Leaves/grass  េ្របើស�ឹកេឈើ ឬ េ��    2 
Cloth/paper េ្របើ្រកណ‌ត់ ឬ ្រកដ‌ស់   3 
Tool e.g. shovel េ្របើសំភារេផ្សងៗ ឧ> ែប៉លចូក   4 
epSgeTot Other specify   
____________________________ 
7 
Refused to respond បដិេសធមិនេឆ�ើយ     8 
Don’t know    មនិដឹង     9 
TOILET
9 
23. េតើអ�កលាងសមា� តគូថកនូរបស់អ�កភា� មេទ បន‌� ប់ពីេគbenÞarbង់រួច ?េហើយ ញឹកញ‌ប់ប៉ុន‌� ណ‌?
េបើមិនធា� ប់សូមរ�លងេ�សំនូរេលខ 27
(េបើសិនជ‌ចំាបាច់្រត�វបេង�ើបចំេលើយ)
Do you clean your child immediately after s/he defecates, and
how often?
(Prompt if necessary). If No, Never to this question – jump to 
question 27 
No, never េទ, មិនធា� ប់      0 
Yes sometimes បាទ/ចាស ធា� ប់េពលខ�ះ    1 
Yes usually  បាទ/ចាស ធា� ប់ជ‌ញឹកញ‌ប់    2 
Yes always បាទ/ចាស ្រគប់េពល    3 
Refused to respond បដិេសធមិនេឆ�ើយ     8 
Don’t know    មនិដឹង     9 
TOILET
10 
24. េតើជ‌ធម�តាអ�កលាង សមា� តគូថកូនរបស់អ�ក យ៉‌ងដូចេម�ច បន‌� ប់ពីេគbenÞarbង់រួច?
(េបើសិនជ‌ចំាបាច់្រត�វបេង�ើបចំេលើយ)
How do you usually clean your child after s/he defecates?
(Prompt if necessary)
With a cloth/paper only សមា� តែតជ‌មួយ្រកណ‌ត់ឬ្រកដ‌ស់ប៉ុេន‌� ះ   0 
With water only លាងែត ជ‌មួយទឹកប៉ុេន‌� ះ   1 
With water and soap/detergent លាងជ‌មួយទឹកនិងសាប៊ូ   2 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
TOILET
11 
25. េតើអ�កសមា� តៃដរបស់អ�កភា� មែដររ�េទ បន‌� បព់ីសមា� តកូនអ�ករចួ េហើយញឹកញ‌ប់ប៉ុន‌� ណ‌?
េបើមិនធា� ប់សូមរ�លង េ�សំនួរទី27
(េបើសិនជ‌ចំាបាច់្រត�វបេង�ើបចំេលើយ)
Do you clean your hands immediately after this process and how
often?
(Prompt if necessary). If No to this question – jump to question
27
No, never េទ, មិនធា� ប់      0 
Yes sometimes បាទ/ចាស ធា� ប់េពលខ�ះ    1 
Yes usually  បាទ/ចាស ធា� ប់ជ‌ញឹកញ‌ប់    2 
Yes always បាទ/ចាស ្រគប់េពល    3 
Refused to respond បដិេសធមិនេឆ�ើយ     8 
Don’t know    មនិដឹង     9 
TOILET
12 
26. េតើជ‌ធម�តាអ�កសមា� តៃដរបស់អ�កដូចេម�ចខ�ះ?
(េបើសិនជ‌ចំាបាច់្រត�វបេង�ើបចំេលើយ)
How do you usually clean your hands?
(Prompt if necessary)
With a cloth/paper only សមា� តែតជ‌មួយ្រកណ‌ត់ឬ្រកដ‌ស់ប៉ុេន‌� ះ   0 
With water only លាងែតជ‌មួយទឹកប៉ុេន‌� ះ   1 
With water and soap/detergent លាងជ‌មួយទឹកនិងសាប៊ូ   2 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
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Form 3: Socio-economic 6/7 
0 3 
មិនដឹង   Don’t know      9 
TOILET
13 
27. េតើអ�កបានអនុវត�ខុសគា� ឬេទចំេពាះលាមករបស់កូនអ�ក េ�េពលែដលគាត់/ន‌ងមានជំងឺរ‌ក? េបើសិនជ‌បាទ/ចាសសូមពន្យល់
Do you manage the feces of your child differently when she /he
has diarrhoea?
If yes, how
េទ   No  0 
បាទ/ចាស   Yes  
ពន្យល់ពិសា� ៖ Specify how:
_______________________________ 
1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
MOSNE
T 
28. េតើផ�ះរបស់អ�កមានចងមងុ ឬេទេ�េពលេគង?
Do you do anything to avoid mosquito bites when you go to
sleep?
If no, go to question 29.
If yes, what do you do? Tick all that apply
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
MOSNET
2 
ចងមុង Use bed nets   1 
ដ‌ក់សំណ‌ញ់ ទា� ឬបង��ច Use window/door nets   2 
េ្របើថ‌� ំបាញ់ឬធូកមូសUse spray or coils   3 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
INCOM
E1 
29. េតើ្របភពចំណូលសំខាន់របស់្រគ�សាររបស់អ�កបានមកពីណ‌ខ�ះ?
KUscMelIyEtmYy
What is the main source of income for this household?
Circle ONLY ONE answer
ម្រន�ីរ‌ជការFormal/public sector work   1 
ការង‌រឯកជន Private  sector   2 
ការង‌រសំណង់ Construction work  3 
ការង‌រេរ‌ងច្រក Factory work   4 
រត់មូតូឌបុ ឬ តុក តុកMotodop/tuktuk   5 
លក់ដូតិចតួច Trading (small shop/vendor)    6 
េរ�សសំរ‌ម Waste picking    
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
INCOM
E2 
30. េតើ្របភពចំណូលសំខាន់ទី២ របស់្រគ�សាររបស់អ�កបានmkBIណ‌ េបើសិនជ‌មានសូមពន្យល់?
KUscMelIyEtmYy
What is the second source of income for this household, if any?
Circle ONLY ONE answer
No second source of income គា� ន្របភពចំណូលសំខាន់ទី២េទ  
ម្រន�ីរ‌ជការFormal/public sector work   1 
ការង‌រឯកជន Private  sector   2 
ការង‌រសំណង់ Construction work  2 
ការង‌រេរ‌ងច្រក Factory work   3 
រត់មូតូឌបុ ឬ តុក តុកMotodop/tuktuk   4 
លក់ដូតិចតួច Trading (small shop/vendor)    5 
េរ�សសំរ‌ម Waste picking    6 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
INCOM
E3 
31. េតើ្របាក់ចំណូលជ‌មធ្យមក��ង្រគ�សារបស់អ�កក��ងមួយែខ េស�ើប៉ុន‌� នែដរ? សេសរចមេលើយែតមួយ
What is this household’s average income each month?
$ _____________________ 
1 
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Write ONLY ONE answer ឬេរៀល OR Riel _____________________
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
INCOME
4 
េតើ្រគ�សាររបស់អ�កមានសមា� រ³ ឬ ក៏សមាជកិណ‌មា� ក់ៃន្រគ�សាររបស់អ�កជ‌មា� ស់ៃនរបស់ទាងំេនះ....ឬេទ? 
គូសរង�ង់ ១ ឬ ២ ស្រមាប់របស់នីមួយៗ 
Does your household have OR Does any member of your household 
have: 
Circle 1 or 2 for each item 
 
មានYe
s 
េទ
N
o 
អគ�ិសនី Electricity 1 2 
វ�ទ្យ�ម៉ាេញ៉វ�សីុឌី radio 1 2 
ទូរទស្សន៍ television 1 2 
ទូរសព�័ៃដ mobile phone 1 2 
ទូរទឹកក refrigerator 1 2 
m:asIunedr  sewing machine 1 2 
kg; Bicycle/Cyclo : 1 2 
m:UtU Motorcycle/Scooter 1 2 
Lan Car/Truck/Van 1 2 
កុំព្យ�ទ័រ computer 1 2 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
IDPOO
R 
32. េតើ្រគ�សារេនះ្រត�វបាន កត់សំគាល់ថ‌្រកី្រកឬេទ
តាមរយៈការកំណតអ់ត�ស�� ណ្រគ�សារ្រកី្រកែដលេធ�ើេឡើងេដ‌យអ�កតំណ‌ងរភូមិនិង្រត�វបានដ‌ក់េ�េលើប��ីរ្រគ�សារ្រក្ីរកឬទទួលបាន
b½NÑmUlniFismFm’ b¤ b½NÑGaTiPaBRkIRk  Edrb¤eT?
សំុេមើល b½NÑmUlniFismFm’ b¤ b½NÑGaTiPaBRkIRk  និង កាតេផ្សងៗេទៀត
រួមទំាងកាតេចញេ្រកាយ ការកណំត់អត�ស�� ណ។ កត់ចំណំ‌ថ‌បានេមើលេឃើញ / មិនបានេឃើញ
Has this household been identified as poor through the
Identification of Poor Households process conducted by village
representatives, and been placed on the List of Poor
Households or received an Equity Card or Priority Access Card?
Ask to see the equity, priority access card and other card
include post-identification.  Note is seen/not seen
ចាស, 
បានេឃើញb½N
Ñ 
Yes, card 
seen 
េទ, មិនបាន
េឃើញb½NÑ
Yes, card not 
seen 
េទ
No 
1 2 0 
b½NÑmUlniFismF
m’ (ពណ៏ផ‌� ឈូក)
Equity card (pink) 
      
b½NÑGaTiPaBRkI
Rk(ពណ៏ស)
Priority access 
card (white) 
      
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
SUBSIDY
1 
33. េតើមានសមាជិក្រក�ម្រគ�សារណ‌មា� ក់ ែដលទទួលបានការ ែថទាសុំខភាពឥតគិតៃថ�ពីអ�កណ‌ និង/ឬមានអ�កណ‌បង់ៃថ�ែថទាំសុខភាពេន‌ះឲ្យអ�ក?
េបើសិនជ‌គា� ន សូមបន�េ សំនួរចុងប��ប់
Do members of this household receive free or subsidized health care
that other people would normally have to pay for? If no, go to question 
end
េទ   No   0 
)aT¼cas+ minbg;éf Yes, free   1 
)aT¼cas+ eKbg;éføCMnYs  Yes, subsidised   2 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
SUBSIDY
2 
34. េតើ ការឧបត�ម� និង/ឬការបង់ៃថ�េលើការែថទាំសុខភាព្របេភទណ‌ខ�ះែដលសមាជិក្រក�ម្រគ�សារណ‌មា� ក់ ែដលទទួលបានការ?
What are free and/or subsidized health care that any member of this
household received?
mUlniFismFm’ Health equity funds   1 
karFanar:ab;rgsuxPaBtamshKmn_ Community 
based health insurance   
2 
sMbuRtbBa¢ak;Ca®sþImanépÞeBaH 
Maternity voucher   
3 
epSgeTot Other specify   
____________________________ 
7 
បដិេសធមិនេឆ�ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ចេម�ើយរបស់អ�ក។ សូមយកប��ីសំនួរេន‌ះេហើយអេ��ើញេ�តុបន‌� ប់ ។ 
Say:  Thank you for answering these questions.  Please take this questionnaire and go to the next station. 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):
Form 3: Anthropometry 1/3 
0 3 
ទ្រមង់ទី៣៖ ្របសិទ�ភាពនំ្រតីរបស់ការសិក្សោ- ទ្រមង់ប�� ីសំនួរ្របមូលទិន�ន័យមូលដ� ន - mnusSmaRtviTüa 
Form 3F:  Efficacy trial, baseline data collection form - anthropometry 
eQµaHkumar  Name of child  (NAMECH) 
eQµaHអ�កេមើលែថកុមារ  Name of caregiver
(NAMECG) 
ឥឡូវេយងនឹងេធ�ករថ�ឹងទម�ន់ និង វស់កំពស់របស់អ�ក ្រពមទំងេធ�ករថ�ឹងទម�ន់ វស់កំពស់ ក្រមាស់ៃដនិងជាតិខ� ញ់របស់អ�ក។ 
Now we are going to measure your weight and height and your baby’s weight, height, arm thickness, and fat. 
MUMWT1 1. ថ�ឹងទម�ន់អ�កេមើលែថកុមារ  េលើកទ១ី គិតជ‌គីឡ�្រកាម(ក្រមិតលេម� ង0.1kg)? បន‌� ប់មក េ�េពលែដលអ�កេមើលែថកុមារ  កំពងុស�ិត
េ�េលើជ��ីងដែដលេន‌ះ ចុចជ��ឹងឲ្យេ�េលខ០ េហើយហុចកុមារឲ្យេ�អ�កេមើលែថកុមារ
េហើយកត់្រតានូវទម�ន់កុមារែដលបង‌� ញេលើជ��ីងគិតជ‌គីឡ�្រកាម
Weigh mother 1st time in kilograms to the closest 0.1kg . With
mother still on scale, zero, pass child to mother, record child’s
weight in kilograms to the closest 0.1kg
ទម�ន់អ�កេមើលែថកុមារ ១(kg) 
Mother’s weight 1 
(kg) 
CHWT1 ទម�ន់កុមារ១(kg) 
Child’s weight 1 
(kg)  
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
MUMWT2 2. ឲអ�កេមើលែថកុមារ  េឡើងេលើជ��ីងម�ងេទៀត ថ�ឹងទម�នអ់�កេមើលែថកុមារ  ជ‌េលើកទ២ី គិតជ‌គីឡ�្រកាម(ក្រមិតលេម� ង0.1kg)?
បន‌� ប់មក េ�េពលែដលអ�កេមើលែថកុមារ  កំពុងស�ិតេ�េលើជ��ីងដែដលេន‌ះ ចុចជ��ឹងឲ្យេ�េលខ០
េហើយហុចកុមារឲ្យេ�អ�កេមើលែថកុមារ  េហើយកត់្រតានូវទម�ន់កមុារជ‌េលើកទី២ ែដលបង‌� ញេលើជ��ីងគិតជ‌គីឡ�្រកាម
Caregiver  steps on scale again.  Weigh caregiver    2nd time in
kilograms to the closest 0.1kg . With caregiver  still on scale,
zero, pass child to caregiver  , record child’s 2nd weight in
kilograms to the closest 0.1kg
ទម�ន់អ�កេមើលែថកុមារ ២ (kg) 
Mother’s weight 2 
(kg) 
CHWT2 ទម�ន់កុមារ២(kg) 
Child’s weight 2 
(kg)  
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
MUMMUA
C1 
MUMMUA
C2 
3. ĉМъФЋŨ Ї єЇ Ŏ ″ У ТЋċЋєыВъН▪Ї Ĵ ЋщУ שּׂ� (MUAC)ТМЧ єអ�កេមើលែថកុមារ
ЉпЗ ļ  Ч ЋєЙръРђĉЗ ъВУ Ј пЗщΌ ЏпЗ ֳ . ִ Ч ЋєЙръРђĉЗ ў � ŲЧ єֵ ВЋ�
Caregiver’s mid upper arm circumference (MUAC) in cm closest 
0.1cm  Measure 2nd time.
អ�កេមើលែថកុមារ
Mother MUAC 1 
(cm)  
អ�កេមើលែថកុមារ 
Mother MUAC 2 
(cm) 
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
CHMUAC1 
CHMUAC2 
4. ĉМъФЋŨ Ї єЇ Ŏ ″ У ТЋċЋєыВъН▪Ї Ĵ ЋщУ שּׂ� (MUAC)ТМЧ єЇ уŪ Т ЉпЗ ļ  
Ч ЋєЙръРђĉЗ ъВУ Ј пЗ щΌ ЏпЗ ֳ . ִ Ч ЋєЙръРђĉЗ ў � ŲЧ єļ щУ שּׂЇ Йрֵ �
ĉМЧ пЛщМשּׂОЖјĉЇ ШРН″У єВюЖсЋщΌ Ъ▪Ї ĉЉМєĉЉЋТхЌ�
Ч фРЛпū С Ŗ Ґ � ЪТЉуЖ Ч ĉŪ МєЎЛℓёЌфУ ТхРў �
МђуъЛ″Ч фРщŗ Ч ъВУ Ъ▪Ї � ЛпЋЇ фЛТМЧ єЪ▪Ї Р пЛŪ ЛУ Ї ☺Ж ёЧ Р▫З ″п�
ĉЉМєĉĵ ЛєЇ ▪уЋį ТЌфУ ТхР � щŊ С ŵ ТЇ уŪ Т�
កុមារ
Child MUAC 1 
(cm) 
Child MUAC 2 
(cm) 
បដិេសធ Mother refused     8 
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េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):
Form 3: Anthropometry 2/3 
0 3 
&щŅ āя'Ū ЛЏюЋтЇ Ћċяſ Ŷ ТТфМЗ℅РĀК♀ЛєК♀Тў щЛяЉсОпЗ ļ К♀ЛєК♀ТŎ
Ч єў �
щС שּׂЋк Ĉщū МУ єŖ Ъ▪Ї ЉхТъЗМψ ♣фЛЇ фЛщΌ ОпЛпЗ ĈщΏ РЛℓрТщОЙĈў �
щС שּׂЋЛсЋйĈУ уС Ъ▪Ї щВשּׂР▫рщΌ РЛℓрТщОЙĈĉМЧ пЛщМשּׂĸ юŦ Ќєў  
РпЛЙЙхУ С Ї į ТЌфУ ТхР � Мψ ♂МєЧ юЛхТ 
Child’s mid upper arm circumference (MUAC) in cm closest 
0.1cm  Measure 2nd time..  If red, Inform supervisor – say: 
Thank you for your willingness to participate.  Unfortunately, 
you and your child are not eligible to participate because 
(name) is severely malnourished.  This is very serious.  You 
need to take your child to the hospital.  We will give you 
money for transport to go to the hospital if necessary . 
EXCLUDE AND END QUESTIONNAIRE  
េផ្សងៗ   Other        9 
មិនទទួលយកការសិក្សោEXCLUDED    99 
MUMTSF1 
MUMTSF2 
5. kMras;Es,kbt;edIméd របស់អ�កេមើលែថកុមារ (ក្រមិតលេម� ង0.2cm)
Caregiver’s triceps Skinfold Thickness (TSF) (to the closest
0.2cm).  Measure twice.
អ�កេមើលែថកុមារ 1
Mother’s TSF 1  
(cm)  
អ�កេមើលែថកុមារ 2 
Mother’s TSF 2  
(cm)   
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
CHTSF1 
CHTSF2 
6. kMras;Es,kbt;edIméd របស់កុមារ (ក្រមិតលេម� ង0.2cm) វស់២ដង
Child’s Triceps Skinfold Thickness (TSF) (to the closest 0.2cm).
Measure twice.
កុមារ 1
Child’s TSF 1  
(cm) 
កុមារ 2
Child’s TSF 2  
(cm) 
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
SCAPSF1 
SCAPSF2 
7. kMras;Es,k ចុងស� ប្របេចៀវ របស់កុមារ
(ក្រមិតលេម� ង0.2cm)
Child’s Subscapular Skinfold Thickness (SSF) (to the closest
0.2cm)
SSF 1  (cm) 
SSF 2  (cm) 
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
MUMHT1 Ї Р ◦Ч єអ�កេមើលែថកុមារ (cm) 
8. ЉпЗ ļ Ч ЋєЙръРђĉЗ&Ї ĉРпЗ У щРėυЋ0.1cm' =
ŲЧ єщŊ С Ŋ Ї єЇ уŪ Тк ĈА Т 
Caregiver’s height in centimetres to the closest 0.1cm.
កម�ស់អ�កេមើលែថកុមារ ១ (cm)
Mother’s height 1 
(cm) 
MUMHT2 កម�ស់អ�កេមើលែថកុមារ ២(cm)
Mother’s height 2 
(cm)
266
េឈា� ះអ�កសមា� សន៍ Name of interviewer:________________ GñkRbmUlTinñn½y (Interviewer ID, IVID): (Form ID, FORMID) 
kumar   (Child´s ID, CHID):
Form 3: Anthropometry 3/3 
0 3 
Measure standing. 
Measure twice.  
បដិេសធMother refused     8 
េផ្សងៗ   Other        9 
CHHT1 
CHHT2 
9. វស់្របែវងЇ уŪ ТЉпЗ ļ Ч ЋєЙръРђĉЗ&Ї ĉР пЗ У щРėυЋ0.1cm' =
ŲЧ єщОУ ъВУ Ŋ Ї єєєє
єєє
Ї уŪ Тк ĈщВЇ Ќуяў �
ŲЧ єļ щУ שּׂЇ Йрֵ щŊ С Ŋ Ї єЇ уŪ Тк ĈщВЇ �
ЉЖ ŝ ТЇ  WHZ � ĉМЧ пЛщМשּׂ<-3 � Тт >+3
ĉЗ ύФН″У єВюЖсЋщΌ Ъ▪Ї ĉЉМєĉЉЋ� ĉМЧ пЛщМשּׂ<-3 � Ч фРЛпū С Ŗ Ґ �
ЪТЉуЖ Ч ĉŪ МєЎЛℓёЌфУ ТхРў � МђуъЛ″Ч фРщŗ Ч ъВУ Ъ▪Ї �
ЛпЋЇ фЛТМЧ єЪ▪Ї Р пЛŪ ЛУ Ї ☺Ж ёЧ Р▫З ″п� ĉЉМєĉĵ ЛєЇ ▪уЋį ТЌфУ ТхР �
щŊ С ŵ ТЇ уŪ Т� &щŅ āя' �
Ū ЛЏюЋтЇ Ћċяſ Ŷ ТТфМЗ℅РĀК♀ЛєК♀Тў щЛяЉсОпЗ ļ К♀ЛєК♀ТŎ Ч єў �
щС שּׂЋк Ĉщū МУ єŖ Ъ▪Ї ЉхТъЗМψ ♣фЛЇ фЛщΌ ОпЛпЗ ĈщΏ РЛℓрТщОЙĈў �
щС שּׂЋЛсЋйĈУ уС Ъ▪Ї щВשּׂР▫рщΌ РЛℓрТщОЙĈ 
РпЛЙЙхУ С Ї į ТЌфУ ТхР � Мψ ♂МєЧ юЛхТ 
Child’s length in centimetres to the closest 0.1cm.  Measure
lying down. Measure 2nd time lying down. SOP. Calculate WHZ.
If <-3 or >+3, inform supervisor.  Say: Thank you for your
willingness to participate.  Unfortunately, you and your child
are not eligible to participate because (name) is severely
malnourished.  This is very serious.  You need to take your child
to the hospital.  We will give you money to go to the hospital.
EXCLUDE AND END QUESTIONNAIRE
្របែវងកុមារ(cm)
Child length 1 
(cm) 
្របែវងកុមារ(cm)
Child length 2 
(cm) 
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
WHZ � ĉМЧ пЛщМשּׂ<-3 � Тт >+3 <-3or  >+3 
េទ   No  
បាទ/ចាស   Yes  
មិនទទួលយកការសិក្សោ EXCLUDED    
99 
េបសិនជាអ�កទទួលបានចេម�យែដលមិនទទួលយកករចូលរមួពីសំនាក់អ�កែថរកុមារ សូមនិយយាយថា៖ 
អរគុណស្រមាប់ឆន�ៈចូលរមួ។ បុ៉ែន�សូមេទសែដលអ�ក និងកូនរបស់អ�កមិនមានលក�ណៈសម្បត�ិ ្រគប់្រគាន់ក�ុងករចូលរមួ 
េដយសរកុមារ (េឈ� ះ) មានជំងឺកង�ះអហររបូត�ម� ស�ច�សវ វជាជំងឺធ�ន់ធ�រ។ អ�ក្រត�វែតយកកូនរបស់អ�កេទមន�ីេពទ្យ។ 
េយងនឹងផ�ល់្របាក់ដល់អ�កស្រមាប់ករចំណាយេលករេធ�ដំេណ រក�ុងករយកកូនរបស់អ�កេទមន�ីេពទ្យេបសិនជាចំបាច់។ 
If you get a WHZ or MUAC that excludes the child, say:  Thank you for your willingness to participate.  Unfortunately, your child is not 
eligible to participate because s/he is severely malnourished.  This is very serious.  You need to take your child to the hospital.  We 
will give you money for transport to go to the hospital if necessary. 
េបសិនជាអ�កសួរនូវសំនួរទំងអស់េហយ េហយអ�កែថរកុមារ/កុមារេនាះមានលក�ណៈ្រគប់្រគាន់ក�ុងករចូល រមួ សូមនិយាយថា៖ 
អរគុណស្រមាប់ចេម�យរបស់អ�ក។ សូមយកប�� ីសំនួរេនាះេហយអេ�� ញេទតុបនា� ប់  
If the child is eligible to participate, say:  Thank you for answering these questions.  Please take this questionnaire and go to the 
next station. 
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េ�� ះអ�កស�� សន៍ Name of interviewer (4IVNAME1):________________ អ�ក្របមូលទិន�ន័យ (Interviewer ID, 4IVID1): (Form ID, FORMID)
 
កុ�រ   (Child´s ID, CHID): ែខ Month
 
Form 4: Monthly follow-up  1/20 
0 4 
ទ្រមង់ទី៤៖ ្របសិទ�ភាពទិន�ន័យជ‌េរៀងរ‌ល់ែខ៖ែខ៤ Form 4: Efficacy Trial - monthly data collection, month 4 
ទ្រមង់ទី៤.១៖ ទ្រមង់ស្រមាប់េ្រជើសេរ�សការចូលរួម និងសំណួរស្រមាប់មិនទទួលយកការសិក្សោ Form 4.1: recruitment and exclusion 
 
េ�� ះកុ�រName of the child  (M4CHNAME1) 
េឈ� ះអ�កែថទំកុមារ  Name of caregiver  (M4CGNAME1)
េលខកំណត់អត�ស�� ណកុមារ  Child´s ID (M4CHID1)
ទីកែន�ងផ�ល់អហរ  Data collection site name: (M4SITE)
ទីកែន�ងផ�ល់អហរ  Data collection site number: (M4SITENBR)
កាលបរ�េច�ទ Date  (M4DATE1)
ៃថ� Day ែខ Month ឆា� ំ  Year
្របាប់េទអណាព្យោបាល៖ Tell caregiver: (M4CONSENT)
ជំរបសួរ ខ�ុំបាទ/នាងខ�ុំេឈ� ះ_____________________ ។ ខ�ុំបាទ/នាងខ�ុំេធ�ករងរជាមួយគំេរងផលិតនំ្រតី។ 
អ�កបានយល់្រពមចូលរមួក�ុងករសិក្សោនូវករទទួលយកបានៃនអហរបំប៉នែដលអចញំុាបានែតម�ងេដយមិនបាច់ចម�ិនេហយផ
លិតក�ុង�ស�ក 
េយងនឹងេធ�ករ្របមូលព៌តមានអំពីកូនរបស់អ�កនិង ខ�ួនអ�កផា� ល់ ដូចជាសុខភាព កម�ស់ ទំងន់ និងរបបអហរ ។ 
មកេលកេនះមិនមានករបូមឈមេទៀតេទ។ ព៌តមានទំងអស់ែដលបាន្របមូលនឹង្រត�វរក្សោេដយសមា� ត់។ 
វនឹងមិនមានហនិភ័យអ�ីទំងអស់។ 
Hello, my name is _________________________ and I work with the Num Trey Project.  You have agreed for you and your child to participate in the Num Trey project which is a trial of a locally produced ready-to-use-
supplementary food.   
We will collect information about your child’s and your health, height, weight and diet.  We will not collect blood or stool again until the end of the project. 
All information collected will be kept private and confidential.  There are no risks to this study.   
ករចូលរមួរបស់អ�កគឺជាជំេរ សរបស់អ�កទំង�ស�ង។ េយងសង្ឹឃមថាអ�កនឹងបន�ចូលរមួជាមួយករសិក្សោរបស់េយងសំរប់រយៈេពល៦ែខេពញ 
បុ៉ែន� អ�កអចប�្ឈប់ករចូលរមួរបស់អ�កេពលណាក៏បានក�ុងកំឡុងេពលសិក្សោេនះ។ េយងដឹងថាេពលេវលរបស់អ�កមានតំៃល 
ដូេច�ះេហយអ�កនឹងទទួលបានអំេណាយឬក៏អហរ្របសិនេបអ�កចូលរមួ ក�ុងរយះេពល៦ែខេពញ។ មិនែតបុ៉េណា� ះ 
េយងនឹងផ�ល់ជូននូវថវកិរសំរប់េធ�ដំេណ រ ចំនួន៤០០០េរៀលនិងអំេណាយតិចតួចជាេរៀងរល់េពលែដលអ�កអេ�� ញមកកែន�ងសិក្សោេនះ។ 
Your participation is your choice.  We hope you will continue with the study for the full 6 months, but you are free to stop participating at any time.  We realize that your participation is valuable, so you will receive $1 for 
transport and a small gift or food each time you come.   
េបសិនជាអ�កមានសំណួរ ឬេបអ�កចង់ពិភាក្សោអំពីករចូលរមួរបស់អ�កក�ុងករសិក្សោេនះ 
អ�កអចនិយាយេទកន់បុគ�លិករបស់គេ្រមាងេនះ ឬអ�កអចទូរសព�័មក េលខ:០១១ ៥៦៤៨០១ 
If you have any questions or if you would like to discuss your participation in this study, you can talk to the project staff, or you can call this number: 011 564 801.   
េតអ�កចង់បន�ករសិក្សោជាមួយេយងែដរឬេទ ? បាទ/ចស    េទ  
Do you want to continue to participate?  (M4CONSENTQ) Yes    No (M4WDRAW)   
2 0 1 6 
Appendix 5.4 Form 4:  Monthly questionnaire
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េ�� ះអ�កស�� សន៍ Name of interviewer (4IVNAME1):________________ អ�ក្របមូលទិន�ន័យ (Interviewer ID, 4IVID1): (Form ID, FORMID)
 
កុ�រ   (Child´s ID, CHID): ែខ Month
Form 4: Monthly follow-up  2/20 
0 4 
េបសិនជាមានសូមអនុ��ត�ិឲ្យ 
ខ�ុំសួរនូវសំនួរមួយចំនួនេដម្ីបដឹងថាអ�កនិងកូនអ�កមានលក�ណៈ្រគប់្រគាន់ស្រមាប់បន�ក�ុងករសិក្សោេនះែដរឬេទ។ 
សួរសំនួរដូចខងេ្រកម 
If yes, please let me ask some questions to see if you and your child are still suitable participants.  Ask the following questions: 
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េ�� ះអ�កស�� សន៍ Name of interviewer (4IVNAME1):________________ អ�ក្របមូលទិន�ន័យ (Interviewer ID, 4IVID1): (Form ID, FORMID)
 
កុ�រ   (Child´s ID, CHID): ែខ Month
Form 4: Monthly follow-up  3/20 
0 4 
Variable 
name សូមសួរេ�អ�កេមើលែថកុមារ PLEASE ASK THE CAREGIVER ចេម�ើយ RESPONSE កូដ Code
M4EXILL1 
M4EXILL2 
1. щЗ שּׂЇ фЛТМЧ єЪ▪Ї Ї юОуЋŪ ЛЏюЋтК♀ЛєК♀Тд щЙ= ВфЌļ ЏюЋтщЪВЧ і�
д ТщМЋў У ў щМשּׂЇ уŪ ТŪ ЛЏюЋтК♀ЛєК♀ТЧ фР Лпū С Ŗ 8�
ЪТЉуЖ ЌющŨ яЎЛℓёТМЧ єЪ▪Ї щВשּׂР ▫рЌфУ ТхР ў �
ែតគួរឲ្យស� យЪ▪Ї ЛпЋЇ фЛТМЧ єЪ▪Ї Р пЛŪ ЛУ Ї ☺Ж ёĉЉМєĉĵ ЛєЌфУ ТхР
щŊ С ŵ ТъЗ � &щŅ āя' Ū ЛЏюЋтК♀ЛєК♀Тў  
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។ 
Does this child have any major illness right now (e.g. HIV, TB, etc)?  If the child has a major 
illness, say: Thank you for your willingness to participate.  Unfortunately, (name) is not eligible 
to participate because s/he has a major illness. EXCLUDE AND END QUESTIONNAIRE AND GO TO 
EXCLUSION STATEMENT 
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      99 
M4EXALRGY 
M4EXALGY2 
2. េតើកូនរបស់អ�ក�� ប់�ន្របតិកម� មួយ��រអ� ីខ� ះ? (ឧ.
��ំេហើយេធ� ើឲ្យពិ�កក� �ង�រដកដេង� ើម
ឬ�នកន� �លរ�ស់េ�េពល��ំ �រ�មួយ)
េបើកុ�រ�ន្របតិកម�សូមនិ�យ�: 
អរគុណចំេ�ះឆន� ៈរបស់អ�កេដើម្ីបចូលរមួ។
ែតគួរឲ្យ�� យអ�កនិងកូនរបស់អ�កមិន�នលក�ណៈ្រគប់្រ�ន់ចូ
លរមួេ�យ�រែត (េ�� ះ)�ន្របតិកម� �រ។
មិនទទួលយកករចូលរមួ ប�� ប់សំនួរ 
និងរលំងេទសរចុងប�� ប់ៃនករមិនមិនទទួលយក ។
Does this child have allergies or intolerances to any food (e.g. difficulty breathing or a rash if 
they eat certain foods).  If the child has food intolerances, say: Thank you for your willingness to 
participate.  Unfortunately, (name) is not eligible to participate because s/he has food 
intolerances. EXCLUDE AND END QUESTIONNAIRE AND GO TO EXCLUSION STATEMENT 
េទNo       0 
បាទ/ចាសYes       1 
មិនទទួលយកការចូលរួម EXCLUDED      99 
M4EXSTUDY 
3. щЗ שּׂЇ фЛТМЧ єЪ▪Ї Ї юОуЋЌфУ ТхР щКċשּׂį ТЧ пЇ · ļ Р хС ЉющŬЋд į ТЧ пЇ · ВјыЙ
щЙςЗ щЙ=
Is the child currently participating in any other study? 
េទNo     0 
�ទ/�ស �ម�នសុខ�ពនឹង��ររបូត�ម�
Yes, health & nutrition  study      
1 
�ទ/�ស សិក�គំរងេផ្សង  Yes, another study       2 
សរចុងប�� ប់ៃនករមិនទទួលយក щМשּׂЪ▪Ї ЙЙхУ Ŧ ЛЛфФЌщР ĊשּׂС ъВУ Р пЛЙЙхУ С Ї į ТЌфУ ТхР ТМЧ єЪ▪Ї ъИŗ юЇ уŪ ТщЙ� щŝ яЧ фР Лпū С Ŗ Ґ
ЪТЉуЖ ЌющŨ яЎЛℓёъВУ ЌЋєЌфУ ТхР Ї ▪уЋį ТЧ пЇ · ļ Р хС ОхЇ щС שּׂЋ� ъЗ ЉхТк Ĉщŵ Ї ŵ ″С ъВУ Ъ▪Ї �
ЛпЋЇ фЛТМЧ єЪ▪Ї Р пЛŪ ЛУ Ї ☺Ж ёĉЉМєĉĵ ЛєщВשּׂР ▫рЌфУ ТхР Ї ▪уЋį ТЧ пЇ · � щŊ С ŵ ТъЗ  
[ĉŦ МєЛфФР фУ щШЗ уВфЌщΏ Ї ▪уЋЙĉР ЋєР пЛЙЙхУ С Ї į ТЌфУ ТхР ТМЧ єĵ З є� Я,� Ї уŪ ТР пЛŪ Лſ С уЌщŝ Ċ]ў មិនប���លគាត់ក��ងការសិក្សោ 
EXCLUSION STATEMENT: If you get an answer that excludes the caregiver, please say:  Thank you for your willingness to participate.  Unfortunately, you and your child are not eligible to participate because [give the 
reason from the exclusion form that they were excluded]. Excluded   
270
េ�� ះអ�កស�� សន៍ Name of interviewer (M4IVNAME2):________________ អ�ក្របមូលទិន�ន័យ (Interviewer ID, M4IVID2): (Form ID, FORMID)
 
កុ�រ   (Child´s ID, CHID): ែខ Month
Form 4: Monthly follow-up  4/20 
0 4 
 
ទ្រមង់ទី៤.២៖ ្របសិទ�ភាពទិន�ន័យជ‌េរៀងរ‌ល់ែខ Form 4.2: Efficacy Trial - monthly data collection  
 
េ�� ះកុ�រName of the child  (M4CHNAME2) 
េលខកំណត់អត�ស�� ណកុមារ Child´s ID (M4CHID2)
កាលបរ�េច�ទ Date  (M4DATE2)
�ដំបូង ខ� � ំសូមសួរអំពីព៌ត�នទូេ�មួយចំនួនអំពីកុ�រ (First, I will ask some questions about the child(CHILDQS)  
Variable name  Question  Response Code 
M4RSHP 
M4RSHPDES 
1. េតើអ�ក�នទំ�ក់ទំនងអ� ី មួយនឹងកុ�រេនះ?
សូមគួសរង�ង់យកចំេលើយែតមួយ
្របសិនេបើអ�កែថទាំមិនែមនជ‌ (េឈា� ះ) មា� យ, រ�លងេ�សណួំរទី២។
្របសិនេបើអ�កែថទាំគឺជ‌ (េឈា� ះ) មា� យ, រ�លងេ�សណួំរទី៣ ។
What is your relationship to (NAME)? Select ONLY ONE answer 
If the caregiver is not (NAME’S) mother, go to question 2. 
If the caregiver is (NAME’S) mother, go to question 3. 
មា� យបេង�ើត Biological mother   1 
ជីដូន Grandmother   2 
ឪពុក Father   3 
បង្រសី Sister   4 
 បងប� �ន្រប �សBrother   5 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)       7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4MUMWHR 2. េតើមា� យ (ៃនេឈា� ះ) េ�ឯណ‌េពលេនះ?
សូមគួសរង�ងយ់កចំេលើយែតមួយ
Where is (NAME’S) mother now? Select ONLY ONE answer 
At work in PP  េ�កែន�ងេធ�ើការេ�ក��ងរ‌ជធានីភ�ំេពញ   1 
At work outside PP េ�កែន�ងេធ�ើការេ�ខាងេ្រ�រ‌ជធានីភ�ំេពញ   2 
At work outside Cambodia   េ�កែន�ងេធ�ើការេ�េ្រ�្របេទសកម��ជ‌   3 
សា� ប់ Not alive   4 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)       
M4MUMWHR2
7 
បដិេសធមិនេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4USUALCG 
3. េតើអ�កជ‌អ�កែថទំា របស់កូនេនះជ‌ប់លាបឬេទ?
សូមគួសរង�ងយ់កចំេលើយែតមួយ
Are you the child’s usual caregiver?  Select ONLY ONE answer 
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
2 0 1 6 
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M4CARE2W 4. េតើ២ស�� ហ៏ចុងេ្រ�យេនះ អ�ក�នេមើលែថ�កុំ�រេនះែដរឬេទ?
សូមគួសរង�ងយ់កចំេលើយែតមួយ
Have you been looking after (NAME) for at least the last two weeks? Select ONLY ONE answer
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4ILL2W 
5. េតើ២សបា� ហ៍ចុងេ្រកាយ េនះ កមុារ(េឈា� ះ)មានឈឺេទ?
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ៨ 
In the past 2 weeks, has (NAME) been ill? If No to this question – jump to question 8 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4ILL2W2 
6. ជ‌គំនិតរបស់អ�ក េតើកុមារ(េឈា� ះ) មានជងំឺធ�ន់ មធ្យម ឬ្រសាល?
េបើសិនជ‌ជំងធឺ�ន់ធ�រ សូមរ�លងេ�សំនួរ៧ 
In your opinion , was (NAME’S) illness serious, moderate or slight? 
If Serious go to question 7.
ជំងឺធ�ន់  Serious       1 
មធ្យម  Moderate    2 
្រសាល Slight   3 
បដិេសធមិនេឆ�ើយ  Refused to respond   8 
មិនដឹង  Don’t know      9 
M4ILLDR 
M4ILLDREX 
7. េតើអ�កបានយក (េឈា� ះ) េ�ជួប្រគ�េពទ្យឬេទ?
្របសិនេបើបានេ�េវជ�បណ� ិត សូមនិយ‌យថ‌៖ អរគុណស្រមាប់ឆន�ៈែដលចង់ចូលរួម។ 
បុ៉ែន�សូមេទាសេដ‌យអ�កនិងកូនរបស់អ�កមិនមានលក�ណៈ្រគប់្រគាន់ក��ងការចូលរួមេដ‌យ
សារ(េឈា� ះ)មានជំងឺធ�ន់ធ�រកាលពី២សបា� ហ៍មុនេនះ ។ មិនយកេហើយប��ប់សំនួរ 
Did you take (NAME) to the doctor?  If yes, visited the doctor – Say: Thank you for your willingness to 
participate.  Unfortunately, you and your child are not eligible to participate because (name) has been 
seriously ill in the last 2 weeks.  EXCLUDE AND END QUESTIONNAIRE  
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ  Refused to respond   8 
មិនដឹង  Don’t know      9 
មិនទទួលយកការសិក្សោ  EXCLUDED      99 
M4FEVER2W 
8. េតើកុមារ(េឈា� ះ)មានេ�� ខ��នេទ ក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (NAME) been ill with a fever at any time in the past 2 weeks?  
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4ARI2W1 9. េតើកុមារ(េឈា� ះ)មានក�កេទក��ងរយះេពល២សបា� ហ៍ចងុេ្រកាយេនះ?
េបើសិនជ‌ចេម�ើយេទ សូមរ�លងេ�សំនួរ១២
Has (NAME) had an illness with a cough at any time in the past 2 weeks? If No to 
this question – jump to question 12
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4ARI2W2 10. េ�េពលកុមារ(េឈា� ះ)មានជំងឺក�ក េតើេគមានដកដេង�ើមញ‌ប់ជ‌ងធម�តាេដ‌យដង�ក់
ដកដេង�ើយញឹក ឬមានការពិបាកក��ងការដកដេង�ើមឬេទ?
េបើសិនចេម�ើយេទ សូមរ�លងេ�សំនរួ១២
When (NAME) had an illness with a cough, did he/she breathe faster than usual with short, fast breaths or had 
difficulty breathing?). If No to this question – jump to question 12 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
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M4AR2W3 
11. មានការដកដេង�ើមញឹកញ‌ប់
ឬមានការពិបាកក��ងការដកដេង�ើមេដ‌យមានប�� េ�េដើម្រទ�ង 
ឬមានស�ះេ�្រចមុះ? 
Was the fast or difficult breathing due to a problem in the chest or a blocked 
nose?) 
េដើម្រទ�ងChest only   1 
្រចមុះNose only   2 
ទាំង២Both   3 
េផ្សងេទៀត ចរូេរៀបរ‌ប ់Other (describe)        
M4ARIOTH __________________________ 
7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹងDon’t know      9 
M4DIAR2W1 
12. េតើកុមារមានរ‌គេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
ឧ. បេន‌� របង់៣េ�៤ដងក��ងរយៈេពលល២៤េម៉ាង 
េបើមាន បន�េ�សំនួរ ១៣ េបើេទ បដិេសធ មិនដឹង រ�លងេ�សំនួរ១៤ 
Has (NAME) had had diarrhoea in the past 2 weeks? i.e.  3 or more loose stools during a 24 hour period.  If Yes 
– go to question 13. If No, Refused, Don’t know – go to question 14
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4DIAR2W2 
M4DIAR2WEX 
13. េតើកុមារមានបេន‌� របង់េដ‌យមានឈាមជ‌ប់លាមកេទ?
េបើមាន សមូនិយ‌យថ‌៖ អរគណុស្រមាប់ឆន�ៈចលូរួម។ 
ប៉ុែន�សូមេទាសែដលអ�ក និងកនូរបស់អ�កមិនមានលក�ណៈសម្បត�ិ 
្រគប់្រគាន់ក��ងការចូលរមួ េដ‌យសារកុមារ (េឈា� ះ) មានបន‌� របង់ឈាម 
ែដលប�� កថ់‌គាត់មានជំងឺធ�ន់ក��ងរយះេពល២សបា� ហ៍មុនេនះ។េយើងឲ្យេយ‌ប
ល់ថ‌អ�កគរួែតេ�ពិនិត្យេ�មណ� លសុខភាព ឬគ�ីនិក។ 
េបើេទ បដិេសធ មិនដងឹ រ�លងេ�សំនួរ ១៤ 
Was there any blood in the stools?  If Yes – Say: Thank you for your willingness to participate.  Unfortunately, 
you and your child are not eligible to participate because (name) has had blood in their stools, which indicates 
a serious illness, in the last 2 weeks.  We suggest that you visit a health care provider or clinic.  EXCLUDE AND 
END QUESTIONNAIRE  
If No, Refused, Don’t know – go to question 14
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
មិនទទួលយកការសិក្សោ  EXCLUDED     
99 
M4VOMIT2W 
14. េតើកុមារមានក��តេទ  រយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ?
Has (name) vomited in the past 2 weeks?  
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4APPET2W 
15. េតើកុមារ(េឈា� ះ)ញ‌� ំឣ‍ហារជ‌ធម�តា ឬេ្រចើនជ‌ងធម�តា
ឬតិចជ‌ងធម�តាេ�ក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ េនះ? 
Has (name) been eating normally, more than usual, or less than usual in the 2 
weeks? 
ធម�តាNormally       0 
េ្រចើនជ‌ងធម�តាMore than usual      1 
តិចជ‌ងធម�តាLess than usual        2 
បដិេសធមិនេឆ�ើយRefused to respond   8 
មិនដឹងDon’t know      9 
M4RASH2W 
16. េតើកុមារ
(េឈា� ះ)មានេឡើងកន��លេលើែស្បកេទក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ 
េនះ?
Has (name) had a skin rash in the past 2 weeks? 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
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M4SYMP2W 
17. េតើកុមារមានេរ‌គស��
ឬជំងឺអ�ីេផ្សងេទៀតែដលខ��ំមិនបានសួរក��ងរយះេពល២សបា� ហ៍ចុងេ្រកាយ 
េនះ?
េបើមាន សូមប�� ក់
Has (name) had any other sickness or symptoms that I have not asked about in the 
past 2 weeks?  If yes - Please specify. 
េទNo       0 
បាទ/ចាសYes       
េបើសិនជ‌មាន េតើេរ‌គស��  ឬជំងអឺ�ីែដរ  
If yes, what sickness or symptoms? 
M4SYMP2W2__________________________ 
1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4MEDS2W 18. េតើកុ�រ
(េ�� ះ)�នេលប�� អំ� ីេទក� �ងរយះេពល២ស�� ហ៍ចុងេ្រ�យ េនះ?
្របសិនេបើេលប េតើ�នេលប�� អំ� ីខ� ះ?
គូសនូវចេម� ើយ�ងំអស់ែដលទទួល�ន
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4MEDSDES Has (name) taken any medicine in the past 2 weeks?  
If yes, which medicines did (NAME) take? Tick all that apply. M4MEDSDES/1   វ � មីន Vitamins 
  
1 
M4MEDSDES/2  �� កំ�ត Anti-vomiting 
  
2 
M4MEDSDES/3  �� �ំគ Anti-diarrhea   3 
M4MEDSDES/4  �� កំ�ក Anti-cough 
  
4 
M4MEDSDES/5  �� បំំ�ត់�រឈឺ�ប; Painkillers
  
5 
M4MEDSDES/6 �� បំំ�ត់�ររ�ក Anti-inflammatories   6 
M4MEDSDES/7  �� អង់ទី� �យូទិក Antibiotics 
  
7 
M4MEDSDES/11    �� ជំំងឺ្រគ �ន់�ញ់Anti-malarial   11 
M4MEDSDES/12    
�� េំផ្សងៗេទៀតែដលេ�យេ�យអ�កជំ�ញ�
ងសុខ�ព ពិព៌ណន‌  
M4MEDOTH1___________________________________________ 
Other medicine supplied by health professionals (describe) 
12 
M4MEDSDES/13    
�� េំផ្សងៗេទៀតែដលេ�យេ�យមិនែមនអ�ក�នជំ
�ញ�ងសុខ�ពពិព៌ណន‌  
M4MEDOTH2____________________________________________ 
Other medicine supplied by non-health professionals (describe)  
13 
M4MEDSDES/8  បដិេសធមិនេឆ�ើយ   Refused to respond   8
M4MEDSDES/9  មិនដឹង   Don’t know      9 
េបើសិន�អ�កទទួល�នចេម� ើយែដលមិនទទួលយក�រចូលរមួពីកុ�រ សូមនិយ�យ�៖ អរគុណស្រ�ប់ឆន�ៈចូលរមួ។ បុ៉ែន�សូមេ�សែដលអ�ក 
និងកូនរបស់អ�កមិន�នលក�ណៈសម្បត� ិ ្រគប់្រ�ន់ក� �ង�រចូលរមួ េ�យ�រេ�យផ�ល់នូវមូលេហតុែដលទទួលដូចេ�ក� �ងប�� ីសនួំរ�ងេលើ 
េបើសិន�ប�� េ�ះ�ក់ពន� ័ មួយនឹងប�� សុខ�ព សូម្រ�ប់�ត់ឬឲ្យ�ត់យកកូនរបស់�ត់េ�មណ� លសុខ�ព/មន� ីរេពទ្យ។ 
If you get an answer that excludes the child, say:  Thank you for your willingness to participate.  Unfortunately, you and your child are not eligible to participate because [give the reason].  [If health related reason, say] We 
suggest that you go to OR you take your child to the health clinic.  
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ឥឡ�វេនះខ��ំនឹងសួរសំណួរមួយចំនួនអំពីឥរ�យ‌បទរបស់កូនេនះ។ Now I’m going to ask some questions about this child’s behaviour. 
Variable  
name សូមសួរេ�អ�កេមើលែថកុមារ PLEASE ASK THE CAREGIVER ចេម�ើយ RESPONSE Code 
M4SMILE 
M4SMILEOB 
19. щЗ שּׂЇ уŪ ТщЛяБ Б сР ъВТд щЙ=
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фР щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТБ Б сР �
&ОǾū Р щВשּׂР ▫рщКċשּׂй ĈЇ уŪ ТщЧ שּׂЌ' � ў
Does this child smile? 
Can we try to observe that? See if the child smiles (try to make it laugh).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4SOUND 
M4SOUNDO
20. щЗ שּׂщЇ āЋщЛяŦ Лķ Ї Ї ǽУ ТМЧ єщЉщΌ ТЇ Ч ющЩЋд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?щР שּׂУ Ŗ щЗ שּׂЇ уŪ Т
щЛяŦ ЛъĉМЇ ǽУ ТМЧ єщЉщΌ ТЇ Ч ющЩЋд щЙ�
&А ТщΏ Орщĉį С Ї уŪ ТЛпЋĴ ℓЧ єĉŪ Р ыВ' � ў
Does this child turn its head to sounds?  Can we try to observe that? See if the child 
turns its head to sounds (stand behind it and snap fingers ). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4SIGHT 
M4SIGHTOB 
21. щЗ שּׂщЇ āЋщЛяŦ Лŏ Р щР שּׂУ ЪċръВУ ĉМŗ Ї єЛсЋъП▪Ї ТМЧ єщЉд щЙ?
� щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фР щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тŏ Р щР שּׂУ �
&Ї ющТשּׂЇ ĉŪ Р ыВщΏ ОрР уЈ ъП▪Ї ТМЧ єщЉ� ' � ў
Does this child follow things with its eyes? 
Can we try to observe that? See if the child follows (move fingers in front of eyes). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4HEAD 
M4HEADOB 
22. щЗ שּׂЇ фЛщЛяſ ЌщЋשּׂМЇ ǽУ ТМЧ єщЉщЩשּׂЋŦ ЛщЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фРщР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌщЋשּׂМЇ ǽУ ТМЧ єщЉщЩשּׂЋ&Ч уюк Ъ▪Ї ъИŗ юŊ
Ї єЇ уŪ ТщЉЋŧ ◙МєРуЈ � ТхЌщУ שּׂЇ ыВĉЇ ФрщΏ ОрРуЈ щЇ āЋ� щВשּׂР▫рк ĵ З єщЋשּׂМщР שּׂУ '
Does this child hold its head up?  Can we try to observe that? See if the child holds its head up (ask 
caregiver to put child on tummy and wave to make it look up).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4ROLL 
M4ROLLOB 
23. щЗ שּׂЇ фЛщЛящЌяĉЇ ŷ МєщЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фР щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌĉЇ ŷ МєŦ Л&Ч уюк Ъ▪Ї ъИŗ юŊ Ї єЇ у
Ū ТщЉЋŧ ◙МєР уЈ � щУ שּׂщŨ яЛпЋщУ שּׂЇ ЙсЇ ЌпЗ ″щВשּׂР ▫рк ĉЇ ŷ Мє 
Does this child roll over? Can we try to observe that? Ask caregiver to put child on tummy and 
encourage to roll. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4REACH 
M4REACHOB 
24. щЗ שּׂЇ фЛщЛяŦ ЛщŅ ЋщΌ ĸ МєЪċрŦ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фРщР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ Тſ ЌщŅ ЋщΌ ĸ МєФЗ ℅уЪċрР хС ъВУ щΏ ОрРуЈ щЉ
ў
Does this child reach for things? Can we try to observe that? See if the child reaches for an object in 
front of it. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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M4BABBLE 
M4BABBLOB 
25. щЗ שּׂЇ фЛщЛяſ ЌНĊующУ ЋЙсЇ Ū З єŦ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?  
Ч фР к Ū″С НĊующУ ЋЙсЇ Ū З єщΌ į ЛєЇ уŪ Т 
Does this child babble? 
Can we try to observe that? Ask caregiver to babble to child.
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4TALK 
M4TALKOB 
26. щЗ שּׂЇ фЛщЛяſ ЌЛпū С МщЋ◙שּׂЗ ļ Ũ Ї ĈŦ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?
Ч фР к Ъ▪Ї ъИŗ юЛпū С � Ũ Ї ĈЇ уŪ Т 
Does this child form words? 
Can we try to observe that? Ask caregiver to “say” its words.
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4USTAND 
M4USTNDOB
27. щЗ שּׂកូនщЛяſ ЌС У єŨ Ї ĈŦ ЛЈ Ċя� ъВТд щЙ?  
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?  
щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяĉМЗ пЇ Р āщЎĊשּׂС З МщΌ ЛсЋŨ Ї ĈР хС ЌюЛхЛ 
Can this child understand some words? 
Can we try to observe that? See if the child responds to some words.
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4MOUTH 
M4MOUTHO
B 
28. щЗ שּׂកូនщЛяſ ЌŊ Ї єТМЧ єЌфУ Ї ▪уЋŪ З єъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?  
щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяſ ЌŊ Ї єЧ ◙Тĉĵ МєЌфУ Ї ▪уЋŪ З є�
к Ч ◙Тĉĵ МєщΌ Ъ▪Ї ъИŗ ю� - � Р пЛщĉМשּׂщЩשּׂЋФпБ �  
Does this child bring things to its mouth? Can we try to observe that? See if the child 
brings a candy to its mouth – leave the candy with caregiver – do not reuse. 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4SIT 
M4SITOB 
29. щЗ שּׂកូនщЛящЌяЪЋ☻уС щŊ С Ū Лį ТЏхС �Ŧ ЛъВТд щЙ?  
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?  
щР שּׂУ ĉМЧ пЛщМשּׂЇ уŪ ТщЛяſ ЌŊ Ї єЧ ◙Тĉĵ МєЌфУ Ї ▪уЋŪ З є�
к Ч ◙Тĉĵ МєщΌ Ъ▪Ї ъИŗ ю 
Can this child sit with support? Can we try to observe that? See if the child can sit with  
support (ask caregiver to sit child up). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4SIT2 
M4SIT2OB 
30. щЗ שּׂЇ фЛщЛяſ ЌЪЋ☻уС � щŊ С ĵ āЛЏюЛхС Ŧ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌЪЋ☻уС Ŧ ЛщŊ С Ū ЛЏюЛхС д щЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к ЪЋ☻уС '
Can this child sit without support? Can we try to observe that? See if the child can sit 
without support (ask caregiver to sit child up). 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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M4CRAWL 
M4CRAWLOB 
31. щЗ שּׂЇ фЛщЛяſ ЌŲТ� щŊ С щĉМשּׂыВЛпЋ� ЏЋ☻ЋєŦ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌŲТ� щŊ С щĉМשּׂыВЛпЋ� ЏЋ☻ЋєŦ Лд щЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к щЉЋŧ ◙МєРуЈ � ТхЌщΞ щЇ āЋ'
Can this child crawl on its hands and knees? Can we try to observe that? See if the child can crawl 
on its hands and knees (ask caregiver to put child on tummy and call it to them).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4STAND 
M4STANDOB 
32. щЗ שּׂកូនщЛяſ ЌА Т� щŊ С Ū ЛЏюЛхС Ŧ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌА ТŦ ЛщŊ С Ū ЛЏюЛхС д щЙў �
&ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋ к А ТъНėЇ щỳ Ър'  
Can this child stand with assistance? Can we try to observe that? See if the child can 
stand with assistance (ask caregiver to stand child against chair).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ      caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4WALK 
M4WALKOB 
33. щЗ שּׂកូនщЛяſ ЌщВשּׂТŦ ЛщŊ С Ū ЛЏюЛхС д щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С Ū ЛЏюЛхС д щЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А ТъНėЇ щỳ Ър� щШשּׂС щΞ Ї уŪ Т 
Can this child walk with assistance? Can we try to observe that? See if the child can 
walk with assistance (ask caregiver to stand child against chair and call it to them).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4STAND2 
M4STND2OB  
34. щЗ שּׂកូនщЛяſ ЌА Т� щŊ С ĵ āЛЏюЛхС Ŧ ЛъВТд щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌА ТŦ ЛщŊ С ĵ āЛЏюЛхС д щЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А Т�  
Can this child stand without assistance? Can we try to observe that? See if the child 
can stand without assistance (ask caregiver to stand child).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4WALK2 
M4WALK2OB 
35. щЗ שּׂកូនщЛяſ ЌщВשּׂТŦ ЛщŊ С ĵ āЛЏюЛхС д щЙ?
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ? �
щР שּׂУ Ŗ щЗ שּׂЇ фЛщЛяſ ЌщВשּׂТŦ ЛщŊ С ĵ āЛЏюЛхС д щЙў �
ĉŦ Мєк Ъ▪Ї ъИŗ ю� Ŋ Ї єщЇ āЋк А Т� щШשּׂС щΞ Ї уŪ Т 
Can this child walk without assistance? Can we try to observe that? See if the child 
can walk without assistance (ask caregiver to stand child and call it to them).
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
M4LOOK 
M4LOOKOB 
36. щЗ שּׂកូនщЛящЌяŏ Р ТЇ щР שּׂУ ТМЧ є� щОУ ъВУ щС שּׂЋŭ Ї єщУ Ћ�
ъВТд щЙ?  
щЗ שּׂщС שּׂЋſ ЌщКċשּׂį ТЧ щЋ◙З щР שּׂУ Ŧ ЛъВТд щЙ?  
Мķ ĕБ ФЗ ℅уР хС щΌ Ї уŪ Т�
Мŝ ℓМєР Ї ŭ Ї єФЗ ℅ущŝ ящШשּׂС щР שּׂУ Ŗ щЗ שּׂЇ фЛŏ Р ТЇ щР שּׂУ �
ФЗ ℅ущŝ яд щЙў  
Does this child look for things out of view? Can we try to observe that? Show the 
អ�កេមើលែថកុមារនិយ‌យថ‌ េទ  caregiver says no   0 
អ�កេមើលែថកមុារនិយ‌យថ‌ចាស ឬ បាទ   caregiver says yes   1 
į ТЧ щЋ◙З ТМЧ єЪ▪Ї Ч юũ Ч Лј Interviewer observed    3 
Ъ▪Ї Ч юũ Ч ЛјР пЛŦ ЛщКċשּׂį ТЧ щЋ◙З  Interviewer didn’t observe    4 
អ�កេមើលែថកុមារបដិេសធមិនេឆ�ើយ caregiver refused to respond   8 
អ�កេមើលែថកុមារនិយ‌យថ‌មិនដឹង  caregiver doesn’t know      9 
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child an object, then hide the object and see if the child looks for it.  
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�តំបូង ខ� � ំសូមសួរអំពីរបប��រកុ�រ Now I will ask some questions about the child’s diet (4DIET)
M4BFG 37. េតកុមារ(េឈ� ះ)បានកំពុងេបទឹកេដះមា� យឬេទ?
េបមាន សូមបន�េទសំនួរេលខ៣៨ េបអត់
សូមរលំងេទសំនួរេលខ៣៩
Is (NAME) still being breastfed? If yes go to question 38.  If no, go to question 39
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4BFGFREQ 38. េតកុមារ(េឈ� ះ)បានេបទឹកេដះមា� យបុ៉នា� នដង
កលពីម្ិសលមិញ និង យប់មិញ ?
(ចេនា� ះ២៤េម៉ាងចុងេ្រកយ)
How many times did (NAME) breastfeed yesterday (last 24 hours) during the day 
and the night? 
កលពីម្សិលមិញ មិនបានេបទឹកេដះមា� យ    
Did not breastfeed yesterday
0 
បានេបទឹកេដះមា� យ ១ េទ ២ដង   
Breastfed 1-2 times
1 
បានេបទឹកេដះមា� យ ៣ េទ ៥ដង   
Breastfed 3-5 times
2 
បានេបទឹកេដះមា� យ ៦ េទ ៨ដង   
Breastfed 6-8 times
3 
បានេបទឹកេដះមា� យ េ្រចនជាង៨ដង   
Breastfed >8 times
4 
បដិេសធមិនេឆ�យ   Refused to respond    8 
មិនដឹង   Don’t know      9 
M4BMS24H 39. េតើម្ិសលមិញ ឬ យប់មិញ ( េ�� ះ )
�នផឹកទឹកអ� ីមួយពីដបទឹកេ�ះេ�ែដរឬេទ ?
Did (NAME) drink anything from a bottle with a nipple yesterday or last 
night? 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
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M4DDGEN 
40. េតកុមារ (េឈ� ះ)
បានញំុាអហរ
ឬផឹកទឹកអ�ីខ�ះចប់តំងពី
េគេចះញំុាអហរមក?
គូសនូវចេម�យទំងអស់ែដ
លទទួលបាន 
What foods or drinks does 
(NAME) usually eat or drink 
since they began solids? Tick all 
that apply 
M4DDGENOT 
Plain water ទឹកធម�       1 
Liquids such as tea, juice, soda, etc     �រ�តុ�វដូច�ទឹកែត ទឹកែផ�េឈើ ទឹកសូ�។ល។   2 
Soup  ទឹកស៊ុប   3 
Milk (tinned, powdered, or fresh animal milk) ទឹកេ�ះេ� ដូច� ទឹកេ�ះេ�កំបុ៉ងេម៉�ទឹកេ�ះេ�ឬទឹកេ�ះេ�្រសស់ៗ    4 
Infant formula.  ��ំទឺកេ�ះេ�កូនេក�ង ែដលផ្ស�ំមរបូមន�  ដូច� �ហ� ង់េបេប ឌុយមិុច  មី�ក់ ឬេទ? េបើ�ន េតើ   5 
Any brand of commercially fortified baby food, e.g., Cerelac]? 
��ំ �រែដលប�� �លពពួកមី្រក� រ�តិែដល�ន�៉កេ�� ះ�ណជិ�កម� ដូច�េស�� ក់ ែដរឬេទ?   
6 
��ំ នំប័ុង �យ នំប�� � ក មី បបរ ឬ��រេផ្សងេទៀតេធ� ើពី្រ�ប់ធ�� តិ?  
Bread, rice, noodles, borbor or other food made from grain
10 
Pumpkin, carrots, yellow or orange sweet potatoes  េ��  �រ�ុត ដំឡ� ង�� ពណ័េលឿង ឬ ពណ័ទឹក្រក�ច  11 
White potatoes, white yams, manioc, cassava, roots  
��ំ ដំឡ� ងស ្រ�វ ដឡំ� ងមី ៃឆ�វ ឬ��រេផ្សងេទៀតែដល�ន េមើម ឬស ែដរឬេទ?  
12 
Dark green, leafy vegetables ��ំ បែន� ៃបតង�ស់ បែន� នស� ឹកេ្រចើន ែដរឬេទ   13 
Ripe mangoes, papayas? �� យទុំ ល� �ងទុ ំ  14 
Any other fruit or vegetables ��ំ ែផ�េឈើ ឬបែន� េផ្សងេទៀត ឬេទ?    15 
Liver, kidney, heart or other organ meats? េថ�ើមសត� , ្រក�ន,េបះដូងសត�ឬេ្រគ�ងក� �ងសត�េផ្សងៗ ?   16 
�ច់សត�េផ្សងៗេទៀត ឧ. �ច់េ�,�ច់្រជ�ក, �ច់េជៀម,�ច់ពែព,�ច់�ន់ឬ�ច់�   
Any other meat, e.g. beef, pork, lamb, goat, chicken, or duck    
17 
Eggs ពង�ន់   18 
Fresh or dried fish or shellfish   ្រតី្រសស់ឬ្រតីេ្រគ�មឬខ្យងេ��    19 
ចំណី��រែដលផលិតពីសែណ� កេសៀង សែណ� កេ��ំង�វ សែណ� ក�យ ឬ សែណ� កេផ្សងៗ  
Any foods made from beans, peas, lentils, or nuts 
20 
Yoghurt, cheese or any other food made from milk �អួរ ឈឺស ឬ ��រដ៏ៃទេទៀតែដលផលិតពីទឹកេ�ះេ�  21 
Any foods made with oil, fat, or butter ចំណី��រ�ែដលផលិតពីេ្របង �� ញ ់ឬប៊រ  22 
Any snake, snail, frog, rat, or insects ្របេភទពស់េផ្សងៗ, ខ្យង, កែង�ប, កណ� � រ, ឬសត�ល� ិត    23 
Sweet or salty snacks eg chips, cakes, candies   បែង�ម ឬ��រ��ំេលងៃ្រប ឧ. ្របេភទនំ្រស�យៗ នំេខក ស� រ្រ�ប់   24 
Any other solid, semi-solid, or soft food? ្របេភទ��ររ �ង េផ្សងៗ ្របេភទ��រ ្រ�យៗ ឬ្របេភទ��រទន់ៗ     
Other (describe)      េផ្សងេទៀត ចូរេរៀប�ប់
M4DDGENOT_________________________________ 
7 
បដិេសធមិនេឆ�យRefused to respond    8 
មិនដឹងDon’t know      9 
M4FOOD24H 41. េតើកុ�រ (េ�� ះ) �ន��ំ �ររ �ង
��រ្រ�យឬ��រទន់េទេ�េពលៃថ�
ឬេពលយប់�លពីម្ិសលមិញ?
្របសិនេបើ�ន សូមបន�េ�សំនួរេលខ ៤២
្របសិនេបើអត់  សូមបន�េ�សំនួរេលខ ៤៥
Did (NAME) eat any solid,  semi-solid, or soft foods yesterday during the day or at night? If yes, go 
to question 42.  If no, go to 45 
េទ   No   0 
បាទ/ចាស   Yes   1 
បដិេសធមិនេឆ�ើយ   Refused to respond   8 
មិនដឹង   Don’t know      9 
M4DD24H 
42. េតើ �លពីម្ិសលមិញកុ�រ
(េ�� ះ) �ន��ំ ឬផឹកអ� ីខ� ះ?
គូសនូវចេម�យែដលទ
ទួលបាន
What foods yesterday did 
(NAME) eat or drink yesterday? 
Plain water ទឹកធម�       1 
Liquids such as tea, juice, soda, etc     �រ�តុ�វដូច�ទឹកែត ទឹកែផ�េឈើ ទឹកសូ�។ល។   2 
Soup  ទឹកស៊ុប   3 
Milk (tinned, powdered, or fresh animal milk) ទឹកេ�ះេ� ដូច� ទឹកេ�ះេ�កំបុ៉ងេម៉�ទឹកេ�ះេ�ឬទឹកេ�ះេ�្រសស់ៗ    
M4MILK24     If yes, how many times?ebIman³ etI ¬eQµaH¦ júa b:unµandg?
4 
Infant formula.  ��ំទឺកេ�ះេ�កូនេក�ង ែដលផ្ស�ំមរបូមន�  ដូច� �ហ� ង់េបេប ឌុយមិុច  មី�ក់ ឬេទ? េបើ�ន 
េតើ   
5 
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Tick all that apply M4IF24H   If yes, how many times?ebIman³ etI ¬eQµaH¦ júa b:unµandg? 
Any brand of commercially fortified baby food, e.g., Cerelac]? 
��ំ �រែដលប�� �លពពួកមី្រក� រ�តិែដល�ន�៉កេ�� ះ�ណជិ�កម� ដូច�េស�� ក់ ែដរឬេទ?   
6 
��ំ នំប័ុង �យ នំប�� � ក មី បបរ ឬ��រេផ្សងេទៀតេធ� ើពី្រ�ប់ធ�� តិ?  
Bread, rice, noodles, borbor or other food made from grain
10 
Pumpkin, carrots, yellow or orange sweet potatoes  េ��  �រ�ុត ដំឡ� ង�� ពណ័េលឿង ឬ ពណ័ទឹក្រក�ច  11 
White potatoes, white yams, manioc, cassava, roots  
��ំ ដំឡ� ងស ្រ�វ ដឡំ� ងមី ៃឆ�វ ឬ��រេផ្សងេទៀតែដល�ន េមើម ឬស ែដរឬេទ?  
12 
Dark green, leafy vegetables ��ំ បែន� ៃបតង�ស់ បែន� នស� ឹកេ្រចើន ែដរឬេទ   13 
Ripe mangoes, papayas? �� យទុំ ល� �ងទុ ំ  14 
Any other fruit or vegetables ��ំ ែផ�េឈើ ឬបែន� េផ្សងេទៀត ឬេទ?    15 
Liver, kidney, heart or other organ meats? េថ�ើមសត� , ្រក�ន,េបះដូងសត�ឬេ្រគ�ងក� �ងសត�េផ្សងៗ ?   16 
�ច់សត�េផ្សងៗេទៀត ឧ. �ច់េ�,�ច់្រជ�ក, �ច់េជៀម,�ច់ពែព,�ច់�ន់ឬ�ច់�   
Any other meat, e.g. beef, pork, lamb, goat, chicken, or duck    
17 
Eggs ពង�ន់   18 
Fresh or dried fish or shellfish   ្រតី្រសស់ឬ្រតីេ្រគ�មឬខ្យងេ��    19 
ចំណី��រែដលផលិតពីសែណ� កេសៀង សែណ� កេ��ំង�វ សែណ� ក�យ ឬ សែណ� កេផ្សងៗ  
Any foods made from beans, peas, lentils, or nuts 
20 
Yoghurt, cheese or any other food made from milk �អួរ ឈឺស ឬ ��រដ៏ៃទេទៀតែដលផលិតពីទឹកេ�ះេ�  21 
Any foods made with oil, fat, or butter ចំណី��រ�ែដលផលិតពីេ្របង �� ញ់ ឬប៊រ  22 
Any snake, snail, frog, rat, or insects ្របេភទពស់េផ្សងៗ, ខ្យង, កែង�ប, កណ� � រ, ឬសត�ល� ិត    23 
Sweet or salty snacks eg chips, cakes, candies   បែង�ម ឬ��រ��ំេលងៃ្រប ឧ. ្របេភទនំ្រស�យៗ នំេខក ស� រ្រ�ប់   24 
Any other solid, semi-solid, or soft food? ្របេភទ��ររ �ង េផ្សងៗ ្របេភទ��រ ្រ�យៗ ឬ្របេភទ��រទន់ៗ     
Other (describe)      េផ្សងេទៀត ចូរេរៀប�ប់ 
M4DDOT24H ___________________________________ 
7 
បដិេសធមិនេឆ�យRefused to respond    8 
មិនដឹងDon’t know      9 
M4FF24H 43. េតើ (េ�� ះ) �ន��ំ �ររ �ងឬ ��រ្រ�យល� ម
ឬ��រទន់ បុ៉�� នដង�លពីម្សិលមិញ
េ�េពលៃថ� ឬេពលយប់? (
ែតមិន�ប់ប�� �ល្របេភទេ្រគ�ងទឹកេទ )
How many times did (NAME) eat solid or semisolid foods (NOT drinks) yesterday during the day
or at night?
១ េ� ២ ដង 1-2 times   1 
៣ េ� ៤ ដង 3-4 times  3 
៥ ឬ េ្រចើនជ‌ងេនះ  5 or more times   5 
បដិេសធមនិេឆ�ើយRefused to respond   8 
មិនដឹងDon’t know      9 
M4FOODAMT 44. កលពីម្ិសលមិញ អំឡុងេពលៃថ� និង េនេពលយប់
េតកុមារបានបរេិភាគអហររងឹ អហរ្រជាយ និង
អហរទន់បាន្របែហលបុ៉នា� នែដរ ?
( ែតមិន�ប់ប�� �ល្របេភទេ្រគ�ងទឹកេទ )
Approximately how much eat solid or semisolid foods (NOT drinks) did 
(NAME) eat each time yesterday during the day or at night? 
<2 tablespoonfuls each time  ម�ង <២ �� ប្រ��យេពញ   ០ 
2-3 tablespoonfuls each time  ម�ង ២ េ� ៣ �� ប្រ��យេពញ   1 
< 1/2 bowl each time ម�ងតិច�ងកន�ះ�នចង� ឺះ ម�ង< ១/២ �នចង� ឺះ  2 
 About 1 bowl each time ម�ងកន�ះ េ� មួយ�នចង� ឺះ  3 
>1 bowl each time ម�ងេ្រចើ�ង១�នចង�ះឺ  4 
បដិេសធមិនេឆ� ើយRefused to respond    8 
មិនដឹងDon’t know      9 
M4SUPPS 45. េតកូនរបស់អ�កធា� ប់បានញុា ំ�ស�ីងខល េហបី៊
សីុេអសបី៊េផ�សេផ�សឬអហរបំប៉ន�សេដៀងគា�  ឬអហរបំប៉នបែន�ម
ឬ វតីមីនេផ្សងៗណាឬេទ ? េបសិនជាចេម�យេទ
សូមរលំងេទសំនួរចុងប�� ប់
Has (NAME) ever used Sprinkles, HEBs, CSB++ or similar supplementary foods or 
supplements/vitamins?  If No to this question – jump to end. 
េទ   No   0 
�ទ/�ស   Yes   1 
បដិេសធមិនេឆ� ើយ   Refused to respond    8 
មិនដឹង   Don’t know      9 
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M4WHSUPPS 
M4WHSUPP2 
46. េតើ��របំប៉នមួយ�
ឬ��របែន�ម�/វ � មីន�ែដលកូនរបស់អ�ក�នេ្របើ?
សូមគូស្រគីសចំេ�ះ��រ�ងំនុះ (ប�� ញក�� ប់ ឬគំរៃូន��រ)
េបើេ្របើ�ស� ីងខល បន�េ�សំនួរទី 47។
េបើសិន�េហ� �សូមរ�លងេ�សំនួរទី49។ េបើសិន�មិនេ្របើ�ស� ីងខល
ឬេហ� �សូមប�� ប់សំនួរ។
េបើមិន�នេ្របើ�ស� ីងខលេទ សូមរ�លងេ�សំនួរចុងប�� ប់
Which supplementary foods or supplements/vitamins has (NAME) used?  Tick all that apply.  (show packages or 
examples of foods). If using Sprinkles, go to question 47.  If using HEBs go to question 49. If not using Sprinkles or 
HEBs, go to end. 
�ស� ីងខលSprinkles    1 
សីុេអស� �ផ� ឺសផ�ឺសCSB++    2 
េហ� � HEBs    3 
នំ ្រតី Num Trey       4 
��របំប៉នេផ្សងេទៀតេបើ�ន េហើយសូមេរៀប�ប់   
Other supplementary foods (describe)   
______________________________ 
5 
បដិេសធមិនេឆ� ើយ   Refused to respond    8 
មិនដឹង Don’t know      9 
M4SPRINK1 
47. េតើ កុ�រញំុា�ស�ីងខល ញឹកញាប់បុ៉ណា� ?
How often does (NAME) have Sprinkles?
េស� ើែតមិនែដល��េំ ះ Almost never   0 
��េំស� ើែត�ល់ៃថ� Almost daily    1 
��២ំ េ� ៣ ដងក� �ងមួយ 2-3 times/week    2 
១ស�� ហ៏ ��មំ�ង Once a week    3 
បដិេសធមិនេឆ� ើយ   Refused to respond   8 
មិនដឹង Don’t know      9 
M4SPRINK2 
48. េតកុមារញំុា�ស�ីងខល ម�ងបុ៉នា� នក�� ប់ក�ុងមួយៃថ�?
How many sachets of Sprinkles does (NAME) have each day? 
១ក�� ប់ 1 sachet   1 
២ក�� ប់ 2 sachets   2 
>២ក�� ប់ >2 sachets   3 
បដិេសធមិនេឆ� ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4HEB1 49. េតើ កុ�រញំុាេហបី៊ញឹកញាប់បុ៉ណា� ?
How often does (NAME) eat HEBs?
េស� ើែតមិនែដល��េំ ះ Almost never   0 
��េំស� ើែត�ល់ៃថ� Almost daily    1 
��២ំ េ� ៣ ដងក� �ងមួយ 2-3 times/week    2 
១ស�� ហ៏ ��មំ�ង Once a week    3 
បដិេសធមិនេឆ� ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4HEB2 
50. េតកុមារញំុាេហបី៊ម�ងបុ៉នា� នក�ុងមួយៃថ�?
How many HEBs does (NAME) have each day?  
១-២ 1 -2   1 
៣-៤  3-4   3 
>៤  >4   5 
បដិេសធមិនេឆ� ើយ   Refused to respond   8 
មិនដឹង Don’t know      9 
សូមនិ�យ�៖ អរគុណស្រ�ប់ចេម� ើយរបស់អ�ក។ សូមយកប�� ីសំនួរេ�ះេហើយអេ�� ើញេ�តុប�� ប់ ។ 
Say:  Thank you for answering these questions.  Please take this questionnaire and go to the next station. (1THANK)
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ទ្រមង់ទី៤.៣៖ - mnusSmaRtviTüa Form 4.3: Efficacy Trial - anthropometry
កាលបរ�េច�ទ Date  (M4DATE3)
េ�� ះកុ�រName of the child  (M4CHNAME3) 
េលខកំណត់អត�ស�� ណកុមារ Child´s ID (M4CHID3)
ៃថ�ែខឆា� ំកំេនើតកុមារ Child’s date of birth (M4DOB3)
  éf  Day          Ex  Month             qñaM  Year           
ែយនឌ័រ Child’s sex (M4SEX3) ្រប�ស Male           1 ្រសី Female          2
ឥឡូវេយងនឹងេធ�ករថ�ឹងទម�ន់ និង វស់កំពស់របស់កុមារ ្រពមទំងេធ�ករថ�ឹងទម�ន់ វស់កំពស់ ក្រមាស់ៃដនិងជាតិខ� ញ់របស់កូនរបស់អ�ក ។ 
Now we are going to measure your baby’s weight, height, arm thickness, and fat. (1ANTHRO) 
M4MUMWT1 51. ថ�ឹងទម�ន់អ�កេមើលែថកុ�រ  េលើកទ១ី
គិត�គីឡ� ្រ�ម(ក្រមិតលេម� ង0.1kg)? ប�� ប់មក
េ�េពលែដលអ�កេមើលែថកុ�រ  កំពុងស� ិតេ�េលើជ�� ីងដែដលេ�ះ
ចុចជ�� ឹងឲ្យេ�េលខ០ េហើយហុចកុ�រឲ្យេ�អ�កេមើលែថកុ�រ
េហើយកត់្រ�នូវទម�ន់កុ�រែដលប�� ញេលើជ�� ីងគិត�គីឡ� ្រ�ម
Weigh mother 1st time in kilograms to the closest 0.1kg . With mother still on scale, zero, 
pass child to mother, record child’s weight in kilograms to the closest 0.1kg 
ទម�ន់អ�កេមើលែថកុមារ ១(kg)
Mother’s weight 1 (kg) 
M4CHWT1 
ទម�ន់កុមារ១(kg) 
Child’s weight 1 (kg)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
M4MUMWT2 52. ឲអ�កេមើលែថកុ�រ  េឡើងេលើជ�� ងីម�ងេទៀត
ថ�ឹងទម�ន់អ�កេមើលែថកុ�រ  �េលើកទ២ី
គិត�គីឡ� ្រ�ម(ក្រមិតលេម� ង0.1kg)? ប�� ប់មក
េ�េពលែដលអ�កេមើលែថកុ�រ  កំពុងស� ិតេ�េលើជ�� ីងដែដលេ�ះ
ចុចជ�� ឹងឲ្យេ�េលខ០ េហើយហុចកុ�រឲ្យេ�អ�កេមើលែថកុ�រ
េហើយកត់្រ�នូវទម�ន់កុ�រ�េលើកទ២ី
ែដលប�� ញេលើជ�� ីងគិត�គីឡ� ្រ�ម
Caregiver  steps on scale again.  Weigh caregiver  2nd time in kilograms to the closest 0.1kg . With caregiver  
still on scale, zero, pass child to caregiver  , record child’s 2nd weight in kilograms to the closest 0.1kg 
ទម�ន់អ�កេមើលែថកុមារ ២ (kg)
Mother’s weight 2 (kg) 
M4CHWT2 
ទម�ន់កុមារ២(kg) 
Child’s weight 2 (kg)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
M4CHMUAC1 
M4CHMUAC2 
M4MUACEXC 
53. ្របែវង�ក់ក�� លរង�ង់ៃដែផ�ក�ងេលើ (MUAC)របស់កុ�រ គិត�
សង់ទីែម៉្រតែដលខិតេ�ជិត០.១សង់ទីែម៉្រត។
�ស់�េលើកទី២ 
្របសិនេបើពណ៏្រកហមផ�ល់ដណំឹងេ�អ�ក្រគប់្រគងរចួ សូមនិ�យ�៖
អរគុណស្រ�ប់ឆន�ៈចូលរមួ។ បុ៉ែន�សូមេ�សែដលអ�ក
និងកូនរបស់អ�កមិន�នលក�ណៈសម្បត� ិ ្រគប់្រ�ន់ក� �ង�រចូលរមួ 
េ�យ�រកុ�រ
(េ�� ះ)�នជំងឺកង�ះ��ររបូត�ម�ធ�ន់ធ�រ។េនះគឹពិត�ធ�ន់ធ�រ ស់។
េយើងឲ្យេ�បល់�អ�កគួរែតប�� �នកូនេ�ពិនិត្យេ�មន� ីរេពទ្យ។
េយើងនឹងឱ្យលុយអ�កេដើម្ីបេ�មន� ីរេពទ្យ្របសិនេបើ��ំច់។
មិនទទួលយក�រចូលរមួ ប�� ប់សំនួរ
Child’s mid upper arm circumference (MUAC) in cm closest 0.1cm.  Measure 2nd time..  If 
red, Inform supervisor – say: Thank you for your willingness to participate.  Unfortunately,
you and your child are not eligible to participate because (name) is severely malnourished.
This is very serious.  You need to take your child to the hospital.  We will give you money 
for transport to go to the hospital if necessary . EXCLUDE AND END QUESTIONNAIRE 
កុមារ
Child MUAC 1 (cm)  
Child MUAC 2 (cm)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
មិនទទួលយកការសិក្សោEXCLUDED    
99 
2 0 1 6 
2 0 1 5 
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M4CHTSF1 
M4CHTSF2 
54. កំ�ស់ែស្បកបត់េដើមៃដ របស់កុ�រ (ក្រមិតលេម� ង
0.2cm) �ស់២ដង
Child’s Triceps Skinfold Thickness (TSF) (to the closest 0.2cm).  Measure twice.
កុមារ 1
Child’s TSF 1  (cm)  
កុមារ 2 
Child’s TSF 2  (cm)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
M4SCAPSF1 
M4SCAPSF2 
55. កំរ‌ស់ែស្បក ចុងសា� ប្របេចៀវ របស់កុមារ (ក្រមិតលេម� ង
0.2cm) 
Child’s Subscapular Skinfold Thickness (SSF) (to the closest 
0.2cm) 
SSF 1  (cm)  
SSF 2  (cm)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
M4CHHT1 
M4CHHT2 
M4WHZ 
M4CHHTEXC 
56. �ស់្របែវងកុ�រគិត�សង់ទីែម៉្រត(ក្រមិតលេម� ង0.1cm)?
�ស់េពលែដល�ក់់់់់់់កុ�រឲ្យេដកចុះ។
�ស់�េលើកទី២េ�យ�ក់កុ�រឲ្យេដក
គណ�រក WHZ ្របសិនេបើ<-3   រ � >+3
្រត�វផ�ល់ដំណឹងេ�អ�ក្រគប់្រគង ្របសិនេបើ<-3 សូមនិ�យ�៖
អរគុណស្រ�ប់ឆន�ៈចូលរមួ។ បុ៉ែន�សូមេ�សែដលអ�ក
និងកូនរបស់អ�កមិន�នលក�ណៈសម្បត� ិ ្រគប់្រ�ន់ក� �ង�រចូលរមួ 
េ�យ�រកុ�រ (េ�� ះ)
�នជំងឺកង�ះ��ររបូត�ម�ធ�ន់ធ�រ។េនះគឹពិត�ធ�ន់ធ�រ ស់។
េយើងឲ្យេ�បល់�អ�កគួរែតប�� �នកូនេ�ពិនិត្យេ�មន� ីរេពទ្យ។
េយើងនឹងឱ្យលុយអ�កេដើម្ីបេ�មន� ីរេពទ្យ
មិនទទួលយក�រចូលរមួ ប�� ប់សំនួរ
Child’s length in centimetres to the closest 0.1cm.  Measure lying down. Measure 2nd time lying down.
SOP. Calculate WHZ.  If <-3 or >+3, inform supervisor.  Say: Thank you for your willingness to participate.
Unfortunately, you and your child are not eligible to participate because (name) is severely malnourished.
This is very serious.  You need to take your child to the hospital.  We will give you money to go to the 
hospital.  EXCLUDE AND END QUESTIONNAIRE 
្របែវងកុមារ(cm)
Child length 1 (cm) 
្របែវងកុមារ(cm)
Child length 2 (cm)
បដិេសធ Mother refused     8 
េផ្សងៗ   Other        9 
WHZ � ĉМЧ пЛщМשּׂ<-3 � Тт >+3 <-3or  >+3  
េទ   No  
បាទ/ចាស   Yes   
មិនទទួលយកការសិក្សោ EXCLUDED     
99 
េបសិនជាអ�កសួរនូវសំនួរទំងអស់េហយ េហយអ�កែថរកុមារ/កុមារេនាះមានលក�ណៈ្រគប់្រគាន់ក�ុងករចូល រមួ សូមនិយាយថា៖ 
អរគុណស្រមាប់ចេម�យរបស់អ�ក។ សូមយកប�� ីសំនួរេនាះេហយអេ�� ញេទតុបនា� ប់  
If the child is eligible to participate, say:  Thank you for answering these questions.  Please take this questionnaire and go to the next station. (1THANK3) 
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ទ្រមង់ទី៤.៤៖�រេ្របើ្រ�ស់និង �រអនុេ�ម�មច�ប់ Form 4.4: Consumption and compliance 
្របសិនេបើេលើ្រក �ម្រត�តពពីនិត្យរ�លងែផ�កេនះ If control group, skip this section. (1NOTCTRL) 
េ�� ះកុ�រName of the child  (M4CHNAME4) 
េលខកំណត់អត�ស�� ណកុមារ 
Child´s ID (M4CHID4)
កាលបរ�េច�ទ Date  (M4DATE4)
 
ឥឡ�វេនះខ��ំនឹងសួរសំណួរមួយចំនួនអំពីឥរ�យ‌បទរបស់កូនេនះ អំពីឣ‍ហារេ�ែខមុន 
Now I’m going to ask some questions about this child’s consumption of the food in the past month.  (CONSUMP) 
M4EATMTH 
ែខរបស់ឣ‍ហារ
Month on this food:  
ែខទី១ 1st    1 ែខទី៣ 3rd   3 ែខទី៥ 5th     5 
ែខទី២ 2nd    2 ែខទី៤ 4th     4 ែខទី៦ 6th   6 
M4PRODUCT Code M4AMTPVD  M4AMTRMG M4DIFF 
ផលិតផល
Product  
បរ�មាណែដល្រត�វការស្រមាប់ែខមុន
េមើលេ�ក��ង ID ចាស់ 
Amount of food provided last month 
Fill in from the ID card
បរ�មាណេ�សល់
Amount of food remaining today
បរ � ណ��រែដរេក�
ង��ំអស់ 
Amount of food the child ate 
នំ ្រតី Num Trey       1 Sachets Ї ψ ♂Мє = M4NTBAGPV M4NTBAGRM M4NTBAGEAT 
(Wafers МюъЖ Ї = ' M4NTPCPV M4NTPCRM M4NTPCEAT 
សីុេអស� �ផ� ឺសផ�ឺសCSB++    2 Kg M4CSBPVD M4CSBRM M4CSBEAT 
�ស� ីងខលSprinkles    3 Sachets Ї ψ ♂Мє = M4SPRPVD M4SPRRM M4SPREAT 
្រក�មេផ� ងផ‌� ត់–អត់មានផលិតផល 
Control group – no product    
4 
Variable  Question Response Code 
M4NAMEEAT 57. េតើ (េ�� ះ) �ន��ំ �រ?
្របសិនេបើ�ន េតើ(េ�� ះ) �ន��ំអស់បុ៉ន�� ?
Did (name) eat the food?
If yes, how much of the food did (name) eat?
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4HOWMCH1 េស� ើែតមិន�ន��េំ ះ None or almost none   0 
អស់ជិត�ក់ក�� ល Almost half   1 
េស�ើែតទំាងអស់ Most   2 
ញ‌� ំបានទាំអស់ All    3 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4WHOEAT 58. េតើ�ននរ�េផ្សង�ន��ំ �រ?
្របសិនេបើ�ន នរ�េគ?
គូសចំេលើយេ្រចើន
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4WHOEAT2 Did anyone else eat the food?  
If yes, who? Tick all that apply មា� យបេង�ើត/ ឪពុក Mother/father   1 
2 0 1 6 
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ជីដូន Grandmother/grandfather   2 
bgb¥ÚnRbus // បង្រសី Siblings   3 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)      
M4WHOEAT3
7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4HOWMCH2 59. េតើពួកេគ�ន��អំស់បុ៉�� ?
How much of the food did they eat?
េស� ើែតមិន�ន��េំ ះ None or almost none   0 
អស់ជិត�ក់ក�� ល Almost half   1 
េស�ើែតទំាងអស់ Most   2 
ញ‌� ំបានទាំអស់ All    3 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4GIVESELL 60. េតើ��រេនះ�នេ�យអ�ក� អ�កជិត�ង លក់
េ�ះេ�ល �ក់េ�យសត�សុី ឧ�ហរណ៏: ( សត� ន់ )
�ត់ កណ� � រសុី យកេ�េ�ះេ�ល ?
គូសចំេលើយេ្រចើន
Was any of the food given away, sold, thrown away, fed to 
animals (e.g. chickens), lost, eaten by rats, or disposed of 
some other way?  Tick all that apply 
េទ No   0 
បាទ/ចាស េឣ‍យេ�េគ Yes, given away   1 
បាទ/ចាស យកេ�លក ់Yes, sold   2 
បាទ/ចាស េបាះេចាល Yes, thrown away   3 
បាទ/ចាស េឣ‍យសត�សុ ីYes, fed to animals   4 
បាទ/ចាស បាត ់Yes, lost   5 
បាទ/ចាស កណ�� រសុអីស ់Yes, eaten by rats,   6 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)      
M4GIVEDES
7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4HOWMCH3 ្របសិនេបើ�នអស់បុ៉�� ? 
If yes, how much? 
េស� ើែតមិន�ន��េំ ះ None or almost none   0 
អស់ជិត�ក់ក�� ល Almost half   1 
េស�ើែតទំាងអស់ Most   2 
ញ‌� ំបានទាំអស់ All    3 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4REMAIN 61. ĉМЧ пЛщМשּׂщΏ Ч У єſ Ŷ ТЧ хТ�
щШЗ уЪċрŦ Лļ Ч У єſ Ŷ ТщЛя= 
គូសចំេលើយេ្រចើន
If there is remaining food ask: Why has some of the food 
not been eaten?  Tick all that apply 
មិន�នសល់��រ No food remaining   10 
មិនចូលចិត� �រេនះេទ Didn’t like the food at all   0 
 ចូលចិត�ែតញ‌� ំេ្រចើនេហើយ Too much to eat   1 
 ចូលចិត�ែតធុញេហើយញ‌� ំរ‌ល់ៃថ�Like food but boring to eat every day    2 
េភ�ចឬរវល់មិន�ន�ក់េ�យ��េំទ   
Forgot or too busy to eat the food every day  
3 
��រេនះ�នេធ� ើេ�យកុ�រេនះឈឺ  
Our food made baby sick (vomiting, diarrhea) so stopped/ate less  
4 
��រេផ្សងេទៀតែដរេធ� ើេ�យកុ�រឈឺេហើយឈប់��ំ   
 Something else made my baby sick and  baby stopped eating food/ate less  
5 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)      
M4REMAIN2
7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
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មិនដឹង Don’t know      9 
M4DFRC 62. េតើអ�កគិត���រេធ� ើេ�យសុខ�ព�កប្ប
កិរ � កុ�ែ្រប្រប�លែដលឬេទឬក៏េ�ដែដល?
Do you think that the food has made any difference (positive or negative) to 
the child’s health or behaviour?
េទ No   0 
បាទ/ចាស Yes   1 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4DFRC2 
្របសិនេបើ�ន េតើ�នអ� ីខុសែប�ក? 
គូសចំេលើយេ្រចើន 
If yes, what difference? Tick all that apply
�នកំ�ងំ ឬក៏បែន�មកំ�ងំ More energy   1 
 ចូលចិត� �ំេ្រចើន Better appetite   2 
 ធំលូត�ស់េលឿន Growing faster (height, weight)   3 
កុ�រ�� ត�ងៃវនឹងរពឹសេចះ�� ប់នឹងនិ�យ�នេ្រចើន  
Baby seems smarter, listens/speaks more 
4 
កុ�រឈឺ Baby got sick   5 
កុ�រធម�  Baby normal, no change   6 
េផ្សងៗ(ពិពណ៌ន‌) Other (describe)      
M4DFRC3
7 
បដិេសធមនិេឆ�ើយ Refused to respond   8 
មិនដឹង Don’t know      9 
M4LIKE 63. ្រត�វនិ�យ�៖ កូនរបស់អ�ក�ន��ំ �រអស់រយៈេពល…… េហើយ។ 
េតើអ�កគិត�កូនរបស់អ�កចូលចិត� �រេនះឬេទ? 
Say: Your child has been eating this food for ____ month/s.  How do you think your child likes this food
1 =មិនចូលចិត�ទាល់ែតេសាះ
1 = Dislikes a lot
2 =មិនចូលចិត�តិចៗ
2 = Dislikes a little
3 =ធម�តា
3 = Neither likes nor dislikes
4 =ចូលចិត�តិចៗ
4 = Likes a little
5 =ចូលចិត�ខា� ំង
5 = Likes a lot
    
អរគុណស្រមាប់ចេម�យរបស់អ�កេនះជាអហរសំរប់ែខេ្រកយកូនរបស់អ�ក សូមយកប�� ីរសំនួរេនាះេហយអេ�� ញេទតុបនា� ប់  
Thank you for answering these questions.  Here is your baby’s food for the next month.  Please go to the next station.  
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សូម្រតឡប់មកវ �ញ�ថ�ីៃនែខេ្រ�យម�ងេទៀត 
PLEASE COME BACK AGAIN NEXT MONTH! (CSB++ & RUSF) 
្រក�មករងរខងអង� នឹងទំនាក់ទំនងេទបងេទតមេលខទូរស័ព� 
We’ll give you a call in advance. 
ទីកែន�ងផ�ល់អហរ Site: ______________________
សូមចំថា: 
 ផ�ល់អហរបំប៉នបែន�មេនះេទកូនរបស់អ�កនូវបរមិាណែដលបាន
ែណនំា
 អហរបំប៉នេនះគឺ្រគាន់ែតជានំបែន�ម
 ផ�ល់ចំណីអហរដល់កូនរបស់អ�កតមធម�ត (៣-
៥ដងក�ុងមួយៃថ�អ�ស័យេលអយុ)
 បន�បំេបេដះកូនរបស់អ�កតមធម�ត
 លងៃដអ�កនិងៃដកូនរបស់អ�កមុនេពលបរេិភាគអហរ /
េពលប��ុ កអហរ
 េកបនិងេបាះេចលលមកឲ្យបាន្រតឹម្រត�វ
 លងៃដរបស់អ�កបនា� ប់ពីអ�កបេនា� របង់ ឬ បនា� ប់ពីទរកបេនា� របង់ 
Please remember: 
- Feed your baby this supplementary food in the recommended dosage
- This food is an extra snack.
- Continue to feed your baby normally, 3-5 times daily.
- Continue breastfeeding your baby
- Wash your hands and baby’s hands before eating/feeding
- Dispose safely of stool
- Wash your hands after you or baby defecate
សូម្រតឡប់មកវ �ញ�ថ�ៃីនែខេ្រ�យម�ងេទៀត 
PLEASE COME BACK AGAIN NEXT MONTH! (CONTROL) 
្រក�មករងរខងអង� នឹងទំនាក់ទំនងេទបងេទតមេលខទូរស័ព� 
We’ll give you a call in advance. 
ទីកែន�ងផ�ល់អហរ Site: ______________________
សូមចំថា: 
 ផ�ល់ចំណីអហរដល់កូនរបស់អ�កតមធម�ត (៣-
៥ដងក�ុងមួយៃថ�អ�ស័យេលអយុ)
 បន�បំេបេដះកូនរបស់អ�កតមធម�ត
 លងៃដអ�កនិងៃដកូនរបស់អ�កមុនេពលបរេិភាគអហរ /
េពលប��ុ កអហរ
 េកបនិងេបាះេចលលមកឲ្យបាន្រតឹម្រត�វ
 លងៃដរបស់អ�កបនា� ប់ពីអ�កបេនា� របង់ ឬ បនា� ប់ពីទរកបេនា� របង់ 
Please remember: 
- Continue to feed your baby normally, 3-5 times daily.
- Continue breastfeeding your baby
- Wash your hands and baby’s hands before eating/feeding
- Dispose safely of stool
- Wash your hands after you or baby defecate
សូម្រតឡប់មកវ �ញ�ថ�ៃីនែខេ្រ�យម�ងេទៀត 
PLEASE COME BACK AGAIN NEXT MONTH! (SPRINKLES) 
្រក�មករងរខងអង� នឹងទំនាក់ទំនងេទបងេទតមេលខទូរស័ព� 
We’ll give you a call in advance. 
ទីកែន�ងផ�ល់អហរ Site: ______________________
សូមចំថា: 
 ផ�ល់អហរបំប៉នបែន�មេនះេទកូនរបស់អ�កនូវបរមិាណែដលបាន
ែណនំា
 ផ�ល់ចំណីអហរដល់កូនរបស់អ�កតមធម�ត (៣-
៥ដងក�ុងមួយៃថ�អ�ស័យេលអយុ)
 បន�បំេបេដះកូនរបស់អ�កតមធម�ត
 លងៃដអ�កនិងៃដកូនរបស់អ�កមុនេពលបរេិភាគអហរ /
េពលប��ុ កអហរ
 េកបនិងេបាះេចលលមកឲ្យបាន្រតឹម្រត�វ
 លងៃដរបស់អ�កបនា� ប់ពីអ�កបេនា� របង់ ឬ បនា� ប់ពីទរកបេនា� របង់ 
Please remember: 
- Feed your baby this supplementary food in the recommended dosage
- Continue to feed your baby normally, 3-5 times daily.
- Continue breastfeeding your baby
- Wash your hands and baby’s hands before eating/feeding
- Dispose safely of stool
- Wash your hands after you or baby defecate
-
Appendix 5.5: Come back cards
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